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Abstract 
In the last two decades, unnatural amino acid (UAA) mutagenesis has emerged as a 
powerful new method to probe and engineer protein structure and function. This 
technology enables precise incorporation of a rapidly expanding repertoire of UAAs into 
predefined sites of a target protein expressed in living cells. Owing to the small footprint 
of these genetically encoded UAAs and the large variety of enabling functionalities they 
offer, this technology has tremendous potential for deciphering the delicate and complex 
biology of the mammalian cells. We describe the application of this technology to the 
modification of adeno-associated virus (AAV) for the first time, enabling the generation 
of vectors with precisely re-engineered cell-targeting for gene therapy.  Our UAA-AAV 
production platform enables the incorporation of UAAs bearing bio-orthogonal reactive 
handles into multiple specific sites on the virus capsid and their subsequent 
functionalization with various labeling molecules. Incorporation of an azido-UAA 
enabled site-specific attachment of a cyclic-RGD peptide onto the capsid, retargeting the 
virus to the αv β3 integrin receptors, which are overexpressed in tumor vasculature. This 
work provides a general chemical approach to introduce various receptor binding agents 
onto the AAV capsid with site selectivity to generate optimized vectors with engineered 
infectivity. 
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Next, we used our unique UAA-AAV vector as a tool for the directed evolution of 
more active UAA incorporation machinery in mammalian cells. It is well known that the 
efficiency of unnatural amino acid mutagenesis in mammalian cells is limited by the 
suboptimal activity of the suppressor tRNAs currently in use. The ability to improve their 
performance through directed evolution can address this limitation, but no suitable 
selection system was previously available to achieve this. We have developed a novel 
platform for virus-assisted directed evolution of enhanced suppressor tRNAs (VADER) 
in live mammalian cells. Our system applies selective pressure for tRNA activity via the 
nonsense suppression-dependent production of UAA-AAV, and selectivity for the 
specific incorporation of interest comes from a novel virus purification strategy based on 
the unique chemistry of the UAA. We demonstrated > 10,000-fold selectivity for active 
tRNAs out of mock libraries and used this system to evolve libraries generated from the 
commonly used archaeal pyrrolysyl suppressor tRNA, ultimately identifying a variant 
which is three times as active as the original tRNA. Finally, we used next-generation 
sequencing to analyze the fate of every library member over the course of the selection 
and found that our VADER selection scheme is indeed selective for the enrichment of 
more active tRNA variants. This work provides a general blueprint for the evolution of 
better orthogonal suppressor tRNAs in mammalian cells.   
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My research has focused on using genetic code expansion to study and engineer the 
behavior of human viruses, and using viruses as tools to carry out directed evolution in 
the context of human cells. Like most chemical biology tools, genetic code expansion and 
directed evolution have been most widely developed in lower organisms like bacteria and 
yeast, and significant challenges remain for their implementation in higher eukaryotic 
systems such as human cells. However, these systems hold the promise of being able to 
precisely investigate, manipulate, and engineer human biology, and so the improvement 
of our chemical biology tools in this context remains an important goal. This thesis 
addresses this challenge in two ways. First, genetic code expansion was used to precisely 
modify the capsid of a human virus and develop new methodologies for engineering viral 
cell entry. This led to the observation that these engineered viruses could in turn form the 
basis of a new strategy to evolve more efficient tools for genetic code expansion in 
human cells. The second part of this thesis describes the development and application of 
a new virus-assisted directed evolution scheme in human cells.  
  
 
 2    
1.1 Genetic code expansion 
This section is based on the following published review:  
Italia, J. S.; Zheng, Y.; Kelemen, R. E.; Erickson, S. B.; Addy, P. S.; Chatterjee, A. Expanding the 
Genetic Code of Mammalian Cells. Biochem. Soc. Trans. 2017, 45 (2), 555–562.1  
 
Understanding the chemistry and biology of living cells requires the development 
of new enabling technologies to precisely probe and engineer highly complex 
biochemical processes. Co-translational site-specific incorporation of novel unnatural 
amino acids (UAAs) into target proteins offers an attractive approach to achieve these 
goals.2–6 Because these UAAs are genetically encoded into the protein of interest, this 
field is often referred to as genetic code expansion (GCE). This technology has made 
impressive progress over the last decade, and has been applied to probe and manipulate 
protein function in mammalian cells and tissues in exciting new ways.7,8 For example, 
bio-orthogonal reactive groups allow for the site-specific modification of proteins9,10, 
post-translational modification (PTM) mimics allow the defined installation and 
investigation of specific protein modifications11, and light-reactive UAAs allow the 
photo-activation and photo-crosslinking of proteins12. This thesis will discuss 
advancements in two major areas: the extension of genetic code expansion to modify 
adeno-associated virus, a key vector for human gene therapy; and the development of a 
virus-based directed evolution strategy to improve the efficiency of UAA incorporation 
in mammalian cells.  
1.1.1 Principles of genetic code expansion 
Genetically encoding and incorporating a UAA into a protein of interest requires 
several key components: a unique “blank” codon, an orthogonal suppressor tRNA to 
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decode it, and an aminoacyl tRNA-synthetase enzyme to selectively ligate the UAA onto 
the orthogonal tRNA (Figure 1.1a). 2–6 The majority of reported applications, particularly 
in mammalian cells, rely on a repurposed TAG nonsense codon to encode the UAA of 
interest.7,8 However, the feasibility of using the other two nonsense codons (TGA and 
TAA)13–15 and four-base frameshift codons16,17 has also been demonstrated. In any host 
organism, it is critically important to ensure that the aaRS/tRNA pair is specific for the 
UAA over any natural amino acids and does not cross-react with any of its counterparts 
from the host cell (Figure 1.1b). Bacterial aaRS/tRNA pairs are generally orthogonal in 
eukaryotic cells and are used for mammalian genetic code expansion, while most 
archaeal pairs adapted for use in bacteria (with the exception of the pyrrolysyl pair) are 
not orthogonal in eukaryotes. The specifics of the aaRS/tRNA pairs used for mammalian 
cell GCE are discussed below.  
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Figure 1.1. Co-translational incorporation of UAAs by genetic code expansion.  (A) 
Schematic of genetic code expansion. (B) Potential sources of cross-reactivity with the 
host cell.  
 
1.1.2 Expanding the genetic code of mammalian cells 
There are four aaRS/tRNA pairs available for use in mammalian cells1: the 
pyrrolysyl pair from the methanogenic archaea Methanosarcina barkerii and 
Methanosarcina mazei (abbreviated MbPyl and MmPyl)18, which use pyrrolysine as a 
natural 21st amino acid; and the tyrosyl19–22, leucyl23–25, and tryptophanyl15 pairs from E. 
coli (abbreviated EcY, EcL, and EcW). Most of these pairs are derived from bacteria and 
the aaRSs are evolved in yeast21,23,26 Although archaebacterial aaRS/tRNA pairs are 
typically cross-reactive with their eukaryotic counterparts, the pyrrolysyl-tRNA 
synthetase/tRNA pair is an exception owing to its unique structural features27,28 and has 
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also been adapted for eukaryotic genetic code expansion18. This pair has become 
extremely popular because aaRSs for novel UAAs can be evolved in E. coli, where 
directed evolution is facile and larger library sizes are possible.29 Finally, a system was 
recently developed whereby E. coli aaRSs can be evolved directly in bacteria15, and this 
system was used to develop the EcW15 and improve the EcY20 pairs. The origins of the 
tRNA/aaRS pairs used for mammalian cell genetic code expansion are shown in Figure 
1.2 and representative UAAs are shown in Figure 1.31,4. For the purposes of this work, 
the MbPyl pair was used to incorporate lysine derivatives, EcY was used to incorporate 
p-substituted phenylalanine derivatives, and EcL was used for large hydrophobic UAAs.  
 
Figure 1.2. Pairs for mammalian cell genetic code expansion and their origins.  (A) 
Evolution of E. coli-derived aaRSs in yeast and the archaeal pyrrolysyl aaRS in bacteria.  
(B) Evolution of E. coli-derived aaRSs in engineered altered translational machinery E. 
coli.  
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Figure 1.3. Structures of representative UAAs incorporated by each pair in 
mammalian cells. UAAs are grouped by function and color coded by the aaRS/tRNA 
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Genetic code expansion is more challenging in mammalian cells than in simpler 
organisms like bacteria or yeast, but a variety of recent accomplishments highlight the 
promises of this technology1. One significant motivation for the expansion of the 
mammalian genetic code is to develop tools to study human biology in its native context. 
UAAs bearing bio-orthogonal handles have been used to introduce small-molecule 
fluorophores into proteins in a minimally invasive and site-selective manner, enabling 
super-resolution imaging of protein dynamics in living cells30,31. Many mammalian 
proteins are post-translationally modified, but the effect of most individual modifications 
is poorly understood. Recent advances have enabled the incorporation of one or more 
acetyl-lysine UAAs into histones in mammalian cells and the investigation of the 
biological effects of these site-defined post-translational modifications32, as well as the 
incorporation of phosphothreonine and its non-hydrolyzable analogue33. In addition to 
post-translational modification, many important facets of mammalian cell biology are 
mediated by complex protein-protein interactions networks. These often weak, transient 
interactions are difficult to dissect, but the incorporation of light-reactive UAAs known 
as photo-crosslinking reagents has enabled the covalent tethering of a UAA-bearing 
“bait” protein to its interaction partners and their subsequent identification by mass 
spectrometry12,34–36.  Complex signaling networks can also be directly activated by 
incorporating photo-caged UAAs in place of key residues in an upstream protein 
followed by photo-deprotection and investigation of the downstream results37. This was 
notably used for the activation of ion channels in cultured neurons and live mouse 
brains38, and the activation of a signaling network implicated in cancer39.  
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A few recent papers in particular highlight how far GCE in higher organisms has 
come in the last few years. UAAs have been incorporated into several live animals 
including zebrafish and mice40. Zebrafish are an important model organism in 
developmental biology, and UAAs were used to generate a photo-activatable Cre 
recombinase which could be used to control fluorescent protein expression for lineage 
tracing during development41 and a photo-activatable kinase to investigate the effects of 
particular cell-signaling pathways on development42. Mice, meanwhile, are common 
model organisms for a variety of human diseases and therapeutics, a viral delivery system 
was developed which enables delivery and expression of GCE machinery in the mouse 
brain43. This system recently enabled cell-type-specific proteome tagging in live mice 
using neuron or glial cell-specific promoters and a variant of the pyrrolysyl aaRS/tRNA 
pair which introduces a bio-orthogonal handle in response to sense codons44. Meanwhile, 
our lab has expanded the applications of GCE in mammalian cells by incorporating two 
distinct UAAs into one protein, including multiple mutually compatible bio-orthogonal 
handles for dual fluorophore labeling towards the goal of minimally-invasive FRET14,25. 
However, both the set of available UAAs and efficiency of incorporation in mammalian 
cells still lags behind what is possible in bacteria as exemplified by two recent 
publications from our lab – the incorporation of acetyl-lysine and a photo-crosslinking 
UAA into recombinant histones, and the incorporation of three distinct UAAs into a 
model protein.  
1.1.3 Challenges of mammalian cell genetic code expansion 
Several important differences set bacterial and mammalian cell GCE apart. 
Specialized bacterial strains for GCE feature elongation factors with improved UAA 
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tolerance45, engineered biosynthetic46 and metabolic pathways47,48 which increase the 
availability of UAAs, orthogonal ribosomes which support improved nonsense 
suppression49 and even the complete removal of the TAG stop codon and its associated 
release factor50,51. The Chin lab has begun to apply similar principles to mammalian cells, 
developing a dominant-negative variant of the eukaryotic release factor eRF1 which 
improves nonsense suppression52 and a phosphoserine-compatible variant of the 
eukaryotic elongation factor eEF1α33, but more advanced cellular engineering like the 
expression of orthogonal ribosomes or the complete deletion of a nonsense codon 
remains out of reach. Gene delivery presents another challenge. Bacterial gene delivery 
via transformation is facile and the relative promoter strength and copy number of each 
gene can be precisely controlled, while delivery of the genetic components for GCE into 
mammalian cells has so far relied largely on transient transfection, which leads to the 
accumulation of a very high number of plasmids in a sub-set of well-transfected cells53 
with limited control over the relative expression levels of various components54. The 
development of an optimized baculovirus vector for the transduction of cultured cells and 
mouse brain explants exemplifies the importance of copy number control, with the 
orthogonal tRNA required at a particularly high level54.  
The inefficiency of the orthogonal tRNAs used for mammalian GCE hints at a 
greater problem with how these aaRS/tRNA pairs are currently evolved. Because most of 
the pairs used for GCE in bacteria are not orthogonal in mammalian cells, new aaRSs are 
generally evolved in yeast and then transferred to mammalian cells. The suppressor 
tRNAs are minimally engineered aside from changing the stop codon and installing a 
mammalian small RNA promoter, unlike in bacteria where efficient UAA incorporation 
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has greatly benefitted from evolutionary optimization of the suppressor tRNAs. 
Specialized bacterial strains with altered translational machinery developed in our lab 
have made aaRS evolution for mammalian cell GCE significantly more facile, but tRNAs 
interact with many components of the host translational machinery and must be evolved 
directly in the host cell of interest. Because there was no available strategy for the 
evolution of suppressor tRNAs in mammalian cells, we and others have addressed this 
inefficiency by building increasingly large multi-copy tRNA cassettes52,54. For instance, 
the optimized pAcBac3 baculovirus vector carries 20 copies of the E. coli tyrosyl tRNA 
expressed from alternating U6 and H1 promoters, 16 copies of which form a single 3.5 
kbp cassette54. These types of constructs present a significant cloning challenge and their 
use is restricted to applications that tolerate very large, highly repetitive genetic cargos, 
which excludes most viral gene delivery vectors43 as well as stable cell lines32. Chapters 3 
and 4 of this thesis describe our efforts to address this problem more directly by 
developing a system that enables the directed evolution of suppressor tRNAs directly in 
mammalian cells.  
1.2 Adeno-Associated Virus 
Adeno-associated virus (AAV) consists of a very small icosahedral protein capsid 
surrounding a ~5,000 base genome55. It was initially discovered as a contaminant in 
adenovirus purifications56, but despite the name the biology of the two viruses is distinct. 
AAV has garnered intense interest in recent years as a vector for human gene therapy 
because it is non-pathogenic, relatively non-immunogenic, and the various naturally 
occurring serotypes of the virus have the ability to transduce a variety of cell types of 
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therapeutic interest57,58. Two AAV-based gene therapies have been approved59,60 and a 
number of others are in various stages of clinical trials58.  
1.2.1 AAV biology 
AAV is a member of the parvovirus family, a group of small non-enveloped viruses 
(those without lipid membranes)61. To date approximately ten naturally occurring AAV 
serotypes have been identified in humans and nonhuman primates, none of which are 
associated with any pathogenicity55,62. All AAVs are naturally replication-deficient, 
meaning that they can only replicate in cells which are co-infected with an additional, 
larger virus such as adenovirus48. This so-called “helper” virus provides key factors 
which the AAV genome is too small to encode, mainly involved in priming the host cell 
for viral replication. Unusually, AAV uses the host cell’s DNA polymerase to replicate 
its own genome. The AAV virion (Figure 1.4a) consists of 60 capsid proteins which form 
an icosahedral shell around a 5 kilobase single-stranded DNA genome containing a pair 
of inverted terminal repeats (ITRs) surrounding three open reading frames (ORFs), rep, 
cap, and AAP (Figure 1.4b, Table 1.1, detailed map in appendix), which each play key 
roles in different steps of the viral life cycle63.  
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Figure 1.4. AAV capsid and genome structure.  (A) The crystal structure of AAV-264, 
highlighting the three-fold (left panel) and five-fold symmetry (right panel) axes. 
Monomers are shaded in different colors.  (B) The AAV-2 genome showing the rep, cap, 
and AAP open reading frames (ORFs) and the proteins encoded in each. The capsid 
proteins are expressed in a roughly 5:5:50 VP1:VP2:VP3 ratio. VP1 is expressed from a 
minor splice product and VP2 is expressed from a non-canonical ACG (Thr) start codon. 
The AAP ORF is frameshifted relative to Cap and AAP starts with a non-canonical CUG 
(Leu) start codon.  
 
The cap ORF codes for the three capsid proteins VP1, VP2, and VP3 which are 
expressed from a common reading frame from three different start codons. The smallest 
protein, VP3, is the major protein, while VP1 and VP2, which are expressed from a 
minor splicing product and a non-canonincal XXX start codon respectively, are present at 
about 1/10th of the VP3 level55. The longer N-termini of VP1 and VP2 contain critical 
sequences including a nuclear localization sequence (VP1 and VP2) and a phospholipase 
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A2 domain which is involved in endosomal escape (VP1 only)65. VP1 is critical for AAV 
infection, while VP2 has been found to be non-essential66. AAV-2 first docks with the 
host cell using a basic cluster of arginine and lysine residues surrounding the threefold 
symmetry axis to bind a negatively charged receptor, heparan sulfate proteoglycan, on the 
surface of the cell67,68. Endocytosis is currently thought to be mediated by a secondary 
receptor AAVR, which traffics the virus to the endosomal pathway69. The next steps are 
less thoroughly understood, but the VP1 N-termini, which are initially located inside the 
viral particle, are thought to become externalized and participate in endosomal escape 
and nuclear localization70,71. Finally, the virus is imported into the nucleus through the 
nuclear pore complex72.  
Once in the nucleus, the single-stranded AAV genome must be converted to a 
transcriptionally active double-stranded form. This second-strand synthesis step is the 
rate-limiting step in the absence of a helper virus64. From this point the fate of the AAV 
genome depends on whether the cell is co-infected with another virus like adenovirus. In 
the absence of a co-infecting virus, the viral genome is integrated into a specific locus on 
chromosome 1955, but in the presence of a helper virus the viral genome is replicated in a 
complex “rolling circle” pathway which involves the host DNA polymerase, with the 
ITRs acting as origins of replication, and the endonuclease activity of the larger two Rep 
proteins55,57,71. Upon replication, the AAV-2 genome becomes highly transcriptionally 
active and the capsid proteins VP1, VP2, and VP3 are synthesized. Capsid assembly 
occurs in the nucleolus, where VP monomers are stabilized and scaffolded by the protein 
product of the final open reading frame, assembly activating protein or AAP73. AAP is 
required for both the nucleolar localization of VP3 and virion assembly74, which it 
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promotes by binding the C terminus of the VP proteins75. Genome packaging is thought 
to occur after virion assembly by means of pores at the fivefold symmetry axis in a 
process which requires the helicase activity of the smaller Rep proteins76.  
 
Table 1.1. Proteins encoded by the AAV-2 genome.  
Protein ORF Role(s) Domain(s) 
Rep78 rep Genome replication, packaging, 
chromosomal integration 
Endonuclease, helicase 
Rep68 rep Genome replication, packaging, 
chromosomal integration 
Endonuclease, helicase 
Rep52 rep Genome replication, packaging Helicase 
Rep40 rep Genome replication, packaging Helicase 
VP1 cap Structural (minor), infection Phospholipase A2, nuclear localization 
sequence, receptor binding 
VP2 cap Structural (minor), infection        
(non-essential) 
Nuclear localization sequence, receptor 
binding 
VP3 cap Structural (major), infection Receptor binding 
AAP aap Assembly Nuclear localization sequence 
 
1.2.2 AAV as a gene therapy vector 
As mentioned above, AAV is the subject of intense interest as a vector for human 
gene therapy from both academic labs and biopharmaceutical companies58. AAV is an 
attractive gene therapy vector for several reasons. It is non-pathogenic and relatively non-
immunogenic, and in the absence of the Rep proteins the genome is not integrated into 
the host cell, which leads to a better safety profile than other candidates like adenovirus 
or lentivirus57. Furthermore, AAV cargo has been shown to persist episomally for years 
in some cells57.The various naturally occurring serotypes of the virus have the ability to 
transduce a variety of dividing and non-dividing cells62 including the liver77 (AAV-2), the 
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retina (AAV-2 via direct injection)78 and the central nervous system (AAV-9)79. In recent 
years the first viral gene therapy treatments have been approved in Europe and the US, 
both based on AAV vectors. UniQure’s Glybera (alipogene tiparvovec, AAV-1) was 
approved by the European Medicines Agency in 2015 to treat the rare disease lipoprotein 
lipase deficiency60 (although it was pulled from the market due to low usage80). Spark 
Therapeutics’ Luxterna (voretigene neparvovec-rzyl, AAV-2) was approved by the FDA 
in 2017 as a sub-retinal injection to treat a progressive form of blindness59,81. Many more 
treatments are now in advanced stages of clinical trials, and AAV remains the dominant 
viral vector for human gene therapy58,82.  
1.2.3 Engineered AAV vectors with novel properties 
The majority of AAV gene therapies in ongoing trials, and both approved therapies, 
are based on naturally occurring AAV serotypes58, but there is great interest in 
engineering novel AAV capsids to address two major disadvantages associated with 
using existing capsids: broad targeting profiles which can lead to reduced infectivity 
towards the target cells or toxic off-target activity, and the prevalence of pre-existing 
neutralizing antibodies against the virus83–88. The first efforts to engineer AAV tropism 
involved the genetic engineering of cell-targeting peptides into surface-exposed loops on 
the viral capsid89,90 – this idea has been extended to a number of different modification 
sites and targeting ligands, and the resulting modified viruses showed improved 
selectivity towards target cells in vitro91–95. More recently, it has been shown that small 
cell-targeting proteins including designed ankyrin repeat proteins (DARPins) 96–99 and 
affibodies100 can be fused to the N-terminus of VP2 and displayed on the viral particle, 
although unmodified N-termini are generally located on the inside of the viral particle71. 
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Combined with the deletion of key heparan sulfate binding residues, this technique has 
recently been used to target viruses carrying a lethal gene to tumor cells in vivo98,99.   
These types of genetic engineering based techniques are promising, but they are 
restricted to peptide or protein sequences which can be fused with the viral capsid 
proteins, excluding all non-peptidic targeting agents such as small molecules or aptamers 
as well as more complex re-targeting proteins like multi-chain antibodies. Several recent 
papers have sought to provide more augment these techniques by inserting peptide 
sequences into the capsid which are substrates for the enzymatic ligation of biotin-like 
molecules101,102 or the selective conversion of a cysteine residue to an aldehyde-
containing formylglycine103. The enzymatically modified peptide loops can then be 
selectively functionalized with targeting molecules such as cyclic peptides102 or full-
length antibodies103. The aldehyde tag example was particularly interesting as the 
chemical conversion is catalyzed by the formylglycine generating enzyme which is 
natively expressed in the virus-producing cells, obviating the need for a separate in vitro 
enzymatic reaction step. However, both strategies were restricted to a relatively few sites 
on the capsid which tolerate peptide loop insertion. A more recent, enzyme-free example 
of selective capsid modification using a tetra-cysteine motif illustrates both the promise 
and shortcomings of peptide tag-based techniques104. Selective labeling of this sequence 
with maleimide reagents enabled visualization of AAV-9 infection in the brains of live 
mice and recovery of cellular interaction partners using selectively biotinylated AAV 
particles, but the tetra-cysteine tag was poorly tolerated and its introduction was only 
feasible at the N terminus of VP2.  
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The AAV capsid modification techniques discussed above each share a few 
significant drawbacks. In all cases, the targeting moiety must be displayed at one of a few 
sites in the capsid which permits peptide insertion or protein fusion. Even at permissive 
sites, these modifications can perturb the virus or require significant optimization, and 
with the exception of the aldehyde tag and tetracysteine insertion all of the 
aforementioned methods are restricted to peptidic molecules or require a distinct 
enzymatic modification step. We sought to address these combined shortcomings and 
develop a technique for introducing cell-targeting moieties into the AAV capsid with 
precise chemical control, a greater choice of modification sites, minimal perturbation of 
the virus capsid, and a broader selection of targeting agents. We incorporated unnatural 
amino acids bearing bio-orthogonal chemical handles into a selection of sites in the 
AAV-2 capsid, then demonstrated the functionalization of these residues with a cyclic 
peptide and re-targeting of the virus towards cancer cells105. This work provides a 
blueprint for future ligation of other targeting molecules, more detailed investigation of 
the effects of the targeting ligand attachment site and stoichiometry on infectivity106, and 
the incorporation of other UAAs with novel functions107. This work is described in 
Chapter 2.  
In recent years, meanwhile, the main focus of non-chemical AAV engineering has 
shifted to directed evolution of capsids with novel properties such as improved cell 
targeting and immune evasion, in vitro and in vivo83,85,88,108,109. Rather than rationally 
introducing cell targeting peptides, libraries of randomized peptide loops can be 
introduced at surface-exposed positions and selected for specific cell-targeting in vitro110–
112 or in vivo113–117 in a process designated “AAV display”. Recently this technique has 
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been expanded to combat immune neutralization through the randomization of amino 
acids in known neutralizing antibody binding epitopes and selection of variants which 
were still infectious but lacked the previous immunogenic sequences118. The AAV capsid 
can also be engineered more holistically by introducing diversity throughout its structure 
using error-prone PCR119 or DNA shuffling between different serotypes120–122. Regardless 
of the randomization technique, a major advance in the last few years has been the 
performance of selections in vivo rather than on cultured cells113–117,122. Meanwhile, 
advanced computational techniques have facilitated the phylogenetic alignment of 
multiple AAV serotypes and computational reconstruction of “ancestral” viruses has led 
to capsid variants which transduce a wide range of cells but evade the modern immune 
system123–125, and computational identification and mutation of sites of pro-degradation 
phosphorylation by the host cell have been identified and mutated to improve 
transduction efficiency126,127. Evolved AAV capsids continue to be of great interest in the 
pharmaceutical industry as more gene therapies move into clinical trials, and we also 
found the robust AAV evolution literature quite useful as we developed a system to 
utilize AAV as a directed evolution vector for enhanced suppressor tRNAs for genetic 
code expansion, described in chapters 3 and 4.  
 
Table 1.2. Advantages and disadvantages of AAV capsid engineering methodologies.  
Method Advantages Disadvantages 
Loop insertion89–95 No special modifications to the 
production process; well tolerated at 
some sites 
Can destabilize the capsid; limited to 
< 20 amino; no demonstrated in vivo 
studies with rationally designed 
peptide loops 
N-terminal fusion 
to a minor capsid 
protein96–100 
Can be used to attach entire folded 
protein domains such as affibodies and 
DARPins; demonstrated in vivo re-
targeting 
Disrupts the capsid (N-termini are 
usually located inside the capsid); 
limited to minor protein VP2 
 





Can be used to attach non-natural 
functionalities like PEG, fluorophores, 
and quantum dots 
No site specificity; likelihood of 
modifying an important residue 
Tetracysteine 
insertion104 
Labeling appears to be site-specific; 
versatile chemistry of attached groups 
Disrupts capsid assembly and 




Versatile chemistry of attached groups Still requires peptide insertion; some 
techniques require in vitro 
enzymatic modification step 
AAV display110–117 Allows in vivo selection of cell-binding 
peptides which perform well in the 
AAV capsid; allows the identification 
of cell-binding peptides directly in 
mammalian cells or animals  
Requires peptide insertion; limited 
to natural amino acids; in vivo 




Diversification across the whole capsid 
has the potential to find unexpected 
mutations which improve function 
Low mutation rate; sequence space 
is too large to cover during 
selection; limited in vivo validation.  
Serotype 
shuffling120–122 
Combines benefits from multiple 
serotypes and allows quick generation 
of significant sequence diversity; 
computational strategies allow fusion of 
protein fragments at logical break 
points 
Capsids made from natural 
serotypes are unlikely to acquire 
functions which are not present in 





Ancestral capsids efficiently transduce 
a variety of cells but are not recognized 
by the modern immune system 
Requires individual synthesis and 
screening of reconstructed variants 
to identify improved capsids 
Mutation of 
phosphodegredons 
on the capsid 
surface126,127 
Improves in vitro and in vivo 
transduction abilities 
Does not affect immune 






Does not perturb the capsid; site-
selective at a wide choice of attachment 
sites; versatile chemistry of attached 
groups 
Inefficient nonsense suppression 
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1.3 UAA incorporation and chemical modification of virus capsids 
Parts of this section were published in the following review:  
Kelemen, R. E.; Erickson, S. B.; Chatterjee, A. Synthesis at the Interface of Virology and Genetic 
Code Expansion. Curr. Opin. Chem. Biol. 2018, 46, 164–171.135  
 
Viruses employ highly sophisticated strategies to infect host cells with the ultimate 
goal of using the host machinery and resources for their self-replication. The virus capsid, 
as well as the proteins and RNAs encoded in the viral genome, have evolved to possess 
numerous fine-tuned functions to facilitate various stages of this process including viral 
entry, altering the physiology of the host cell for optimal viral replication, packaging of 
progeny virus, and their escape back to the environment136–140. In addition to their 
importance in fundamental virology and the development of new antiviral therapeutics, 
understanding the molecular processes associated with viral infection can provide 
important lessons and resources to further enrich the toolbox for synthetic biology141. 
Indeed, genetic elements derived from viruses (e.g., promoters and enhancer 
elements142,143, polymerases144, multi-cistronic expression sequences145,146, and origins of 
replication147,148) are frequently borrowed in numerous synthetic biology applications. 
The ability to site-specifically introduce novel chemical probes and modification handles 
into virus capsids offers significant promise for understanding viral infectivity and 
engineering viral vectors with desirable traits such as novel cell-type selectivity, immune 
evasion, or photo-activation149 (Figure 1.5).  
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Figure 1.5. UAAs and bio-orthogonal chemistries used to modify viruses and VLPs.  
(A) UAA structures.  (B) Bio-orthogonal modification of UAA-viruses.  
 
1.3.1 UAA incorporation into virus-like particles in bacteria 
Virus-like particles (VLPs) are protein cages resembling viruses, assembled from 
viral capsid proteins without their usual genetic cargo150,151. Despite lacking the highly 
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sophisticated properties of live viruses for efficient cell-entry, they have been developed 
as vehicles to deliver small-molecule cargo in vitro and in vivo, including imaging agents 
and cytotoxic drugs, as well as for vaccine development152–155. The techniques used to 
engineer viruses and VLPs as drug nano-carriers in bacteria can provide a blueprint for 
similar engineering of mammalian viruses for gene delivery. Chemical modification has 
been widely used to functionalize VLPs with both targeting agents and cargo156–158. 
However, functionalizing canonical amino acid residues on VLPs intrinsically lacks site-
specificity, unless a restricted number of target residues are surface-accessible. Global 
methionine replacement takes advantage of the relative rarity of methionine residues and 
can be used to introduce bio-orthogonal reactive handles such as azidohomoalanine (Aha) 
and homopropargylglycine (Hpg) in response to all methionine codons. This strategy has 
been utilized in bacteria to functionalize the surface of bacteriophage Qβ and hepatitis B 
virus (HBV)-derived VLPs on both the inner and outer surface using copper-catalyzed 
alkyne-azide cycloaddition (CuAAC)159,160, although the HBV VLPs tolerated the 
reaction conditions poorly. VLPs have also been generated incorporating Aha or Hpg 
using a bacterial cell-free protein expression system and subsequently functionalized with 
PEG, nucleic acids, and proteins161. 
Genetic code expansion provides an attractive alternative by enabling site-specific 
incorporation of UAAs in response to stop codons. The Francis group has site-
specifically introduced this p-aminophenylalanine (pAmF) onto the surface of Qβ VLPs 
for chemoselective oxidative coupling with electron-rich aromatic amines162 (Figure 2b, 
Table 1) The pAmF residues were subsequently labeled with PEG163 and cell-targeting 
groups including peptides164, aptamers165, proteins166, and antibodies167. This labeling 
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strategy has been further combined with cysteine functionalization on the interior of the 
capsid for the targeted delivery of PET168 and MRI169 imaging agents and cytotoxic 
photodynamic therapy agents170 to cancer cells in vivo, and for in vivo imaging of fibrin 
clots171. Plant-derived tobacco mosaic virus (TMV) VLPs, which assemble into rod or 
disc shapes depending on conditions, have also been functionalized with Uaas using the 
GCE technology172. Taken together, these reports illustrate the vast potential of GCE and 
bio-orthogonal chemistry for the engineering of viruses with novel properties.  
 
Table 1.3. Genetic code expansion of VLPs in bacteria 
Virus or VLP UAA(s) Purpose(s) 
Phage Qβ VLP162-171 pAmF Oxidative coupling of targeting molecules 
Phage Qβ VLP159–161 Aha, Hpg Click chemistry 
Tobacco mosaic virus VLP172 KPN Proof of concept biotinylation 
 
1.3.2 Phage display with unnatural amino acids 
One of the grand promises of GCE technology is the ability to create novel 
biological functions using expanded chemical space. One such application involves the 
development of novel affinity reagents (e.g., antibodies) using non-natural functionalities 
that provide significant advantage for binding specific targets. Indeed, the phage display 
technology based on the filamentous bacteriophage M13 has been used to demonstrate 
that the incorporation of Uaas with such privileged “chemical warheads” provides a 
distinct advantage when evolving novel protein or peptide-based affinity reagents.173–176 
Using this strategy, a cyclic peptide harboring metal-binding Uaa bipyridyl alanine 
(BpyA) was developed with strong affinity for Ni2+-NTA.176 It has also been used to 
develop antibody fragments harboring a boronate-containing Uaa that selectively 
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interacts with 1,2-diols174, and those harboring an O-sulfotyrosine with high affinity for 
the HIV gp120 protein, which naturally binds a sulfated receptor175. In each case the Uaa 
residue significantly contributed to the binding affinity. In another interesting example of 
virus-assisted evolution with non-natural chemical handles, Hpg-containing peptide 
sequences (generated through global methionine replacement) were evolved that 
participate in accelerated palladium-catalyzed Sonogashira coupling177. 
 
Table 1.4. Phage display with unnatural amino acids.  
UAAs Incorporated into Purpose 
pAzF173 Peptide Proof of concept 
pAcF173 Peptide Proof of concept 
BpyA176 Peptide Selection of metal-binding peptides 
Hpg177 Peptide Selection of a peptide context for accelerated Sonogashira coupling 
pBOF174 Antibody fragment Selection of sugar-binding peptides 
sY175 Antibody fragment Selection of anti-HIV antibodies which used sulfated UAAs to 
mimic the virus’s natural receptor 
 
1.3.3 Mammalian viruses 
Mammalian viruses employ a series of complex molecular maneuvers to enter their 
host cells with remarkable efficiency136–140. To ensure that these delicate processes are 
not perturbed, extra care must be taken when introducing modifications on the virus 
particle. Indeed, the proteins associated with various mammalian viruses are remarkably 
complex and multifunctional136–140– for example, a single capsid protein of adeno-
associated virus (AAV), a relatively small and simple virus, can contain multiple 
essential cell-surface receptor binding domains, nuclear and nucleolar localization 
sequences, and a phospholipase A2 domain55,63,71, the latter of which are initially located 
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inside of the capsid but must be externalized via conformational changes during 
infection70,178. The same proteins must interact with neighboring capsid subunits63, an 
assembly-scaffolding protein73,75 and the viral DNA packaging machinery76, and 
mutations in any one of these regions have proved detrimental67,68,179,180. Consequently, 
viral proteins are often refractory to traditional genetic manipulations, such as 
incorporation of peptide or protein tags, the large size of which can significantly perturb 
their native function. This is particularly true for viruses like AAV and adenovirus which 
lack a lipid envelope, where the capsid is composed entirely of protein subunits which 
interact with precise and complex symmetry.  
Unnatural amino acid incorporation presents an elegant solution to the problems of 
viral capsid protein modification. UAA mutation involves a single change to the viral 
protein sequence, and the ability to precisely choose the modification site means that 
regions of the capsid involved in assembly and infection can be avoided (or deliberately 
modified to study their biochemistry or alter their function). While the capsid proteins of 
viruses like AAV are not particularly stable on their own73, assembled AAV virions are 
remarkably resistant to heat, pH, and salt concentration181. Therefore, UAAs bearing bio-
orthogonal handles can theoretically be introduced into viral capsid proteins before 
assembly, and then the assembled viral particles can be purified and functionalized with 
molecules such as fluorophores, cell-targeting agents, or PEG. Furthermore, unlike many 
of the strategies discussed in section 1.2.3, this method should be agnostic to the size, 
biological origins, and chemical nature of the new functionality. Despite this potential, 
when we began the work described in Chapter 2, there were relatively few examples of 
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GCE in mammalian viruses and no examples of GCE in non-enveloped viruses (those 
without a lipid membrane). 
The first examples of mammalian virus modification with unnatural functionalities 
were the generation of azide-containing adenoviruses via the metabolic incorporation of 
azido sugars182 or the global replacement the global replacement of methionines with 
azidohomoalanine183 (Aha) by Isaac Carrico and co-workers. The resulting azide groups 
were used to attach fluorophores, as well as retargeting agents such as folate, illustrating 
the potential of this technique for engineering the cell-targeting behavior of mammalian 
viruses. However, metabolic incorporation of modified sugars is restricted to native 
glycosylation sites, viruses that do not undergo glycosylation are not amenable to this 
strategy, and there is no site-specificity in the case of viruses with multiple glycosylation 
sites. The global methionine replacement strategy also suffers from a lack of site 
specificity and a relatively small set of UAAs which can be incorporated. Despite these 
limitations, this remained the only example of UAA incorporation into a non-enveloped 
virus until the work described in Chapter 2.  
In contrast, the incorporation of UAAs in response to stop codons via genetic code 
expansion had been reported for several enveloped mammalian viruses, with the UAA 
incorporation site(s) in a surface-exposed membrane protein. The first reported example 
of GCE in a mammalian virus was the incorporation of several UAAs into surface-
exposed sites on the hepatitis D virus (HDV), a satellite virus of the more well-known 
hepatitis B virus, using the pyrrolysyl tRNA/aaRS pair184. These included the azido UAA 
PenK, which was used for fluorophore labeling by copper-catalyzed alkyne-azide 
cycloaddition (CuAAC) and visualization of cell entry, and the photo-crosslinking UAA 
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DiZPK, although no photo-crosslinking was demonstrated. Similarly, UAAs were 
incorporated into a vesicular stomatitis virus G (VSVG) protein incorporated into the 
membrane of lentivirus.185 The authors used AzK to conjugate polyethylene glycol 
(PEG), fluorophores for single-virus tracking, and cyclic peptides to re-target the virus to 
cancer cells. They also used the photo-crosslinking UAA DiZPK to capture several 
potential cellular interacting partners, but these proteins were not identified. Both reports 
demonstrated the promise of GCE for engineering re-targeted gene therapy vectors via 
bio-orthogonal chemistry, and identification of virus-host interaction partners during 
infection via photo-crosslinking.  
Since the work described here in Chapter 2, several additional papers have been 
published describing UAA incorporation into AAV. Simultaneously to the work 
described in Chapter 2, the Zhou group also published the re-targeting of AAV vectors 
using GCE and the chemoselective attachment of targeting agents131. They and others 
later expanded upon this technique to site-specifically attach fluorophores133 and long 
polyethylene glycol (PEG) chains to AAV132,134. Existing neutralizing antibodies against 
natural AAV serotypes often present a significant issue for AAV gene therapy, so the 
ability to site-specifically introduce immune-modulating agents such as PEG without 
disrupting target cell infection is highly desirable. Oligonucleotide-conjugated viruses 
have also been reported using this technique, although no aptamer-based virus targeting 
was demonstrated. Instead, the AAV particle was first functionalized with 10 kDa DNA 
oligos, then complexed with the cationic lipid transfection reagent lipofectamine to cloak 
the virus from the immune system134. Finally, our group reported the incorporation of a 
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photo-caged lysine UAA in place of vital primary receptor-binding residues in AAV-2, 
generating a virus whose infectivity could be controlled with light.107 
Genetically encoded UAAs also have provided powerful new ways to interrogate 
the complex biology of viruses. Due to their complex nature, viral proteins are often not 
compatible with traditional genetically encoded probes such fluorescent proteins, but 
UAAs bearing bio-orthogonal handles provide a facile and selective strategy to attach 
small biophysical probes at pre-defined sites in a virus capsid. GCE-based site-specific 
labeling of viruses with fluorophores has been used to study the dynamic assembly 
processes of HIV31 and influenza30 viruses by super-resolution microscopy. In the first 
example, HIV envelope glycoproteins were specifically labeled with a fluorescent probe 
and their mobility and clustering during virus assembly and budding at the cell membrane 
was recorded using fluorescence recovery after photobleaching (FRAP)31. This represents 
an improvement over previous attempts to study the mobility of the HIV Env protein, 
which relied on immunofluorescence with antibodies as large as the Env protein itself 
(compromising resolution and potentially changing the behavior of the Env protein). In 
the second study, influenza capsid proteins were selectively labeled with two different, 
non-cross-reactive bio-orthogonal handles in a pulse-chase manner, enabling the labeling 
of proteins produced at different times with distinct fluorophores30. Super-resolution 
imaging was used to study the virus assembly process, visualizing individual filamentous 
membrane protrusions involved in virus budding and determining that nascent virions 
contained proteins which were synthesized at different times.  
Lastly, several groups have demonstrated the use of genetic code expansion for the 
biocontainment of pathogenic viruses, which is of interest for the development of safe 
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live-virus vaccines. These live but replication-incompetent viruses contain nonsense 
codons in the coding regions of essential genes, such that the virus can only replicate the 
in the presence of the nonsense suppressor aaRS/tRNA pair and substrate UAA, and 
represent an attractive middle ground as vaccines between inactivated viruses, which are 
safe but not always antigenically representative, and live-virus vaccines, which are 
prohibitively unsafe. This principle has recently been extended to influenza A virus, with 
multiple stop codons in important proteins186, and HIV, with one or more nonsense187,188 
or four-base frameshift17 codons. The insertion of multiple stop codons and/or the use of 
frameshift codons is important to avoid escape of the virus through reversion to sense 
codons, a legitimate concern for rapidly mutating viruses such as HIV and influenza. 
Overall, recent years have seen a number of exciting papers reporting the genetic code 
expansion of mammalian viruses, and this technology should continue to be useful for 
virological and translational studies135.  
 
Table 1.5. Genetic code expansion of mammalian viruses 
Virus UAA(s) Purpose(s) 
AAV-2 AzK SPAAC click chemistry for targeting
105,131, 
PEGylation132, imaging133 
AAV-2 NBK Photocaging primary receptor binding107 
Hepatitis D 
virus 
PenK, ACPK, DiZPK, 
ONBK, BCNK 
Proof of concept, CuAAC click chemistry to label with 
biotin184 
Lentivirus AzK, DiZPK 
SPAAC click chemistry for targeting and PEGylation; 
photo-crosslinking185 
HIV-1 BCNK, SCOK, TCOK SPIEDAC click chemistry for super-resolution imaging31 
HIV-1 AzK Biocontainment187 
Influenza A AzK Biocontainment186 
Influenza VLP TCO*K, SCOK 
SPIEDAC click chemistry, dual-color labeling and 
super-resolution microscopy30 
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1.4 Directed evolution 
Directed evolution has emerged as a powerful strategy for the laboratory 
development of biomolecules with new properties including enzymes which efficiently 
catalyze novel or non-natural reactions; peptides, antibodies, and aptamers which 
selectively bind molecules of interest; novel fluorescent proteins and RNAs; and even 
organisms with new properties. The 2018 Nobel Prize in Chemistry was awarded to 
Frances H. Arnold, George P. Smith, and Gregory H. Winter, three pioneers of this 
work189. In essence, laboratory directed evolution involves three basic steps: (1) 
generation of a library of biomolecules with different sequences; (2) applying selective 
pressure to perform a new function, and (3) recovery and sequencing of the “hits” which 
passed190. In practice, the most challenging parts of a directed evolution campaign are 
often figuring out how to apply selective pressure such that only the desired library 
members survive, how to compartmentalize the selection so each biomolecule is solely 
responsible for its own fate, and how to link genotype and phenotype such that hit 
sequences can be efficiently recovered and characterized after selection.  
1.4.1 Library diversification strategies 
All directed evolution strategies rely on the ability to identify biomolecules with 
new sequences which perform new functions, but there are a variety of ways to generate 
these new sequences both in vitro (Table 1.6) and in vivo (Table 1.7). These methods can 
be divided into two main categories: random mutagenesis in which an entire gene is 
mutated at a low frequency, and focused mutagenesis in which a few specific positions 
are mutated to all possible variants191. Random mutagenesis can be accomplished in vitro 
by error-prone PCR or DNA shuffling and in vivo by elevation of the global mutation rate 
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in bacteria192 or specific mammalian cells193. Such structure-agnostic mutation strategies 
are often used to improve or gradually change the function of biomolecules, and and 
indeed many evolved biomolecules including UAA-specific aaRSs have accumulated 
difficult-to-rationalize mutations far from the active site194. However, when evolving 
enzymes for completely new functions or substrate specificities it is often better to use 
structure-guided site-saturation mutagenesis to completely randomize the active site of 
the enzyme, a technique commonly used to generate UAA-specific orthogonal aaRSs 
with new specificities2. This allows us to drastically change the enzyme’s function in 
only a few rounds of evolution, but to access all 20 amino acids at N randomized 
positions the library size will be 32N. Newer methods wherein DNA can be synthesized 
with randomized codons rather than randomized nucleotides195,196 can reduce this to 20N, 
and although they have been useful for directed evolution197 they remain expensive and 
difficult to implement191. Focused mutagenesis is particularly important for tRNA 
evolution, where the preservation of base-pairing in stem regions is vital for 
function198,199. Finally, recent advances in chip-based DNA synthesis have enabled the 
design of oligonucleotide pools in which every member has a distinct, precisely defined 
sequence191. This technique holds enormous promise for more precise and targeted 
library design, particularly when combined with computational insights, but libraries are 
currently limited to relatively small sizes (~104 members) and oligo lengths (200 nt). 
Chapter 5 discusses the implementation of this strategy for the design of fully base-paired 
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Table 1.6. In vitro library diversification strategies191 





Complete control over which residues 
are randomized.  
SSM libraries are readily 
commercially available.  
Protein evolution requires very large 
libraries (32n including some 
redundant and nonsense codons).  
Effective library design requires 
specific structural and mechanistic 
knowledge.  
SSM using trimer 
oligonucleotides  
Smaller and more customizable 
libraries than standard SSM.  
Challenging to synthesize and 
expensive to purchase.  
Error-prone PCR Allows diversification of an entire 
gene, which can lead to serendipitous 
mutations which improve biomolecule 
stability or activity.  
Low mutation frequency makes 
drastic changes in protein function 
challenging. 
DNA shuffling  Combines beneficial mutations across 
different regions of a biomolecule of 
interest.  
Must be used in tandem with another 
diversification method or on a 





Complete control over the sequence of 
all library members.  
Limited to relatively small libraries 
(~104 members).  
Oligo length is limited to < 200 
nucleotides.  
Expensive to purchase 
 
All of the aforementioned in vitro library diversification strategies require human 
intervention to generate the libraries and perform error-prone PCR or DNA shuffling 
between rounds of selection, leading to discontinuous evolution. Achieving continuous 
evolution, where diversification and selection take place simultaneously over many 
generations with no human intervention, requires strategies to continuously generate 
sequence diversity in vivo191. These typically fall into two categories, targeted and 
untargeted mutagenesis. In untargeted mutagenesis the mutation rate of the entire 
organism in which the evolution takes place is elevated by expressing more error-prone 
DNA polymerases or inhibiting quality control factors192. These strategies are fairly 
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simple to implement, but the toxic accumulation of mutations across the host genome can 
be an issue. Recent advances have placed the evolutionary target gene on a unique piece 
of DNA, either a separate engineered chromosome200 or a viral genome201–204, which can 
be replicated by a more error-prone DNA polymerase without interfering the replication 
of the host organism. Targeted in vivo mutagenesis strategies are a more recent 
innovation and rely on a catalytically dead Cas9 protein and sequence-specific guide 
RNA or a promoter-targeted T7 RNA polymerase tethered to an error-prone DNA 
polymerase or DNA-modifying enzyme. While this technique holds great promise, 
mutagenesis is currently limited to relatively small windows (<50 nt). The mutation rates 
for all of these strategies, even targeted mutation, remain at or below 10-4 (1 mutation per 
10,000 bases), lower than what is achievable with error-prone PCR.  
 
Table 1.7. In vivo library diversification strategies 
Method Organism Targeted?  




< 50 nucleotide window specified by a 
guide RNA 
Orthogonally replicating 
chromosome200 Yeast Entire orthogonal chromosome 
Somatic hypermutation193 Mammalian cells Global 
CRISPR-guided cytidine deaminase 
“CRISPR-X”206 
Mammalian cells 
100 nucleotide window specified by a 
guide RNA 
Error-prone viral genome 
replication202,204 
Higher eukaryotes Entire viral genome.  
 
The next two requirements for directed evolution are the encapsulation of library 
members in different compartments, so that each can be evaluated independently and a 
method for linking genotype and phenotype so that the genes which lead to successful 
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phenotypes can be recovered. Some methods effectively combine these two steps by 
physically tethering the library genes to their products (the most extreme example being 
aptamer evolution via SELEX, where the gene and the product are the same thing), while 
others compartmentalize individual genes and their products in droplets, viruses, or living 
cells190. This section will focus on strategies to evolve biomolecules in living cells, 
because the goal of improving GCE machinery is to engineer the biology of living 
systems.  
1.4.2 Directed evolution of the GCE machinery in lower organisms  
Directed evolution in lower organisms is a widely studied topic and has been used 
to evolve a wide variety of biomolecules with novel functions207–209, but this section will 
focus on strategies used to evolve the GCE machinery because this work served as an 
example for the mammalian-cell orthogonal tRNA evolution discussed in Chapters 3 and 
4. The most commonly used strategy for the directed evolution of aaRS and tRNA 
variants for GCE in lower organisms is to select for active variants (“positive selection”) 
by requiring nonsense suppression in an essential gene in the presence of the UAA 
followed by selection against inactive variants by requiring a lack of nonsense 
suppression in a toxic gene in the absence of the UAA (Figure 1.6)2. This strategy has 
successfully been used to evolve many active and orthogonal aaRS variants in S. 
cerevisiae21,23,26 and active and orthogonal aaRS3–5 and tRNA198,199,210,211 variants in E. 
coli. An alternative method, compartmentalized partnered replication, has also been used 
to evolve new aaRS197 and tRNA212,213 variants in E. coli. Both of these strategies are 
types of so-called discontinuous evolution, in which alternating rounds of positive and 
negative selection are performed, each of which represents a single generation of cells 
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and requires human intervention. An alternative strategy, called phage-assisted 
continuous evolution (PACE)203 links the activity of a biomolecule to the survival of 
bacteriophages infecting a continuously exchanged pool of E. coli, allowing positive and 
negative214 selection over many generations in a matter of hours with minimal researcher 
intervention. This strategy has also been used for aaRS evolution194 as well as the 
development of many other biomolecules with new functions190.  
 
 
Figure 1.6. Directed evolution of the GCE machinery in bacteria and yeast. An 
example evolution of a new aaRS variant in bacteria is shown, but similar schemes are 
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used for tRNA evolution and for aaRS evolution in yeast.  (A) Diversification of the 
library and transformation of the library such that one variant is distributed per cell.  (B) 
Positive selection for active variants. One or more TAG codons is introduced into an 
essential gene (e.g. antibiotic resistance) and cells are subjected to selective pressure (e.g. 
grown on antibiotic) in the presence of the UAA such that only cells containing active 
nonsense suppression machinery survive.  (C) Negative selection against inactive 
variants. One or more TAG codons is introduced into a toxic gene (e.g. the nuclease 
barnase) and cells are grown in the absence of the UAA. If the cell contains cross-
reactive GCE machinery, such as an aaRS which charges a natural amino acid or a tRNA 
which cross-reacts with a host aaRS, the cell dies, but cells containing orthogonal GCE 
machinery survive.  
 
1.4.3 Directed evolution in higher eukaryotes 
Directed evolution in higher eukaryotic contexts such as mammalian cells and 
animals is a much less widely explored topic than evolution in bacteria and yeast. This 
can be attributed to a variety of technical barriers, most notably the lack of a method for 
the efficient delivery of single genes to a pool of target cells analogous to transformation 
of bacteria or yeast; a relative paucity of methods for linking the properties of a 
biomolecule of interest to cell survival; comparatively slower cell growth; and more 
challenging gene recovery after selection. While many bacterial evolution strategies link 
the activity of a biomolecule of interest to the replication or death of the cell, there have 
only been two examples using this strategy in mammalian cells, both of which used a 
dCas9-guided cytidine deaminase to diversify an endogenous gene coding for the protein 
targets of various cytotoxic drugs used for the treatment of cancer, then selected for cell 
survival in the presence of the drug.  
Instead, most directed evolution strategies in mammalian cells fall into two 
categories: fluorescence-based cell screening, and selection based on viral replication 
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(Table 1.8). Fluorescent screening is not a true selection strategy because it requires 
researcher intervention for the recovery of fluorescent cells, but advances in high-
throughput droplet sorting215 and robotic cell picking technologies have made this a 
viable strategy for library screening. Fluorescence activated cell sorting (FACS) has been 
used to identify fluorescent proteins with novel properties from libraries generated by 
global and dCas9-targeted somatic hypermutation and to develop more potent cell-fate 
reprogramming factors using a fluorescence-based screen for cell fate conversion216, and 
enhanced fluorescent voltage reporters have been identified using fluorescence-guided 
robotic cell picking217. The last two examples used libraries diversified in vitro by site-
saturation mutagenesis and error-prone PCR respectively, but the library sizes in question 
were < 100,000 members and the library delivery strategies were much less efficient than 
bacterial transformation. The reprogramming factor libraries were delivered by lentiviral 
transduction, in which the target gene integrates randomly into the host cell genome, 
while the fluorescent voltage reporter libraries were delivered by calcium phosphate-
mediated transfection with excess carrier DNA such that each cell received ~ 1 copy of 
the library plasmid, with an overall transfection efficiency of < 10% and a nonzero 
number of cells receiving multiple plasmids.  
It is often difficult to link the activity of a biomolecule of interest to a screenable 
fluorescent readout, so several additional selection strategies have been developed which 
link the activity of the target gene to the replication of a mammalian virus. There has 
been a significant number of reports of directed  evolution of mammalian viruses with 
new infective properties (see section 1.2.3), and a few interesting reports of viral 
evolution of non-viral genes. In the first example, the doxycycline-inducible rtTA (“Tet-
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On”) transcription factor and its target promoter were used to drive the expression of 
essential genes for HIV replication, and an enhanced doxycycline-induction system was 
evolved over many generations of viral replication201,202. To develop the most 
doxycycline-sensitive rtTA variant, virus the virus was cultured for 200 days. In the 
second example, an engineered adenovirus with a more error-prone polymerase (~10-5 
mutations per base per viral passage) was used to evolve a doxycycline-resistant version 
of the tTA (“Tet-Off”) transcription factor. Several different single mutations which 
conferred doxycycline resistance were identified by high-throughput sequencing after 6-
12 passages (4-8 days each). These methods are relatively slow, and in both cases 
mutagenesis occurs in each cell before progeny virus is produced, so each virus-
packaging cell contains multiple library members with different activities and different 
gene sequences by the time the next generation of viral genomes are packaged which 
could lead to packaging of inactive variants.  
 
Table 1.8. Methods for directed evolution in mammalian cells 
Selection/screening 
strategy Evolution target Library generation and delivery  
Fluorescence screen 
(FACS or robotic cell 
picking) 
Fluorescent proteins193,206 
Diversification of genomically integrated target 
gene by global somatic hypermutation193 or 
dCas9-targeted cytidine deaminase206 
Fluorescent voltage 
reporters217 
Diversification by error prone PCR and library 
delivery by low copy-number transfection of 
plasmids containing SV40 origin of replication 
Factors for induced 
pluripotent stem cell 
generation216 
Site-saturation mutagenesis and library delivery 
by lentiviral transduction 
Cell lives or dies in the 
presence of toxic drug 
Endogenous targets of 
anti-cancer cytotoxic 
drugs206,218 
Diversification of endogenous loci with dCas9-
guided cytidine deaminase 
Virus replication Tet-On rtTA transcription Naturally error-prone viral genome replication 
 




Tet-Off tTA transcription 
factor204 
Viral genome replication with an engineered 
error-prone polymerase 
 
1.5 Optimizing suppressor tRNAs for genetic code expansion 
This section is based on a review manuscript which is in preparation with Katherine Grasso and 
Abhishek Chatterjee.  
 
Most of the engineering of new aaRS/tRNA pairs for genetic code expansion 
focuses on altering the amino acid specificity of the aaRS, but the orthogonal tRNA is an 
equally important component of this machinery219. All of the tRNAs used for GCE have 
their anticodon changed for nonsense suppression (except for the pyrrolysyl tRNA, a 
natural amber suppressor), but this is not necessarily sufficient to ensure robust activity in 
the new host cell. Bacterial GCE has benefitted considerably from the evolution and 
engineering of enhanced suppressor tRNAs198,199,210–213,220, while the tRNAs used in 
mammalian GCE have undergone very little optimization1. These heterologous 
suppressor tRNAs must navigate a number of challenges in their new host cells, starting 
with proper expression and processing by the host cell machinery. To maintain the 
fidelity of translation, each tRNA must selectively be charged with the correct amino acid 
by its cognate aaRS, so the newly introduced suppressor tRNA must be orthogonal to the 
endogenous aaRSs present in the host cell but efficiently recognized by its own cognate. 
Then, an elongation factor (EF-Tu for bacteria and EF1α in eukaryotes) chaperones the 
aminoacylated tRNA to the A-site of the ribosome for participating in translation. It has 
also been suggested that the elongation factor plays an important role in the selection of 
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the correct aminoacylated tRNA in response to a specific codon, as simple codon-
anticodon base pairing is an insufficient driving force. Finally, the tRNA must be stable 
to degradation. Given the divergent nature of the cellular machinery responsible for the 
efficient expression, processing and performance of the tRNA, the introduction of a 
heterologous tRNA into a host cell for expanding its genetic code can be frequently 
challenging221.  
1.5.1 tRNA structure, expression, and processing 
Almost all tRNAs fold into a cloverleaf-shaped secondary structure consisting of 
several stem-loop structures. The cloverleaf then further folds into an L-shaped structure 
mediated by tertiary interactions between the D and T loops. All tRNAs also harbor the 
conserved CCA sequence in the 3’ terminus, and the cognate amino acid is attached 
through an ester bond to the terminal adenosine222,223. In bacterial genomes, tRNAs can 
be found encoded both as an independent monomeric gene, and clustered with other 
genes224. Additionally, the bacterial tRNA genes are typically expressed from standard 
extragenic promoters, and usually encode the terminal CCA. In contrast, eukaryotic 
tRNA genes are typically monomeric, lack the terminal CCA, and are transcribed by 
RNA polymerase III that require intragenic promoter elements (A and B boxes)225. This 
presented significant problems for the expression of bacterial suppressor tRNAs in 
mammalian cells until the discovery of the U6226,227 and H1228,229 external RNA 
polymerase III promoters.  
Primary tRNA transcripts are subjected to extensive processing to generate the 
mature tRNA molecule230,231. In all cases, the transcribed tRNA precursor typically 
contains excess sequence on the 5’ and 3’ termini. Additionally, depending on which 
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domain of life it is expressed in, it may be encoded in a polycistronic sequence and can 
harbor introns. Furthermore, for tRNA genes that do not encode the 3’-terminal CCA, 
this sequence must be added post-transcriptionally. Thus, to generate mature tRNAs, the 
transcribed precursors are subjected to a series of processing events that vary within each 
kingdom of life and subcellular location. In addition to such processing events, tRNAs 
are subjected to an astounding variety of different post-transcriptional modifications by 
dedicated enzymes232. Some of these modifications are common – such as the 
pseudouridine (ψ) and dihydrouridine (D) in TψC and D arms, respectively – whereas 
others are restricted to specific domains of life. While the roles for some of these 
modifications have been elucidated, such as those facilitating the codon-anticodon 
interaction, the functions of many others remain elusive. 
1.5.2 Suppressor tRNA engineering in bacteria 
Wild-type tRNA-aaRS pairs imported from an evolutionarily distant species often 
do not have optimal levels of activity and orthogonality in the expression host. In general, 
the aaRS requires less host-specific optimization, since it does not need to interact 
directly with the translation system. Unlike the aaRS, the activity and the orthogonality 
heterologous suppressor tRNA often requires significant optimization in the expression 
host219,221. The molecular basis of its suboptimal performance is often hard to pin down, 
given the numerous possibilities, including deficiencies in expression, stability, post-
transcriptional processing and modification, nuclear export, and interactions with 
elongation factors and the ribosome. In the absence of a clear understanding of its origin, 
it is challenging to address this limitation through rational design. Attempts at rationally 
improving the activity and the orthogonality of the suppressor tRNA has typically 
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involved iterative synthesis and evaluation of a large number of different mutants. For 
example, the pyrrolysyl-tRNA was engineered to create variants with improved activity 
in E. coli, by creating and evaluating a large number of mutants targeting a region at the 
junction of A and T stem that is known to interact with EF-Tu220. From numerous tRNA 
engineering studies, some general patterns have emerged, such as the deleterious effect of 
G-U pairs in the stem regions233, and that specific anticodons work better in certain 
anticodon loop contexts (e.g. CUCUAAA for amber suppressors)211. However, a general 
guiding principle to rationally improve suboptimal tRNAs is still lacking, and even for 
cases where improved tRNAs were developed, the molecular basis of the improvement 
remains unclear. 
Given the challenges associated with rationally addressing suboptimal tRNA 
activity, directed evolution offers an attractive general solution. By randomizing key 
regions of the tRNA to create a large library of mutants, followed by subjecting these 
libraries to selection schemes that efficiently enrich variants that are active but orthogonal 
(see section 1.4.2), it has been possible to overcome suboptimal properties of suppressor 
tRNAs used for genetic code expansion. The directed evolution approach has been 
applied to improve the activity of nearly all suppressor tRNAs that have been developed 
for expanding the genetic code of E. coli. The A and the T stem regions have been 
frequent targets of such engineering efforts198, given these directly interact with the host 
translation machinery. Additionally, directed evolution of the anticodon loop/stem has 
enabled the development of improved suppressor tRNAs in several cases211, particularly 
where the desired anticodon sequence is significantly different from the native one199 or 
suppression of four-base frameshift codons is desired16, and in some cases regions of the 
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D and TψC loops have also been targeted. Almost all of these evolutionary efforts have 
relied on site-saturation mutagenesis because the unique structure of tRNAs imposes a 
few important library design considerations which are not present when diversifying a 
library of protein-coding genes. Base pairing in stem regions is a key requirement for 
tRNA activity, so while random mutagenesis would allow diversification of the whole 
tRNA sequence, it is highly unlikely that two paired bases would simultaneously mutate 
such that pairing is preserved. Chapter 5 of this thesis discusses the use of 
oligonucleotide pool libraries consisting entirely of fully base-paired variants. 
Additionally, tRNAs are quite compact (< 100 nucleotides) and so significant regions of 
the sequence can be covered by site-saturation mutagenesis at one time.  
1.5.3 Suppressor tRNA engineering in mammalian cells 
Both the expression and engineering of heterologous suppressor tRNAs is more 
challenging in mammalian cells than in bacteria. The expression of native mammalian 
tRNAs relies on intragenic promoter elements recognized by the RNA polymerase III 
(Pol III)225,234, which made it challenging to express heterologous tRNAs lacking such 
sequences. Consequently, early ncAA incorporation efforts in mammalian cells were 
restricted to the use of bacterial tRNAs that happened to contain the so called A and B 
box internal promoter sequences21. This limitation was circumvented later by the 
development of efficient extragenic polIII promoters (e.g., U6226,227 and H1228,229), 
enabling the expression of any heterologous tRNA in higher eukaryotes. However, 
further technical challenges have prevented the use of directed evolution to improve these 
tRNAs and only a few modest improvements have been made by rational engineering, all 
to the pyrrolysyl tRNA. A single point mutation which converts a U-G base pair in the 
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anticodon stem to C-G which was initially discovered in bacteria was found to also be 
beneficial in mammalian cells52, and screening of mutations at a small number of sites in 
the D and T stems which are conserved in mammalian cells but not the pyrrolysyl tRNA 
led to the identification of a tRNA variant with modestly improved activity235. Not 
surprisingly, the efficiency of ncAA incorporation in eukaryotes lags behind that of E. 
coli, and the suboptimal activity of the suppressor tRNA has been identified as a major 
contributing factor54. To overcome the poor intrinsic efficiency of the suppressor tRNAs, 
they are often heavily overexpressed from multi-copy cassettes to achieve robust 
suppression efficiency in mammalian cells1,52,54. Chapters 3 and 4 discuss the 
development of a system to evolve improved suppressor tRNAs directly in mammalian 
cells for the first time.  
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Chapter 2 
 Incorporation of unnatural amino acids into the capsid of 
adeno-associated virus 
 
The ability to target the adeno‐associated virus (AAV) to specific types of cells, 
by altering the cell‐surface receptor it binds, is desirable to generate safe and efficient 
therapeutic vectors. Chemical attachment of receptor‐targeting agents onto the AAV 
capsid holds potential to alter its tropism, but is limited by the lack of site specificity of 
available conjugation strategies. The development of an AAV production platform is 
reported that enables incorporation of unnatural amino acids (UAAs) into specific sites 
on the virus capsid. Incorporation of an azido‐UAA enabled site‐specific attachment of a 
cyclic‐RGD peptide onto the capsid, retargeting the virus to the αvβ3 integrin receptors, 
which are overexpressed in tumor vasculature. This work provides a general chemical 
approach to introduce various receptor binding agents onto the AAV capsid with site 




Figure 2.1. Unnatural amino acid incorporation into the AAV capsid for bio-orthogonal 
ligation of cell-targeting molecules.  
 
The majority of the work described in this chapter was published as: 
Kelemen, R. E.; Mukherjee, R.; Cao, X.; Erickson, S. B.; Zheng, Y.; Chatterjee, A. A Precise 
Chemical Strategy To Alter the Receptor Specificity of the Adeno-Associated Virus. Angew. 
Chem. Int. Ed.  2016, 55 (36), 10645–10649.1  
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2.1 Introduction 
For a more complete discussion of genetic code expansion, the biology and gene 
therapy applications of AAV, and UAA incorporation into viruses and virus-like 
particles, see Chapter 1. This section discusses specific AAV capsid engineering work 
which was influential for the development of this work and the practicalities of AAV 
production, purification, and characterization.  
2.1.1 Incorporating re-targeting motifs into the AAV capsid 
The engineering of adeno-associated virus vectors to generate capsids with new in 
vivo properties is of great interest for the development of the next generation of human 
gene therapies. An overview of this topic was given in Section 1.2.3, but several methods 
for incorporating cell-targeting ligands into the AAV capsid merit further discussion here. 
The first reported method for the introduction of new cell-targeting moieties was the 
genetic encoding of peptide loops containing cell-type-specific targeting peptide ligands 
as into surface-exposed loops on the AAV-2 capsid, providing a mechanism for HSPG-
independent cell entry and re-directing the virus towards new target cells2–8. The peptide 
loop insertion strategy has since expanded to utilize peptide sequences selected from 
either phage display or AAV-based directed evolution9,10. Although several sites on the 
capsid, particularly the three-fold proximal spike and the HSPG binding region, have 
been shown to tolerate peptide insertion fairly well11 (Figure 2.2), the production 
efficiency and stability of the modified viruses depends on the sequence of the inserted 
peptide and is often compromised4,6. Furthermore, this strategy offers limited control 
over how the new peptide sequence is displayed and is restricted to fairly small peptides 
with entirely natural chemistry.  
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Figure 2.2. Summary of the sites on the AAV-2 capsid which are permissive to 
modification.  (A) Insertion sites for peptide loops2–8.  (B) Alanine mutations12–16.  
 
A complementary genetic engineering strategy which has been widely used for 
other viruses and was recently extended to AAV is the fusion of cell-targeting proteins to 
the terminus of a viral surface protein.9 In AAV, the minor capsid protein VP2 is not 
essential for infection and was found to tolerate protein fusion at its N terminus17. AAV 
has recently been targeted to cancer cell in vitro and in vivo using cancer-targeting 
designed ankyrin repeat proteins (DARPins)18–21 and affibodies22. This strategy has 
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shown great promise for in vivo delivery of toxic genes to tumors20,21. However, these 
types of protein fusions represent a major change to the AAV capsid structure – the N 
terminus of VP2 is typically inside of the viral particle after assembly23, but in the fusion 
constructs the targeting domain and N terminus are on the outside of the viral particle18. 
Finally, both the peptide loop insertion and antibody fusion strategy require novel genetic 
engineering and optimization of the production of each targeted vector, and both 
strategies are restricted to linear, peptide-based targeting moieties.  
More versatile chemical groups such as fluorophores24, quantum dots25, sugars26, 
and PEG27 have been attached to the AAV capsid by non-specific lysine or arginine 
modification, but this technique offers minimal control over labeling site and 
stoichiometry, resulting a heterogeneous virus pool and potentially altering essential 
regions of the viral capsid. Two recent reports have taken advantage of peptide loops 
which can be enzymatically modified to provide unique reactive handles to develop a 
site-specific chemical labeling strategy. A BirA peptide inserted into the AAV-1 capsid 
was enzymatically modified with a ketone analogue of biotin, which was then 
functionalized with a cyclic peptide-hydrazide conjugate for re-targeting28. More 
recently, AAV-2 was produced with a peptide containing a cysteine which is converted to 
an aldehyde by formylgycine generating enzyme directly in the virus-producing cells, 
then labeled with a hydrazide-functionalized cyclic peptide and an antibody against 
human leukocyte antigen29.  
We sought to develop a new strategy for the site-selective, bio-orthogonal 
functionalization of AAV capsids which would not require peptide loop insertion and 
consequently would afford greater versatility control over the modification site. Genetic 
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code expansion, which has been used for the modification of other viruses in both 
bacteria and mammalian cells30 (see section 1.3), will allow us to site-selectively 
introduce minimally perturbative bio-orthogonal handles into the AAV capsid at sites of 
our choosing, then purify the assembled viral particles and functionalize them with 
targeting ligands with total control over the modification site and the ligand chemistry. 
This section discusses the incorporation of UAAs into AAV, the first time such a 
modification was made to non-enveloped viruses in mammalian cells, and re-targeting of 
the virus to cancer cells via chemoselective attachment of a cyclic peptide.  
2.1.2 AAV production  
Adeno-associated virus is naturally replication-deficient, meaning that it relies on 
the presence of another “helper” virus, typically adenovirus, to replicate. Originally, this 
meant that the AAV production in the lab also required adenovirus. The adenoviral genes 
required for AAV production have since been identified and AAV can now be produced 
entirely by transient transfection using “helper-free” systems in which the adenoviral 
helper genes are provided on a plasmid31,32. The AAV genome itself is quite small, 
around 5 kb, and can also be provided on a separate plasmid (see section 1.2.1 for a more 
complete description of AAV biology). Often, AAV produced in the laboratory is so-
called “recombinant” AAV (rAAV) in which the natural AAV genes have been replaced 
entirely. In these systems, the AAV rep, cap, and AAP genes are provided in trans 
without packaging signals31. Meanwhile, the packaging signals or inverted terminal 
repeats (ITRs) flank a different gene(s), often encoding a fluorescent protein marker or a 
therapeutic protein, which is then packaged into the virus. A schematic of the plasmids 
used to produce rAAV is shown in Figure 2.3. Small-scale production of AAV is done by 
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transient transfection of human cells, typically HEK293T, with these three plasmids, 




Figure 2.3. Plasmids for the production of AAV.  (A) Required genetic elements for 
the production of wild-type AAV.  (B) Required genetic elements for the production of 
recombinant AAV (rAAV) carrying a GFP reporter gene as the cargo.  (C) 3-plasmid 
system used for the production of rAAV. Plasmid components are color coded as in (B).  
 
2.1.3 AAV purification 
AAV purification has been the subject of a significant amount of study due to the 
virus’s clinical applications, but many of the approaches which have been developed are 
intended for the extremely stringent purification of large batches of virus for animal or 
human trials, and are not optimal for small-scale laboratory use. The most common 
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method used for medium to large scale purification is density gradient ultracentrifugation, 
either with a continuous CsCl2 or discontinuous iodixanol gradient31. Chromatographic 
purification strategies (e.g. size exclusion, ion exchange) are also used alone or in 
combination with ultracentrifugation33. However, we initially sought methods which 
were cheaper, required less specialized equipment (ultracentrifuge, FPLC), and most 
importantly were amenable to the purification of small batches of virus.  
Conveniently, it is often possible to assess whether a lysate contains infective 
AAV simply by adding some of the lysate to a fresh batch of cells, then assaying for 
expression of the viral cargo (e.g. GFP). However, at least some purification is necessary 
before performing chemical modification and/or SDS-PAGE visualization on the virus. 
For easy semi-purification of the virus, we used PEG (polyethylene glycol) precipitation, 
which is often used for the preliminary concentration of large complexes such as viruses 
from cell lysates34. When more stringent purification was required, we used a simplified 
affinity chromatography method based on heparin sulfate, a close analog of the heparan 
sulfate on the primary AAV-2 cell-surface receptor35. This required significant 
optimization for small-batch purification and decreased yields of UAA-containing 
viruses, as discussed in section 2.2.3. A major disadvantage of this method is that it 
cannot be used to purify viruses lacking HSPG binding, a property which is desirable 
when re-targeting the virus to a new receptor. Since this work, a different, antibody-based 
resin has become available for AAV purification which is agnostic to HSPG affinity and 
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2.1.4 Titering AAV for packaging and infectivity 
When engineering a virus, it is important to have different titration and analysis 
methods which give insight into the success of different steps in the virus production 
process. AAV titer is often described in three different ways: particle concentration, 
typically measured using antibodies against fully assembled capsids; genomic titer, 
formerly measured by Northern-style dot blot and now by quantitative PCR (qPCR) to 
count DNase-resistant encapsidated viral genomes; and infective titer, measured by 
treating target cells with a virus carrying a fluorescent protein marker and counting 
successfully infected cells by flow cytometry31. In this work, we used a commercial AAV 
qPCR kit37 as an aggregate measure of capsid protein production, assembly, and genome 
packaging, and then infective titer as a measure of the effect of our various modifications 
on the viral infection pathway.  
2.2 Results and discussion 
2.2.1 Incorporation of lysine-derived UAAs with the Methanosarcina pyrrolysyl 
tRNA/aaRS pair 
We chose to use the archaeal pyrrolysyl pair for our initial studies because of the 
wide variety of UAAs available in mammalian cells for this pair. Our first task was to 
modify the three standard plasmids used for AAV-2 production31,38 (see section 2.1.2) to 
accommodate UAA mutagenesis. We first checked for existing TAG stop codons in the 
AAV-2 genome and fortuitously found that there were none. We purchased plasmids for 
the packaging of a wild-type AAV-2 carrying a GFP reporter cargo from Cell Biolabs, 
but rather than modify these we decided to construct our own UAA-AAV production 
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plasmids starting from an empty pIDT-Kan vector to minimize overall plasmid size and 
generated two new UAA-AAV packaging vectors. pIDT-8xMmPytR-ITR-GFP carries 
eight copies of the TAG-suppressing M. mazei pyrrolysyl tRNA driven by a U6 promoter 
and the GFP reporter cargo flanked by AAV-2 ITRs from the Cell Biolabs AAV 
packaging plasmid. pIDT-MbPylRS-RC2 carries a CMV-driven wild-type M. barkerii 
pyrrolysyl aaRS, which accepts a number of lysine-derived UAAs, and the ITR-free 
AAV-2 genome from the Cell Biolabs system (“RC2”, named for Rep/cap of the serotype 
AAV-2). The adenoviral helper plasmid, which contains several adenoviral genes known 
to be involved in AAV packaging, was used as purchased. These plasmids are shown in 




Figure 2.4. UAA-AAV packaging plasmids.  (A) The production recombinant AAV 
(rAAV) carrying a fluorescent protein reporter cargo requires the cargo flanked by ITR 
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(inverted terminal repeat) packaging signals, the AAV-2 genome containing the Rep, 
Cap, and Aap genes (AAP overlaps with Cap, not shown) with packaging signals 
removed, and several adenoviral genes identified as essential for AAV production. 
Meanwhile, UAA incorporation requires the expression of a UAA-specific aaRS and 
multiple copies of its cognate suppressor tRNA.  (B) UAA-AAV production plasmid 
structure. pIDT-8xPytR-ITR-GFP contains eight copies of the M. mazei pyrrolysyl 
tRNACUA (MmPytR) expression cassette driven by a human U6 promoter (yellow) and 
a CMV-GFP cargo flanked by packaging signals (ITRs) (green). pIDT-MbPylRS-RC2 
contains a wild-type M. barkerii pyrrolysyl aminoacyl-tRNA synthetase (MbPylRS) 
expressed from a CMV promoter (orange) and the rep and cap genes from the AAV-2 
genome (blue). pHelper contains the adenoviral E2A, E4, and VA genes required for 
AAV production (red) (the E1 gene is provided by the HEK293T cells used for virus 
packaging). pHelper and the AAV cargo and genome cassettes were purchased from Cell 
Biolabs while MbPylRS and MmPytR cassettes were obtained from other members of the 
Chatterjee lab.  
 
When we first set out to incorporate UAAs into the AAV-2 capsid, the availability 
of a crystal structure and extensive literature on which sites in the capsid were permissive 
to either point mutations12–16 or loop insertion2–8 (Figure 2.2) were extremely useful. We 
chose to focus our UAA-AAV modifications on the 533 amino acids which are common 
to VP1, VP2, and VP3 and focused our attention on the UAA substitution of five surface-
exposed residues in three different regions of the capsid: G453 and T454 at the tip of the 
threefold proximal spike, R585 and R588 which are essential for binding heparan sulfate 
proteoglycan, and D327 surrounding the pore at the fivefold symmetry axis. The first two 
sites have been shown to tolerate peptide loop insertion and the display of cell-targeting 
peptides at these sites has been used to re-target the virus to new cell types, but no 
successful capsid modifications around the fivefold pore have been reported. The tight 
packing of this residue from five different capsid proteins in a functionally important 
region makes it a more challenging target for UAA mutagenesis relative to the other 
chosen sites, but the pore is known to function in genome packaging and infection and we 
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reasoned that UAAs could potentially be used to study the biology of this region in more 
detail. The AAV-2 capsid modification sites and their location in the viral genome are 
shown in Figure 2.5. 
 
Figure 2.5. UAA mutagenesis sites in the AAV capsid.  (A) Location of mutations in 
the AAV capsid (PDB structure 1LP339).  (B) Close-up view of mutation sites in the 
capsid.  (C) Location of mutations in the AAV genome.   
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2.2.2 Production and characterization of wild-type AAV in our engineered system 
We first validated that our new AAV production plasmids could lead to high-titer 
AAV production and that the presence of UAAs did not affect the production of AAV 
with a wild-type capsid. Small-scale virus production tests were carried out using our 
UAA-AAV production plasmid system in the presence and absence of the UAA azido-
lysine (Figure 2.6a) and subsequent viral titration using a commercial qPCR assay37 
revealed high viral titers on the order of 5x1010 genome-containing viral particles (GC) 
per mL of cell lysate, or 2.5x109 GC from a single well in a 12-well tissue culture plate 
(Figure 2.6b). We infected HEK293T cells with virus-producer cell lysate containing the 
resulting virus at an MOI (multiplicity of infection) of 20 GC / cell and imaged GFP 
fluorescence, which is indicative of successful rAAV transduction and cargo gene 
expression, after 48 hours. Encouragingly, we observed no difference between virus 
produced in the presence and absence of AzK.  
2.2.3 Production and characterization of UAA-AAV with azido-lysine 
We then repeated the virus production using pIDT-MbPylRS-RC2 plasmids with 
TAG codons introduced into the capsid at the sites indicated in Figure 2.5 and measured 
packaged viral genomes in the presence and absence of 1 mM AzK. We were excited to 
see robust UAA-AAV production at all sites in the presence of AzK (Figure 2.6c), 
although virus yields were 4-10 times lower than the wild-type, which is not uncommon 
for mammalian-cell GCE. However, we were slightly concerned to see any evidence of 
packaged viral genomes in the absence of UAA, as the pyrrolysyl system is known for its 
low background40 and AAV assembly should be impossible if the capsid proteins were 
truncated at the TAG codons because the process requires AAP binding to the C terminus 
 
 68  
of the VPs41. We therefore infected cells with equivalent genome copy numbers of 
representative viruses produced in the presence and absence of AzK (Figure 2.6e) and 
observed no fluorescence from the – AzK product. It therefore seems likely that the 
relatively low qPCR readouts in the absence of UAA are an assay artifact and not in fact 
indicative of virus production.  
 
Figure 2.6. Production of AAV in the presence and absence of the UAA azido-lysine.  
(A) Structure of azido-lysine (AzK).  (B) Efficiency of wild-type AAV production in the 
presence and absence of 1 mM AzK as measured by qPCR.  (C) Efficiency of UAA-
AAV production in the presence and absence of 1 mM AzK as measured by qPCR.  (D) 
Images of cells infected with equal genome copies of the virus from (B).  (E) Images of 
cells infected with equal genome copies of selected viruses from (C).   
 
 
 69  
One of our initial goals was to demonstrate that UAAs could be incorporated into 
a variety of sites on the AAV capsid without significant impact on the behavior of the 
virus, thus potentially paving the way for the introduction of UAAs bearing biochemical 
or biophysical probes (e.g. photo-crosslinkers, fluorophores) to study native AAV 
virology. We infected HEK293T cells with equal genome copy numbers of all of our 
AzK-bearing viruses (Figure 2.7) and observed wild-type levels of transduction with 
almost all of our mutants, the exception being R588 where we replaced an arginine which 
is essential for infection with a neutral UAA12,13. We were very pleased with this result, 
particularly in the case of the D327-AzK and N587-AzK mutants. D327 is located where 
five different capsid monomers come together to make the fivefold pore (Figure 2.5b, top 
panel), and we were able to substitute all five of these aspartate residues with azido-
lysine and still obtained virus with reasonable genomic and infective titers. N587, 
meanwhile, is directly adjacent to both R585 and R588 (Figure 2.5b, bottom panel), but 
substitution was tolerated with no effect on infectivity. These results highlight the non-
perturbative nature of UAA mutagenesis in the AAV capsid and the potential usefulness 
of UAAs as a tool to study AAV biology without perturbing native interactions.  
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Figure 2.7. Transduction efficiencies of AzK-containing viruses relative to wild-type 
on HEK293T cells. All cells were infected at an equal MOI of 50 GC / cell.  (A) 
Fluorescence images of infected cells 48 hours after infection.  (B) Fluorescence 
measurements of lysate from the cells in (A) to quantify infectivity.  
 
2.2.4 Strain-promoted alkyne-azide cycloaddition “click” chemistry on the surface of 
the virus 
We next demonstrated bio-orthogonal labeling on our azide containing viruses to 
confirm that the UAAs were indeed displayed on the surface and could participate in 
further reactions. Azides can be bio-orthogonally labeled by several methods, most 
commonly the cycloaddition reactions with alkynes shown in Figure 2.842–44. The copper-
catalyzed alkyne-azide cycloaddition or CuAAC occurs between azides and terminal 
alkynes and requires a copper catalyst, while the strain-promoted alkyne-azide 
cycloaddition or SPAAC occurs between azides and highly strained alkynes such as 
cyclooctynes. Each reaction has distinct advantages and disadvantages. Terminal alkynes 
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are more easily synthetically accessible and the CuAAC reaction is more specific, but 
copper catalysts can be toxic to biological systems. SPAAC is driven entirely by the ring 
strain of the cyclooctyne and does not require a catalyst, but the reaction is less specific 
as highly strained cyclooctynes can undergo side reactions with other groups such as 
oxidized thiol derivatives which are present in biological systems. Both reactions are fast 
at room temperature42–44. We decided to use SPAAC as we were concerned about the 
effect of copper catalysts on the virus. Indeed, we later found that AAV incubated with 
the Cu(I) CuAAC catalyst lost the ability to transduce cells (Figure 2.8b).  
 
Figure 2.8. Bio-orthogonal reactions between azides and alkynes and their 
compatibility with AAV.  (A) Copper-catalyzed alkyne-azide cycloaddition (CuAAC, 
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left) and strain-promoted alkyne-azide cycloaddigion (SPAAC, right).  (B) Incubation 
with both CuSO4 and reducing agent, which generates catalytically active Cu(I), 
significantly reduces the infectivity of AAV. AAV was incubated with the indicated 
reagents for 1 hour and then added to HEK293T cells to measure infectivity. TCEP = 1 
mM tris(2-carboxyethyl)phosphine; Cu = 1 mM CuSO4; ligand = TBTA (Tris((1-benzyl-
1H-1,2,3-triazol-4-yl)methyl)amine.  
 
We therefore decided to take advantage of the increasing commercial availability 
of strained cyclooctyne reagents for bio-orthogonal labeling. However, such reagents are 
not perfectly orthogonal in biological systems and so we needed a more stringent method 
to purify the virus. Most literature AAV purification strategies focus on obtaining large 
amounts of virus in high enough quality for animal experiments and rely on specialized 
protocols like gradient ultracentrifugation or multiple rounds of FPLC. We instead 
adapted a simple heparin sulfate affinity chromatography method from the literature35 
and optimized it for our own small-scale use (heparin sulfate is closely related to heparan 
sulfate, the polysaccharide found on the AAV-2 primary receptor). We confirmed the 
purity of the resulting viruses by silver-stained SDS-PAGE, and we were additionally 
gratified to note that all three capsid proteins were present in the expected 1:1:10 ratio for 
both the wild-type and T454-AzK viruses with no evidence of incorporation of truncated 
proteins into viral particles (Figure 2.9a, e). After obtaining purified wild-type and T454-
AzK viruses as confirmed by silver stained SDS-PAGE, we incubated both viruses with 
the strained dibenzylcyclooctyne-fluorophore conjugate DBCO-Cy5 and confirmed 
selective labeling of the T454-AzK virus by SDS-PAGE. We also performed similar 
analysis on the R588-AzK virus, although this virus was not amenable to our purification 
method because it does not bind heparin sulfate and so was semi-purified by PEG 
precipitation instead. Although we observed identical background labeling of remaining 
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cellular proteins in both the wild-type and R588-AzK virus lanes, the only the R588-AzK 
lane shows proteins matching the sizes of VP1, VP2, and VP3.  
 
 
Figure 2.9. Bio-orthogonal labeling of azido-AAVs with strained cyclooctynes.  (A) 
Silver stained SDS-PAGE of purified wild-type and T454-AzK viruses. The expected 
molecular weights of VP1, VP2, and VP3 are 82, 67, and 60 kDa respectively.  (B) 
DBCO-Cy5 labeling and SDS-PAGE of purified wild-type and T454-AzK viruses. 
Viruses were incubated with 5 µM DBCO-Cy5 for two hours at room temperature.  (C) 
DBCO-Cy5 labeling and SDS-PAGE of semi-purified wild-type and R588-AzK viruses.  
(D) Structure of DBCO-Cy5.  (E-G) Full-length images of the gels from A-C. E and F 
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show  4-15% pre-cast TGX gradient gels while G shows a standard 10% gel. We believe 
that the Cy5-labeled protein shown at ~ 30 kDa in F could be a small amount of residual 
GFP reporter, which is heavily over-expressed during AAV production and ends with a 
TAG stop codon.  
 
2.2.5 Re-targeting AAV to cancer cells through site-specific chemical modification 
Next, we explored the possibility of using site-selective bio-orthogonal chemistry 
to re-target our UAA-AAV to a new cell-surface receptor. When we first started this 
project many important cellular factors which influence AAV infection were unknown, 
including the AAV-2 secondary receptor AAVR45, and it was entirely possible that even 
if we could attach an appropriate primary receptor binding motif onto the virus, a later 
step in the infection process would be unsuccessful in the new target cell line46. We 
therefore decided to start with a proof-of-concept re-targeting scheme using peptides 
containing an RGD motif as the targeting molecule. These peptides are known to bind the 
αvβ3 integrin receptors which are highly expressed on tumor vasculature and have 
previously been genetically encoded into the AAV capsid for the HSPG-independent 
transduction of cancer cell lines2–8. Previous studies have encoded linear or disulfide-
bridged RGD peptides into surface-exposed loops, but we settled on a cyclic c(RGDFC) 
peptide because cyclic peptides bind αvβ3 with several fold higher affinity47 but represent 
a class of molecules which cannot be genetically encoded. Ovarian tumor-derived SK-
OV-3 cells (high αvβ3 and low HSPG expression) were used as the new target cell line 
while HEK293T cells (high HSPG and low αvβ3 expression) were used as the control6.  
A cyclic c(RGDFC) peptide containing was purchased and conjugated to 
commercially available DBCO-maleimide to generate the DBCO-c(RGDFC) targeting 
molecule, which was able to efficiently label EGFP-AzK (Figure 2.10). We decided to 
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start our re-targeting experiments labeling PEG-precipitated T454-AzK and R588-AzK 
virus with varying concentrations of c(RGDFC) these represented viruses which had 
retained or lost their heparan binding abilities upon UAA mutagenesis (Figure 2.7). We 
incubated both viruses with 50 μM DBCO-c(RGDFC) for two hours, then infected both 
HEK293T and SK-OV-3 cells with labeled or unlabeled virus (Figure 2.11). HEK293T 
cells, which are excellent substrates for AAV-2 infection, were infected at an MOI of 50 
GC/cell, while SK-OV-3 cells, which are naturally poor AAV-2 targets, were infected at 
an MOI of 2,000 GC/cell. Because SK-OV-3 have low but non-zero levels of HSPG 
expression, the wild-type virus was moderately able to transduce these cells6. The R588-
AzK virus was minimally infective on both HEK293T and SK-OV-3, as expected, but 
DBCO-c(RGDFC) functionalization modestly improved the activity of the virus towards 
SK-OV-3 cells. Surprisingly, the T454-AzK virus became non-infective towards both cell 
lines upon DBCO-c(RGDFC) labeling, so we decided to move forward by optimizing re-
targeting of the R588-AzK virus. This virus is already almost completely non-infectious 
due to the loss of HSPG binding, making it a prime candidate for re-targeting to the αvβ3 
integrin without off-target HSPG-based infection. We labeled this virus with varying 
concentrations of DBCO-c(RGDFC) (Figure 2.12) and determined 20 μM to be the 
optimal concentration for re-targeting the R588-AzK virus to the αvβ3 integrin receptor. 
Interestingly, both under- and over-functionalization of the virus seem to be detrimental 
to infectivity. This phenomenon was subsequently investigated  with greater precision by 
Sarah Erickson48, whose work confirmed the importance of stoichiometry control in re-
targeting AAV.  
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Figure 2.10. Structure, synthesis and characterization of DBCO-c(RGDFC).  (A) 
Synthetic scheme.  (B) Characterization of DBCO-c(RGDFC).  (C) EGFP-AzK labeling 
with DBCO-c(RGDFC) (20 µM, overnight).  
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Figure 2.11. Initial re-targeting experiments with DBCO-c(RGDFC) functionalized 
viruses.  (A) HEK cells infected at an MOI of 50 GC/cell.  (B) SK-OV-3 cells infected at 
an MOI of 2,000 GC/cell.  Virus was labeled with 50 μM DBCO-c(RGDFC) for 2 hours 
at room temperature and then used to infect target cells. Cells were imaged for GFP 
expression 48 hours after infection.  
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Figure 2.12. Optimization of DBCO-c(RGDFC) labeling concentration of the R588-
AzK virus for SK-OV-3 cell transduction. All labeling reactions were conducted at 
room temperature for 2 hours and cells were imaged 48 hours after infection.  
 
With optimized conditions in hand, we used flow cytometry to quantify the 
infectivity of unlabeled and c(RGDFC)-functionalized wild-type, T454-AzK, and R588-
AzK viruses towards HEK293T and SK-OV-3 cells (Figure 2.13).  As we had previously 
observed, the T454-AzK virus lost all infectivity towards both cell types upon DBCO-
c(RGDFC) functionalization, but the R588-AzK virus, which was initially non-infective 
towards both cell types, showed a dramatic increase in SK-OV-3 cell infectivity but no 
change in HEK293T cell infectivity upon labeling. We further confirmed that this 
alteration of viral tropism was due to a switch from heparan sulfate proteoglycan to αvβ3 
integrin as the primary cell-surface receptor by using competitive inhibitors which 
selective block either HSPG or αvβ3-based transduction.  
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Figure 2.13. Infectivity of wild‐type, T454AzK, and R588AzK AAV2 towards SK‐
OV‐3 and HEK293T cells upon functionalization with DBCO‐cRGDFC.  (A) SK-
OV-3 cell infectivity.  (B) HEK293T cell infectivity. Infectivity was measured as the 
percentage of EGFP‐expressing cells (FACS), and was normalized relative to unmodified 
wild‐type AAV2 (at a fixed genome‐copy/cell).  (C) Infectivity of wild‐type and DBCO‐
cRGDFC‐modified R588AzK AAV2 towards SK‐OV‐3 cells in the presence of RGDS 
peptide or heparin. Infectivity for each virus was measured as the percentage of EGFP‐
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2.2.6 Choice of ligand attachment site and removal of the existing heparan sulfate 
binding domain are important factors for AAV re-targeting 
We conducted a brief further investigation of the unexpected result wherein 
DBCO-c(RGDFC) functionalization rendered the T454-AzK virus non-infectious toward 
both HEK293T and SK-OV-3 cells despite this virus containing both the original HSPG 
binding domain and αvβ3-binding peptide. We incubated T454-AzK virus with varying 
concentrations of DBCO-c(RGDFC) and found that infectivity towards both target cell 
lines was lost in a dose-dependent manner at very low label concentrations (Figure 2.14a, 
compare to Figure 2.12). Upon further reading, a similar result was observed when an 
RGD peptide was genetically inserted into the threefold spike between residues 453 and 
454 and the authors of that paper found that deletion of the HSPG binding motif via 
alanine mutation of R585 and R588 restored αvβ3-based infectivity8. We made the same 
HSPG-neutralizing mutations to our T454-AzK virus (rendering it non-infectious towards 
HEK293T cells) and repeated the c(RGDFC) labeling experiment. While the T454-
AzK/R585A/R588A virus did gain infectivity upon c(RGDFC) functionalization (Figure 
2.14b), it did not reach the level of R588-AzK infectivity towards αvβ3 as measured by 
flow cytometry (Figure 2.14c-d, compare to Figure 2.13a-b). This result confirms that the 
targeting ligand attachment site is an important parameter for AAV re-targeting, and we 
have since used our site-selective functionalization strategy to further explore this 
phenomenon48.  
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Figure 2.14. αvβ3-based transduction virus labeled with DBCO-c(RGDFC) requires 
deletion of the HSPG binding domain via R585A and R588A mutations.  (A) Effect 
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of DBCO-c(RGDFC) labeling on T454-AzK virus transduction of HEK293T and SK-
OV-3 cells.  (B) Effect of DBCO-c(RGDFC) labeling on T454-AzK/R585A/R588A 
(“T454-AzK/R-A”) virus transduction of HEK293T and SK-OV-3 cells.  (C) Flow 
cytometry quantification of the infectivity of viruses functionalized with 20 μM DBCO-
c(RGDFC) on HEK293T cells.  (D) Flow cytometry quantification of the infectivity of 
viruses functionalized with 20 μM DBCO-c(RGDFC) on SK-OV-3 cells.  
 
2.3 Conclusions 
We have demonstrated for the first time the site‐specific incorporation of an UAA 
into the capsid of a non‐enveloped eukaryotic virus and its use for attaching a synthetic 
ligand that successfully retargets the virus to a new cell surface receptor. Since the AzK 
residue was well‐tolerated in multiple distinct regions of the capsid, including seemingly 
challenging areas such as around the pore, our approach significantly expands the 
selection of sites that can be evaluated for attaching a variety of retargeting motifs. 
Additionally, since AAV is a model system to understand the assembly, cell entry, and 
the genome release of parvoviridae family of viruses, and the platform described here 
will greatly facilitate such studies by enabling site‐specific incorporation a number of 
powerful genetically encoded biochemical and biophysical UAA‐probes such as 
fluorophores and photo‐crosslinkers. 
We used site-selective UAA incorporation and bio-orthogonal chemistry to re-
direct AAV-2 from its original primary receptor to the αvβ3 integrin which is over-
expressed in certain types of cancer cells. We believe that this work and subsequent 
follow-up optimization of the labeling site and stoichiometry should provide a blueprint 
for more general AAV re-targeting while providing greater control over the targeting 
ligand site and stoichiometry than previous genetic engineering-based strategies48. 
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Furthermore, as we demonstrated, our strategy is flexible towards the nature of the 
targeting ligand, avoiding the sequence-specific differences in AAV packaging efficiency 
and infectivity encountered for genetically encoded peptides and allowing the attachment 
of cyclic peptides which have higher affinities or improved in vivo properties compared 
to their linear counterparts47,49. This also opens up the possibility of incorporating other 
non-natural targeting molecules including unnatural peptides with novel properties,50,51 or 
non-peptidic small molecules such as glycans52 or folic acid53,54. Ongoing work in our lab 
is focused on expanding this strategy beyond small molecules for the attachment of cell-
targeting proteins like antibodies55,56 (Sarah Erickson, ongoing work) and we envision 
future work with immune-modulating agents like PEG27.   
 
2.3.1 Ongoing and future directions 
The work described here has opened up a number of avenues for follow-up 
studies, several of which have been or are being pursued in our lab. We are currently 
preparing a publication describing detailed studies into the impact of re-targeting site and 
stoichiometry by Sarah Erickson, which confirms that both parameters are very important 
for efficient AAV re-targeting. An undergraduate researcher, Xiaofu Cao, adapted the 
system described here for the incorporation of UAAs into only the minor capsid proteins 
VP1 or VP2 by mutating the start codons of VP1, VP2, or both, to delete the 
corresponding protein(s) from the AAV-2 genome without disrupting other capsid 
proteins or AAP. The deleted proteins could then be selectively mutated with TAG 
codons at various sites and re-introduced on a separate CMV promoter. We expect that 
the modified viruses should have 5, 5, or 10 UAAs per particle respectively, as opposed 
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to the 60 we would see if we modified all three proteins. This represents an attractive 
alternative method for controlling the stoichiometry of targeting ligand attachment, also 
confirmed by Sarah Erickson. Together these results underscore the benefit of the precise 
site and stoichiometry control afforded by our strategy. Sarah is now working on 
attaching larger and more complex re-targeting molecules such as antibodies. We have 
also used this system to incorporate other UAAs into the AAV capsid containing photo-
caged and photo-crosslinking groups – for more information, see section 5.1.  
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2.5 Experimental procedures  
More detailed UAA-AAV production protocols have been published as part of the 
Methods in Molecular Biology book series57.  
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2.5.1 Cell culture 
HEK293T cells (ATCC) were maintained at 37 °C and 5% CO2 in DMEM-high glucose 
(HyClone) supplemented with penicillin/streptomycin (HyClone, final concentration of 
100 U/mL penicillin and 100 µg/mL streptomycin) and 10% fetal bovine serum 
(Corning). SK-OV-3 cells (gift from Prof. Eranthie Weerapana, Boston College 
Chemistry) were maintained in RPMI (Corning) supplemented with 
penicillin/streptomycin and 10% fetal bovine serum.  
2.5.2 Plasmids 
All primer and plasmid sequences can be found in the Appendix.  
 
Basic AAV2 production plasmids were obtained from Cell Biolabs (AAV2 helper-free 
packaging system, VPK402, containing the plasmids pHelper, pAAV-RC2, and pAAV-
GFP). AAV2 is naturally replication deficient and requires gene products from helper 
viruses (e.g., adenovirus) to replicate in a host cell. pHelper, which contains these 
adenoviral helper genes, was used as obtained.  
 
pIDTSmart-MbPylRS-RC2 was generated by first amplifying a CMV-MbPylRS-bGHpA 
cassette out of plasmid pAcBac1-tR4-MbPylRS. The PCR product was digested with 
AvrII and NheI and cloned into pIDTSmart-Kan between the same sites to generate 
pIDTSmart-MbPylRS. The AAV-2 genome (rep/cap) was amplified out of pAAV-RC2, 
digested with NotI and SbfI, and ligated into pIDTSmart-MbPylRS between NotI and 
SbfI restriction sites.  
 
To generate pIDTSmart-8xMmPytR-ITR-GFP, we started by PCR amplifying a single-
copy U6-MmPytR cassette out of plasmid pAcBac1-tR4-MbPylRS, digesting with AvrII 
and NheI, and cloning into a pIDTSmart-Kan between the same restriction sites. To 
generate a plasmid with multiple tandem copies of the tRNA expression cassette, the 
pIDTSmart-1xMmPytR was digested separately with NheI alone, or AvrII and NheI. The 
linear tRNA expression cassette released from the 2nd digestion was purified and ligated 
into the linearized vector generated from the first digestion, introducing an additional 
copy of the tRNA expression cassette into pIDTSmart-1xMmPytR. This procedure was 
repeated to generate pIDTSmart vectors with 2, 4, and finally 8 copies of the tRNA. 
Insert direction was verified by AvrII/NheI digestion after each round to make sure that 
the resulting plasmid retained AvrII and NheI sites at the ends of the tRNA cassette. The 
ITR-GFP cassette was then amplified out of pAAV-GFP, digested with AvrII and NheI, 
and cloned into the NheI site of pIDTSmart-8xMmPytR.   
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TAG mutations were introduced into the cap reading frame by site-directed mutagenesis. 
Mutated sequences were digested and cloned into pIDTSmart-MbPylRS-RC2 using 
HindIII and SbfI sites.  
 
For all cloning, the E. coli TOP10 strain was used for transformation and plasmid 
propagation and bacteria were grown using LB for solid and liquid culture. All PCR 
reactions were carried out using Phusion Hot Start II DNA Polymerase (Thermo 
Scientific) according to the manufacturer’s protocol. Restriction enzymes and T4 DNA 
ligase were from New England Biolabs (NEB). All DNA oligos were purchased from 
Integrated DNA Technologies (IDT). Sanger sequencing was performed by Eton 
Bioscience. Plasmids were purified using SpinSmart Mini or Maxi plasmid prep kits 
(Machery-Nagel).  
2.5.3 Unnatural amino acids 
Azido-lysine was synthesized as previously described58.  
2.5.4 Production of UAA-AAV 
HEK293T cells were seeded in 12-well plates or 10 cm dishes (700,000 cells per well in 
a 12 well plate or 8 million cells in a 10 cm culture dish) and transfected at 70% 
confluency with pHelper, pIDT-MbPylRS-RC2, and pIDT-8xMmPytR-ITR-GFP using 
polyethyleneimine (Sigma). 1.4 µg DNA per well for a 12 well plate, or 22 µg DNA per 
10 cm dish were mixed with 3.5 µL of 1 mg/mL PEI and 17.5 µL of serum-free DMEM 
per µg of DNA, allowed to stand for 10 minutes at room temperature, and then added to 
cells. UAA was added at the same time as transfection mixture. Cells were harvested 3 
days post-transfection. 
 
To determine virus production efficiency via qPCR analysis, and to determine the 
infectivity for each mutant AAV at a fixed genome copy per cell, virus was produced at a 
small scale (12 well plates), and harvested using AAVPro Extraction Solution (Clontech) 
following the manufacturer’s instructions. For retargeting experiments, virus was 
produced in 10 cm dishes and cells were collected, pelleted, and resuspended in PBS with 
300 mM NaCl (1 mL per 10 cm dish), and lysed by repeated freeze/thaw cycles using dry 
ice/ethanol bath and warm water. The lysate was clarified by centrifugation at 5,000 x g 
for 5 minutes and virus was precipitated from the supernatant using 11% polyethylene 
glycol (PEG-8,000, Fluka) at 4 °C overnight. Precipitated virus was pelleted by 
centrifuging at 12,000 x g for 30 minutes at 4 °C, resuspended in PBS + 10% glycerol, 
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2.5.5 qPCR  
Titers were obtained using the AAVPro Titration Kit (Clontech) following 
manufacturer’s instructions. Briefly, virus-containing lysates were treated with DNase I 
to remove non-packaged DNA, then DNase was inactivated and capsids were opened, 
releasing viral genomes which were counted using SYBR Green qPCR with ITR-specific 
primers on an Applied Biosystems 7500 Fast system. Titers were determined by 
comparison to standards of known concentration.  
2.5.6 Assessing the infectivity of UAA-AAV 
To determine the infectivity of wild-type or mutant AAV preparations, HEK293T cells 
were infected with 50 genome copies per cell as measured by qPCR (or 20 genome 
copies per cell for virus produced without UAA,  since significantly larger lysate volumes 
were required due to very low titers) in the presence of 5 mM sodium butyrate. 48 hr after 
infection, cells were imaged for EGFP expression using a Zeiss Axio Observer 
fluorescence microscope with an XCite Series 120Q light source and Zeiss filter set 44 
(excitation 475/40 nm, beamsplitter 500 nm, emission 530/50 nm), then lysed with 
CelLytic M (Sigma) and total EGFP fluorescence was measured on a Molecular Devices 
SpectraMax M5 (488 nm excitation, 530 nm cutoff filter, 532 nm emission). The 
fluorescence value of lysate from a well treated with sodium butyrate but no virus was 
subtracted.  
2.5.7 Optimized heparin sulfate column purification of AAV 
Virus was purified using a heparin sulfate gravity flow column as previously described35 
using heparin agarose (Sigma) with minor modifications. Briefly, virus was produced in 
10 cm dishes and cells were lysed by freeze/thawing twice in serum free DMEM. The 
resulting lysate was clarified by centrifugation at 10,000 x g for 10 minutes. Clarified 
lysate was incubated with a final concentration of 0.5% sodium deoxycholate at 37 °C for 
30 minutes, then centrifuged at 20,000 x g for 5 minutes to remove any debris. The 
column was packed with heparin agarose (Sigma) in a 1 mL syringe (BD Biosciences) 
plugged with cotton wool to maximize the length to bed volume ratio. 150-350 μL settled 
resin was used to purify virus from one to three 10 cm dishes. Deoxycholate-treated, 
clarified lysate was loaded onto the column and allowed to flow through by gravity. The 
column was washed with 10 bed volumes of PBS, then eluted with 2 bed volumes of PBS 
containing 0.65 M NaCl. Eluted virus was precipitated with 9% polyethylene glycol as 
described above, then resuspended in PBS and desalted using size exclusion spin 
columns (Bio-Rad) equilibrated with PBS, following the manufacturer’s instructions. 
Overall yields were between 10% and 30% of initial infectious titer.  
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2.5.8 SDS-PAGE, Cy5 labeling, and silver stain  
To verify azido-labeling on AAV2 using SPAAC, equal infective units of purified wild-
type and T454AzK AAV2 were incubated for 2 h with 5 μM DBCO-Cy5 (Sigma), then 
denatured by heating at 100 °C in SDS loading buffer, and loaded directly onto 4-15% 
TGX polyacrylamide gradient gels (Bio-Rad). Following resolution by electrophoresis, 
gels were subjected to Cy5-specific fluorescence imaging using a Chemidoc MP Imaging 
System (Bio-Rad). To visualize the resolved protein bands using silver stain, viruses were 
denatured by heating at 100 °C in SDS loading buffer for two minutes before loading. 
After electrophoresis the resolved proteins bands were “fixed” using overnight incubation 
in 30% ethanol / 10% acetic acid at room temperature, followed by three 5 minute washes 
with 30% ethanol. The fixed gel was rehydrated in water for 20 minutes, then sensitized 
with 2.5 mM sodium thiosulfate for 2 minutes and rinsed twice with water, for 10 
minutes each. The gel was stained with a solution of 0.2% silver nitrate and 0.03% 
formaldehyde for 30 minutes, rinsed briefly with water, and developed with a solution of 
350 mM sodium carbonate, 20 µM sodium thiosulfate, and 0.02% formaldehyde for 5 
minutes. Development was halted by the addition of glacial acetic acid and the developed 
gels were imaged using a Chemidoc MP imaging system.   
2.5.9 DBCO-cRGDFC synthesis and characterization 
DBCO-cRGDFC was synthesized from DBCO-maleimide (Sigma) and cyclic RGDFC 
peptide (Peptides International) by thiol-maleimide coupling. 9 mM DBCO-maleimide (1 
equiv) and 11 mM cRGDFC (1.2 equiv) were incubated in DMF containing 2% N-methyl 
morpholine for 2 h at room temperature. Formation of the product was confirmed by 
LCMS (1620 Agilent Infinity Series HPLC using a Phenomenex C18 column and water / 
acetonitrile mobile phase with 0.1% formic acid; Agilent 6230 TOF MS in positive 
ionization mode. Expected M/Z values of 1006.38815 and 503.69799, observed 
1006.38072 and 503.69453 for +1 and +2 charge states respectively). Yield was 
determined by monitoring the absorbance of the DBCO group at 309 nm and 90-95% 
conversion of DBCO-maleimide to DBCO-cRGDFC was obtained.  
 
Azido labeling with this compound was tested by using the resulting product to label 
sfGFP bearing a p-azidophenylalanine residue at position 151. 0.1 mg/mL purified 
protein was incubated with 50 µM DBCO-cRGDFC at room temperature overnight and 
analyzed by LCMS as described for the peptide above. The resulting spectrum was 
deconvoluted using MagTran.  
2.5.10 Re-targeting and flow cytometry 
DBCO-cRGDFC produced as described above was used at a final concentration of 20 μM 
to label AAV2 (107 genome copies per µL) for 2 h at room temperature. The resulting 
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labeled virus was immediately used to assess infectivity. For flow cytometry, HEK293T 
cells were infected with 50 GC per cell and SK-OV-3 cells were infected with 2,000 GC 
per cell. 48 h post-infection, cells were detached with 0.25% trypsin (HyClone), trypsin 
was quenched with DMEM + 10% FBS (described above) and cells were washed once 
with PBS. Cells were analyzed for EGFP fluorescence using an S3 cell sorter (Bio-Rad). 
For inhibition experiments, cells were infected in the presence of 0.2 mg/mL RGDS 
peptide (Tocris) or 0.5 mg/mL heparin (Fisher) for 48 h and then analyzed by flow 
cytometry. All flow cytometry plots were generated in ProSort (Bio-Rad).  
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 Development of a system for virus-assisted directed 
evolution of enhanced suppressor tRNAs in mammalian 
cells (VADER) 
 
We used our unique UAA-AAV vector as a tool for the directed evolution of 
more active UAA incorporation machinery in mammalian cells. It is well known that the 
efficiency of unnatural amino acid mutagenesis in mammalian cells is limited by the 
suboptimal activity of the suppressor tRNAs currently in use. The ability to improve their 
performance through directed evolution can address this limitation, but no suitable 
selection system was previously available to achieve this. We have developed a novel 
platform for virus-assisted directed evolution of enhanced suppressor tRNAs (VADER) 
in live mammalian cells. Our system applies selective pressure for tRNA activity via the 
nonsense suppression-dependent production of UAA-AAV, and selectivity for the 
specific incorporation of interest comes from a novel virus purification strategy based on 
the unique chemistry of the UAA. We demonstrated > 10,000-fold selectivity for active 
tRNAs out of mock libraries. This work provides a general blueprint for the evolution of 
better orthogonal suppressor tRNAs in mammalian cells.   
 
 
This work has been submitted along with Chapter 3 as: 
Kelemen, R. E.; Jewel, D.; Levinson, S. D.; Cao, X.; Pasha, M.; Zhu, Z.; Anthony, J.; van 






3.1.1 Identification of the tRNA as the limiting component for mammalian cell genetic 
code expansion 
To generate a UAA-modified target protein in a mammalian cell, the engineered 
aaRS/tRNA pair and the nonsense mutant of the target must be co-expressed (Figure 3.1). 
One of the challenges of mammalian cell GCE is that efficient protein production 
requires these components to be delivered at high copy number via transient transfection 
or viral transduction for over-expression in the target cell2. Most mammalian cell GCE 
has so far relied on transient transfection, which leads to the accumulation of a very high 
number of plasmids in a sub-set of well-transfected cells3. However, viral vectors based 
on recombinant lentivirus4, baculovirus5,6, adenovirus7 and adeno-associated virus 
(AAV)8,9 have been recently developed to extend this technology to cells that transfect 
poorly, and to mammalian tissues ex vivo and in vivo. One advantage of viral vectors like 
baculovirus is that transgene expression increases with multiplicity of infection (MOI). 
While a wild-type GFP baculovirus showed the expected linear relationship, a virus used 
to express UAA-containing GFP showed almost no detectable expression until relatively  
high MOIs5,6. This result suggests that a shortage of at least one of the GFP-TAG, aaRS, 
or tRNA genes in the viral cargo is limiting for the overall efficiency of GCE in 
mammalian cells.  
A previous student in the Chatterjee lab, Dr. Yunan Zheng, used this baculovirus 
to identify the limiting component(s) for GCE in mammalian cells6. She infected cells 
with the vector containing all of the required components for GCE at a low MOI and used 
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a second vector to supplement the level of GFP-TAG target gene, aaRS, or tRNA one at a 
time with a second baculovirus and found that supplemental tRNA provided by far the 
most significant boost for GFP-TAG expression. The orthogonal nonsense suppressor 
tRNA is therefore the limiting component for mammalian cell GCE. This result was 
unsurprising for two reasons –although E. coli GCE has greatly benefitted from the 
evolution of more active suppressor tRNAs10–14, the suppressor tRNAs used in 
mammalian cells are completely un-optimized15–17 or contain only a small number of 
rationally designed mutations which provide limited improvement18–20. We currently 
address this deficiency by building large multi-copy tRNA cassettes into our mammalian 
cell GCE plasmids, such as the eight-copy cassette from Chapter 2 or Dr. Zheng’s 
optimized baculovirus vector which contains 16 copies of the E. coli tyrosyl tRNA in a 
single cassette and four more elsewhere in the vector. These multi-copy tRNA cassettes 
can be further supplemented by co-delivery of a dominant-negative mutant of the 





Figure 3.1. The orthogonal tRNA is the limiting factor for mammalian cell GCE.  
(A) Successful stop codon suppression results in the production of full-length, UAA-
containing proteins.  (B) Unsuccessful suppression results in release factor-mediated 
termination of translation and the production of prematurely truncated proteins.  
 
The construction of enormous multi-copy tRNA cassettes and the delivery of yet 
another piece of GCE machinery in the form of an engineered eRF1 are not optimal 
solutions to the problem of inefficient suppressor tRNAs. These types of constructs 
present a significant cloning challenge, and their use is restricted to contexts where cargo 
size is not limited (ruling out most viral vectors such as AAV) and recombination is not 
an issue (again problematic for most viruses, as well as the generation of stable cell lines 
for GCE). A better solution would be to design or evolve more efficient suppressor 
tRNAs for mammalian cell GCE like we do in bacteria (see section 1.5). However, tRNA 
structure, tRNA/aaRS interactions, tRNA/host interactions are highly complex and 
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rational engineering has so far been limited to relatively mild improvements in tRNA 
function20. Better aaRS mutants can be evolved in bacteria or yeast and then transferred 
to mammalian cells2, but tRNA/host interactions are substantially different in different 
types of organisms and so this is not a useful solution for tRNA evolution. The best 
solution would seem to be to evolve the tRNA directly in a mammalian cell context, but 
no applicable mammalian cell evolution system was available. This chapter presents the 
development of a novel virus-assisted directed evolution scheme to address this 
deficiency in mammalian cells, and Chapter 4 describes the evolution of improved M. 
mazei pyrrolysyl tRNA variants.  
3.1.2 Basic challenges and viral solutions in mammalian cell directed evolution 
There are several reasons that the development of directed evolution systems in 
mammalian cells has been slower than in bacteria or yeast. Key steps including controlled 
gene delivery and maintenance, linking the target gene activity to a selectable phenotype 
such as cell replication or cell death, and the subsequent recovery and characterization of 
the selected genes are all more challenging in mammalian cells (Figure 3.2). However, 
viruses provide elegant solutions to most of these problems. Viruses like AAV, 
adenovirus, and HIV are masters at manipulating host cell biology, and their survival 
depends on their ability to evolve new capabilities in the complex context of mammalian 
cells. This has been exploited in a number of ways to evolve viral vectors with new 
properties21–23, and in several cases to evolve artificial inducible promoters which were 
linked to the expression of key viral proteins24–26. These examples are discussed in more 
detail in section 1.4. We reasoned that the UAA-AAV described in Chapter 2, which 
depends on successful stop codon suppression for capsid protein production27, could form 
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the basis of an analogous selection system for the evolution of more active GCE 
machinery. In short, rather than trying to find a way to replicate bacterial or yeast 
selections in which UAA incorporation is linked to the survival of the host cell, we could 
link it to the survival of our engineered virus.  
 
 
Figure 3.2. Requirements for directed evolution in mammalian cells. Steps circled in 
orange represent challenges which can be overcome by viruses.   
 
 Directed evolution requires the compartmentalization of each library variant gene 
into different cells to avoid the scrambling of signals from different library members 
which could result in accidental selection for inactive variants or against active, 
orthogonal hits28. Therefore we first need a system for gene delivery which is both highly 
efficient, to accommodate large libraries, and highly controllable, to avoid the delivery of 
multiple library members to the same cell. This is accomplished in bacteria or yeast 
through the chemical or electro-transformation of plasmids. However, as discussed 
above, mammalian cell transfection delivers many plasmid copies per cell3. Viral 
delivery by genomically integrating vectors like lentivirus can be controlled such that 
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each cell is only infected by one virus, but the lentiviral cargo is then integrated into 
random sites in the human genome. The remaining solution, then, is to package the viral 
cargo into a virus whose cargo is episomally expressed, such as AAV29.  
The next challenge is the maintenance and amplification of the target gene. 
Plasmids are routinely replicated in bacteria and yeast, their copy numbers can be 
controlled through the choice of an appropriate origin of replication, and they provide an 
easy way to recover hit DNA after selection. Comparable plasmid maintenance has not 
been achieved in mammalian cells, but we knew that the AAV genome is amplified 
considerably during the viral replication process30 and then conveniently packaged into 
viral vectors from which it could be isolated after selection. Furthermore, based on the 
high levels of fluorescent protein cargo expression we regularly see during AAV 
production, we surmised that the viral genome is transcriptionally active during 
replication and could provide an elegant solution to what we termed the “copy number 
paradox.” Previous baculovirus experiments have demonstrated UAA incorporation in 
mammalian cells requires a vector containing four copies of the E. coli tyrosyl tRNA at 
an MOI of approximately 200 virus per cell6, but a stringent selection requires the 
delivery of only one library member per cell. Therefore, the robust amplification and 
transcription of the tRNA gene during AAV replication will be a critical step in our 
evolution scheme.  
3.1.3 Designing AAV-based positive and negative selections 
Most importantly, we need a way to apply selective pressure to viral replication 
such that only viral genomes containing the desired active, orthogonal tRNA genes are 
re-packaged into a new generation of viruses and recovered from selection. Our 
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previously developed UAA-AAV vectors depend on TAG codon suppression for the 
production of capsid proteins27, so even though each AAV genome will be amplified 
regardless of the tRNA gene it contains, only those genomes containing active tRNAs 
will be able to support full-length capsid protein production subsequently be packaged 
into AAV virus particles (Figure 3.3). A nuclease digestion step, commonly employed 
during the purification of AAV31, can be used after selection to destroy remaining viral 
genomes which were replicated but not packaged. Our confidence in these steps depends 
on two additional fortuitous properties of AAV. First, capsid assembly depends on a 
scaffolding protein which binds the extreme C-terminus of the capsid proteins32, meaning 
that the truncated capsid proteins produced in the context of unsuccessful nonsense 
suppression are highly unlikely to form genome-encapsulating particles. Second, it is 
well known that viral genomes which are packaged into intact AAV particles are resistant 
to DNase digestion31 and this strategy is commonly used to specifically remove non-
encapsidated viral DNA before qPCR titration.  
 
Figure 3.3. AAV-based positive selection for active nonsense suppressor tRNAs. A 
pool of viruses carrying tRNA genes with varying activity are used to transduce 
HEK293T cells such that each cell receives only one AAV. The cells are then transfected 
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with the remaining genes required for UAA-AAV production: the AAV-2 Rep and Cap 
genes, aaRS, and adenoviral helper genes. Capsid production depends on the activity of 
each tRNA gene, which leads to robust capsid synthesis and viral genome packaging in 
cells expressing active tRNAs, and no genome packaging in cells expressing inactive 
tRNAs.  
 
Conceiving of an AAV-based negative selection against cross-reactive tRNAs 
was less straightforward. The type of negative selections used to evolve bacterial 
aaRS/tRNA pairs employ highly toxic genes such as barnase with one or more stop 
codons in the absence of the UAA such that any background suppression of the stop 
codon(s) (presumably by a non-orthogonal tRNA aminoacylated by a host aaRS) kills the 
cell33. Tuning the selectivity of these selections is difficult and it would have been very 
challenging to develop an analogous system in mammalian cells from scratch. Instead, 
we designed a novel bio-orthogonal chemistry-based selection based on the unique 
chemical properties of UAAs like azido-lysine34. AAVs made by orthogonal tRNAs will 
have a distinct, non-natural handle in each capsid protein, while any virus capsids made 
by cross-reactive tRNAs will consist entirely of natural amino acids. We hypothesized 
that, rather than directly selecting against the incorporation of natural amino acids, we 
could select for the incorporation of UAAs by selectively recovering DNA from UAA-
containing capsids (Figure 3.4). This step also ended up being important for removing 
leftover library input virus which would otherwise contaminate the results of the selection 
at a small but significant level. Altogether the selection scheme outlined here requires a 
number of steps which had not yet been proven when we started this project, and this 
chapter discusses the optimization and testing of our new selection system in detail. We 
named the resulting selection scheme virus-assisted directed evolution of suppressor 




Figure 3.4. Selection for orthogonal tRNAs based on the unique chemistry of a UAA. 
Viruses made in cells expressing orthogonal tRNAs will contain a UAA with a bio-
orthogonal handle at the position of the TAG codon, while viruses made in cells 
expressing tRNAs which cross-react with a host aaRS will have a natural amino acid 
instead. Incubation of the virus pool with a purification handle like biotin attached to a 
bio-orthogonal handle will enable specific of isolation UAA-bearing viruses carrying 
orthogonal tRNAs.  
 
3.2 Results and discussion 
3.2.1 Can a single tRNA gene per cell really support progeny virus production?  
Our first step was to confirm the hypothesis that amplification of the AAV genetic 
cargo during viral replication could address the copy number paradox in which we 
deliver only one single copy of the GCE-limiting tRNA gene per cell, a crucial 
requirement for selection. We started by adding a single copy of the tRNA to the AAV 
genome. The M. mazei pyrrolysyl tRNA (tRNAPyl) driven by the human U6 small RNA 
promoter was cloned into the AAV-2 cargo ahead of the CMV-GFP or CMV-mCherry 
reporter cassette to generate the plasmid pAAV-ITR-tRNAPyl-Reporter (Figure 3.5). To 
quantify the extent of tRNA-containing viral cargo amplification and expression during 
AAV replication, we infected HEK293T cells with AAV-ITR-tRNAPyl-mCherry virus at 
an MOI of 1 infectious unit (IFU) per cell and measured the fluorescence in the presence 
and absence of the AAV replication machinery. After three days, cells infected with 
AAV-tRNAPyl-mCherry and transfected with pAAV-RC2 and pHelper were 
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approximately 20 times more fluorescent than those which were infected but not 
transfected (Figure 3.6).  
 
 
Figure 3.5. Adding a tRNA to the AAV-2 cargo.  (A) Schematics of viral cargos 
carrying a U6-driven tRNAPyl and a CMV-driven fluorescent reporter. The total size of 
each cargo is 3.3 kilobases, well within the AAV 5kb size limit.  (B) pAAV-ITR-tRNA-





Figure 3.6. Visualization of AAV genome amplification and expression during virus 
replication.  (A) HEK293T cells were infected with AAV carrying tRNAPyl and an 
mCherry fluorescent reporter gene at an MOI of 1 IFU/cell. Several hours later, cells 
were transfected with the Rep and Cap-containing plasmid AAV-RC2 and the adenoviral 
pHelper plasmid or a mock transfection mix containing only PEI.  (B) Fluorescence 
measured for each well after 3 days.  (C) Fluorescence images of each well 3 days post-
infection. Two different exposure settings were used due to the extreme difference in 
fluorescence between transfected and non-transfected wells.  (D) Fluorescence images of 
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the + Transfect well taken every 24 hours using the same microscope settings to track 
mCherry expression over time show that genome amplification occurs fairly quickly.  
 
To confirm that UAA-AAV could replicate using only the tRNA contained in the 
viral genome, which is at the core of our positive selection strategy, we followed the 
experimental protocol described in Figure 3.7. HEK293T cells were infected with AAV 
carrying a fluorescent reporter and single copy of the M. mazei tRNAPyl and transfected 
with the AAV production plasmids pHelper and pIDT-RC2-MbPylRS. We were not sure 
how robust our AAV production would be or whether one virus per cell would provide 
significant tRNA levels for UAA-containing capsid production, so we conducted our first 
experiment using MOIs of approximately 1, 10, and 100 tRNAPyl-GFP viruses per cell 
(Figure 3.8). We observed wild-type AAV production at even the lowest MOI, but 
significant UAA-AAV production was only apparent at higher levels. We had included a 
control well during virus production which received AAV-tRNAPyl-GFP but no virus 
production plasmids, and we were concerned to note a non-negligible number of 
fluorescent cells in the well infected with this lysate, indicating carryover of some of the 
input virus which could be problematic during selection. Additionally, a control 
experiment analyzing the mutual compatibility of AAV infection and transfection showed 
that PEI transfection severely attenuated the efficiency of AAV infection (Figure 3.9). 
Any one of these issues could serious problems for the selection, so we conducted a 
series of optimization experiments aimed at discovering positive selection conditions 
with compatible infection and transfection, less background from leftover input virus, and 




Figure 3.7. Overview of positive selection validation and optimization experimental 
protocols.  (A) HEK293T cells are infected with AAV-tRNAPyl-Reporter and transfected 
with pIDT-MbPylRS-RC2 while varying specific conditions. The AAV production plates 
are imaged for infection and transfection efficiency, and then the resulting progeny virus 
is harvested and used to infect a fresh batch of HEK293T cells.  (B) pIDT-MbPylRS-RC2 





Figure 3.8. A very early positive selection test. Cells were infected at MOIs of roughly 
1, 10, or 100 IFU/cell.  (A) Virus producing cells 3 days after infection and transfection.  







Figure 3.9. Incompatibility of AAV infection and PEI transfection.  (A) HEK293T 
cells were infected with AAV carrying a GFP reporter and transfected with a plasmid 
carrying an mCherry reporter.  (B) Cells were imaged 48 hours after transfection and 
infection.  
 
3.2.2 Optimizing the positive selection 
Our first goal was to find a set of conditions under which delivery of AAV-tRNA-
Reporter by infection and the remaining viral replication machinery by transfection 
would be compatible. Most of the AAV evolution literature uses calcium phosphate 
precipitation rather than PEI or cationic lipids for transfection, and while it was more 
compatible with infection we found that that this transfection method was significantly 
worse than PEI for UAA-AAV production (Figure 3.10a-b). We hypothesized that 
harsher transfection reagents could cause cellular stress which has a disproportionate 
effect on UAA-AAV production, which we feared could apply selective pressure against 
very active or slightly toxic tRNA variants. To develop a more compatible PEI-based 
method for transfection and infection, we instead found that we were able to partially 
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rescue AAV infection by adding the virus up to four hours before transfection (Figure 
3.10c), which resulted in the observation of UAA-AAV production at low MOIs of 1-5 
virus per cell for the first time (Figure 3.10d-f). However, we were concerned by the 
continued presence of fluorescent cells in wells infected with lysate from the negative 
control well which received PEI but no AAV production plasmids.  
 
Figure 3.10. Optimizing the mutual compatibility of infection and transfection.  (A) 
Comparison of the compatibility of PEI versus calcium phosphate transfection with AAV 
 
 110 
infection.  (B) Wild-type and UAA-AAV produced by calcium phosphate transfection. 
Cells were infected with equal volumes of lysate from virus producing wells.  (C) Adding 
AAV several hours before PEI transfection partially rescues infectivity.  (D) Cells were 
infected with AAV-GFP-tRNAPyl 2-4 hours before transfection with UAA-AAV 
production plasmids.  (E) Higher exposure image of the PEI only well shows the 
effective MOI for this experiment.  (F) Fresh HEK293T cells were infected with equal 
volumes of lysate from the cells in (D).  
 
We next investigated the origin of this remaining input virus and were surprised 
to see that the presence of PEI caused input virus remained in both the cell lysate and 
culture media (Figure 3.11). We use a branched PEI with an average MW of 25,000 Da 
which could conceivably form some sort of large non-infectious PEI-AAV aggregate 
which remains in the culture media. Furthermore, our virus harvest protocol at that point 
included a 10,000 x g centrifugation step to pellet the virus-producing cells before lysis, 
during which sufficiently large aggregates could be recovered as well. Based on this 
working hypothesis we set up a test in which AAV-tRNAPyl-Reporter virus was added to 
cells before or during transfection with virus production plasmids in duplicate, followed 
24 hours later by either a complete media change or no additional processing (Figure 
3.12). After the addition of a media change step, we observed a significant reduction in 
the amount of background virus in PEI-only control wells, indicating that this step 





Figure 3.11. Leftover input virus is only observed in the presence of PEI.  (A) AAV 
was added to cells in the presence or absence of a mock transfection mixture containing 
only media and PEI. The cells and culture media were harvested separately and used to 
infect fresh cells to look for any remaining virus.  (B) Mock-transfected cells were 
imaged and harvested 3 days after the addition of AAV and PEI.  (C) Fresh cells were 





Figure 3.12. Testing a 24-hour media exchange to remove leftover input virus. The 
initial incompatibility of infection and transfection can be addressed through a 
combination of adding the AAV-tRNAPyl-Reporter virus 4 hours before transfection and 
changing the media 24 hours after.  (A) Virus-producing cells. PEI only wells are shown 
at higher MOI for visualization of the effective MOI for this experiment.  (B) Fresh 
HEK293T cells were infected with the cell lysate from (A).  
 
The combination of infecting several hours before transfection and exchanging 
the culture media one day after transfection facilitate mutually compatible AAV infection 
and PEI transfection, so we moved on to see if we could increase the efficiency of 
progeny virus production (Figure 3.13). We found that transfection with more DNA than 
is standard for protein expression and an excess of the adenoviral helper plasmid led to 
increased UAA-AAV production. We also optimized the protocol for harvesting this 
virus and found that a higher-salt lysis buffer prevents aggregation and that virus should 
be recovered from both the cell lysate and culture media after selection due to premature 
lysis of some virus-producing cells. From this point we used the optimized protocol 
described here, followed by concentration of the recovered virus by PEG precipitation27. 
With optimized conditions in hand, we quantified the extent of wild-type and UAA-AAV 
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production under our infection and transfection conditions at an AAV-GFP-tRNAPyl MOI 
of < 0.01 IFU/cell in the presence and absence of AzK (Figure 3.14). Under these 
stringent infection conditions in which it is unlikely that any cell received more than one 
virus, AAV-T454-TAG production was highly dependent on the presence of AzK, which 






Figure 3.13. Optimization of UAA-AAV production and recovery. The best 
conditions from each experiment are indicated.  (A) Cells were transfected with the 
previous 1:1 ratio of plasmids or a 2-fold excess of either pHelper or pAAV-MbPylRS-
RC2-T454TAG.  (B) Cells were transfected using standard conditions (1-1.5 μg / million 
cells) or excess transfection mixture.  (C) Cells were lysed by the standard freeze/thaw 
method in the indicated buffers. 150 mM is the standard NaCl concentration in both 
DMEM and PBS, while the 300 mM buffers were supplemented with extra salt. Lysates 
were then clarified at 1,000 x g or 10,000 x g for 10 minutes.  (D) Cells were infected 







Figure 3.14. UAA-dependent replication of AAV-tRNAPyl-Reporter at a very low 
MOI.  (A) Cells were infected with AAV-tRNAPyl-mCherry at an MOI of < 0.01 IFU / 
cell and the resulting virus output was used to infect fresh cells and analyzed by flow 
cytometry.  (B) Infectivity of the progeny virus relative to the input virus for each 
condition. Inset excludes wild-type.  (C) Images of wells infected with progeny virus. 
 
3.2.3 A quantifiable mock selection scheme based on fluorescent protein markers 
We had demonstrated that the replication of AAV-tRNAPyl-Reporter during our 
positive selection depends on the presence of the UAA, and now we set out to quantify 
how efficiently this selection could discriminate between viruses bearing active and 
inactive tRNAs. We constructed two AAV vectors containing different suppressor 
tRNAs: M. mazei tRNAPyl, which is active when paired with MbPylRS under our 
selection conditions, and the E. coli tRNATyr TAG suppressor, which is orthogonal in 
mammalian cells and has been demonstrated not to cross-react with MbPylRS35. To 
enable rapid screening of multiple selection conditions, we paired our simulated mock hit 
tRNAPyl with an mCherry reporter and our mock inactive tRNATyr with a GFP reporter. 
AAV-mCherry-tRNAPyl and AAV-GFP-tRNATyr were produced separately, titered for 
infectivity, and mixed at a ratio of 1:10,000 to simulate a moderate-sized library 
containing only one active variant. This pooled virus was added to 3 10-cm dishes of 
HEK293T cells under our optimized positive selection conditions and the resulting virus 
was harvested and PEG precipitated (Figure 3.15). The ratio of AAV-mCherry-tRNAPyl 
to AAV-GFP-tRNATyr was quantified by flow cytometry, which showed a 200-500 fold 
increase in the abundance of tRNAPyl relative to tRNATyr virus over one round of positive 
selection. We were pleased that our positive selection was indeed selective, but at the 
observed rate it would take several rounds of selection to identify hits out of even small 
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libraries. We therefore turned to the pulldown step to both act as a negative selection and 
help remove unwanted background from the positive selection.  
 
 
Figure 3.15. Testing the positive selection using a mock library of active and inactive 
tRNAs distinguished with fluorescent markers.  (A) Diagrams of the AAV genomes 
containing tRNAPyl and an mCherry reporter or tRNATyr and a GFP reporter.  (B) Images 
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of the positive selection plates before harvest.  (C) Fresh cell infected with PEG 
precipitated virus from (B). Fluorescent cells were quantified by flow cytometry.  
 
3.2.4 Optimizing the negative selection 
Our design for the negative selection involved selectively ligating a biotin handle 
onto UAAs displayed on viruses packaging orthogonal tRNAs, then isolating these 
viruses by streptavidin pulldown. However, the biotin-streptavidin interaction is quite 
strong so we would need to incorporate some sort of a cleavable linker into our design 
(Figure 3.16a-b). We tested whether AAV tolerated the cleavage conditions for either a 
chemically cleavable diazo or a photo-cleavable nitrobenzyl linker, and found that while 
incubation with the dithionite reducing agent which cleaves the diazo linker rendered the 
virus non-infectious, the 365 nm UV light used for nitrobenzyl cleavage was well 
tolerated. However, AAV with DBCO-nitrobenzyl-sulfo-biotin attenuated viral 
infectivity (Figure 3.16c-d). We hypothesized that this could be due to the ~ 1 kDa mass 
of each label, but disappointingly infectivity was not restored upon cleavage of the linker 
under previously validated conditions36, which leaves only the relatively small 
modification shown in Figure 3.16e. Previous work incorporating alternative UAAs into 
the AAV capsid showed a low tolerance for highly hydrophobic groups at this position 
(see section 5.1), which could explain the low infectivity of the virus after linker 
cleavage. We were concerned that this loss of infectivity would impair our ability to 
measure selection output and potentially proceed directly from pulldown to a second 
round of positive selection, and so we optimized the DBCO-biotin labeling and pulldown 
strategy to maximize the recovery of infectious AzK-containing capsids both in absolute 





Figure 3.16. Evaluating cleavable DBCO-biotin molecules for UAA-AAV recovery.  
(A) Negative selection strategy in which UAA-AAV is selectively labeled by a DBCO-
biotin molecule with a cleavable linker.  (B) Structure of the photo-cleavable DBCO-
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nitrobenzyl-sulfo-biotin. The nitrobenzyl linker can be cleaved by non-toxic 365nm UV 
light, and the sulfo group increases water solubility.  (C) Structure of the chemically 
cleavable DBCO-diazo-biotin. The diazo linkage can be reduced and cleaved by sodium 
dithionite (Na2S2O4).  (D) Treatment of AAV-T454-AzK with each set of linker cleavage 
conditions. PEG-precipitated AAV-T454-AzK was treated with the indicated conditions, 
desalted to remove excess small molecules, and then added to HEK293T cells to measure 
infectivity.  (D) PEG-precipitated AAV-T454-AzK was labeled with DBCO-nitrobenzyl-
sulfo-biotin in PBS and subjected to the UV release condition, then used to infect 
HEK293T cells.  (E) Structure of what remains attached to AAV after nitrobenzyl linker 
cleavage.  
 
First, we sought to control the stoichiometry of virus labeling by using a recently 
developed variant of the UAA-AAV production strategy which results in the selective 
incorporation of UAAs into a minor capsid protein only (Figure 3.17a). The advantages 
of this protocol include higher yields of viruses made with the all-transfection system 
described in Chapter 2, and a reduced number of azides (5-10) per capsid which was 
shown to be beneficial for labeling and re-targeting the virus with cyclic peptides37. We 
carried out positive selections on our mock AAV-tRNAPyl-mCherry + AAV-tRNATyr-
GFP mock libraries in which pAAV-MbPylRS-RC2 was replaced by pAAV-RC2-
ΔVP1+VP1-T454-TAG37 and pIDT-MbPylRS. Indeed, we found that the infectivity of 
this virus was unaffected by DBCO-Biotin labeling and that we were able to recover 
approximately 50% of the labeled virus following streptavidin pulldown and UV linker 
cleavage (Figure 3.17). However, the efficiency of the VP1-T454-TAG positive selection 
was significantly lower than what we had seen for selections where all capsid proteins 
had the T454-TAG mutation (such as those shown in Figure 3.15 and Figure 3.18). 
Furthermore, the AAV literature suggests that while VP1 is required for infection, it is 
not required for capsid formation and genome packaging. We measure the success of our 
mock selections by infecting cells with the recovered virus pool, but this assay would not 
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be able to detect non-infectious capsids whose DNA would still be recovered and 
amplified after selection.  
 
Figure 3.17. Evaluating positive selection and pulldown using VP1-T454-TAG.  (A) 
VP1 is knocked out of the standard Rep/cap cassette by mutating its start codon. VP1-
T454-TAG is expressed from a CMV promoter, and the expression of VP2 and VP3 from 
this construct is prevented by mutating their start codons.  (B) pAAV-RC2-ΔVP1+CMV-
VP1-T454-AzK.  (C) Infectivity and pulldown of VP1-T454-AzK virus after mock 
selection. Virus was labeled with 50 µM DBCO-nitrobenzyl-sulfo-biotin for 1 hour and 
subjected to streptavidin pulldown and UV release. HEK cells were infected with 
unlabeled and labeled viruses and the unbound and recovered fractions from the 
streptavidin pulldown. The infectivity of AzK-containing AAV-tRNAPyl-mCherry at each 
stage was analyzed by flow cytometry and is shown as % of unlabeled virus infection.  
(D) Library composition before and after two independent VP1-T454-AzK selections and 
pulldowns on a mock library containing 1x AAV-tRNAPyl-mCherry to 5,000x AAV-
tRNATyr-GFP analyzed by flow cytometry.  
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Next, we investigated whether we could find a DBCO-nitrobenzyl-sulfo-biotin 
labeling condition in which most capsids selected by our original T454-TAG selection 
strategy would be sufficiently biotinylated to bind streptavidin resin, but still infectious. 
We labeled virus from a positive selection with DBCO-biotin at varying concentrations 
and attempted to purify AzK-containing AAV-tRNAPyl-mCherry by streptavidin 
pulldown. As shown in Figure 3.18a, the extent of capsid inactivation and pulldown 
recovery depends on the concentration of DBCO-biotin label used, with the most virus 
recovered and almost no decrease in infectivity observed for viruses labeled with 5 µM 
DBCO-biotin for 1 hour. Wondering if at higher label concentrations we were recovering 
non-infectious capsids, we concentrated the selection output and used a colony PCR 
protocol with AAV genome-specific primers to look for recovered viral DNA and only 
observed strong and consistent amplification from the 5 µM sample (Figure 3.18c). When 
we used this protocol for positive selection and pulldown on a mock library containing 1x 
AAV-tRNAPyl-mCherry to 5,000x AAV-tRNATyr-GFP, we found that the pulldown 
added at least a further 100-fold selectivity for tRNAPyl on top of the positive selection 
and that we recovered approximately 40% of the tRNAPyl-containing virus produced 
during the positive selection from the pulldown (Figure 3.18b and d). Comparing the 
results from mock selections using the optimized T454-TAG and VP1-T454-TAG 
selections, it was clear that the T454-TAG protocol is > 10-fold more selective (Figure 
3.19). We applied the final optimized selection scheme to the 1x AAV-tRNAPyl-mCherry 
to 10,000x AAV-tRNATyr-GFP mock libraries used in Figure 3.15 with between 15,000-
fold and 50,000-fold overall selectivity for tRNAPyl over three independent selections, the 




Figure 3.18. Optimizing positive selection and pulldown using T454-TAG.  (A) 
Infectivity and pulldown of T454-AzK virus after labeled after mock selection with 
varying concentrations of DBCO-nitrobenzyl-sulfo-biotin. Virus was labeled with 5µM, 
18 µM, or 50 µM DBCO-nitrobenzyl-sulfo-biotin for 1 hour and subjected to streptavidin 
pulldown and UV release. HEK cells were infected with unlabeled and labeled viruses 
and the unbound and recovered fractions from the streptavidin pulldown. The infectivity 
of AzK-containing AAV-tRNAPyl-mCherry at each stage was analyzed by flow 
cytometry and is shown as % of unlabeled virus infection.  (B) Library composition 
before and after two independent VP1-T454-AzK selections and pulldowns on a mock 
library containing 1x AAV-tRNAPyl-mCherry to 5,000x AAV-tRNATyr-GFP analyzed by 
flow cytometry.  (C) Amplification of DNA from the virus recovered after the pulldown 
shown in (A). Virus was concentrated using a centrifugal Speed-Vac system and 
resuspended directly in Kapa 2G colony PCR master mix and diluted into PCR reactions 
at the indicated ratios. An initial 10 minute 98 °C PCR step was used to open the viral 
capsids and release DNA. The results of two independent amplifications by agarose gel 
electrophoresis are shown.  (D) % recovery of each virus produced from the positive 




Figure 3.19. Comparison of optimized T454-TAG and VP1-T454-TAG selection 
strategies.  (A) Average selectivities over two independent selections for each protocol 
starting from a mock library containing 1x AAV-tRNAPyl-mCherry to 5,000x AAV-
tRNATyr-GFP.  (B) Library compositions before and after the selections shown in (A).  
(C) Individual fold selectivity data from the T454-AzK selections shown in (A).  (D) 
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Individual fold selectivity data from the VP1-T454-AzK selections shown in (A).  (E) 
Visual representations of library composition during each type of selection. Images are of 
cells infected with a mock library containing 1x AAV-tRNAPyl-mCherry to 5,000x AAV-
tRNATyr-GFP after positive selection and pulldown.  
 
 
Figure 3.20. The optimized VADER selection scheme.  (A) Final selection protocol.  
(B) Results of three independent selections on a mock library containing 1x AAV-
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tRNAPyl-mCherry to 5,000x AAV-tRNATyr-GFP.  *Many thanks to Lily Jewel for 
performing repeat 3.  
 
3.2.5 Recovery of viral DNA after selection  
The final piece of the selection system was a strategy to recover, amplify, and 
sequence the tRNA genes carried by viruses which survived the selection (Figure 3.21a). 
We initially tested our ability to amplify the region of the viral cargo which contained the 
tRNA out of PEG-precipitated capsids. We used our standard Phusion HS II DNA 
polymerase to amplify either an 800 bp region containing the tRNA only or a 2,000 bp 
region containing both the tRNA and fluorescent protein (Figure 3.21b) and found that to 
get efficient amplification we needed at least 100 IFU of virus. After trying several 
methods to concentrate the DNA from selections including a SpeedVac centrifugal 
vacuum system, phenol chloroform extraction, and ethanol precipitation with excess 
yeast tRNA as the carrier nucleotide, we settled on a 100 °C incubation to denature the 
virus capsids followed by an optimized ethanol precipitation protocol (Figure 3.21c-d) as 
the most reliable method. Importantly, the DNA sample should be kept cold at all times 
and amplified by PCR immediately. Because we found that excess yeast tRNA, which is 
required for the precipitation, inhibited PCR reactions at high concentrations, we 
decreased the amount we used and also pre-concentrated the virus recovered from 
streptavidin pulldown approximately 10-fold using 100 kDa MWCO centrifugal protein 
concentrators (Figure 3.21d-e). With this optimized protocol in hand we were able to 
reliably amplify the viral DNA after selection using the tRNA-only primer pair as shown 





Figure 3.21. Recovery, cleanup, and amplification viral DNA post-selection.  (A) 
Schematic overview of a DNA recovery protocol and the location of the amplification 
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primers.  (B) Amplification of DNA from PEG-precipitated virus at the indicated titers 
using the tRNA-only primer pair. NC = buffer only negative control.  (C) Ethanol 
precipitation and amplification of DNA from a 1x tRNAPyl to 5,000x tRNATyr mock 
selection at different indicated dilutions. Left panel: amplification of fresh DNA. Right 
panel: the same experiment was repeated the next day with sample stored at -80 °C 
overnight and no amplification was observed.  (D) Optimization of the ethanol 
precipitation protocol. Standard protocol (“std”), storage of the DNA on ice (“ice”), and 
storage on ice plus a 20,000 x g centrifugation step to remove any denatured proteins 
which may inhibit PCR. (E) Concentration of AAV with 100 kDa MWCO protein 
concentrators.  (F) Amplification of the DNA from real library selections (see Chapter 4). 
On all gels, the molecular weight marker is 1 Kb Plus DNA Ladder from Thermo Fisher 
Scientific and the size of the expected band is marked with a red arrow.  
 
3.3 Conclusions 
We have developed the first selection system for the evolution of components of 
the genetic code expansion machinery, specifically tRNAs, in mammalian cells. A library 
of randomized tRNA variants could contain active and orthogonal, active and cross-
reactive, and inactive variants. Our selection system links the tRNA activity to viral 
replication by requiring successful nonsense suppression for full-length capsid protein 
production, and discriminates between orthogonal and non-orthogonal tRNAs using a 
virus isolation step which depends on the unique chemistry of UAAs. We demonstrated 
that a single hit tRNA can be reliably identified from a 10,000-member simulated library 
and that active tRNAs are enriched over inactive ones by a factor of approximately 
30,000 over one round of selection. With these highly selective conditions in hand, we 
used our system to evolve more efficient variants of the M. mazei pyrrolysyl tRNA as 




3.3.1 Ongoing and future work 
In addition to the applications of this selection system for the evolution of 
enhanced suppressor tRNAs, which is an ongoing effort in our lab, we are interested in 
further improving the selection system and expanding its applications. Further 
improvements to the selection system and novel applications explored by other Chatterjee 
lab graduate students are briefly discussed here. First, we were interested in evolving 
larger libraries than the 10,000-member simulated tRNAPyl and tRNATyr mixtures 
discussed here and the 4,000-member site-saturation tRNAPyl libraries from Chapter 4. 
Lily Jewel, has demonstrated successful selections with mock libraries up to 100,000 
members and site-saturation tRNAPyl libraries up to 65,000 members. Second, we were 
interested in potentially replacing the positive selection transfection step with baculovirus 
infection, an area explored by Sam Levinson. Finally, we are interested in expanding the 
selection systems to new targets. Sam Levinson is developing an inducible promoter 
based selection system towards the goal of performing two-hybrid screens for a variety of 
protein-protein interactions in mammalian cells. Rachel Troyan, the newest member of 
Team AAV, is developing a selection variant focusing on the promoter which drives 
tRNA expression for the evolution of highly active DNA polymerase III-specific 
promoters which could be used to express other small RNAs for CRISPR or RNAi.  
3.4 Acknowledgements 
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many early directed evolution experiments. Lily did some of the final 1:10,000 mock 
selection experiments and is carrying the tRNAPyl part of the project forward with larger 
and more interesting libraries. Sam is continuing the development of new mammalian 
cell directed evolution technologies including an entirely new AAV-based two-hybrid 
screening strategy. Rachel 2.0 is beginning to use this system for the evolution of other 
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3.5 Experimental procedures 
3.5.1 Cell culture. 
HEK293T cells (ATCC) were maintained at 37 °C and 5% CO2 in DMEM-high glucose 
(HyClone) supplemented with penicillin/streptomycin (HyClone, final concentration of 
100 U/mL penicillin and 100 µg/mL streptomycin) and 10% fetal bovine serum 
(Corning). All references to DMEM below refer to the complete medium described here. 
3.5.2 Plasmids 
All primer and plasmid sequences can be found in the Appendix.  
 
The AAV-2 production plasmids pHelper and pAAV-RC2 were purchased from Cell 
Biolabs. pIDT-RC2(T454TAG)-MbPylRS has been previously described27. pIDT-RC2-
ΔVP1+VP1-T454-TAG was obtained from Xiaofu Cao37. pIDT-MbPylRS was generated 
by cloning the wild-type MbPylRS into the pIDT backbone at the AvrII and NheI sites.  
 
pAAV-ITR-PytR-GFP was generated by amplifying the U6-tRNA cassette from pIDT-
PytR35 with primers tRNA-AAV-F and R and inserting into the MluI site of the AAV 
cargo plasmid pAAV-GFP (purchased from Cell Biolabs). A KpnI site was added before 
the U6 promoter using primer tRNA-Amp-F. pAAV-ITR-EcYtR-GFP was constructed in 
a similar manner, and pAAV-ITR-PytR-mCherry was generated by replacing the GFP 




For all cloning, the E. coli TOP10 strain was used for transformation and plasmid 
propagation and bacteria were grown using LB for solid and liquid culture. All PCR 
reactions were carried out using Phusion Hot Start II DNA Polymerase (Thermo 
Scientific) according to the manufacturer’s protocol. Restriction enzymes and T4 DNA 
ligase were from New England Biolabs (NEB). All DNA oligos were purchased from 
Integrated DNA Technologies (IDT). Sanger sequencing was performed by Eton 
Bioscience. Plasmids were purified using SpinSmart Mini or Maxi plasmid prep kits 
(Machery-Nagel). 
3.5.3 Unnatural amino acids 
Azido-lysine (AzK) was purchased from Iris Biotech GMBH (Germany). Boc-lysine 
(BocK) was purchased from Chem Impex.  
3.5.4 Packaging and titration of mock library into AAV (wild-type capsid) 
To package various cargoes into AAV-2, 8 million HEK293T cells were seeded in a 10 
cm tissue culture dish. The following day, the cells were transfected with 8 µg each of the 
appropriate cargo plasmid (pAAV-ITR-tRNA-fluorescent protein), pHelper, and pAAV-
RC2 using polyethylenimine (PEI) (Sigma). Media was exchanged for fresh DMEM 24 
hours after transfection. 72 hours after transfection, the cells were resuspended, pelleted, 
and lysed by freeze/thawing as previously described. Virus was concentrated and semi-
purified by PEG precipitation, resuspended in 1 mL DMEM with FBS and flash frozen. 
These methods have been previously described27,38.  
 
Infective titers for each batch of virus were determined using flow cytometry. 0.7 million 
HEK293T cells were seeded in a 12-well plate and infected the next day at full 
confluency (1 million cells per well) with a dilution of AAV corresponding to 0.05 µL of 
virus mixture. 5 mM sodium butyrate (Sigma) was added with infection. Two days later, 
the cells were trypsinized, washed with PBS, and analyzed by flow cytometry to count 
the fluorescent population. 
3.5.5 Transfection to determine overexpression of AAV genes with Rep and AdHelper 
0.7 million HEK293T cells per well were seeded in a 12-well plate and infected the next 
day with AAV carrying a tRNAPyl-mCherry cargo at an MOI of 1. Cells were transfected 
four hours after infection with 0.6 µg pAAV-RC2 and 1.4 µg pHelper. PEI-only negative 
control wells received the equivalent amount of PEI to the transfected wells, but no 
plasmids. Virus-only wells were not transfected at all. Three days after infection and 
transfection, cells were lysed with CelLytic M buffer (Sigma) and mCherry fluorescence 
 
 132 
was measured on a Molecular Devices SpectraMax M5 microplate reader. The 
background from an uninfected well was subtracted.  
3.5.6 Positive selection – optimized protocol 
For large-scale selections 8 million HEK293T cells each were seeded in three 10 cm 
tissue culture dishes. The next day, the cells were infected with virus containing a mock 
library at an apparent MOI of 5 (the actual MOI is substantially reduced in the presence 
of PEI, the transfection reagent). Four hours after infection, the cells were transfected 
with 22 µg of pHelper and 10 µg of pIDT-RC2(T454TAG)-PylRS per dish using PEI. 1 
mM AzK was also added at this point. A scaled-down protocol was used for small-scale 
mock selections, using 0.7 million cells seeded per well and transfection, infection, and 
UAA mixes scaled down by a factor of 15.  
 
At both scales the culture media was exchanged with fresh DMEM containing 1 mM 
AzK 24 hours after transfection. Cells were harvested three days after transfection and 
lysed as for virus isolation. The culture media was saved and recombined with clarified 
lysate, and this mixture was treated with 500 U universal nuclease (Thermo Scientific) 
for 30 minutes. Virus was recovered by PEG precipitation using 11% polyethylene glycol 
(Fisher) and resuspended in 3 mL PBS (large scale) or 100 µL PBS (small scale).  
 
For direct analysis of positive selections, confluent cells in a 12-well plate were infected 
with 100-200 µL of the mock selection output and analyzed by flow cytometry. Red and 
green fluorescent cells were counted to determine the virus ratio.  
3.5.7 Streptavidin pulldown – optimized protcol 
The virus from positive selection (3 mL) was labeled with photocleavable DBCO-sulfo-
biotin (Jena Biosciences) at a concentration of 5 µM for one hour in the dark with 
mixing. Immediately after labeling, excess DBCO-biotin was quenched with AzK (1 mM 
final concentration) and the reactions were dialyzed overnight using Slide-A-Lyzer 100 
kDa MWCO devices (Thermo Scientific) against 1 L PBS at 4 °C. The dialyzed virus 
mixtures were split into three 2 mL tubes and each rotated overnight with 400 µL 
streptavidin agarose resin (Thermo Scientific) at 4 °C. The next day, each tube of beads 
was washed eight times with 1 mL PBS containing additional NaCl (final concentration 
300 mM) with mixing between washes. Finally, the washed beads were resuspended in 8 
mL PBS (300 mM NaCl) and the virus was eluted from the resin via four 30-second 





For direct analysis of pulldowns, confluent cells in a 12-well plate were infected with 
100-200 µL of the applicable fraction (labeled and dialyzed, unbound, or eluted) and 
analyzed by flow cytometry. Red and green fluorescent cells were counted to determine 
the virus ratio.  
3.5.8 Viral DNA recovery and amplification – optimized protocol 
The eluted virus was concentrated from 3 mL to 300 µL using Amicon Ultra-4 100 kDa 
MWCO centrifugal concentrators (Millipore). This mixture was heated to 100 °C for 10 
minutes in order to denature the viral capsid proteins and expose the DNA. Viral DNA 
was then cleaned up and concentrated by ethanol precipitation using yeast tRNA 
(Ambion) and resuspended in a final volume of 50 µL. 20 µL of this mixture was added 
to a 200 µL PCR reaction and amplified with tRNA-Amp-F and R primers.  
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Chapter 4 
 The evolution of enhanced pyrrolysyl suppressor tRNAs in 
mammalian cells 
 
The efficiency of unnatural amino acid mutagenesis in mammalian cells is limited 
by the suboptimal activity of the suppressor tRNAs currently in use. We have developed 
a novel platform for virus-assisted directed evolution of enhanced suppressor tRNAs 
(VADER) in live mammalian cells and used this system to evolve libraries generated 
from the commonly used archaeal pyrrolysyl suppressor tRNA. We created four libraries 
covering the acceptor and T stems and after selection identified a variant which is three 
times as active as the original tRNA at TAG, TGA, and TAA suppression with multiple 
aaRSs. Finally, we used next-generation sequencing to analyze the fate of every library 
member over the course of the selection and found that our VADER selection scheme is 
indeed selective for the enrichment of more active tRNA variants. This work provides a 
general blueprint for the evolution of better orthogonal suppressor tRNAs in mammalian 
cells, and we anticipate that our evolved tRNAPyl will be useful for challenging 
applications of mammalian cell genetic code expansion.    
 
Figure 4.1. tRNA evolution in mammalian cells.  
 
This work has been submitted along with Chapter 3 as: 
Kelemen, R. E.; Jewel, D.; Levinson, S. D.; Cao, X.; Pasha, M.; Zhu, Z.; Anthony, J.; van 
Opijnen, T.; Chatterjee, A. Virus-Assisted Directed Evolution of Enhanced Suppressor tRNAs in 
Mammalian Cells.1  
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4.1 Introduction 
4.1.1 The pyrrolysyl tRNA-aaRS pair in more detail 
The pyrrolysyl tRNA/aaRS pair is unique in that it is orthogonal in bacteria and 
mammalian cells2. This pair was originally identified in methanogenic archaea3, and 
since then homologous aaRS/tRNA pairs have been identified in other archaea and 
certain bacteria4,5. In nature, this unusual pair incorporates pyrrolysine (Figure 4.2c) as a 
21st amino acid in response to the TAG codon, making tRNAPyl an unusual natural 
nonsense suppressor. The structure of the original M. mazei tRNAPyl is shown in Figure 
4.2a-b and other tRNAPyls found in nature are shown in Figure 4.2c. The M. mazei 
tRNAPyl is commonly used with wild-type or evolved variants of both M. mazei and M. 
barkeri PylRS for genetic code expansion. Recently, the M. alvus tRNAPyl has also been 
confirmed to be orthogonal in bacteria and mammalian cells and its variable arm has been 
co-evolved with its cognate aaRS to generate a new pyrrolysyl pair which is orthogonal 
to the commonly used M mazei PylRS- tRNAPyl pair as well as the bacterial and 
eukaryotic translational systems6,7.  
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Figure 4.2. Structure of pyrrolysyl tRNAs found in nature.  (A) Sequence and 
secondary structure of the Methanosarcina mazei tRNAPyl.  (B) Crystal structure of the 
M. mazei tRNAPyl (PDB 5V6X)8.  (C) Structure of pyrrolysine.  (D) Other tRNAPyls from 
Methanosarcina barkeri MS, Methanomethylophilus alvus, and Desulfitobacterium 
hafniense with differences from M. mazei  highlighted in red.  
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The molecular basis of the unusual orthogonality of the pyrrolysyl pair has been 
traced to the unusual structure of tRNAPyl, which differs from typical tRNA sequences 
and secondary structures in several ways, most importantly through the unusually small 
variable arm. The methanosarcina PylRS’s are fairly insoluble and have been refractory 
to crystallization, but certain bacterial PylRS enzymes are “split” into a two-protein 
heterodimer which has enabled crystallization of the D. hafniense tRNAPyl with the C-
terminal segment PylSC which catalyzes the ligation of pyrrolysine onto the tRNA9 
(Figure 4.3b). More recently a M. mazei PylRS variant was evolved which developed an 
analogous “split” during evolution and enabled crystallization of the M. mazei tRNAPyl 
with the N-terminal portion of M. mazei PylRS (Figure 4.3d), and the unusually small 
variable arm was found to be a key factor for discrimination between tRNAPyl and other 
host cell tRNAs8. These crystal structures and various biochemical studies have identified 
the so-called identity elements which mediate recognition between PylRS and its cognate 
tRNA in both the D. hafniense10 and M. mazei / M. barkeri11 systems. Positions which 
were (or were not) found to influence recognition and aminoacylation of M. mazei and D. 
hafniense tRNAPyl by the cognate aaRS are shown in Figure 4.3a-c. Crucially, PylRS 
does not recognize the anticodon of the tRNA, enabling the incorporation of UAAs in 
response to stop codons besides TAG11. Recently, anticodon stem directed evolution was 
used to generate an efficient four-base frameshift codon suppressor tRNAPyl variant in the 
context of an orthogonal ribosomes12.  
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Figure 4.3. tRNAPyl recognition by PylRS.  (A) M. mazei tRNAPyl. Identity elements 
are shown in orange (found by biochemical assays) and blue (identified from crystal 
structure). Bases which were found not to influence aaRS binding are shown in green and 
one base which had a moderate effect on aminoacylation is shown in yellow. The size of 
the variable arm, rather than its specific sequence, is critical to aaRS/tRNA recognition 
and so this region is shaded in blue.  (B) Co-crystal structure of the N-terminal domain of 
M. mazei PylRS (magenta) with its cognate tRNA (PDB 5V6X)8.  (C) D. hafniense 
tRNAPyl. Identity elements are shown in orange. This tRNA is has a substantially 
different primary sequence than M. mazei and it is unclear whether the same bases play a 
role in recognition in both systems.  (D) Co-crystal structure of the C-terminal portion of 
D. hafniense PylRS (cyan) with its cognate tRNA (PDB 2ZNI)9.  
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4.1.2 Rational optimization of tRNAPyl in bacteria and mammalian cells 
Because of the importance of the M. mazei / M. barkeri tRNA/aaRS pair for 
genetic code expansion, it may seem surprising that this tRNA has not been extensively 
evolved in bacteria in the same manner as the M. janaschii tyrosyl tRNA. Instead, most 
efforts towards improving this pair have instead focused on improving PylRS as this 
relatively inefficient and insoluble enzyme is the limiting factor in bacteria and tRNA 
evolution campaigns have been restricted to the improvement of four-base suppressors12 
and the generation of mutually orthogonal pyrrolysyl aaRS/tRNA pairs6. Nonetheless, 
several rational improvements have been made to tRNAPyl by screening specific 
mutations which were hypothesized to stabilize the tRNA13,14, improve EF-Tu binding15, 
or introduce canonical mammalian tRNA elements16. These improved tRNAs and the 
organisms in which they are more efficient than the wild-type M. mazei tRNAPyl are 
shown in Figure 4.4. First, a G-U wobble pair in the anticodon stem was mutated to a 
canonical G-C pair, resulting in a tRNA with higher activity in both E. coli13 and 
mammalian cells14 (Figure 4.4a). tRNAPyl differs from mammalian tRNAs at conserved 
positions including the internal promoter A and B box elements located in the D and T 
stems respectively17. Mammalian consensus bases or pairs were introduced into tRNAPyl 
individually or in combination and the results ranged from decreased activity to an 
approximately two-fold improvement in tRNA function (Figure 4.4b)16. Finally, sets of 
two base pairs involved in EF-Tu binding were mutated to create a libraries of 36 mutants 
which were screened individually, resulting in the discovery of the tRNA shown in 
Figure 4.4c which is more active for the incorporation of challenging UAAs in E. coli15.  
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Figure 4.4. Rationally and semi-rationally improved tRNAPyl variants. Differences 
from the wild-type M. mazei tRNAPyl are shown in red.  (A) A G-U wobble pair in the 
acceptor stem was mutated to G-C resulting in improved activity in E. coli and 
mammalian cells.  (B) Canonical bases making up part of the A and B box sequences 
found in mammalian tRNAs were introduced individually or in combination resulting in a 
tRNA with higher activity in mammalian cells.  (C) Mutations in base pairs involved in 
EF-Tu/tRNA recognition were screened individually and in combination resulting in a 
tRNA with higher activity in E. coli.  
 
4.1.3 Next-generation sequencing as a tool for directed evolution 
We typically analyze hits which emerge from a directed evolution experiment by 
DNA sequencing, a field which has undergone a tremendous revolution in the last 
decade. Using an Illumina NextSeq instrument, for example, it is entirely feasible to 
sequence up to 400 million DNA sequences up to 300 bases in length for under $5,00018. 
Such high-throughput next-generation sequencing technologies have the potential to 
change how we do laboratory evolution – rather than picking a small number of surviving 
clones after selection it is now possible to measure the abundance of every member of 
even a very large library before and after each selection step and track the trajectory of 
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each hits under different types of selective pressure. One example which shows the 
promise of this strategy for evolving solutions to challenging problems is the use of 
parallel selections in E. coli to alter the selectivity of an archaeal aaRS from 
phosphoserine to phosphothreonine19. Traditional alternating positive and negative 
selections would have been challenging in this case because phosphoserine and 
phosphothreonine are structurally extremely similar and phosphothreonine is naturally 
abundant in E. coli. Parallel selections were performed in the presence and absence of 
phosphothreonine and the trajectory of each hit was followed by Illumina sequencing. An 
active, phosphothreonine-selective hit was identified after a single round of positive 
selection performed in triplicate. This paper is representative of the benefits next-
generation sequencing can bring to directed evolution, benefits we incorporated into the 
VADER selection scheme by using next-generation sequencing to follow each tRNA in 
our libraries during the selection.  
4.2 Results and discussion 
4.2.1 Library design and construction 
As discussed in section 1.5, tRNA activity can be influenced by a number of 
factors including expression, stability, aaRS recognition and aminoacylation, and 
interactions with host cell translational machinery such as elongation factors and the 
ribosome. In the face of this complexity we decided to start by randomizing the acceptor 
and T stems, areas where evolution has been fruitful in E. coli and which are located 
along the elongation factor eEF1α interaction surface. Full base pairing in tRNA stems is 
known to be critical for activity, which means that for stem-region libraries both paired 
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bases must be randomized simultaneously to preserve base pairing. This is highly 
unlikely to occur in libraries created using error-prone PCR or other low mutational 
frequency techniques, so we decided to use site-saturation mutagenesis to randomize 
several adjacent nucleotides or base pairs in the A and T stems. At this point we had 
confirmed that one round of VADER selection could identify a single hit out of a 10,000-
member mock library, so we decided to construct four adjacent six-nucleotide site-
saturation libraries in the acceptor and T stems which each contained 4,096 distinct 
sequences, starting from the G-C:G-U mutant shown in Figure 4.4a. The location of these 
libraries is shown in Figure 4.5.  
 
 
Figure 4.5. 1st-generation tRNAPyl libraries.  (A) Location of the libraries.  (B) Library 
size versus number of randomized bases.  
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4.2.2 Library synthesis and selections 
Each library was synthesized using oligonucleotide primers containing an equal 
ratio of all 4 nucleotides at the randomized positions and cloned into a special tRNA-free 
version of the pAAV-ITR-tRNA-GFP plasmid described in Chapter 3 (Figure 4.6). We 
obtained >4x105 colony forming units from each library cloning, indicating >100-fold 
coverage of the library sequence diversity. Sanger sequencing of the full plasmid pool 
(Figure 4.7), sequencing of individual clones (section 4.2.3) and Illumina sequencing 
(section 4.2.4) showed a random distribution of sequences without significant bias. The 
resulting pool of tRNA mutant-containing plasmids were transfected into HEK cells 
along with the wild-type AAV-2 packaging plasmids described in Chapter 2 and 
approximately 109 infectious virus particles were recovered per library. Each library was 
subjected to two independent replicates of VADER positive and negative selection 
(Figure 4.8) and the viral cargo after selection was amplified by PCR and cloned back 
into the tRNA-free pAAV-ITR-GFP plasmid, again with >100-fold library coverage (see 
Figure 4.8d-e for an example). 30-50 surviving clones from each library were 
characterized by Sanger sequencing (section 4.2.3) and the entire library plasmid pools 
before and after selection were characterized by Illumina next-generation sequencing 
(section 4.2.4).  
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Figure 4.6. Library synthesis.  (A) pAAV-ITR-tRNA-GFP and the tRNA-free library 
cloning vector.  (B) Location of tRNA and relevant restriction sites in the AAV cargo.  
(C) Library cloning strategy using oligonucleotide primers with randomized bases.   
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Figure 4.7. Characterization of the full library plasmid pools by Sanger sequencing. 
The traces show no significant nucleotide bias at the randomized positions.  
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Figure 4.8. Selection details and representative results.  (A) Postive selection.  (B) 
Fluorescence image of A1 library positive selection cells.  (C) Negative selection.  (D) 
DNA gel showing amplification of the tRNA out of the viral cargo after selection.  
 
4.2.3 Individual surviving tRNAs characterized by Sanger sequencing 
After each selection the hit tRNA genes were PCR amplified, cloned back into an 
empty pAAV-ITR-GFP vector, and 30-50 surviving tRNA clones were recovered from 
individual colonies and analyzed by Sanger sequencing. Because tRNAs containing 
unpaired bases are much less likely to be active, we were extremely gratified to see that 
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many more of the post-selection clones were fully base paired than would be expected 
from a completely unbiased library or was observed for the individual clones 
characterized before selection as shown in Figure 4.9. The sequence of each fully base-
paired clone is shown in Table. We observed a striking enrichment of sequences 
matching the original wild-type tRNAPyl in the T stem libraries, so we also recovered and 
sequenced a small number of individual clones from the AAV pool packaging the T1 
library and identified 7 unique clones, none of which matched the wild-type tRNAPyl. 
Sequence alignments and randomized base sequences for all hits characterized by Sanger 
sequencing can be found in the appendix.  
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Figure 4.9. Abundance of tRNAs which are fully base-paired.  (A) Theoretical 
abundance of fully base-paired hits in 6-nucleotide libraries in which 3 or 2 base pairs are 
expected (T2 includes two nucleotides in the T loop which are not expected to be paired).  
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(B) Base pairing in the individual clones analyzed from the pre-selection libraries.  (C) 
Base pairing in the individual clones analyzed from the post-selection libraries. The 
original tRNAPyl sequence is indicated separately in (B) and (C).  
 
All of the fully base paired hits were assayed for TAG suppression efficiency in 
HEK293T cells using a multiple fluorescence reporter transfection assay in which GFP-
Y39-TAG (“GFP*”) reports on TAG suppression efficiency and wild-type mCherry 
fluorescence from the pAAV-ITR-tRNA-mCherry plasmid is used as a control for 
transfection efficiency (Figure 4.10). All of the tRNA mutants from the A stem libraries 
and most from the T stem supported AzK-dependent GFP* expression, and no mutant 
showed activity in the absence of AzK, indicating that VADER selection yields active 
and orthogonal hits. We were very excited to see that a number of the A stem mutants 
were two to three fold more active than the wild-type tRNAPyl, with the most active 
variant, which we called tRNAPyl-A2.1, showing a three-fold increase in UAA-containing 
GFP expression relative to the original tRNA as shown in Figure 4.12.  
 
 
 151  
 
Figure 4.10. Testing of tRNA clones recovered from selection.  (A) Testing scheme. 
HEK293T cells are transfected with three plasmids: pAAV-ITR-tRNA-mCherry, 
pAcBac1-GFP-Y39-TAG, and pIDT-MbPylRS in the presence and absence of AzK.  (B) 
Example images showing tests of the original tRNAPyl and the best hit from the A2 
library, GGG/CCU. Cells were imaged and fluorescence was measured 48 hours after 
transfection.  
Figure 4.11. Testing of tRNA clones recovered from selection.  (A) Testing scheme. 
HEK293T cells are transfected with three plasmids: pAAV-ITR-tRNA-mCherry, 
pAcBac1-GFP-Y39-TAG, and pIDT-MbPylRS in the presence and absence of AzK.  (B) 
Example images showing tests of the original tRNAPyl and the best hit from the A2 
library, GGG/CCU. Cells were imaged and fluorescence was measured 48 hours after 
transfection.  
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Figure 4.12. Testing of all fully base-paired tRNA clones recovered from selection.  (A) 
A1 hits.  (B) A2 hits.  (C) T1 hits.  (D) T2 hits.  Fluorescence was measured 48 hours 
after transfection. Values are the average of at least 4 tests + AzK or 2 test – AzK, 
normalized to wild-type tRNAPyl transfected at the same time.  
 
4.2.4 Analysis of sequence trajectories for the full library by Illumina sequencing 
We observed a variety of different activities in the hits we identified by individual 
clone sequencing, from three-fold more active than wild-type to less active or in a few 
cases completely inactive. To gather more information about which hits were most 
enriched over the course of the selection, we measured the abundance of every sequence 
in the libraries before and after selection using next-generation sequencing. We amplified 
a 120-base region including the tRNA out of the pAAV-ITR-tRNAPyl-GFP plasmid pool 
before and after selection and sequenced the resulting DNA on an Illumina MiSeq 
instrument with ~ 100-fold coverage of each 4,000-member library. The reads were 
quality filtered and randomized base sequence abundances extracted by Jon Anthony 
from the biology department, and we used custom Python code to analyze the data. We 
observed each sequence at least five times in the libraries before selection, indicating that 
this approach has the power to track the behavior of every library member (Figure 4.13a). 
This approach also allows us to visualize the distribution of sequence abundances in the 
library, indicating that our libraries were fairly homogeneous and unbiased (Figure 
4.13b). The Python code and lessons learned for higher-quality Illumina sequencing and 
data processing are discussed in section 5.3 and the relevant code and datasets are shown 
in the appendix.   
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Figure 4.13. Next-generation sequencing of the libraries before and after selection.  
(A) Sequencing coverage statistics for each sample in the quality-filtered data.  (B) Plots 
showing the abundance of each sequence in the libraries.  
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We used this data to calculate enrichment factors for each sequence over the 
course of selection. First the abundance of each sequence after selection was divided by 
its abundance in the library before selection to calculate the fold enrichment of the 
sequence, and then this was normalized to the highest fold enrichment value for that 
particular selection run to generate an enrichment factor value. Following enrichment 
factor calculation, sequences were ranked according to their enrichment over two 
selection repeats.  We were encouraged to see significant agreement between the 
enrichment factors for each hit over two rounds of selection, as shown in Figure 4.14. We 
observed both more consistency between selections and a greater frequency of highly 
enriched hits (top right quadrant of each plot) for the A1 and A2 libraries, which contain 
a higher degree of active hits based on the results from individual clone sequencing and 
testing. As mentioned before, we expect a successful selection scheme to be selective for 
fully base-paired hits over non-base-paired sequences, a trend we observed for all four 
libraries in the next-generation sequencing data. Fully base-paired sequences made up 
>90% of the 1% most enriched sequences after the A1, A2, and T1 selections, despite 
making up only 5% of each library before selection (Figure 4.15). Interestingly, the 
enrichment of hits with more paired bases seems to be a general trend – sequences with 2 
paired bases were enriched more than those with 1 or 0 pairs, and almost no completely 
unpaired sequences were observed in the top 1% or 5% of sequences by enrichment for 
any library.    
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Figure 4.14. Calculating enrichment factors for each sequence after selection.  (A) 
Calculation of fold enrichment and enrichment factor values.  (B) Correlation of 
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Figure 4.15. Base pairing of the most enriched sequences identified by Illumina 
sequencing. The top 0.2%, 1%, and 5% of the library contain 8, 41, and 205 sequences 
respectively.  
 
When we looked into the sequencing data in more detail, we noticed some hits we 
had not yet identified among the most enriched sequences, including some highly 
enriched sequences containing G-G mis-pairs. Upon testing, many of the hits identified 
from next-generation sequencing data had comparable activity to the best hits we 
recovered from individual clone sequencing (Figure 4.16a). Interestingly, both hits 
containing mis-pairs were still active, and one (A2-GGG/GCC) was more active than the 
wild-type, which goes against the conventional wisdom for tRNA evolution. Without the 
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power of next-generation sequencing, we would not have found these additional hits. 
Overall we observed a reasonable correlation between the Illumina enrichment factor and 
activity for most hits, although the relationship was not perfectly linear (Figure 4.16b, 
Table 4.1). The data shown in Figure 4.16 confirms our proposed mechanism in which 
VADER selection enriches fully base-paired and active tRNA variants. We plan to use 
next-generation sequencing as our primary readout in future selections and test 10-20 of 
the top hits. Further improvements to the sequencing protocol and data processing are 
discussed in section 5.3.  
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Figure 4.16. Relationship between Illumina sequencing data and hit activity.  (A) 
Activity of new hits identified from Illumina sequencing. † indicates hits which contain a 
G-G mis-pair.  (B) Illumina enrichment factor versus hit activity.  
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Table 4.1. Activity and enrichment data for all tested hits. The wild-type sequence is 
listed first for each library (shaded gray), followed by our tested hits in order of activity. 
wt indicates wild-type sequence, * indicates a hit which was identified through Illumina 
sequencing, and † indicates a hit which contains mis-paired bases (underlined).   
A1 Library 
Sequence 
% of tRNAPyl GFP* expression Illumina sequencing data 
+ AzK - UAA Rank 1 Rank 2 Enrichment factor 
ACC/GGU wt 100% ± 5% 0% ± 2% 558 537 0.06 ± 0.01 
GGG/CCU   182% ± 17% -4% ± 7% 4 1 0.94 ± 0.08 
GGG/CCC   172% ± 31% -4% ± 5% 2 2 0.96 ± 0.00 
GGG/UCC   169% ± 2% -2% ± 2% 3 5 0.87 ± 0.06 
AGG/CCU * 146% ± 16% 0% ± 3% 5 4 0.85 ± 0.04 
GGC/GCC   143% ± 19% -3% ± 3% 26 31 0.42 ± 0.07 
GGG/CUC   129% ± 22% -2% ± 4% 11 7 0.67 ± 0.05 
GGU/ACC   113% ± 4% -3% ± 0% 1 3 0.97 ± 0.05 
AGG/UCU   89% ± 7% -3% ± 1% 17 14 0.54 ± 0.01 
GCU/AGC   83% ± 13% -2% ± 1% 27 50 0.36 ± 0.15 
CGG/CCG   81% ± 11% -1% ± 1% 39 26 0.39 ± 0.02 
CCU/GGG   79% ± 6% -2% ± 0% 225 282 0.10 ± 0.03 
CCU/AGG   67% ± 3% -3% ± 0% 83 78 0.21 ± 0.02 
GGA/UUC   60% ± 4% -2% ± 1% 24 27 0.44 ± 0.05 
UGG/CCA   58% ± 2% -1% ± 1% 31 23 0.43 ± 0.01 
GCG/CGU   55% ± 3% -1% ± 0% 94 120 0.18 ± 0.05 
AAC/GUU   48% ± 2% -3% ± 0% 220 141 0.12 ± 0.00 
GGG/GCC *† 43% ± 3% -2% ± 2% 13 10 0.59 ± 0.03 
ACA/UGU   41% ± 6% -1% ± 4% 66 100 0.21 ± 0.06 
UAC/GUA   35% ± 2% -2% ± 3% 110 81 0.18 ± 0.01 
GUG/CAC   33% ± 3% -1% ± 1% 35 54 0.32 ± 0.11 




% of wild-type GFP expression Illumina sequencing 
+ AzK - UAA Rank 1 Rank 2 Enrichment factor 
CCG/CGG wt 100% ± 5% 0% ± 2% 46 66 0.21 ± 0.06 
CUG/CAG * 102% ± 9% -1% ± 2% 4 1 0.95 ± 0.07 
GCA/UGC * 70% ± 10% -1% ± 1% 7 5 0.75 ± 0.04 
CCA/UGG   64% ± 6% 0% ± 0% 2 2 0.90 ± 0.03 
CAG/CUG   61% ± 12% -2% ± 3% 3 17 0.72 ± 0.25 
CGG/CCG   57% ± 9% -1% ± 1% 5 14 0.65 ± 0.12 
ACG/CGU   42% ± 9% -2% ± 2% 13 4 0.69 ± 0.20 
CGC/GCG   41% ± 10% 0% ± 1% 20 21 0.49 ± 0.02 
GUU/GAC   14% ± 2% 0% ± 1% 244 40 0.24 ± 0.16 
GGG/UCU   -1% ± 0% -1% ± 0% 1745 970 0.05 ± 0.03 
 




% of wild-type GFP expression Illumina sequencing 
+ AzK - UAA Rank 1 Rank 2 Enrichment factor 
GAA/UUC wt 100% ± 5% 0% ± 2% 1130 240 0.16 ± 0.10 
GGG/CCU   308% ± 13% -1% ± 1% 12 5 0.79 ± 0.12 
GGG/UCC * 294% ± 11% 0% ± 2% 1 1 1.00 ± 0.00 
GGG/UCU   273% ± 21% 0% ± 2% 3 3 0.93 ± 0.06 
AGC/GCU   263% ± 23% -1% ± 2% 13 12 0.75 ± 0.06 
AGG/UCU * 249% ± 18% -1% ± 3% 2 2 0.98 ± 0.03 
UGG/UCA   223% ± 30% 0% ± 3% 21 32 0.62 ± 0.01 
AAC/GUU   208% ± 12% 1% ± 2% 16 10 0.76 ± 0.10 
AUG/CAU   192% ± 2% -1% ± 0% 32 30 0.58 ± 0.06 
AAG/CUU * 189% ± 11% 0% ± 0% 9 4 0.82 ± 0.13 
ACA/UGU * 180% ± 13% 2% ± 0% 6 8 0.81 ± 0.04 
ACU/AGU   176% ± 18% 1% ± 1% 51 31 0.54 ± 0.11 
GGG/GCC *† 154% ± 17% 0% ± 3% 5 14 0.79 ± 0.04 
ACU/GGU   153% ± 10% -1% ± 1% 111 70 0.38 ± 0.09 
ACG/UGU * 132% ± 5% -5% ± 3% 4 7 0.86 ± 0.00 
UGU/ACA   104% ± 18% 0% ± 1% 110 95 0.35 ± 0.05 
UGU/GCA   103% ± 11% 1% ± 2% 120 73 0.36 ± 0.10 
GUG/UGC   102% ± 14% 2% ± 1% 73 108 0.37 ± 0.02 
AAG/UUU   100% ± 4% 0% ± 5% 90 69 0.39 ± 0.07 
GCA/UGU   98% ± 10% 0% ± 4% 91 129 0.33 ± 0.02 
CAU/GUG   80% ± 7% 2% ± 2% 213 167 0.26 ± 0.04 
UCG/UGG   55% ± 2% -1% ± 3% 146 159 0.28 ± 0.02 




% of wild-type GFP expression Illumina sequencing 
+ AzK - UAA Rank 1 Rank 2 Enrichment factor 
GG/UUCC wt 100% ± 5% 0% ± 2% 5 1 0.78 ± 0.31 
AG/UUCU * 68% ± 13% 1% ± 0% 1 2 0.79 ± 0.30 
UG/UUCA * 56% ± 8% 0% ± 0% 2 5 0.57 ± 0.25 
GG/UGCC   51% ± 10% 1% ± 0% 16 12 0.20 ± 0.03 
AG/UGCU   47% ± 14% 0% ± 3% 7 13 0.30 ± 0.12 
UC/AAGG   2% ± 5% 2% ± 5% 268 109 0.07 ± 0.08 
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4.2.5 Using evolved tRNAs for challenging applications of GCE in mammalian cells 
We investigated the performance of our best hit tRNA, A2-GGG/CCU (“tRNAPyl-
A2.1”, Figure 4.17) in several applications of GCE which have historically been 
challenging in mammalian cells. For this purpose we cloned our evolved tRNAPyl-A2.1 
into a pIDT backbone which is our standard tRNA expression vector. Because tRNA 
expression levels are higher with this vector, tRNAPyl-A2.1-TAG has close to 250% of 
wild-type activity in this vector, compared to 300% in pAAV-tRNA-mCherry (Figure 
4.18a). First, we tested whether the enhanced activity of tRNAPyl-A2.1 was specific to the 
wild-type MbPylRS or whether it would also perform better with the evolved PylRS 
variants used to incorporate high-profile but challenging UAAs such as the post-
translational modification acetyl-lysine (AcK). Lysine acetylation is involved many 
important processes in mammalian cells, but we have found it difficult to obtain AcK-
containing proteins in high yields due to the low activity of AcK-specific aaRSs. Using a 
previously evolved AcK-specific PylRS variant, we found that tRNAPyl-A2.1 led to two 
to three-fold more efficient production of GFP containing AcK at one or two sites (Figure 
4.18b).  
Next we constructed TGA and TAA suppressor variants of tRNAPyl-A2.1, each of 
which led to approximately three-fold higher levels of GFP-TGA or GFP-TAA 
expression as the corresponding wild-type tRNAPyl. The efficiency of TGA and TAA 
suppression is typically lower than TAG suppression, which represents a significant 
bottleneck for the important goal of incorporating multiple UAAs into the same 
protein20,21. Using our evolved tRNAPyl-A2.1, we observed TGA suppression efficiencies 
on par with that of TAG suppression using wild-type tRNAPyl, which we expect to be 
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very useful for the incorporation of two distinct UAAs in mammalian cells (Figure 
4.18c). Finally, to demonstrate that tRNAPyl can be used for UAA incorporation into 
complex human proteins, we expressed the transmembrane epidermal growth factor 
receptor (EGFR), which is part of a signaling pathway implicated in numerous cancers, 
with an AzK residue in the extracellular domain. Protein expression was visualized using 
a C-terminal GFP tag and we observed two-fold higher expression using tRNAPyl-A2.1 
(Figure 4.18d). We believe that these improvements will make GCE challenging GCE 
applications more accessible in mammalian cells.  
 
 
Figure 4.17. Structure of tRNAPyl-A2.1 with new mutations shown in red. The U:C 
mutation shown in orange was previously characterized13,14.  
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Figure 4.18. Applications of a more efficient tRNAPyl.  (A) Expression of GFP-39-
TAG with tRNAPyl or tRNAPyl-A2.1 expressed from pIDT-1x-TAG and 1 mM AzK. 
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Images of transfected wells expressing GFP-39-AzK are shown below the plot.  (B) 
Expression of GFP-39-TAG and GFP-39-TAG+151-TAG with tRNAPyl or tRNAPyl-A2.1 
5 mM AcK using AcKRS. Images of transfected wells expressing GFP-39-AcK are 
shown below the plot.  (C) Expression of GFP-39-TGA and GFP-39-TAA using tRNAs 
with the corresponding anticodon and 1 mM AzK. Images of transfected wells expressing 
GFP-39-AzK using a TGA stop codon are shown below the plot.  (D) Expression of 
EGFR-N171-TAG-GFP fusion construct with AzK. Images showing localization of 
EGFR to the cell membrane are shown below the plot.  
 
4.2.6 tRNA activity improvement is more important at lower copy numbers 
We made pIDT-tRNA vectors containing two-copy and four-copy cassettes of 
tRNAPyl-A2.1 to see how our evolved tRNA compared to the wild-type tRNAPyl at higher 
copy numbers. Both the wild-type tRNA and evolved tRNAPyl-A2.1 performed better at 
higher copy numbers, as expected, but 4x-tRNAPyl-A2.1 was still more active than the 
corresponding wild-type 4x- tRNAPyl (Figure 4.19a). Notably, a plasmid containing one 
copy of tRNAPyl-A2.1 led to more GFP-TAG production than one containing four copies 
of tRNAPyl-A2.1. Therefore we believe that this tRNA will be useful during both 
transient transfection, when multi-copy tRNA cassettes are commonly used but time-
consuming to construct; and viral gene delivery for GCE, when the highly repetitive 
nature and large size of multi-copy tRNA cassettes is problematic. Regarding viral 
delivery, we were interested in seeing how these two tRNAs performed at the very low 
copy numbers which are common during in vivo viral gene delivery. In contrast to 
transient transfection, where transfected cells receive thousands of copies of plasmid22, it 
has been shown that the extent of baculovirus-based gene delivery varies linearly with the 
MOI of virus added23. The four-copy tRNAPyl and tRNAPyl-A2.1 cassettes were cloned 
into a baculovirus vector and delivered to cells at a low MOI in combination with a 
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second virus carrying the GFP-39-TAG and MbPylRS genes (Figure 4.19b). In this 
assay, tRNAPyl-A2.1 was more than five times as active as wild-type tRNAPyl at low 
MOIs. From these results, we can conclude that our evolved tRNAPyl-A2.1 will be most 
valuable in challenging conditions including low MOI viral delivery and the applications 
discussed in section 4.2.5.  
 
 
Figure 4.19. tRNA activities at higher and lower copy numbers.  (A) Comparison of 
multi-copy tRNAPyl and tRNAPyl-A2.1 cassettes by transient transfection.  (B) 
Comparison of tRNAs by baculovirus infection. Cells were infected with a constant MOI 
of a baculovirus vector expressing GFP-39-TAG and MbPylRS and a variable, low MOI 
of a second baculovirus vector containing a four-copy tRNA cassette.  Data is shown 
relative to the efficiency of wild-type GFP expression from comparable plasmids.  
 
4.2.7 Comparison of optimized tRNAPyl variants in bacteria vs mammalian cells 
At the beginning of this project, we had postulated that orthogonal tRNAs could 
only be improved by directed evolution directly in the host cell of interest or a closely 
related organism. With mammalian cell-optimized and E. coli-optimized15 tRNAPyl 
variants in hand (Figure 4.20a), we set out to test this hypothesis. We expressed GFP-
 
 167  
TAG in HEK293T cells (Figure 4.20b) and E. coli (Figure 4.20c) with MbPylRS or 
AcKRS using the wild-type, mammalian-optimized, and bacteria-optimized tRNA 
variants and found that tRNAPyl-A2.1 performed comparably to the wild-type tRNAPyl in 
E. coli. tRNAPyl-Opt was more efficient at GFP-AcK production in E. coli, as previously 
reported15, but was significantly worse than the wild-type tRNAPyl in HEK293T cells. 
This is not particularly surprising as this tRNA differs from the wild-type at four 
positions in the T stem, where we found mutations to be detrimental. However, this result 
confirms our hypothesis that tRNA improvements do not necessarily transfer between 
different kingdoms of life, and underscores the value of of evolving improved suppressor 
tRNAs directly in mammalian cells.  
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Figure 4.20. Comparison of mammalian-optimized and bacteria-optimized tRNA 
performance in human cells and E. coli.  (A) tRNA structures with mutations 
highlighted in red.  (B) EGFP-39-TAG expression with various tRNAs and aaRSs in 
HEK293T cells. tRNAs were expressed from pIDT-1x-tRNA.  (C) sfGFP-151-TAG 
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4.3 Conclusions 
We have demonstrated a new platform for directed evolution in mammalian cells 
which links the performance of an orthogonal tRNA to the replication of an adeno-
associated virus. Unlike previously described viral evolution systems, our VADER 
evolution platform permits the use of customized in vitro generated libraries rather than 
being limited to slow, stochastic virus-driven mutagenesis, allowing us to cover the entire 
diversity of sequences within a tRNA stem region in a single round of selection. VADER 
is highly selective for active tRNA sequences – we were able to identify our most active 
hits by sequencing individual colonies after one round of selection, and next-generation 
sequencing analysis then confirmed that these active tRNAs were being selectively 
enriched. Furthermore, several of our best tRNA hits had unusual features which we 
would have been unable to access through rational design. Many highly active sequences 
including the most active hit, tRNAPyl-A2.1, feature weak G-U base pairs in the acceptor 
stem, and one sequence containing a G-G mis-pair was unexpectedly more active than the 
wild-type tRNAPyl. While tRNA-host interactions in mammalian cells are exceedingly 
complex and we do not yet know the molecular basis of the improved efficiency of our 
evolved tRNAs, experiments comparing tRNAPyl-A2.1 to a bacterially optimized 
tRNAPyl-Opt suggest that host-specific interactions play an important role in suppressor 
tRNA performance.  
This application of VADER led to the identification of tRNAPyl-A2.1, which is 
three times as active as wild-type tRNAPyl under transient transfection conditions and 
offers an even more significant advantage in tRNA-limited viral infection studies. We 
anticipate that, although more modest than what is typically seen in bacteria, this 
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improvement in efficiency will aid in pushing back the current barriers which stand in the 
way of challenging genetic code expansion applications in mammalian cells. More 
importantly, we have demonstrated for the first time that the poor performance of 
suppressor tRNAs in mammalian cell genetic code expansion can be addressed through 
directed evolution. We are working on further improvements to tRNAPyl and other 
suppressor tRNAs used in mammalian cells, as well as continuing to develop VADER to 
enable fine-tuning of the selection stringency and the use of larger libraries. Finally, this 
virus-assisted directed evolution strategy is not restricted to tRNA evolution; it could also 
be adapted to engineer other biological molecules whose function can be coupled to AAV 
replication.  
4.3.1 Ongoing and future work 
Several larger and more complex tRNAPyl libraries have been synthesized and 
evolved by Lily Jewel, and we are in the process of validating the hits from these 
selections. First, we designed two four-base-pair libraries, one of which extends the A2 
library by one additional base pair (A3) and one of which made use of the consensus 
sequences from A1 and A2 selections and randomized four bases pairs in the middle of 
the acceptor stem (A4). Preliminary results from Lily Jewel and Rachel Troyan have 
identified an A3 hit which is slightly more active than tRNAPyl-A2.1. So far we have not 
attempted to evolve libraries larger than four base pairs (8 nt, 65,000 members) generated 
by site-saturation mutagenesis, as the addition of a fifth base pair would increase library 
size to 1,000,000. Instead, we used oligonucleotide pool libraries containing only fully 
base-paired variants to evolve six consecutive base pairs in the acceptor stem. The design 
and cloning of this library is described more fully in Chapter 5.2. After characterizing hits 
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from these libraries, we plan to use the most active variants as starting points to evolve 
the D stem, which has been shown to increase performance as well16, and to perform 
anticodon stem evolution for an even better tRNAPylTGA suppressor. Yunan Zheng and 
Rachel Troyan have demonstrated that the E. coli tRNALeu can be improved by point 
mutations converting G-U to G-C pairs, and we plan to evolve this tRNA as well.  
 
 
Figure 4.21. On-going and future evolution of tRNAPyl.  (A) A3 library.  (B) A4 
library. Nucleotides shown in red were fixed to the consensus bases from the A1 and A2 
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libraries.  (C) A5 library. This library consisted of a 12,000-member oligonucleotide pool 
in which the base pairs shown in green were randomized to all six possibilities including 
wobble pairs while the base pairs shown in blue and purple were fixed to the possibilities 
indicated. A3, A4, and A5 were synthesized and evolved by Lily Jewel.  (D) Potential 
locations of future libraries. Identity elements for tRNAPyl recognition by M. mazei PylRS 
are shown in orange11, locations where mutations have previously led to improved 
activity are shown in green14,16, and locations where mutations have previously led to 
worse activity are shown in red16. Several potential library locations are shown in boxes. 
Randomization of the D loop also requires randomization of residues in the T loop which 
are involved in D-T tertiary interactions.  
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4.5 Experimental procedures 
4.5.1 Cell culture. 
HEK293T cells (ATCC) were maintained at 37 °C and 5% CO2 in DMEM-high glucose 
(HyClone) supplemented with penicillin/streptomycin (HyClone, final concentration of 
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100 U/mL penicillin and 100 µg/mL streptomycin) and 10% fetal bovine serum 
(Corning). All references to DMEM below refer to the complete medium described here. 
4.5.2 Cloning  
For all cloning, the E. coli TOP10 strain was used for transformation and plasmid 
propagation and bacteria were grown using LB for solid and liquid culture. All PCR 
reactions were carried out using Phusion Hot Start II DNA Polymerase (Thermo 
Scientific) according to the manufacturer’s protocol. Restriction enzymes and T4 DNA 
ligase were from New England Biolabs (NEB). All DNA oligos were purchased from 
Integrated DNA Technologies (IDT). Sanger sequencing was performed by Eton 
Bioscience.  
4.5.3 Plasmids 
All primer and plasmid sequences can be found in the Appendix.  
 
The AAV-2 production plasmids pHelper and pAAV-RC2 were purchased from Cell 
Biolabs. pIDT-RC2(T454TAG)-MbPylRS has been previously described24.  
 
pAAV-ITR-PytR-GFP was generated by amplifying the U6-tRNA cassette from pIDT-
PytR20 with primers tRNA-AAV-F and R and inserting into the MluI site of the AAV 
cargo plasmid pAAV-GFP (purchased from Cell Biolabs). A KpnI site was added before 
the U6 promoter using primer tRNA-Amp-F. pAAV-ITR-EcYtR-GFP was constructed in 
a similar manner, and pAAV-ITR-PytR-mCherry was generated by replacing the GFP 
reporter in pAAV-ITR-PytR-GFP.  
 
The pAAV-ITR-GFP library cloning vector was generated by cutting pAAV-ITR-PytR-
GFP at two NdeI sites flanking the tRNA and ligating the resulting vector back together. 
This vector retains the library cloning sites but lacks a tRNA which could cause 
background issues during library cloning.  
 
pIDTSmart-1xPytR-evolved was generated by amplifying the best hit tRNA 
(Ac2.GGG/CCU) from selection using primers tRNA-Amp-F and R and cloning this 
insert into the pIDTSmart-PytR backbone using AvrII and NheI. Anticodons were 
mutated using site-directed mutagenesis.  
 
pIDTSmart-MbPylRS and pIDTSmart-AcKRS3 were generated by cloning each 
synthetase into the pIDTSmart backbone at the AvrII and NheI sites.  
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4.5.4 Library generation 
All primer sequences used for library generation can be found in the Appendix.  
 
Libraries were generated by site-saturation mutagenesis using pAAV-PytR-GFP as a 
template. For acceptor stem libraries, the 5’ and 3’ pieces of the tRNA were first 
amplified using primer pairs tRNA-Amp-F + AccLib-Short-R and AccLib-Short-F + 
tRNA-Amp-R respectively. Randomized bases were then added by reamplifying each 
fragment, replacing AccLib-Short-F and R with AccLib1 or AccLib2-NNN-F and R. 
Finally, the fragments were joined by overlap extension PCR and then amplified using 
tRNA-Amp-F and R, digested with KpnI and NcoI, and ligated into the pAAV-ITR-GFP 
library vector which had been digested with the same enzymes. Each ligation used ~1 µg 
each of vector and insert. T stem library generation was similar, but for each library only 
one primer containing randomized nucleotides was used.  
 
Ligations were concentrated by ethanol precipitation with yeast tRNA (Ambion) and 
transformed into electrocompetent TOP10 E. coli. >4x105 transformants were plated 
(>100-fold library coverage). These colonies were pooled and their DNA was 
miniprepped for packaging into AAV.  
4.5.5 Packaging and titration of mock and library tRNAs into AAV (wild-type capsid) 
To package various cargo into AAV-2, 8 million HEK293T cells were seeded in a 10 cm 
tissue culture dish. The following day, the cells were transfected with 8 µg each of the 
appropriate cargo plasmid (pAAV-ITR-tRNA-fluorescent protein), pHelper, and pAAV-
RC2 using polyethylenimine (PEI) (Sigma). Media was exchanged for fresh DMEM 24 
hours after transfection. 72 hours after transfection, the cells were resuspended, pelleted, 
and lysed by freeze/thawing as previously described24. Virus was concentrated and semi-
purified by PEG precipitation, resuspended in 1 mL DMEM with FBS and flash frozen24.  
 
Infective titers for each batch of virus were determined using flow cytometry. 0.7 million 
HEK293T cells were seeded in a 12-well plate and infected the next day at full 
confluency (1 million cells per well) with a dilution of AAV corresponding to 0.05 µL of 
virus mixture. 5 mM sodium butyrate (Sigma) was added with infection. Two days later, 
the cells were trypsinized, washed with PBS, and analyzed by flow cytometry to count 
the fluorescent population.  
4.5.6 Unnatural amino acids 
Azido-lysine (AzK) was purchased from Iris Biotech GMBH (Germany). Nε-acetyllysine 
(AcK) was purchased from Bachem.  
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4.5.7 Positive selection 
8 million HEK293T cells each were seeded in three 10 cm tissue culture dishes. The next 
day, the cells were infected with virus containing a tRNAPyl library at an apparent MOI of 
5 (the actual MOI is substantially reduced in the presence of PEI, the transfection 
reagent). Four hours after infection, the cells were transfected with 22 µg of pHelper and 
10 µg of pIDTSmart-RC2(T454TAG)-PylRS per dish using PEI. 1 mM AzK was also 
added at this point. One day after transfection the culture media was exchanged with 
fresh DMEM containing 1 mM AzK. Cells were harvested three days after transfection 
and lysed as for virus isolation. The culture media was saved and recombined with 
clarified lysate, and this mixture was treated with 500 U universal nuclease (Thermo 
Scientific) for 30 minutes. Virus was recovered by PEG precipitation using 11% 
polyethylene glycol (Fisher) as previously described24 and resuspended in 3 mL PBS.  
4.5.8 Negative selection – streptavidin pulldown 
The virus from positive selection (3 mL) was labeled with photocleavable DBCO-sulfo-
biotin (Jena Biosciences) at a concentration of 5 µM for one hour in the dark with 
mixing. Immediately after labeling, excess DBCO-biotin was quenched with AzK (1 mM 
final concentration) and the reactions were dialyzed overnight using Slide-A-Lyzer 100 
kDa MWCO devices (Thermo Scientific) against 1 L PBS at 4 °C. The dialyzed virus 
mixtures were split into three 2 mL tubes and each rotated overnight with 400 µL 
streptavidin agarose resin (Thermo Scientific) at 4 °C. The next day, each tube of beads 
was washed eight times with 1 mL PBS containing additional NaCl (final concentration 
300 mM) with mixing between washes. Finally, the washed beads were resuspended in 8 
mL PBS (300 mM NaCl) and the virus was eluted from the resin via four 30-second 
irradiations using a 365 nm UV diode array (Larson Electronics), with mixing between 
irradiations.  
4.5.9 Viral DNA recovery, amplification, and cloning 
The eluted virus was concentrated from 3 mL to 300 µL using Amicon Ultra-4 100 kDa 
MWCO centrifugal concentrators (Millipore). This mixture was heated to 100 °C for 10 
minutes in order to denature the viral capsid proteins and expose the DNA. Viral DNA 
was then cleaned up and concentrated by ethanol precipitation using yeast tRNA 
(Ambion) and resuspended in a final volume of 50 µL.  
 
20 µL of this mixture was added to a 200 µL PCR reaction and amplified with tRNA-
Amp-F and R primers. The resulting DNA was digested with KpnI and NcoI and cloned 
into the library cloning vector using the same protocol as for original library generation.  
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4.5.10 Individual hit sequencing and characterization 
For each library, 30-50 colonies were picked from the transformation plates generated 
above and sent for Sanger sequencing (Eton Bioscience). All sequences in which all 
randomized bases were paired were treated as potential hits, and these tRNAs were 
subcloned into pAAV-ITR-PytR-mCherry for analysis.  
4.5.11 Illumina sequencing 
A 105-base region containing the tRNA was amplified from plasmid pools containing 
each library before or after selection to generate a 150-base total amplicon containing 
Illumina primer binding regions, barcodes to distinguish between libraries and selections, 
and adapter sequences for annealing to the Illumina flow cell. 12 pmole of the resulting 
DNA was gel-purified and analyzed on an Illumina MiSeq using the MiSeq Reagent Kit 
v2 300-cycle with 5% PhiX loading control. Reads were automatically de-multiplexed 
using the barcodes and data was filtered to exclude any reads with Phred quality scores 
below 14. Counting of the appearance of individual variants was performed by Jon 
Anthony using the expected sequence coordinates of the randomized bases, and data was 
further analyzed using a custom Python script.  
 
More detail can be found in Chapter 5.3. Full Illumina sequencing results and processing 
code can be found in the Appendix.  
4.5.12 Hit testing 
Fully base-paired individual clones were transferred to a pAAV-ITR-PytR-mCherry 
plasmid to enable activity measurements using a GFP-TAG reporter. Hits identified from 
Illumina sequencing were synthesized using site-directed mutagenesis. Initial hit analysis 
was conducted by transfecting HEK293T cells in 24-well plates with 0.5 µg each of a 
potential hit pAAV-ITR-PytR-mCherry plasmid, pIDTSmart-MbPylRS, and pAcBac1-
GFP(39TAG) in the presence and absence of 1 mM AzK. Two days after transfection, 
cells were lysed with CelLytic M buffer (Sigma) and EGFP and mCherry fluorescence 
were measured on a Molecular Devices SpectraMax M5 microplate reader. Values for an 
untransfected well were subtracted, and EGFP-fluorescence was normalized to mCherry 
fluorescence for each well.  
4.5.13 Validation of tRNAPyl-A2.1 activity 
The best hit, Ac2.1 (GGG/CCU), was selected for further analysis with other stop codons 
and a different synthetase and Uaa, AcKRS3 and AcK. HEK293T cells in a 12-well plate 
were transfected with 0.375 µg pIDTSmart-PytR containing either the wild-type or 
evolved tRNA, 0.375 µg pIDTSmart-aaRS containing the appropriate synthetase, and 
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0.75 µg pAcBac1-EGFP containing one or two of the appropriate stop codon. A wild-
type EGFP control well used pIDTSmart-PytR(TAG, wild-type), pIDTSmart-MbPylRS, 
and pAcBac1-EGFP(wild-type) in the same ratios. Two days after transfection, cells were 
lysed and EGFP fluorescence was measured by microplate reader. Values from an 
untransfected well were subtracted.  
 
Incorporation of the correct UAAs by the evolved tRNA was confirmed by LC-ESI-MS. 
EGFP-39AzK-6xHis was generated by transfecting HEK293T cells in two 10cm tissue 
culture dishes with 5 µg pIDTSmart-PytR-evolved, 5 µg pIDTSmart-MbPylRS, and 10 
µg pAcBac1-GFP(Y39TAG) with 1 mM AzK. EGFP-39AcK-6xHis was generated by 
transfecting HEK293T cells in two 10cm tissue culture dishes with 5 µg pIDTSmart-
PytR-evolved, 5 µg pIDTSmart-AcKRS3, and 10 µg pAcBac1-GFP(Y39TAG) with 5 
mM AcK. Cells were lysed two days after transfection using CelLytic M (Sigma), Halt 
protease inhibitor cocktail (Thermo Scientific), and universal nuclease (Thermo 
Scientific) according to the manufacturers’ instructions. All proteins were isolated from 
clarified lysate on Ni-NTA columns using HisPur resin (Fisher) according to the 
manufacturer’s instructions, but using 60 µL of resin and wash buffers containing 30 mM 
and then 40 mM imidazole. Proteins were analyzed by LC-ESI-MS using an Agilent 
1260 Infinity ESI-TOF.  
4.5.14 tRNA testing in E. coli 
Hits were cloned into a previously reported pUltra-Pyl vector13 which also expresses 
bacterial codon-optimized MbPylRS or AcKRS and transformed into Top10 E. coli along 
with pET-22b-sfGFP-Y151-TAG. Single colonies were grown to OD600 0.5 in LB and 
induced with IPTG in the presence or absence of 1 mM AzK or 10 mM AcK and then 
grown overnight at 30 °C. The following day cells were centrifuged and resuspended in 
PBS and GFP expression was measured as fluorescence / OD600.  
4.5.15 Multi-copy tRNA cassette cloning and testing in pIDT-tRNA and pAcBac1-tRNA 
Multi-copy U6-driven tRNA cassettes were cloned in pIDT-tRNA as previously reported 
using the AvrII and NheI restriction sites, which have mutually compatible cohesive 
ends23. The resulting 4-copy cassette was cloned into an empty VSVG-pseudotyped 
baculovirus packaging pAcBac1 vector and used to produce baculovirus as previously 
described25. Cells were infected with this virus along with a second virus packaging 
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 Various short stories 
 
This chapter contains several short stories which have not (yet) been finalized for 
publication. Most of the work described in this chapter is being or has been followed up 
by other members of the Chatterjee lab – Sarah Erickson has worked on incorporating 
other UAAs into the AAV capsid (section 5.1); Lily Jewel did the final cloning and 
selections for the oligo pool library (section 5.2) and is analyzing the results using the 
improved Illumina sequencing strategy (section 5.3). The photocaged caspase project 
described in section 5.4 was put on hold due to issues maintaining baculovirus-producing 
sf9 cells which have since been addressed by Yunan Zheng and Sam Levinson.  
 
5.1 Incorporation of other UAAs into the AAV capsid 
5.1.1 Introduction  
We briefly investigated the introduction of other UAAs into the AAV-2 capsid, 
with overall mixed results. The experiments described in this section are unpublished and 
some were performed only once, but they are described here as a starting point for 
potential future work. In particular, the successful incorporation of a photo-crosslinking 
UAA with the pyrrolysyl pair (section 5.1.2) could be useful for discovering new AAV-
host interactions which could be relevant for AAV gene therapy, and the successful 
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incorporation of azido-lysine with the E. coli leucyl pair means that this tRNA is also 
accessible for VADER evolution.  
5.1.2 Other UAAs with the pyrrolysyl pair 
The wild-type MbPylRS is known to accept a variety of other UAAs, and we 
were able to incorporate N-ε-boc-lysine as well as the photo-crosslinking UAA diazirine-
lysine (Figure 5.1). The latter is particularly interesting because there remains a 
significant amount we do not know about AAV interactions with the host cell during 
infection and virus assembly, including which part(s) of the capsid are responsible for 
binding the secondary receptor AAVR. A photo-crosslinking UAA1 could potentially be 
used to investigate AAV-host interactions and provide new insight about cellular factors 
that influence AAV gene delivery, a topic of interest for gene therapy. Since this work, 
we have also demonstrated that an engineered MbPylRS derivative NBKRS can be used 
to incorporate a photo-caged lysine into the AAV capsid for the light-control of primary 
receptor binding2.  
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Figure 5.1. Incorporation of other pyrrolysine-derived UAAs into the AAV capsid with 
MbPylRS.  (A) Structures of the model substrate BocK and the photo-crosslinker DiazK.  
(B) GFP fluorescence images of cells infected with an equal volume of cell lysate 
containing wild-type of T454-TAG viruses produced in the presence or absence of UAA.  
 
5.1.3 Use of the E coli leucyl pair 
We also used the E. coli-derived leucyl aaRS/tRNA pair to incorporate various 
UAAs with different degrees of success. We were excited about the idea of directly 
introducing the fluorescent UAA Anap3 (Figure 5.2a) into the AAV capsid for cellular 
imaging of infection, but unfortunately we were not able to incorporate Anap into any of 
our well-suppressed capsid sites D327, T454, and N587 (Figure 5.2b) despite using a 
higher-than-normal concentration of Anap (100 μM) and confirming the activity of the 
AnapRS/EcLtR pair during virus production using a TAG-mCherry fluorescent reporter 
(Figure 5.2c). In the future, the failure of UAAs like Anap to produce infectious virus 
could be investigated in more detail by checking the efficiency of individual virus 
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production steps – full-length capsid production synthesis by Western blotting with the 
B1 anti-VP antibody which binds the C-terminus of the capsid proteins; an ELISA assay 
against assembled capsids; and quantitative PCR for assembled viral genomes. In the 
meantime, we demonstrated an alternate route for capsid fluorophore labeling by 
functionalizing azido-lysine residues with DBCO-Cy5 (section 2.2.4).  
 
 
Figure 5.2. Unsuccessful attempted incorporation of the fluorescent UAA Anap into the 
AAV-2 capsid.  (A) Structure of Anap.  (B) GFP fluorescence images of cells infected 
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with an equal volume of cell lysate containing the indicated viruses produced in the 
presence or absence of UAA.  (C) Confirmation that the AnapRS/EcLtR pair is functional 
during virus production using a TAG-mCherry reporter. Images show the mCherry 
fluorescence of virus-producing cells 3 days post-transfection.  
 
A polyspecific E. coli leucyl-derived aaRS (PolyLeuRS) was recently developed 
in our lab and reported to incorporate a variety of long hydrophobic UAAs including 
some containing azide handles4. We knew this mutant aaRS also accepts azido-lysine and 
also that EcLRS-derived aaRSs often require much lower substrate concentrations than 
MbPylRS, so we tested T454-TAG virus production in the presence of varying amounts 
of the UAAs azido-lysine (AzK) and the long-chain azide C-5-Az (Figure 5.3). We 
observed robust AzK incorporation, but we observed very low levels of C-5-Az virus 
production over multiple experiments using UAA concentrations from 100 μM to 1 mM. 
We often consider UAA toxicity as a factor whenever we observe low incorporation, but 
wild-type AAV production was not significantly affected by 100 μM  C-5-Az (Figure 
5.3c) and infection with the culture media as well as lysate from the producing cells rules 
out the loss of virus through increased escape or producer cell lysis prior to virus harvest 
(Figure 5.3d). We hypothesize that the extremely hydrophobic, almost lipid-like nature of 
C-5-Az could compromise AAV capsid protein stability, virus assembly, or infectivity. 
However, the successful incorporation of AzK, which we have already used in the 
VADER system for directed evolution of tRNAPyl, opens up the possibility of using our 




Figure 5.3. UAA-AAV production using the PolyLeuRS/EcLtR pair.  (A) Structure of 
the UAAs C-5-Az and AzK (also incorporated by MbPylRS).  (B) GFP fluorescence 
images of cells infected with an equal volume of cell lysate containing the indicated 
viruses produced in the presence or absence of UAA.  (C-D) Wild-type and T454-TAG 
viruses were produced in the presence and absence of C-5-Az and HEK293T cells were 
infected with either virus-producing cell lysate (C) or culture media harvested from the 




5.1.4 Use of the E coli tyrosyl pair 
We also had significantly different results for different UAAs using the E. coli 
tyrosyl-derived OMeYRS/EcYtR pair (Figure 5.4). We were able to incorporate the 
model substrate O-methyl-tyrosine (OMeY), although with lower efficiency than AzK, 
but we observed no incorporation of the similar UAA p-azido-phenylalanine (AzF, a 
reasonably good substrate for OMeYRS5). Interestingly, while we observed some virus 
production in the absence of any UAA due to the inherent low-level promiscuity of 
OMeYRS in the absence of a UAA substrate, we observed no infectious virus production 
in the presence of AzF. This apparent suppression of background suppression was highly 
unusual, and even more surprisingly we found that AzF also suppressed OMeY 
incorporation if a mixture of UAAs was provided (Figure 5.4b), although BocK 
incorporation by the MbPylRS/MmPytR pair was unaffected by AzF. Finally, we tested 
whether OMeY or AzF could be incorporated in response to the TGA stop codon and 
found that while OMeY was incorporated at very low levels (see section 5.1.3 for more 
details), AzF could not be incorporated in response to the TGA stop codon either. An 
explanation for these phenomena remain elusive, but one potential reason could be that 
AzF or its reduced counterpart p-aminophenylalanine could be getting incorporated in 
response to a stop codon at the end of a cellular or adenoviral helper protein and having 




Figure 5.4. UAA-AAV production using the MbPylRS/tRNATyr pair from E. coli.  (A) 
Structure of the UAAs OMeY and AzF.  (B-E) GFP fluorescence images of cells infected 
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with an equal volume of cell lysate containing the indicated viruses.  (B) Wild-type and 
T454-TAG virus produced in the presence or absence of 1 mM OMeY or AzF.  (C) 
T454-TAG virus produced using the OMeYRS/EcYtR pair in the presence of OMeY, 
AzF, or a 1:1 mixture of both UAAs.  (D) T454-TAG virus produced using the 
MbPylRS/MmPytR pair in the presence of BocK, AzF, or a 1:1 mixture of both UAAs.  
(E) T454-TGA virus produced using the OMeYRS/EcYtRTGA pair in the presence of 
OMeY or AzF.  
 
5.1.5 TGA suppression in the AAV capisd 
We attempted to suppress TGA codons in the AAV cap gene using both the 
MbPylRS/MmPytR and OMeYRS/EcYtR pairs. In both systems, T454-TGA suppression 
was achieved but at a significantly lower level than the suppression of the corresponding 
TAG mutant. These results suggest two future directions. First, the VADER selection 
system described in Chapters 3 and 4 could be used to evolve better TGA suppressor 
tRNAs. Interestingly, the wild-type virus production efficiencies in Figure 5.5c would 
seem to indicate that EcYtRTGA in particular causes some sort of cellular stress which 
impacts AAV production and could reduce the efficiency of UAA incorporation as well. 
VADER tRNA evolution would provide selective pressure against such tRNA-related 
toxicity. Second, TGA suppression could synergize with the minor-protein-specific 
modification scheme developed by former Chatterjee lab undergraduate Xiaofu Cao, in 
which one or both of the minor capsid proteins VP1 and VP2 is expressed separately 
from the main cap ORF with a TAG mutation coding for UAA incorporation in this 
protein(s) only6. Interestingly, while the introduction of a TAG codon into all three 
capsid proteins decreases the efficiency of AAV production (see Chapter 2), this effect 
was not observed for TAG codons specifically introduced into the minor proteins. This 
observation combined with the MmPytRTGA suppression efficiencies seen in Figure 5.5a 
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indicate that it could be feasible to produce an AAV with a TAG stop codon in VP3 and 
TGA stop codons in VP1 and VP2, incorporating two distinct UAAs into the same viral 
particle without the drastic drop in protein yield observed when two different stop codons 




Figure 5.5. TGA suppression in the AAV capsid. (A-C) GFP fluorescence images of 
cells infected with an equal volume of cell lysate containing the indicated viruses.  (A) 
Wild-type , T454-TAG, and T454-TGA viruses produced using MbPylRS and MmPytR 
with the appropriate anticodon.  (B) Wild-type , T454-TAG, and T454-TGA viruses 
produced using OMeYRS and EcYtR with the appropriate anticodon.  (C) Wild-type 
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AAV production in the presence of OMeYRS and EcYtRTAG or EcYtRTGA in the 
presence and absence of UAA.  
 
5.1.6 Conclusions 
We have successfully incorporated several UAAs besides azido-lysine, which is 
the subject of Chapter 2, into the AAV capsid. The model substrates boc-lysine and O-
methyl-tyrosine (sections 5.1.2 and 5.1.4 respectively) was well tolerated, but these 
UAAs have limited practical applications. More excitingly, we were able to incorporate 
the photo-crosslinking UAA diazirine-lysine into the AAV capsid, opens up the 
possibility of using our system as a tool to investigate AAV-host interactions. One area of 
interest for this type of study is the secondary receptor used for AAV entry – AAV-R was 
recently identified as a very likely candidate8, but its binding site on the AAV capsid 
remains elusive and we could use photo-crosslinkers incorporated at different sites to 
attempt to identify the capsid region involved. However, we were unable to incorporate 
several interesting UAAs including the environmentally sensitive fluorescent probe Anap 
and the bio-orthogonal handle azido-phenylalanine and the reasons remain unclear.  
Finally, the incorporation of UAAs into the AAV capsid in response to the TGA 
codon was less efficient than using TAG, but nevertheless this opens up several exciting 
possibilities. Weak TGA suppression in the capsid would mean plenty of room for tRNA 
improvement during VADER evolution, and it might be feasible to incorporate multiple 
UAAs into the AAV capsid using the distinct minor capsid protein expression system 
developed by Xiaofu Cao6 with a TAG codon in some proteins and a TGA codon in 
others. One can envision several applications for such a doubly-functionalized AAV 
including the site-specific attachment of a targeting molecule and polyethylene glycol 
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(PEG) to mask the virus from the immune system, the attachment of a targeting molecule 
and imaging agent to measure in vivo bio-distribution of a re-targeted virus, or a photo-
crosslinker to covalently link the virus to a cellular interaction partner and a bio-
orthogonal handle to pull out the resulting complex. 
 
5.2 Design and cloning of advanced oligonucleotide pool-based libraries 
5.2.1 Introduction 
During the library design step of any directed evolution campaign, there is a 
trade-off between changing enough of the sequence to gain new functions, and not 
exceeding the library sizes which can reasonably be covered by laboratory evolution. For 
tRNA evolution by VADER, the upper limit we have explored so far is 100,000 library 
members, meaning we can randomize at most 8 bases at once. Furthermore, simply 
randomizing all of the residues of interest is not always the most efficient way to generate 
libraries containing more active hits and can lead to redundancy and wasted space. For 
example, protein sequences are often randomized by mutating each codon to the 
sequence NNK, which covers all 20 natural amino acids in 32 possibilities but contains 
wasteful redundant and stop codons, while completely randomizing stem regions of the 
tRNA leads to many library members which are not fully base-paired, as shown in Table 
5.1. Recently, a number of advanced library synthesis techniques have been developed 
which cover a desired sequence space more efficiently9 and we decided to use one of 
these techniques, oligonucleotide (oligo) pool synthesis, to generate a larger tRNA 
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library. In this method, each library member is a precisely designed <200 base sequence, 
allowing us to specify that the library only contain fully base-paired tRNA sequences.  
 
Table 5.1. Library sizes with various synthesis methods. A standard site-saturation 
library of N base pairs contains 16N members, while an oligo pool library including G-U 
wobble pairs contains 6N.  
Base pairs Size using standard site-saturation library 
Fraction of sequences 
which are fully paired 
Size using fully paired 
oligo pool (incl. G-U) 
1 16 37.5% 6 
2 256 14.1% 36 
3 4,096 5.3% 216 
4 65,536 2.0% 1,296 
5 1,048,576 0.7% 7,776 
6 16,777,216 0.3% 46,656 
 
5.2.2 Library design 
We designed a six base-pair library oligo pool library (Figure 5.6a) which 
contained 11,664 sequences, whereas the same library would have contained more than 
1,500,000 sequences if synthesized by standard site-saturation mutagenesis. Due to cost 
constraints on oligo pool synthesis, we limited the top and bottom pairs to three 
possibilities each based on the best hits from our first-generation libraries. However, we 
included G-U pairs G-U pairs at all positions because we had observed them in many of 
our most active first-generation hits. A complete list of all tRNA sequences in the library 
was generated using a custom Python script (see Appendix) and tRNA sequences 
containing flanking primer binding sites for PCR were ordered from Twist Bioscience. 
The structure of these oligos is shown in Figure 5.6b.  
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Figure 5.6. Design of the Ac5 oligonucleotide pool library.  (A) Library design. Base 
pairs shown as N-N were randomized to the set of pairs shown.  (B) Diagram of the 120-
nucleotide library construct ordered. Primers anneal upstream and downstream of the 
tRNA for amplification.  (C) Sequence of the library construct.  
 
5.2.3 Cloning of oligo pool libraries without sequence scrambling 
When we tried to clone this library into our AAV-tRNA packaging vector, we 
encountered an unexpected problem. The library cloning was very efficient, but when we 
sequenced individual clones we were surprised to see that none of the tRNA sequences 
were fully base-paired (Figure 5.7a-b). Each of the 5’ and 3’ halves of the acceptor stem 
matched those that we had designed for our oligo pool, but they did not pair with each 
other. After troubleshooting the oligo pool synthesis, a specialist from Twist Biosciences 
suggested that the 5’ and 3’ portions of our tRNA could be scrambling during PCR 
because of the overall high degree of homology of our sequences (Figure 5.7c). We tested 
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this hypothesis by amplifying a mock library consisting of four tRNAs with distinct 
sequences and found that the two halves of the acceptor stem were indeed being 
scrambled, probably when a new strand of DNA was incompletely synthesized during 
one round of PCR and annealed to a new template with a different randomized sequence 
during the next. This depends on a property of DNA polymerases known as processivity 
– during DNA amplification, polymerases continually associate and dissociate from the 
template and product strands, and processivity refers to how many nucleotides are added 
to the product by a single polymerase molecule before it dissociates10. The use of a more 
processive polymerase PrimeSTAR Max, which is less likely to dissociate mid-extension, 
dramatically improved sequence fidelity during cloning of our four-member test library 
(Figure 5.7d). However, surprisingly we still saw partial scrambling during cloning of the 
full 11,664-member oligo pool library (Figure 5.7e - experiment was not repeated). We 
next sought a way to reduce the overall number of PCR steps involved in the library 




Figure 5.7. Sequence scrambling during cloning of the oligo pool library.  (A) Initial 
oligo pool library cloning strategy.  (B) Results of individual clone sequencing. Green 
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shading indicates that that the 5’ and 3’ randomized sequences match, while red shading 
indicates that they do not.  (C) Potential mechanism of sequence scrambling.  (D) 
Amplification of a four-sequence test library using our standard DNA polymerase 
Phusion HS II and a more processive polymerase PrimeSTAR Max.  (E) Small-scale test 
of library cloning with two PCR steps and both DNA polymerases.   
 
Our initial cloning strategy required three distinct PCR steps: the initial 
amplification of the oligo pool, overlap extension to join the tRNA library to the 3’ end 
of the U6 promoter, and a final found of amplification to generate enough DNA for 
restriction digest and ligation into the AAV-tRNA packaging vector. This convoluted-
seeming strategy was necessary because small RNA expression from external RNA 
polymerase III promoters is thought to begin within a few nucleotides of the end of the 
promoter and is sensitive to mutations in this region11,12, leaving us no room to include a 
restriction site for tRNA-only cloning; and the entire U6-tRNA piece is too large to be 
synthesized as an oligo pool. Decreasing to two total PCR steps was somewhat helpful, 
but still led to significant scrambling. We turned to Golden Gate assembly, a newer 
cloning strategy which makes use of Type IIs restriction endonucleases whose defining 
feature is that their DNA cleavage site is outside of but adjacent to the recognition 
sequence, allowing the scarless assembly of one or more DNA fragments into a vector13. 
After designing and testing a Golden Gate assembly strategy for library cloning (Figure 
5.8), the project was turned over to Lily Jewel, who used this strategy to clone the oligo 
pool library and perform selections with < 50% sequence scrambling observed by both 
individual clone and Illumina sequencing.  
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Figure 5.8. Cloning of the tRNA library via Golden Gate assembly.  (A) The recognition 
sites (red), cut sites ( | ), and overhangs (underline) of BsaI, a type IIS restriction 
endonuclease commonly used for Golden Gate assembly.  (B) Adding BsaI sites to the 
oligo pool to generate the Golden Gate insert. BsaI sites (in red) were added to the 
primers used for oligo pool amplification.  (C) Adding BsaI site to the AAV-tRNA 
packaging vector. A central stuffer sequence included in place of the tRNA is shown in 
gray.  (D) The AAV-tRNA packaging plasmid product after assembly. The BsaI sites 
have been removed, leaving a scarless product.  
 
5.2.4 Conclusions 
Oligo pool libraries offer an attractive method for designing libraries which make 
more efficient use of sequence space, but their cloning turned out to be unexpectedly 
challenging. We had never worked with a library where we expected distant randomized 
sites to be paired in a particular way, and we learned that our standard library cloning 
protocol involving multiple PCRs with a DNA polymerase which is apparently not 
particularly processive, leads to sequence scrambling. We were able to devise a new 
cloning strategy based on Golden Gate assembly which minimizes PCR steps and uses a 
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more processive DNA polymerase. Furthermore, not only does Golden Gate assembly 
work well for this application, but it takes less time and materials than conventional 
cloning by restriction digest and ligation, and the generation of scarless products could 
have many useful applications in the future. It is also worth noting that the selections 
performed in Chapter 4 used Phusion DNA polymerase and our conventional cloning 
protocol – it is unclear to what extent these results may have been affected by sequence 
scrambling, but in the future PrimeSTAR or a similar DNA polymerase should be used 
wherever the coupling of multiple, distant randomized regions is important and PCR 
steps should be minimized.  
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5.2.6 Experimental procedures 
Oligo pools were purchased from Twist Biosciences. PCR amplification was done with 
Phusion Hot Start II DNA polymerase (Thermo Scientific) or PrimeSTAR Max DNA 
polymerase (Takara) according to the manufacturer’s protocol. Library cloning was as 
described in Chapter 4, and clones were characterized by Sanger sequencing.  
 
Golden Gate assembly was carried out with a homemade mix containing 2 μL T4 DNA 
ligase reaction buffer (Enzymatics), 1 μL each T4 DNA ligase (Enzymatics) and BsaI-
HFv2 (New England Biolabs), 75 ng vector (undigested), and a 2x molar excess of insert 
(gel purified after PCR). The reaction was run in a thermocycler alternating between 37 
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°C and 16 °C for 1 minute each, 30 times, followed by a 55 °C 5 minute step, then 
directly transformed into E. coli.  
 
5.3 A robust pipeline for acquiring and processing Illumina sequencing data 
on tRNA libraries 
5.3.1 Introduction 
Next-generation sequencing is becoming a popular way to analyze the results of 
directed evolution, and we used Illumina sequencing in Chapter 4 to identify highly 
enriched hits and track the fate of thousands of sequences over the course of selection. 
We encountered two major challenges when we added next-generation sequencing to our 
selection protocol – generating high-quality data from our tRNA libraries, which are 
different from the libraries encountered in more typical Illumina applications like whole-
genome sequencing in several important respects, and dealing with the large amount of 
data generated from millions of sequencing reads. This section discusses the way we 
addressed these challenges, with a focus on lessons learned and making the integration of 
this valuable tool into future directed evolution projects as seamless as possible.  
5.3.2 High-quality data from low-diversity libraries 
To discuss the unique data quality issues we encountered in our first round of 
Illumina sequencing, it’s important to briefly discuss the structure of our sequencing 
construct and how the Illumina process works14. For all Illumina sequencing applications, 
the sample DNA to be sequenced is first ligated to adapter sequences which anneal to 
complementary oligos attached to a flow cell. We attach these sequences by PCR during 
sequencing sample prep (Figure 5.9). The sample DNA anneals to these oligos, and each 
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individual DNA sequence is amplified by bridge amplification to generate a cluster of 
homogeneous DNA sequences, which are then sequenced in a process called “sequencing 
by synthesis” in which fluorescently tagged nucleotide monomers are added one at a time 
to synthesize a complementary strand. After each round of monomer addition, the flow 
cell is imaged to record the latest nucleotide incorporated at each cluster, the reversible 
terminators are removed, and the cycle repeats. The quality of the sequencing data 
therefore depends on the sequencer’s ability to distinguish between individual clusters, 
each of which makes up one “read”. When sequencing randomly fragmented genomic 
DNA, each position has a roughly even proportion of A, C, T, and G so adjacent clusters 
fluoresce different colors during each cycle and are therefore easily distinguished, 
allowing the software to make accurate base calls. However, our sequences are “low 
diversity” or highly homogenous, including in the first ~ 10 positions which are used for 
cluster identification15, which led to the lower than expected quality of the first-
generation library sequencing data in Chapter 4.  
 
 
Figure 5.9. Illumina sequencing construct. The piece labeled “From AAV” is amplified 
from the library plasmid pool using two sequential PCR reactions with the primers 
shown. The regions added by PCR include the adapter sequences added which anneal to 
the flow cell (gray), barcodes which are used to de-multiplex data from multiple samples 
run on the same flow cell (cyan), and annealing regions for primers used during Illumina 
sequencing (yellow). The diversity sequence, if used, is added between the Illumina F seq 
primer and the region amplified from the AAV genome. The final reads contain the 
sequences labeled “From AAV”, and the diversity sequence if applicable.  
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After discussing our run quality issues with Illumina technical support and Karen 
Zhu and Prof. Tim van Opijnen from the BC sequencing core facility, we made several 
changes to our sample prep and sequencing protocol based on the best practices for low-
diversity sequencing16,17. Normal sequencing runs use a small amount (typically 5%) of 
DNA from the bacteriophage PhiX genome, but for our samples we increased this to 50% 
of the total reads. We also followed a strategy suggested by Karen Zhu and Prof. van 
Opijnen to add artificial base diversity in the first 10 sequences by using a set of four 
degenerate primers which add a 10-nucleotide “diversity sequence” at the beginning of 
the read. These strategies together were quite helpful as illustrated by comparing the 
overall run quality from the first-generation library A2 (Chapter 4) in which no 
accommodations were made for the low sequence diversity, and A5 oligo pool library, 





Figure 5.10. Comparison of run quality before and after low-diversity sequencing 
adjustments.  (A) A2 library data from Chapter 4, no adjustments and 5% PhiX loading.  
(B) A5 data, 10-nucleotide artificial diversity sequence added at the start of the read and 
50% PhiX loading.  Plots show the frequency of each Q score, a measure of base call 
confidence, in the first 10,000 reads. The right panel shows the entire read, and the left 
panel shows the randomized positions in the library. Higher Q score values indicate better 
quality. A score of 10 indicates a 10% error chance, 20 indicates a 1% chance, and 30 
indicates an 0.1% chance of error.  
 
5.3.3 A modular quality filtering and processing pipeline 
The second significant challenge of Illumina sequencing is the volume of data 
generated. We analyzed the first-generation libraries on a MiSeq instrument, which 
generates ~ 1,000,000 reads per sample. Data is initially received as Fastq sequence files, 
which contain the base calls and quality scores for each read. To make this data useful, 
we need to filter out low-quality reads, then extract the randomized base sequences from 
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every read and finally count the abundance of each variant in the library before and after 
selection. We were aided in this process by Jon Anthony from the biology department for 
the first-generation libraries, but we later developed a custom data pipeline which both 
gives a more detailed view of the data and allows us to perform all data processing 
ourselves. This pipeline is briefly described here and summarized in [], and the code is 
shown in the Appendix. Our goals were to make this pipeline modular so that it could be 
easily adapted for different applications, easy to read and use, and computationally 
efficient enough to run the full data analysis from a sequencing run on a laptop in less 
than an hour.  
We made use of Biopython tools18 to decipher the initial Fastq files, extract the 
quality scores, and filter out low-quality reads. We wanted to keep as many reads as 
possible while ensuring high confidence in the randomized base identification, and also 
make the processing adjustable for data of different qualities. An optional module to 
characterize the overall quality of a run, which was used to generate the plots in Figure 
5.10, is included in the Appendix as well. We set up four quality score filtering 
parameters, shown in Table 5.2, to allow adjustable filtering of base call quality across 
the whole sequence and the randomized bases in particular. Although the overall 
homology of our reads was initially a disadvantage for data quality, we can use this to our 
advantage to add an additional filtering step to remove reads with no resemblance to the 
expected sequence outside of the randomized bases. This step should also remove any 
reads containing insertions or deletions, which would otherwise shift the positions of the 
randomized bases and interfere with the proper identification of the variant sequence. At 
this stage, the frequency of each base at each position as well as the frequency of 
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mismatches from the expected sequences were recorded and plotted. After filtering, the 
randomized bases in each read were identified based on their positions and the 
randomized sequences were extracted and used to identify each variant and count its 
abundance. At this point the enrichment factor calculation for each sequence is the same 
as in Chapter 4. While these filtering and variant counting steps are not trivial, with 
careful optimization the total data processing can be performed in less than 10 minutes 
for a MiSeq data set of 10 million reads using a laptop with mediocre processing power.  
 
Table 5.2. Quality score filtering parameters 
Parameter Recommended value Description 
Q0 10 Do not pass sequences with any Q scores below Q0 
Q1 14 Do not pass sequences with more than QF scores below Q2 
Q2 14 Do not pass sequences with any randomized base Q scores below Q2 
QF 1 Do not pass sequences with more than QF scores below Q2 
 
5.3.4 Validation of the processing pipeline on previously characterized libraries 
We tested our processing pipeline on the previously characterized A1 and A2 
libraries, looking for how well our sequence enrichment factors matched those generated 
from the initial sequence abundance data set produced by Jon Anthony. The parameters 
used for processing are shown in Table 5.3 and the filtering results are shown in Table 
5.4. Overall, enrichment factors calculated using the pipeline described here for read 
filtering and variant counting and those calculated using variant counts from the original 
dataset from Jon Anthony were in good agreement as shown in Figure 5.11a-b. 
Furthermore, this pipeline allows the analysis of the entire tRNA sequence for the first 
time as shown in Figure 5.11c-d. We observed a fairly low mismatch frequency in the 
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non-randomized regions and no significant enrichment of mutations outside of the 
randomized regions. However, this type of analysis could be useful in the future to look 
for fortuitous mutations which sometimes arise during selections.  
 
Table 5.3. Parameters used for A2 library processing. A1 parameters are identical 
except for the location of randomized bases and output formatting.  
Variable Value(s) 
Library name Ac2 
Before selection run Ac2-Lib 
After selection runs - condition 1  Ac2-1 Ac2-2         
After selection runs - condition 2 (use if 
2nd selection condition, e.g. 2xTAG) 
            
Condition 1 name (e.g. 1xTAG)             
Condition 2 name (e.g. 2xTAG)             
Working folder 
C:\Users\Rachel Kelemen\Google Drive\ 
Chatterjee lab\Code\Test data Ac2 Fastq 
Oligo pool sequence file?   






Diversity sequence length - defaults to 0 0 
     
Exclude any bases at the end? (e.g. because 
many truncated runs) - defaults to 0 0      
tRNA 1st base 31 
     
tRNA last base 99 
     
Constant region 1st base 1 35 98       
Constant region last base 31 94 105       
Randomized bases 32 33 34 95 96 97 
Randomized bases expected to be paired - 5' 32 33 34       
Randomized bases expected to be paired - 3' 97 96 95       
Q1 14 
     
Q2 – defaults to Q1 14 
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QF – allowed failures – defaults to 0 1 
     
Q0 – defaults to 0 10 
     
Max mismatches allowed for each 
constant region 4 6 2       
Minimum "abundant" library count - 
defaults to 1 
1 
     
How do you want the randomized sequences 
formatted? 
NNN/NNN 
Create a fuller stem sequence, e.g. for 
comparison to other libraries? 
NNNACC/GGUNNN 
 
Table 5.4. Sample filtering stats from A2 library before selection. Filters are shown in 
the order in which they were applied. Data from other samples was very similar.  
Step Total reads % of initial dataset 
Initial dataset 1,006,902 100% 
Truncated reads 1,120  
Fail on Q0 0  
Fail on Q1 43,077  
Fail on Q2 87  
Q score pass 962,618 95.6% 
Fail on region 1 mismatch 23,087  
Fail on region 2 mismatch 15,199  
Fail on region 3 mismatch 10,582  




Figure 5.11. Testing the Illumina data processing pipeline on the A1 and A2 
libraries.  (A)-(B) Comparison of enrichment factors with sequence filtering and variant 
abundance calculation by Jon Anthony or using the pipeline described here. (A) A1 
library. (B) A2 library.  (C)-(D) Plotting base abundances across the entire sequence 
before and after selection on the A1 library. The expected sequence is shown along the 





Illumina sequencing is a relatively fast an inexpensive way to gain broad insights 
into the results of our tRNA selections. We have learned several important lessons about 
the sequencing of low-diversity libraries which should be useful for analyzing many 
different types of selections moving forward, in particular the importance of including 
good base diversity in the first ten positions. We have also developed a new custom data 
analysis pipeline for the Illumina sequencing of tRNA libraries. The results from this 
method are in good agreement with previously acquired results, indicating that it provides 
accurate analysis of large datasets. Since the results described here, these scripts have 
been used to analyze the results of several additional selections including the oligo pool 
library discussed in section 5.2.  
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5.4 Using photo-caged UAAs to generate a light-activatable caspase-3 
5.4.1 Introduction 
While most of this thesis has focused on using GCE to engineer viruses, it is of 
course also extremely useful for probing and engineering the biology of individual 
proteins. Caspases are among the most important proteins in apoptosis, the process of 
mammalian cell death. They are activated near the beginning of the process and are 
directly or indirectly responsible for most of the dramatic changes and ultimate controlled 
destruction of the cell which results. Proteolysis-sensitive proteomics methods have been 
very useful for generating lists of caspase substrates, but the function of many of these 
cleavage events remains unclear and it can be difficult to tease out functionally important 
targets from less important or even inadvertent cleavage events. In particular, a timeline 
of caspase substrate cleavage events had been challenging to pin down when we started 
this project owing to the difficulty of inducing apoptosis in a population of cells in a 
controlled and synchronous manner. Light-reactive UAAs represent a powerful and non-
invasive way to control biological processes with spatial and temporal precision19. We 
used a photo-caged cysteine derivative to block a key catalytic residue in the active site 
of a constitutively active caspase-3 variant, allowing us to induce caspase-3 activity with 
light in a temporally controlled manner (Figure 5.12).  
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Figure 5.12. Activation of a photo-caged caspase-3 with light.  
 
5.4.2 Incorporating and validating a photo-caged cysteine UAA 
Caspases use a catalytic cysteine residue to cleave their targets, which we can 
photo-cage using a dimethoxynitrobenzyl-protected UAA (DMNB-Cys) variant which 
can be photo-deprotected with non-toxic 365 nm UV light20 (Figure 5.13a). To validate 
UAA incorporation and photo-cleavage, we first incorporated DMNB-Cys into GFP-39-
TAG using the previously reported E. coli leucyl-derived NVocCysRS/tRNALeu pair21. 
Mass spectrometry confirmed UAA incorporation and complete decaging after 90 
seconds of irradiation (Figure 5.13a). Because the irradiation was done in cells, this 
experiment provides important validation that our photo-caged caspase could be 




Figure 5.13. Validation of DMNB-Cys incorporation and decaging.  (A) Structure and 
photo-deprotection of DMNB-Cys.  (B) DMNB-Cys was incorporated into EGFP in 
HEK293T cells. Cells were irradiated 48 hours after transfection and protein was 
harvested and analyzed by LCMS.  
 
With these results in hand, we turned to the design of an appropriate photo-caged 
caspase-3. The ideal protein construct would be completely toxic under non-irradiation 
conditions but lead to rapid cell death upon irradiation, and faithfully replicate the 
substrate specificity of endogenous caspase-3. Because caspases are so toxic, they are 
synthesized as an inactive zymogen which is activated by proteolysis to form the mature 
heterodimeric enzyme. We wanted our caspase to adopt its active conformation after 
decaging, so simply photo-caging the inactive full-length protein was not an option. 
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Instead, we used a constitutively active permuted caspase-3 variant from the literature in 
which the order of the large and small subunits is switched (Figure 5.14a). This artificial 
enzyme is constitutively active and believed to undergo auto-cleavage to resemble the 
endogenous mature form of caspase-3. Indeed, when we transfected HEK293T cells with 
the constitutively active caspase-3, we observed apoptotic morphology and cell death 
within 24 hours (Figure 5.14b). Finally, we demonstrated DMNB-Cys incorporation into 
our constitutively active caspase-3 construct with a C-terminal mCherry fusion to 
visualize full-length protein expression (Figure 5.14c).  
 
 
Figure 5.14. A constitutively active caspase-3 variant.  (A) Caspase-3 and 
constitutively active caspase-3 gene structures.  (B) Transfection of cells with the wild-
type constitutively active caspase-3 construct. Each panel shows a wide-field image (left) 
and zoomed-in section (right). Images were taken 24 hours post-transfection  (C) 
Incorporation of DMNB-Cys into the constitutively active caspase-3 visualized by C-
terminal mCherry fusion. Cells were transfected in the presence or absence of 25 μM 
DMNB-Cys and imaged 48 hours later.  
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We did not observe apoptotic morphology in cells transfected with the photo-
caged caspase variant in the absence of irradiation, but when cells were irradiated with 
UV light we saw an abrupt transition to apoptotic morphology with membrane blebbing 
in a manner of hours (Figure 5.15a). Confocal imaging confirmed the rapid onset of 
drastic morphology changes in irradiated cells (Figure 5.15b). We used an Annexin V-
FITC conjugate to visualize externalization of phosphatidyl-serine on the cell membrane, 
a hallmark of early apoptosis, and while we saw significant background staining the 
extent of staining and the overlap of Annexin V and our caspase-mCherry construct 
appeared to increase in a brief window after irradiation (Figure 5.15c). However, all of 
these experiments suffered from poor transfection efficiency and mild background 
toxicity due to the transfection reagent we were using at the time, the commercial lipid 
mixture XtremeGene. We developed a baculovirus construct expressing our photo-caged 
caspase-mCherry fusion protein, NVocCysRS, and tRNALeu and demonstrated highly 
efficient gene delivery by mCherry fluorescence (Figure 5.16). We observed population-
wide cell morphology changes and death upon irradiation of cells expressing the photo-
caged caspase in the presence of DMNB-Cys, but not in cells which did not receive either 
UAA or irradiation. At this point, unfortunately, the project was paused due to prolonged 




Figure 5.15. Rapid onset of morphology and membrane changes after irradiation of 
cells expressing photo-caged caspase.  (A) Cells expressing photo-caged caspse-
mCherry fusion protein were imaged at various timepoints after irradiation.  (B) Same as 
(A), but with imaging on a laser scanning confocal microscope at higher magnification.  
(C) Annexin V-FITC (green) stains cells with externalized phosphatidyl-serine, a 




Figure 5.16. Baculovirus-based delivery of photo-caged caspase-mCherry fusion 
protein.  (A) Cells were imaged 2h after exposure to the conditions indicated.  (B) Cells 






We have developed a light-activated version of caspase-3 by introducing a photo-
caged cysteine UAA into the active site, delivered this construct to HEK293T cells by 
transfection or baculovirus infection, and shown that the onset of apoptosis is rapid in the 
presence of both UAA and irradiation. Since we started this work, the generation of a 
timeline of caspase cleavages was reported using an alternative light-activated caspase 
strategy in which a different constitutively active caspase-3 variant was fused to a 
photosensitive LOV2 domain22. However, we are still confident that our strategy can be 
useful because LOV2 is a significantly sized protein which must be fused in a very 
particular orientation to generate a caspase-3 which is active upon irradiation but non-
toxic in its inactive form. By contrast, our modification is very small and should be more 
easily extendable to a broader variety of constitutively active forms for the study of 
caspase substrates and biology and to the other ~ 10 naturally occurring caspase 
homologs. The issue we were having with the insect cells has since been resolved by 
Yunan Zheng and Sam Levinson, so this project could be resumed at any time.   
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Item Color code 
Rep  Light blue 
Cap  Dark blue 






























































































































Item Color code 
ITRs  Pink 
GFP  Green 





























































































Item Color code 


































































































































































































Item Color code 
Rep  Light blue 
Cap  Dark blue 
AAP Dark Green 
CMV Yellow 
MbPylRS Orange 
BGH polyA Yellow-orange 
From pAAV-RC2 Underline 
D327-TAG mutation site Red highlight 
G453-TAG mutation site Yellow highlight 
T454-TAG mutation site Green highlight 
N587-TAG mutation site Blue highlight 


























































































































































Item Color code 
ITRs  Pink 
GFP  Green 
CMV promoter Yellow 
Poly-A Yellow-orange 






































































































































Item Color code 
ITRs  Pink 
GFP  Green 
CMV promoter Yellow 
Poly-A Yellow-orange 































































































Item Color code 
ITRs  Pink 
mCherry  Dark red 
CMV promoter Yellow 
Poly-A Yellow-orange 







































































































Item Color code 
ITRs  Pink 
GFP  Green 
CMV promoter Yellow 
Poly-A Yellow-orange 




































































































Chapter 4 plasmids 
pIDT-ITR-no-tRNA-GFP (library cloning vector) 
 
 
Item Color code 
ITRs  Pink 
GFP  Green 
CMV promoter (5’ truncated) Yellow 
Poly-A Yellow-orange 
U6 promoter (3’ truncated) Brown 
KpnI library cloning site Red underline 






















































































Item Color code 
U6 promoter  Yellow 
tRNAPyl  Red 
AvrII restriction site Blue 
NheI restriction site Orange 































































































Item Color code 
CMV Yellow 
MbPylRS Orange 



































































































Item Color code 
CMV Yellow 
GFP Green 
Y39-TAG mutation site Red highlight 
Y151-TAG mutation site Yellow highlight 
WPRE element Light gray 
BGH polyA Yellow-orange 
Polyhedrin promoter Yellow 
VSV-G protein Cyan 




















































































































































 Oligonucleotide primers 














N587mutTAG-R CTGCGGTAGCTGCTTGTCTCTAGCCTCTCTGGAGGTTGGTAGATACAGAA CC 
RC2-SbfI-R GCAAATACCTGCAGGATCCGTTTTGCGCTG 
G328mutTAG-F GAGGTCACGGAGAATGACTAGACGACGACGATTGCCAATAACCTTAACA GC 

































































































All library primers were synthesized with hand-mixed randomized bases in a 1:1:1:1 





























































 Next-generation sequencing data 
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Data was processed using the code listed under Chapter 4 code in Appendix 4.   
 








Selection repeat 1 
  
Selection repeat 2 
  
Average across selections 
 
 













GGUACC 176 2023 4726 17.74 100.0% 1 5875 24.89 93.2% 3 1 96.6% 4.8% 3 
GGGCCC 292 636 7526 17.03 96.0% 2 10088 25.76 96.5% 2 2 96.2% 0.4% 3 
GGGCCU 372 312 8871 15.76 88.8% 4 13319 26.70 100.0% 1 3 94.4% 7.9% 3 
GGGUCC 303 575 7401 16.14 91.0% 3 8931 21.98 82.3% 5 4 86.6% 6.1% 3 
AGGCCU 301 589 6610 14.51 81.8% 5 9455 23.42 87.7% 4 5 84.8% 4.2% 3 
GGGUCU 326 457 6408 12.99 73.2% 7 8419 19.26 72.1% 6 6 72.7% 0.8% 3 
GGAUCC 268 795 5602 13.81 77.8% 6 5408 15.05 56.4% 11 7 67.1% 15.2% 3 
GGGCUC 263 833 4459 11.20 63.1% 11 6627 18.79 70.4% 7 8 66.8% 5.1% 3 
GGAUCU 325 458 6288 12.79 72.1% 8 6460 14.82 55.5% 12 9 63.8% 11.7% 3 
GAUAUC 127 3068 2117 11.02 62.1% 12 2849 16.73 62.7% 9 10 62.4% 0.4% 3 
GGUACU 312 521 4985 10.56 59.5% 14 7034 16.81 63.0% 8 11 61.2% 2.5% 3 
GGGGCC 336 411 5528 10.87 61.3% 13 6830 15.16 56.8% 10 12 59.0% 3.2% 2 
GGUAUC 201 1591 3557 11.69 65.9% 9 3645 13.52 50.6% 16 13 58.3% 10.8% 3 
CGGUCG 169 2167 2906 11.36 64.0% 10 3040 13.41 50.2% 17 14 57.1% 9.8% 3 
GAAUUC 259 881 3815 9.73 54.9% 16 5067 14.59 54.6% 13 15 54.7% 0.2% 3 
AGGUCU 371 316 5440 9.69 54.6% 17 7047 14.16 53.1% 14 16 53.8% 1.1% 3 
GGCGCU 392 260 5608 9.45 53.3% 18 7372 14.02 52.5% 15 17 52.9% 0.5% 3 
GAGCUC 206 1515 3134 10.05 56.7% 15 3408 12.34 46.2% 19 18 51.4% 7.4% 3 
UGGCCG 219 1318 2781 8.39 47.3% 23 3835 13.06 48.9% 18 19 48.1% 1.1% 3 
GACGUC 224 1250 3051 9.00 50.7% 21 3595 11.97 44.8% 20 20 47.8% 4.2% 3 
GGUGCC 208 1488 2899 9.21 51.9% 19 3088 11.07 41.5% 24 21 46.7% 7.4% 3 
AGAUCU 332 422 4530 9.02 50.8% 20 4721 10.60 39.7% 29 22 45.3% 7.8% 3 
AGUACU 298 607 3501 7.76 43.8% 29 4704 11.77 44.1% 21 23 43.9% 0.2% 3 
GGUGCU 302 584 4005 8.76 49.4% 22 4340 10.72 40.1% 28 24 44.8% 6.5% 3 
GGAUUC 286 678 3627 8.38 47.2% 24 4116 10.73 40.2% 27 25 43.7% 5.0% 3 
UGGCCA 222 1277 2570 7.65 43.1% 31 3358 11.28 42.2% 23 26 42.7% 0.6% 3 
GGGUUC 336 410 3625 8.34 47.0% 26 5159 9.77 36.6% 31 27 41.8% 7.4% 3 
GGCGUC 249 960 2684 7.12 40.1% 34 3693 11.06 41.4% 25 28 40.8% 0.9% 3 




GGUGUC 196 1675 2476 8.35 47.0% 25 2440 9.28 34.8% 35 30 40.9% 8.7% 3 
CGGCCG 208 1483 2084 6.62 37.3% 39 2994 10.73 40.2% 26 31 38.8% 2.0% 3 
GGGGCU 522 178 5560 7.04 39.7% 36 6772 9.67 36.2% 32 32 38.0% 2.4% 2 
CGAUCG 174 2084 2114 8.03 45.2% 28 1991 8.53 32.0% 41 33 38.6% 9.4% 3 
CGUACG 111 3370 1219 7.26 40.9% 32 1305 8.77 32.8% 40 34 36.9% 5.7% 3 
AGCGCU 380 287 3561 6.19 34.9% 43 4984 9.78 36.6% 30 35 35.8% 1.2% 3 
GGGGUC 316 502 3143 6.57 37.0% 40 3904 9.21 34.5% 36 36 35.8% 1.8% 2 
GAGUUC 284 695 2877 6.69 37.7% 38 3382 8.88 33.3% 39 37 35.5% 3.2% 3 
GGGACC 226 1225 2102 6.15 34.6% 44 2832 9.34 35.0% 34 38 34.8% 0.3% 2 
GCUAGC 92 3715 1155 8.30 46.8% 27 854 6.92 25.9% 50 39 36.3% 14.7% 3 
GACGUU 290 653 2430 5.54 31.2% 49 3761 9.67 36.2% 33 40 33.7% 3.5% 3 
GCAUGC 193 1725 1866 6.39 36.0% 42 2187 8.45 31.6% 42 41 33.8% 3.1% 3 
GAUGUC 209 1469 2451 7.75 43.7% 30 1908 6.81 25.5% 52 42 34.6% 12.9% 3 
UGGUCA 220 1310 2297 6.90 38.9% 37 2061 6.99 26.2% 49 43 32.5% 9.0% 3 
GGGGGC 1154 50 11244 6.44 36.3% 41 11483 7.42 27.8% 47 44 32.0% 6.0% 1 
GUGCAC 175 2045 1875 7.08 39.9% 35 1548 6.60 24.7% 54 45 32.3% 10.7% 3 
GGCACC 139 2790 950 4.52 25.5% 64 1663 8.92 33.4% 38 46 29.4% 5.6% 2 
AGGGCU 441 209 3752 5.62 31.7% 48 4448 7.52 28.2% 46 47 29.9% 2.5% 2 
GGGACU 295 621 2089 4.68 26.4% 61 3299 8.34 31.2% 43 48 28.8% 3.4% 2 
UGCGCG 141 2752 1111 5.21 29.3% 50 1442 7.63 28.6% 45 49 29.0% 0.6% 3 
GCUAGU 217 1343 1963 5.98 33.7% 45 1927 6.62 24.8% 53 50 29.2% 6.3% 3 
GGAGCC 321 478 2837 5.84 32.9% 47 2643 6.14 23.0% 59 51 28.0% 7.0% 2 
CACGUG 127 3044 547 2.85 16.0% 137 1543 9.06 33.9% 37 52 25.0% 12.7% 3 
CAUAUG 135 2889 820 4.01 22.6% 81 1427 7.88 29.5% 44 53 26.1% 4.9% 3 
GGUGGC 391 262 3483 5.89 33.2% 46 3039 5.80 21.7% 69 54 27.4% 8.1% 2 
UGAUCA 330 431 2354 4.71 26.6% 60 3049 6.89 25.8% 51 55 26.2% 0.5% 3 
GGGCGC 354 347 2653 4.95 27.9% 54 3098 6.53 24.4% 55 56 26.2% 2.5% 2 
CAUGUG 137 2850 1045 5.04 28.4% 52 1165 6.34 23.8% 56 57 26.1% 3.3% 3 
GGUCCU 290 646 1821 4.15 23.4% 76 2789 7.17 26.9% 48 58 25.1% 2.5% 2 
GGAGCU 440 210 3319 4.98 28.1% 53 3468 5.88 22.0% 65 59 25.1% 4.3% 2 
UGCGUG 147 2628 1139 5.12 28.9% 51 1131 5.74 21.5% 70 60 25.2% 5.2% 3 
GGGAUC 203 1569 1387 4.51 25.4% 65 1715 6.30 23.6% 57 61 24.5% 1.3% 2 
GGUUCU 313 517 2128 4.49 25.3% 68 2639 6.29 23.5% 58 62 24.4% 1.3% 2 




GCAUGU 277 733 1885 4.50 25.3% 67 2277 6.13 23.0% 60 64 24.2% 1.7% 3 
UGGUCG 211 1435 1562 4.89 27.6% 57 1585 5.60 21.0% 74 65 24.3% 4.7% 3 
UCAUGA 112 3348 729 4.30 24.2% 72 907 6.04 22.6% 62 66 23.4% 1.1% 3 
GCGCGC 231 1152 1728 4.94 27.9% 55 1669 5.39 20.2% 76 67 24.0% 5.4% 3 
GGUUCC 169 2159 1140 4.46 25.1% 69 1319 5.82 21.8% 68 68 23.5% 2.3% 2 
UGUACG 116 3259 830 4.73 26.6% 59 843 5.42 20.3% 75 69 23.5% 4.5% 3 
GGCUCU 214 1384 1239 3.83 21.6% 86 1755 6.12 22.9% 61 70 22.2% 1.0% 2 
UGCGCA 225 1244 1339 3.93 22.2% 84 1798 5.96 22.3% 63 71 22.2% 0.1% 3 
GGUAGC 127 3062 949 4.94 27.8% 56 798 4.69 17.5% 90 72 22.7% 7.3% 2 
GUGCGC 124 3114 733 3.91 22.0% 85 937 5.63 21.1% 72 73 21.6% 0.6% 3 
GGGCCG 317 496 1989 4.15 23.4% 77 2272 5.34 20.0% 77 74 21.7% 2.4% 2 
GGCGGC 1462 31 10024 4.53 25.5% 63 9617 4.90 18.4% 86 75 22.0% 5.1% 2 
GGCACU 173 2095 925 3.53 19.9% 97 1363 5.87 22.0% 66 76 21.0% 1.5% 2 
CAGCUG 169 2160 1125 4.40 24.8% 71 1133 5.00 18.7% 82 77 21.8% 4.3% 3 
GGUUUC 199 1626 1112 3.69 20.8% 93 1498 5.61 21.0% 73 78 20.9% 0.2% 2 
GGCCCU 187 1836 945 3.34 18.8% 102 1477 5.89 22.1% 64 79 20.4% 2.3% 2 
CCUAGG 84 3823 502 3.95 22.3% 83 590 5.24 19.6% 78 80 20.9% 1.9% 3 
ACAUGU 285 692 1943 4.51 25.4% 66 1712 4.48 16.8% 100 81 21.1% 6.1% 3 
GUAUGC 175 2048 1090 4.12 23.2% 78 1132 4.82 18.1% 87 82 20.6% 3.6% 3 
GGCUCC 160 2343 879 3.63 20.5% 95 1121 5.22 19.6% 79 83 20.0% 0.6% 2 
GUCGAC 90 3748 569 4.18 23.5% 75 563 4.66 17.5% 92 84 20.5% 4.3% 3 
UGAUCG 203 1572 1317 4.29 24.2% 73 1231 4.52 16.9% 97 85 20.5% 5.1% 3 
GGGUGC 363 329 2197 4.00 22.5% 82 2317 4.76 17.8% 89 86 20.2% 3.3% 2 
GAGGUC 259 875 1482 3.78 21.3% 89 1627 4.68 17.5% 91 87 19.4% 2.7% 2 
GACGCC 264 832 1520 3.80 21.4% 87 1644 4.64 17.4% 94 88 19.4% 2.9% 2 
GGGGGU 1760 19 10111 3.80 21.4% 88 10669 4.52 16.9% 99 89 19.2% 3.2% 1 
AGUGCU 373 305 2094 3.71 20.9% 91 2304 4.61 17.3% 95 90 19.1% 2.6% 3 
CCCGAG 99 3605 372 2.48 14.0% 169 759 5.72 21.4% 71 91 17.7% 5.2% 2 
CGGGCG 263 850 1671 4.20 23.7% 74 1410 4.00 15.0% 111 92 19.3% 6.1% 2 
CGCGUG 139 2786 984 4.68 26.4% 62 653 3.50 13.1% 134 93 19.7% 9.4% 3 
UACGUA 164 2259 781 3.15 17.7% 110 1101 5.01 18.8% 81 94 18.2% 0.7% 3 
CUGCAG 134 2916 577 2.85 16.0% 138 938 5.22 19.6% 80 95 17.8% 2.5% 3 
CAAUUG 206 1523 978 3.14 17.7% 111 1360 4.92 18.4% 85 96 18.1% 0.5% 3 




GUAUAC 188 1805 1151 4.05 22.8% 79 953 3.78 14.2% 123 98 18.5% 6.1% 3 
CUCGAG 75 3925 318 2.80 15.8% 146 501 4.98 18.7% 83 99 17.2% 2.0% 3 






Selection repeat 1 
  
Selection repeat 2 
  
Average across selections 
 
 













AGGUCU 212 2165 3385 11.4412 100.0% 1 2725 10.8537 100.0% 1 1 100.0% 0.0% 3 
GGGUCC 190 2621 2913 10.9859 96.0% 2 2438 10.835 99.8% 2 2 97.9% 2.7% 3 
GGGUCU 186 2705 2621 10.0972 88.3% 3 2327 10.5641 97.3% 3 3 92.8% 6.4% 3 
ACGUGU 287 1078 3929 9.80951 85.7% 4 3160 9.2972 85.7% 7 4 85.7% 0.1% 3 
AAGCUU 271 1236 3128 8.27074 72.3% 9 3177 9.89909 91.2% 4 5 81.7% 13.4% 3 
ACAUGU 403 344 5037 8.956 78.3% 6 4330 9.07256 83.6% 8 6 80.9% 3.8% 3 
GGGCCU 138 3602 1563 8.11572 70.9% 12 1556 9.52089 87.7% 5 7 79.3% 11.9% 3 
GGGGCC 207 2262 2712 9.38786 82.1% 5 2016 8.2237 75.8% 14 8 78.9% 4.4% 2 
AGGCUU 154 3302 1760 8.18916 71.6% 10 1704 9.34321 86.1% 6 9 78.8% 10.3% 3 
AGGCCU 166 3060 1860 8.02883 70.2% 14 1777 9.03913 83.3% 9 10 76.7% 9.3% 3 
AACGUU 440 230 4790 7.80064 68.2% 16 4689 8.9986 82.9% 10 11 75.5% 10.4% 3 
GGGCCC 151 3372 1831 8.68878 75.9% 7 1451 8.11405 74.8% 15 12 75.4% 0.8% 3 
AGAUCU 296 1001 3493 8.45579 73.9% 8 2901 8.27567 76.2% 13 13 75.1% 1.7% 3 
AGCGCU 291 1044 3289 8.09875 70.8% 13 2962 8.59487 79.2% 12 14 75.0% 5.9% 3 
AGGCCC 132 3688 1380 7.49122 65.5% 19 1357 8.68067 80.0% 11 15 72.7% 10.3% 2 
GGCGCU 209 2216 2191 7.51179 65.7% 18 1969 7.95512 73.3% 16 16 69.5% 5.4% 3 
AGUGCU 213 2155 2171 7.30344 63.8% 20 2005 7.94844 73.2% 17 17 68.5% 6.6% 3 
GGGCUC 204 2317 2154 7.56594 66.1% 17 1858 7.69064 70.9% 18 18 68.5% 3.3% 3 
GUGUAC 308 891 3420 7.95651 69.5% 15 2629 7.20754 66.4% 25 19 68.0% 2.2% 3 
GGCGCC 212 2167 2408 8.13894 71.1% 11 1738 6.92247 63.8% 27 20 67.5% 5.2% 3 
UGGCCA 129 3735 1108 6.15456 53.8% 31 1174 7.68468 70.8% 19 21 62.3% 12.0% 3 




UGGUCA 235 1732 2351 7.16856 62.7% 21 1862 6.69051 61.6% 32 23 62.1% 0.7% 3 
GGUGCU 180 2802 1571 6.2539 54.7% 30 1602 7.51514 69.2% 21 24 62.0% 10.3% 3 
GGGCUU 175 2916 1466 6.00265 52.5% 38 1580 7.62371 70.2% 20 25 61.4% 12.6% 3 
GGUGUC 183 2754 1545 6.04957 52.9% 36 1611 7.43347 68.5% 23 26 60.7% 11.0% 3 
GAGCUU 343 621 3300 6.89393 60.3% 23 2615 6.43761 59.3% 33 27 59.8% 0.7% 3 
GGUGCC 165 3087 1634 7.09603 62.0% 22 1207 6.1769 56.9% 38 28 59.5% 3.6% 3 
GGGCAC 155 3296 1377 6.36575 55.6% 28 1266 6.89683 63.5% 28 29 59.6% 5.6% 2 
GGGUUC 392 386 3337 6.09982 53.3% 33 3223 6.94259 64.0% 26 30 58.6% 7.5% 3 
GUUGAC 185 2714 1465 5.67431 49.6% 43 1607 7.33485 67.6% 24 31 58.6% 12.7% 3 
GGAUCU 345 605 3193 6.63173 58.0% 24 2594 6.34889 58.5% 35 32 58.2% 0.4% 3 
AUGCAU 257 1423 2198 6.12832 53.6% 32 2067 6.79133 62.6% 30 33 58.1% 6.4% 3 
GGUACC 104 3992 939 6.46963 56.5% 26 763 6.19496 57.1% 37 34 56.8% 0.4% 3 
AUCGAU 257 1407 2331 6.49915 56.8% 25 1869 6.14078 56.6% 39 35 56.7% 0.2% 3 
UCGUGA 165 3083 1466 6.36645 55.6% 27 1216 6.22296 57.3% 36 36 56.5% 1.2% 3 
UACGUA 329 709 2786 6.06782 53.0% 34 2506 6.4318 59.3% 34 37 56.1% 4.4% 3 
ACGCGU 218 2061 1640 5.39057 47.1% 47 1768 6.84815 63.1% 29 38 55.1% 11.3% 3 
GGGGCU 230 1805 1940 6.04395 52.8% 37 1645 6.03928 55.6% 41 39 54.2% 2.0% 2 
ACCGGU 270 1251 2226 5.90757 51.6% 40 1955 6.11407 56.3% 40 40 54.0% 3.3% 3 
ACUAGU 197 2472 1451 5.27774 46.1% 51 1564 6.70375 61.8% 31 41 53.9% 11.1% 3 
AGGGCU 233 1759 1924 5.91693 51.7% 39 1633 5.91803 54.5% 44 42 53.1% 2.0% 2 
GAGCUC 423 280 3580 6.06443 53.0% 35 2841 5.67124 52.3% 50 43 52.6% 0.5% 3 
CAGUUG 344 614 2743 5.71366 49.9% 42 2443 5.9967 55.3% 43 44 52.6% 3.8% 3 
GGAUCC 489 158 3999 5.85989 51.2% 41 3140 5.42211 50.0% 53 45 50.6% 0.9% 3 
AUGUAU 326 736 2318 5.09499 44.5% 55 2329 6.03252 55.6% 42 46 50.1% 7.8% 3 
GGUUCC 149 3395 1085 5.21784 45.6% 52 1004 5.68977 52.4% 48 47 49.0% 4.8% 2 
AGUACU 199 2432 1394 5.01946 43.9% 58 1385 5.87684 54.1% 45 48 49.0% 7.3% 3 
GUGCAU 229 1822 1667 5.21612 45.6% 53 1510 5.56786 51.3% 51 49 48.4% 4.0% 3 
UAGCUA 179 2812 1232 4.93179 43.1% 60 1216 5.73625 52.9% 47 50 48.0% 6.9% 3 
GACGUU 562 83 4150 5.29126 46.2% 50 3570 5.36388 49.4% 57 51 47.8% 2.2% 3 
GUGGAC 231 1787 1816 5.63315 49.2% 45 1372 5.01521 46.2% 62 52 47.7% 2.1% 2 
GUGCAC 229 1827 1805 5.64792 49.4% 44 1339 4.93733 45.5% 65 53 47.4% 2.7% 3 
AUAUAU 447 215 3362 5.38936 47.1% 48 2732 5.16084 47.5% 60 54 47.3% 0.3% 3 
GCGCGC 208 2248 1591 5.48093 47.9% 46 1227 4.98114 45.9% 64 55 46.9% 1.4% 3 




UCAUGA 189 2655 1172 4.44337 38.8% 72 1288 5.75442 53.0% 46 57 45.9% 10.0% 3 
GCGUGC 403 342 2999 5.33235 46.6% 49 2310 4.8401 44.6% 68 58 45.6% 1.4% 3 
GGCGUU 322 767 2136 4.75327 41.5% 63 2052 5.38107 49.6% 55 59 45.6% 5.7% 3 
GGUACU 132 3687 943 5.119 44.7% 54 783 5.00882 46.1% 63 60 45.4% 1.0% 3 
GGCGUC 340 640 2209 4.65547 40.7% 69 2162 5.36938 49.5% 56 61 45.1% 6.2% 3 
AGCGCC 202 2374 1426 5.05842 44.2% 57 1167 4.87828 44.9% 67 62 44.6% 0.5% 2 
UAGUUA 298 976 1824 4.38587 38.3% 74 1902 5.38941 49.7% 54 63 44.0% 8.0% 3 
GAGUUC 891 15 5946 4.78183 41.8% 62 5195 4.92329 45.4% 66 64 43.6% 2.5% 3 
AAUAUU 364 510 2217 4.36427 38.1% 75 2226 5.16382 47.6% 59 65 42.9% 6.7% 3 
UCUGGA 154 3319 1094 5.0903 44.5% 56 808 4.43035 40.8% 82 66 42.7% 2.6% 3 
CAGCUG 207 2257 1367 4.73201 41.4% 65 1164 4.74821 43.7% 71 67 42.6% 1.7% 3 
UACGUG 372 465 2250 4.33398 37.9% 76 2253 5.11406 47.1% 61 68 42.5% 6.5% 3 
UGAUCA 311 854 2057 4.73937 41.4% 64 1722 4.67541 43.1% 76 69 42.3% 1.2% 3 
UUCGAG 119 3854 826 4.97371 43.5% 59 608 4.31424 39.7% 86 70 41.6% 2.6% 3 
GGGGUU 264 1336 1720 4.66844 40.8% 68 1425 4.55783 42.0% 79 71 41.4% 0.8% 2 
AGCACU 177 2878 1104 4.46934 39.1% 70 993 4.73722 43.6% 72 72 41.4% 3.2% 2 
GGCACC 148 3416 779 3.77158 33.0% 97 907 5.17479 47.7% 58 73 40.3% 10.4% 2 
GUCGAC 222 1966 1482 4.78346 41.8% 61 1091 4.14972 38.2% 93 74 40.0% 2.5% 3 
ACGCGC 179 2807 1057 4.23125 37.0% 78 996 4.69844 43.3% 75 75 40.1% 4.5% 2 
GGGUGC 298 978 1948 4.68403 40.9% 66 1470 4.16532 38.4% 91 76 39.7% 1.8% 2 
AUUAAU 207 2252 1207 4.17815 36.5% 79 1144 4.66662 43.0% 77 77 39.8% 4.6% 3 
UCUAGA 76 4090 355 3.34705 29.3% 122 494 5.48859 50.6% 52 78 39.9% 15.1% 3 
AAGUUU 392 385 2157 3.94286 34.5% 90 2236 4.81652 44.4% 69 79 39.4% 7.0% 3 
GAGGUC 725 31 4517 4.46436 39.0% 71 3635 4.23364 39.0% 90 80 39.0% 0.0% 2 
GCGCGU 179 2814 999 3.99908 35.0% 88 976 4.60409 42.4% 78 81 38.7% 5.3% 3 
GGACCC 278 1172 1616 4.16528 36.4% 81 1457 4.4255 40.8% 83 82 38.6% 3.1% 2 
GGGGUC 335 668 2014 4.30786 37.7% 77 1686 4.24972 39.2% 89 83 38.4% 1.1% 2 
UCGCGA 95 4052 532 4.01269 35.1% 87 496 4.40865 40.6% 84 84 37.8% 3.9% 3 
UAUAUA 223 1957 1150 3.69522 32.3% 106 1246 4.71803 43.5% 74 85 37.9% 7.9% 3 
ACUGGU 258 1395 1273 3.53554 30.9% 111 1468 4.80456 44.3% 70 86 37.6% 9.5% 3 
GUGUGC 447 216 2768 4.43717 38.8% 73 2056 3.88385 35.8% 108 87 37.3% 2.1% 3 
UAAUUA 411 316 2161 3.76756 32.9% 98 2211 4.54249 41.9% 80 88 37.4% 6.3% 3 
GACGUC 730 29 4215 4.13735 36.2% 82 3543 4.09822 37.8% 96 89 37.0% 1.1% 3 




GAUGUC 544 100 3089 4.0688 35.6% 84 2631 4.08384 37.6% 97 91 36.6% 1.5% 3 
UGGUCG 227 1862 1172 3.69955 32.3% 105 1195 4.44518 41.0% 81 92 36.6% 6.1% 3 
UAGCUG 195 2514 1039 3.81793 33.4% 95 988 4.27828 39.4% 88 93 36.4% 4.3% 3 
UGUGCA 226 1885 1062 3.36716 29.4% 120 1265 4.72639 43.5% 73 94 36.5% 10.0% 3 
AAUGUU 426 273 2229 3.74928 32.8% 100 2167 4.29533 39.6% 87 95 36.2% 4.8% 3 
UGGCCG 134 3658 724 3.87151 33.8% 93 647 4.07706 37.6% 99 96 35.7% 2.6% 3 
GCCGGC 276 1184 1564 4.06046 35.5% 85 1263 3.86404 35.6% 109 97 35.5% 0.1% 3 
GGUAUC 168 3024 957 4.08178 35.7% 83 758 3.80984 35.1% 114 98 35.4% 0.4% 3 
GGCGGC 255 1453 1420 3.99021 34.9% 89 1175 3.89085 35.8% 107 99 35.4% 0.7% 2 






Selection repeat 1 
  
Selection repeat 2 
  
Average across selections 
 
 













GCAUGC 58 1906 796 9.47297 89.7% 4 2150 26.6837 100.0% 1 1 94.8% 7.3% 3 
CCAUGG 156 246 2204 9.75188 92.3% 2 5100 23.5332 88.2% 2 2 90.3% 2.9% 3 
CUGCAG 158 239 1739 7.59703 71.9% 7 4561 20.7797 77.9% 5 3 74.9% 4.2% 3 
GUGCAC 50 2288 469 6.47447 61.3% 9 1561 22.4734 84.2% 3 4 72.8% 16.2% 3 
CAGCUG 144 275 1986 9.51959 90.1% 3 2924 14.6168 54.8% 17 5 72.5% 25.0% 3 
CGGCUG 96 725 1469 10.5621 100.0% 1 1451 10.8801 40.8% 29 6 70.4% 41.9% 3 
ACGCGU 105 610 883 5.80461 55.0% 13 3253 22.3013 83.6% 4 7 69.3% 20.2% 3 
CGGCCG 113 506 1283 7.83699 74.2% 5 2371 15.1039 56.6% 14 8 65.4% 12.4% 3 
CCUAGG 83 993 926 7.70077 72.9% 6 1699 14.735 55.2% 16 9 64.1% 12.5% 3 
CGAUCG 35 3165 252 4.96974 47.1% 21 991 20.3818 76.4% 6 10 61.7% 20.7% 3 
CUCGGG 106 585 930 6.0559 57.3% 11 2218 15.0623 56.4% 15 11 56.9% 0.6% 3 
CCCGGG 108 554 863 5.51554 52.2% 14 2449 16.323 61.2% 10 12 56.7% 6.3% 3 
CGGUCG 62 1701 429 4.77603 45.2% 22 1565 18.1702 68.1% 8 13 56.7% 16.2% 3 
CCUGGG 103 628 948 6.35291 60.1% 10 1963 13.7189 51.4% 20 14 55.8% 6.2% 3 




GCCGGC 28 3532 242 5.96566 56.5% 12 548 14.0883 52.8% 18 16 54.6% 2.6% 3 
ACCGGU 65 1565 427 4.53436 42.9% 24 1546 17.1211 64.2% 9 17 53.5% 15.0% 3 
CUAUAG 59 1849 337 3.94257 37.3% 28 1502 18.3254 68.7% 7 18 53.0% 22.2% 3 
CGUACG 59 1881 442 5.17096 49.0% 17 1239 15.1166 56.7% 13 19 52.8% 5.4% 3 
CGCGCG 64 1627 461 4.9719 47.1% 20 1199 13.4858 50.5% 21 20 48.8% 2.5% 3 
UCAUGA 55 2075 417 5.23329 49.5% 16 914 11.9624 44.8% 24 21 47.2% 3.3% 3 
AGGCCU 44 2574 214 3.35709 31.8% 34 942 15.4111 57.8% 12 22 44.8% 18.4% 3 
UUGCAA 62 1693 293 3.26195 30.9% 37 1348 15.6507 58.7% 11 23 44.8% 19.6% 3 
GAGCUC 41 2739 257 4.32664 41.0% 26 736 12.922 48.4% 22 24 44.7% 5.3% 3 
CACGUG 90 840 684 5.24584 49.7% 15 1309 10.4697 39.2% 32 25 44.5% 7.4% 3 
UCGCGA 72 1338 465 4.45781 42.2% 25 1110 11.0975 41.6% 26 26 41.9% 0.4% 3 
CGCGUG 77 1146 563 5.04683 47.8% 19 1010 9.44206 35.4% 38 27 41.6% 8.8% 3 
CUCGAG 64 1622 476 5.13367 48.6% 18 771 8.67183 32.5% 42 28 40.6% 11.4% 3 
CAAUUG 67 1505 387 3.98692 37.7% 27 983 10.5612 39.6% 31 29 38.7% 1.3% 3 
UCCGGA 38 2987 177 3.21507 30.4% 38 648 12.2752 46.0% 23 30 38.2% 11.0% 3 
GGCGUC 39 2919 215 3.80518 36.0% 30 561 10.3546 38.8% 33 31 37.4% 2.0% 3 
GUCGAC 36 3058 199 3.8155 36.1% 29 487 9.73784 36.5% 37 32 36.3% 0.3% 3 
GUGCGC 53 2149 357 4.64936 44.0% 23 474 6.43782 24.1% 51 33 34.1% 14.1% 3 
UGGCCA 29 3470 69 1.6423 15.5% 109 562 13.95 52.3% 19 34 33.9% 26.0% 3 
GCUAGC 41 2775 153 2.57578 24.4% 47 645 11.3243 42.4% 25 35 33.4% 12.8% 3 
GGGCCC 22 3813 81 2.54134 24.1% 48 325 10.634 39.9% 30 36 32.0% 11.2% 3 
CCUUGG 71 1367 370 3.59703 34.1% 32 777 7.87769 29.5% 44 37 31.8% 3.2% 2 
GUAUAC 37 3005 110 2.05207 19.4% 71 568 11.0505 41.4% 27 38 30.4% 15.5% 3 
CUUAAG 41 2799 143 2.40743 22.8% 50 536 9.4106 35.3% 39 39 29.0% 8.8% 3 
AGCGCU 36 3069 197 3.77716 35.8% 31 288 5.75872 21.6% 55 40 28.7% 10.0% 3 
GUUAAC 30 3389 86 1.97869 18.7% 74 422 10.1258 37.9% 34 41 28.3% 13.6% 3 
GGCGCC 37 3007 170 3.17138 30.0% 39 364 7.08167 26.5% 48 42 28.3% 2.5% 3 
CUGUAG 124 405 611 3.40111 32.2% 33 1015 5.89224 22.1% 53 43 27.1% 7.2% 3 
ACAUGU 96 744 434 3.12047 29.5% 40 856 6.41858 24.1% 52 44 26.8% 3.9% 3 
AGUGCU 53 2171 207 2.69585 25.5% 43 548 7.44288 27.9% 46 45 26.7% 1.7% 3 
CUCGUG 43 2672 100 1.60521 15.2% 114 595 9.96058 37.3% 35 46 26.3% 15.6% 2 
AGAUCU 28 3547 62 1.52839 14.5% 130 386 9.92351 37.2% 36 47 25.8% 16.1% 3 
AAGCUU 73 1282 206 1.94781 18.4% 78 864 8.51975 31.9% 43 48 25.2% 9.5% 3 




GUUGAC 51 2240 94 1.27221 12.0% 244 662 9.34381 35.0% 40 50 23.5% 16.2% 3 
ACUGGU 71 1355 122 1.18605 11.2% 319 917 9.29709 34.8% 41 51 23.0% 16.7% 3 
CCCAGG 74 1258 242 2.25728 21.4% 57 675 6.56611 24.6% 49 52 23.0% 2.3% 2 
GGUGCC 44 2603 137 2.14916 20.3% 63 355 5.8078 21.8% 54 53 21.1% 1.0% 3 
GCGCAC 72 1328 246 2.35833 22.3% 52 507 5.06888 19.0% 59 54 20.7% 2.4% 2 
CCGCGG 14000 1 52544 2.59058 24.5% 46 85549 4.39869 16.5% 66 55 20.5% 5.7% 3 
GCCGAC 49 2355 236 3.32443 31.5% 36 168 2.46802 9.2% 111 56 20.4% 15.7% 2 
GAAUUC 30 3445 75 1.7256 16.3% 97 270 6.47856 24.3% 50 57 20.3% 5.6% 3 
UUCGGA 45 2519 129 1.97869 18.7% 75 358 5.72673 21.5% 56 58 20.1% 1.9% 3 
CUUGAG 56 2027 183 2.25561 21.4% 58 390 5.01317 18.8% 60 59 20.1% 1.8% 3 
GCGUGC 127 385 430 2.33704 22.1% 53 830 4.70447 17.6% 63 60 19.9% 3.2% 3 
AGUACU 48 2399 145 2.08511 19.7% 69 314 4.70896 17.6% 62 61 18.7% 1.5% 3 
GGUACC 34 3205 109 2.21283 21.0% 60 191 4.04381 15.2% 72 62 18.1% 4.1% 3 
CCCUGG 89 873 196 1.52008 14.4% 131 677 5.47564 20.5% 57 63 17.5% 4.3% 2 
CCGCUC 23 3735 77 2.31081 21.9% 54 111 3.47401 13.0% 83 64 17.4% 6.3% 1 
UGGCUA 42 2731 37 0.60807 5.8% 3126 443 7.5926 28.5% 45 65 17.1% 16.0% 3 
AUGCGU 89 883 276 2.14053 20.3% 64 453 3.66391 13.7% 78 66 17.0% 4.6% 3 
CUAUGG 115 494 326 1.95669 18.5% 76 635 3.97477 14.9% 74 67 16.7% 2.6% 3 
CCCGAG 82 1038 281 2.36534 22.4% 51 326 2.8618 10.7% 98 68 16.6% 8.3% 2 
UCUAGA 57 1955 143 1.73166 16.4% 95 353 4.45796 16.7% 64 69 16.6% 0.2% 3 
CCGUGG 1621 14 5050 2.15035 20.4% 62 7452 3.30922 12.4% 86 70 16.4% 5.6% 3 
GGGCUC 39 2875 100 1.76985 16.8% 91 227 4.18984 15.7% 70 71 16.2% 0.7% 3 
CCGCAG 227 112 643 1.95518 18.5% 77 1167 3.70068 13.9% 76 72 16.2% 3.3% 2 
CCACGG 174 196 529 2.09849 19.9% 66 766 3.16895 11.9% 88 73 15.9% 5.7% 2 
CCCGGU 24 3709 57 1.63932 15.5% 110 143 4.28905 16.1% 69 74 15.8% 0.4% 2 
UCUGGA 45 2556 149 2.28547 21.6% 56 162 2.59143 9.7% 108 75 15.7% 8.4% 3 
CCGCUG 135 334 403 2.0605 19.5% 70 588 3.1353 11.7% 89 76 15.6% 5.5% 2 
CGUGCG 80 1075 175 1.5099 14.3% 136 492 4.42702 16.6% 65 77 15.4% 1.6% 3 
UAGCUA 57 1939 112 1.35626 12.8% 191 380 4.79894 18.0% 61 78 15.4% 3.6% 3 
UUCGAA 59 1830 126 1.47408 14.0% 146 352 4.29464 16.1% 68 79 15.0% 1.5% 3 
GGGUCC 23 3754 59 1.77062 16.8% 90 113 3.53661 13.3% 80 80 15.0% 2.5% 3 
CCGCAA 66 1535 186 1.94523 18.4% 79 283 3.08659 11.6% 93 81 15.0% 4.8% 1 
GUGUGC 45 2561 99 1.51853 14.4% 134 251 4.01511 15.0% 73 82 14.7% 0.5% 3 




CCGGCU 39 2873 114 2.01763 19.1% 73 131 2.41793 9.1% 113 84 14.1% 7.1% 0 
ACCGGG 138 306 303 1.51553 14.3% 135 670 3.49488 13.1% 82 85 13.7% 0.9% 2 
CCGCGU 157 244 386 1.69703 16.1% 104 626 2.87019 10.8% 97 86 13.4% 3.8% 2 
UGUACA 47 2450 74 1.08676 10.3% 473 284 4.34967 16.3% 67 87 13.3% 4.3% 3 
CUGCGG 1358 18 3385 1.72052 16.3% 101 5137 2.72299 10.2% 101 88 13.2% 4.3% 3 
GCUAAC 31 3358 60 1.33595 12.6% 200 158 3.66886 13.7% 77 89 13.2% 0.8% 2 
AGGCUU 59 1837 148 1.73145 16.4% 96 215 2.62315 9.8% 106 90 13.1% 4.6% 3 
CCGCAC 60 1786 136 1.56455 14.8% 123 252 3.02333 11.3% 94 91 13.1% 2.5% 1 
CCGCCU 31 3385 74 1.64767 15.6% 108 119 2.76326 10.4% 100 92 13.0% 3.7% 1 
CGAUUG 54 2121 108 1.38048 13.1% 176 245 3.26594 12.2% 87 93 12.7% 0.6% 3 
CUUAGG 52 2206 84 1.11501 10.6% 428 263 3.64073 13.6% 79 94 12.1% 2.2% 3 
CUAUAU 36 3056 27 0.51768 4.9% 3636 254 5.07887 19.0% 58 95 12.0% 10.0% 2 
CCAGGG 210 133 420 1.38048 13.1% 172 819 2.80738 10.5% 99 96 11.8% 1.8% 2 
UGCGCA 38 2973 59 1.07169 10.1% 509 186 3.52343 13.2% 81 97 11.7% 2.2% 3 
UCAUGG 91 815 139 1.05433 10.0% 545 424 3.35398 12.6% 85 98 11.3% 1.8% 3 
UACACC 36 3059 43 0.82446 7.8% 1504 190 3.79916 14.2% 75 99 11.0% 4.5% 0 






Selection repeat 1 
  
Selection repeat 2 
  
Average across selections 
 
 













AGUUCU 171 1639 10782 59.828 100.0% 1 1016 5.3536 57.3% 2 1 78.7% 30.2% 2 
GGUUCC 5793 1 202669 33.196 55.5% 5 60019 9.3355 100.0% 1 2 77.7% 31.5% 2 
UGUUCA 130 2544 6092 44.465 74.3% 2 534 3.7013 39.6% 5 3 57.0% 24.5% 2 
AGUCCU 162 1800 6201 36.32 60.7% 4 763 4.2439 45.5% 4 4 53.1% 10.8% 2 
GUUCCC 196 1253 3831 18.546 31.0% 12 1151 5.2914 56.7% 3 5 43.8% 18.2% 1 
AGUUCC 161 1837 4166 24.553 41.0% 6 640 3.5818 38.4% 6 6 39.7% 1.9% 1 
CGUUCG 203 1161 7979 37.295 62.3% 3 299 1.3272 14.2% 63 7 38.3% 34.0% 2 




AGUGCU 231 856 5636 23.151 38.7% 7 523 2.0401 21.9% 13 9 30.3% 11.9% 2 
CGUCCG 138 2357 3284 22.58 37.7% 8 264 1.7238 18.5% 22 10 28.1% 13.6% 2 
GGUACC 868 31 17549 19.184 32.1% 10 1775 1.8426 19.7% 17 11 25.9% 8.7% 2 
UGUUCC 99 3291 1226 11.751 19.6% 15 317 2.8852 30.9% 8 12 25.3% 8.0% 1 
UGUCCA 176 1553 3555 19.166 32.0% 11 307 1.5717 16.8% 30 13 24.4% 10.7% 2 
AGUACU 184 1438 4040 20.834 34.8% 9 267 1.3075 14.0% 76 14 24.4% 14.7% 2 
GGUGCC 1346 2 14740 10.391 17.4% 16 3061 2.0491 21.9% 12 15 19.7% 3.2% 2 
GGUUCU 377 249 5417 13.634 22.8% 14 599 1.4317 15.3% 37 16 19.1% 5.3% 2 
CGUUCC 134 2454 824 5.8348 9.8% 24 322 2.1652 23.2% 10 17 16.5% 9.5% 1 
GAUUCC 117 2856 523 4.2415 7.1% 29 292 2.2488 24.1% 9 18 15.6% 12.0% 1 
UGUUCG 100 3274 884 8.3879 14.0% 17 175 1.5768 16.9% 28 19 15.5% 2.0% 2 
GGCUCC 618 117 4297 6.5975 11.0% 21 1182 1.7234 18.5% 23 20 14.7% 5.3% 2 
CGCUCG 161 1848 484 2.8525 4.8% 50 378 2.1155 22.7% 11 21 13.7% 12.7% 2 
GUUUCC 108 3073 378 3.321 5.6% 42 232 1.9356 20.7% 15 22 13.1% 10.7% 1 
GGGUCC 957 16 4125 4.0899 6.8% 33 1813 1.707 18.3% 24 23 12.6% 8.1% 2 
GGUUCG 800 56 5031 5.9672 10.0% 23 1255 1.4135 15.1% 41 24 12.6% 3.7% 1 
GGUCCU 412 216 2843 6.5476 10.9% 22 593 1.2969 13.9% 79 25 12.4% 2.1% 2 
GGUUCA 653 106 4720 6.8585 11.5% 20 825 1.1384 12.2% 329 26 11.8% 0.5% 1 
AGCUCU 132 2518 1101 7.9144 13.2% 18 142 0.9693 10.4% 1408 27 11.8% 2.0% 2 
UGUUCU 83 3621 447 5.1101 8.5% 25 120 1.3027 14.0% 77 28 11.2% 3.8% 1 
UCCGUG 93 3425 80 0.8162 1.4% 335 203 1.9668 21.1% 14 29 11.2% 13.9% 1 
GUUCCA 146 2168 262 1.7028 2.8% 102 296 1.8268 19.6% 18 30 11.2% 11.8% 0 
UGUACA 219 960 1608 6.967 11.6% 19 236 0.971 10.4% 1392 31 11.0% 0.9% 2 
GGAUCC 613 118 2465 3.8156 6.4% 36 946 1.3905 14.9% 48 32 10.6% 6.0% 2 
CAUUCG 107 3099 240 2.1283 3.6% 77 195 1.6421 17.6% 25 33 10.6% 9.9% 1 
AGCACU 186 1418 447 2.2803 3.8% 70 325 1.5744 16.9% 29 34 10.3% 9.2% 2 
GUUUUU 47 4064 187 3.7753 6.3% 38 66 1.2653 13.6% 100 35 9.9% 5.1% 1 
AGUACC 193 1309 869 4.2723 7.1% 28 247 1.1532 12.4% 285 36 9.7% 3.7% 1 
UGCUCA 113 2949 397 3.3336 5.6% 41 159 1.2679 13.6% 99 37 9.6% 5.7% 2 
GGUGCU 606 122 2773 4.3419 7.3% 27 718 1.0676 11.4% 680 38 9.3% 3.0% 2 
AGUGCC 190 1349 778 3.8853 6.5% 35 239 1.1334 12.1% 343 39 9.3% 4.0% 1 
GGUCCA 603 123 2669 4.1999 7.0% 32 724 1.0819 11.6% 589 40 9.3% 3.2% 1 
AGCGCU 172 1619 226 1.2468 2.1% 161 292 1.5297 16.4% 32 41 9.2% 10.1% 2 




GAUACC 211 1045 780 3.5076 5.9% 40 267 1.1402 12.2% 322 43 9.0% 4.5% 1 
UGUGCA 191 1333 846 4.2028 7.0% 31 216 1.019 10.9% 1004 44 9.0% 2.8% 2 
CUCUGA 108 3070 331 2.9081 4.9% 47 146 1.2181 13.0% 158 45 9.0% 5.8% 1 
CGAUCG 186 1419 315 1.6069 2.7% 107 286 1.3855 14.8% 50 46 8.8% 8.6% 2 
UGUGCC 129 2578 575 4.2294 7.1% 30 138 0.9639 10.3% 1473 47 8.7% 2.3% 1 
GGUUGC 972 15 2245 2.1916 3.7% 74 1363 1.2635 13.5% 103 48 8.6% 7.0% 1 
AGGUCU 105 3139 299 2.702 4.5% 57 134 1.1499 12.3% 293 49 8.4% 5.5% 2 
CUCUGG 79 3711 160 1.9217 3.2% 86 109 1.2432 13.3% 120 50 8.3% 7.1% 2 
AGUUCG 134 2460 408 2.8891 4.8% 48 161 1.0826 11.6% 585 51 8.2% 4.8% 1 
GUUCUC 125 2641 434 3.2944 5.5% 43 141 1.0164 10.9% 1024 52 8.2% 3.8% 1 
GCUUCC 111 3000 189 1.6156 2.7% 106 157 1.2745 13.7% 88 53 8.2% 7.7% 1 
UUCCCG 171 1653 402 2.2307 3.7% 72 223 1.1751 12.6% 235 54 8.2% 6.3% 1 
GUGCUC 152 2017 246 1.5357 2.6% 114 214 1.2686 13.6% 96 55 8.1% 7.8% 1 
GGUACU 520 151 2433 4.4396 7.4% 26 470 0.8144 8.7% 3055 56 8.1% 0.9% 2 
GAUUUC 88 3518 227 2.4476 4.1% 64 102 1.0444 11.2% 812 57 7.6% 5.0% 2 
CAGCUG 138 2343 262 1.8015 3.0% 97 175 1.1426 12.2% 314 58 7.6% 6.5% 2 
AGCCCU 155 1941 595 3.6424 6.1% 39 144 0.8371 9.0% 2827 59 7.5% 2.0% 2 
GAUAAC 226 899 573 2.4057 4.0% 66 256 1.0207 10.9% 996 60 7.5% 4.9% 1 
AGCUCC 106 3123 309 2.766 4.6% 53 113 0.9606 10.3% 1505 61 7.5% 4.0% 1 
GGCUCU 317 374 774 2.3168 3.9% 69 358 1.0176 10.9% 1014 62 7.4% 5.0% 2 
GGGGCC 1277 3 2272 1.6882 2.8% 104 1575 1.1113 11.9% 446 63 7.4% 6.4% 2 
GGUGCG 1086 9 1857 1.6225 2.7% 105 1337 1.1093 11.9% 458 64 7.3% 6.5% 1 
CGUACC 163 1784 488 2.8408 4.7% 51 166 0.9176 9.8% 1956 65 7.3% 3.6% 1 
UGUACG 161 1843 323 1.9036 3.2% 88 190 1.0634 11.4% 700 66 7.3% 5.8% 2 
UGUACC 132 2514 530 3.8098 6.4% 37 112 0.7645 8.2% 3454 67 7.3% 1.3% 1 
GUACCC 177 1526 508 2.7233 4.6% 55 182 0.9265 9.9% 1861 68 7.2% 3.8% 1 
UGUCCC 99 3298 282 2.7028 4.5% 56 101 0.9193 9.8% 1938 69 7.2% 3.8% 1 
GGCCCC 587 127 1462 2.3633 4.0% 67 633 0.9717 10.4% 1388 70 7.2% 4.6% 2 
AGUCCC 114 2923 387 3.2211 5.4% 44 105 0.8299 8.9% 2896 71 7.1% 2.5% 1 
GCUAAC 183 1452 557 2.8881 4.8% 49 179 0.8814 9.4% 2342 72 7.1% 3.3% 1 
UGAUCA 141 2270 367 2.4697 4.1% 62 148 0.9458 10.1% 1657 73 7.1% 4.2% 2 
GUCCUC 148 2113 297 1.9041 3.2% 87 169 1.0289 11.0% 932 74 7.1% 5.5% 1 
GUUCGC 187 1388 382 1.9383 3.2% 85 207 0.9974 10.7% 1172 75 7.0% 5.3% 2 




CUAUUG 88 3516 284 3.0622 5.1% 45 79 0.8089 8.7% 3106 77 6.9% 2.5% 1 
GGUCCG 633 112 1610 2.4134 4.0% 65 638 0.9082 9.7% 2072 78 6.9% 4.0% 1 
ACGGUA 138 2346 323 2.2209 3.7% 73 143 0.9337 10.0% 1784 79 6.9% 4.4% 0 
UCACUG 94 3405 248 2.5034 4.2% 60 92 0.8819 9.4% 2333 80 6.8% 3.7% 1 
GCUACC 152 2029 482 3.0089 5.0% 46 134 0.7944 8.5% 3236 81 6.8% 2.5% 1 
GUGCCC 189 1358 370 1.8576 3.1% 91 204 0.9726 10.4% 1382 82 6.8% 5.2% 1 
GUCCCC 138 2345 311 2.1384 3.6% 76 140 0.9141 9.8% 1995 83 6.7% 4.4% 1 
AAGAUC 212 1035 562 2.5154 4.2% 59 196 0.8331 8.9% 2864 84 6.6% 3.3% 1 
GGACCC 600 125 1475 2.3326 3.9% 68 568 0.853 9.1% 2660 85 6.5% 3.7% 2 
UGUACU 134 2448 316 2.2376 3.7% 71 129 0.8674 9.3% 2504 86 6.5% 3.9% 1 
CGUGCG 278 546 733 2.5019 4.2% 61 254 0.8233 8.8% 2969 87 6.5% 3.3% 2 
UCGACG 119 2810 253 2.0173 3.4% 82 118 0.8935 9.6% 2214 88 6.5% 4.4% 1 
AGACCU 186 1417 480 2.4487 4.1% 63 169 0.8187 8.8% 3005 89 6.4% 3.3% 2 
CGUUCA 144 2206 295 1.9438 3.2% 84 142 0.8885 9.5% 2259 90 6.4% 4.4% 1 
GGCACC 687 93 1477 2.04 3.4% 81 665 0.8722 9.3% 2457 91 6.4% 4.2% 2 
ACCAGG 197 1240 384 1.8496 3.1% 92 196 0.8965 9.6% 2175 92 6.3% 4.6% 1 
AGAUCU 136 2416 314 2.1908 3.7% 75 127 0.8414 9.0% 2780 93 6.3% 3.8% 2 
UGUCCU 116 2870 256 2.094 3.5% 79 107 0.8311 8.9% 2886 94 6.2% 3.8% 1 
GUUCAC 200 1207 400 1.8977 3.2% 89 191 0.8605 9.2% 2583 95 6.2% 4.3% 2 
UUACAU 108 3077 228 2.0032 3.3% 83 100 0.8343 8.9% 2849 96 6.1% 4.0% 1 
CCGGAC 143 2230 403 2.6741 4.5% 58 107 0.6742 7.2% 3895 97 5.8% 1.9% 0 
UAAUUU 68 3883 198 2.7629 4.6% 54 49 0.6493 7.0% 3967 98 5.8% 1.7% 1 
CAUGGC 191 1340 426 2.1163 3.5% 78 150 0.7076 7.6% 3775 99 5.6% 2.9% 0 
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All code was written in Python 3.6.2 with module versions Biopython 1.69, csv 1.0, 
MatPlotLib 2.0.2, and NumPy 1.13.1 using Spyder 3.2.3.   
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Chapter 4 code: 1st-generation Illumina data analysis 
 
This code was used for the original data processing shown in Chapter 4. The pipeline 





from statistics import mean as mean 
 
# read in files, calculate total counts, % of total, rank, then sort alphabetically 
lib_data = [] 
with open(Parameters.path + '\\' + Parameters.lib_file + '.csv') as csvfile: 
    lib_reader = csv.reader(csvfile) 
    for row in lib_reader: 
        modrow = [] 
        modrow.append(row[0].replace('T','U')) 
        modrow.append(row[1]) 
        lib_data.append(modrow) 
read_count = 0 
for seq in lib_data: 
    read_count = read_count + int(seq[1]) 
lib_read_count = read_count 
rank = 1 
for seq in lib_data: 
    percent = int(seq[1]) / lib_read_count 
    seq.append(percent) 
    seq.append(rank) 
    rank = rank + 1 
lib_data = sorted(lib_data) 
 
s1_data = [] 
with open(Parameters.path + '\\' + Parameters.s1_file + '.csv') as csvfile: 
    s1_reader = csv.reader(csvfile) 
    for row in s1_reader: 
        s1_data.append(row) 
read_count = 0 
for seq in s1_data: 
    read_count = read_count + int(seq[1]) 
s1_read_count = read_count 
rank = 1 
for seq in s1_data: 
    percent = int(seq[1]) / s1_read_count 
    seq.append(percent) 
    seq.append(rank) 
    rank = rank + 1 
s1_data = sorted(s1_data) 
 
s2_data = [] 
with open(Parameters.path + '\\' + Parameters.s2_file + '.csv') as csvfile: 
    s2_reader = csv.reader(csvfile) 
    for row in s2_reader: 
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        s2_data.append(row) 
read_count = 0 
for seq in s2_data: 
    read_count = read_count + int(seq[1]) 
s2_read_count = read_count 
rank = 1 
for seq in s2_data: 
    percent = int(seq[1]) / s2_read_count 
    seq.append(percent) 
    seq.append(rank) 
    rank = rank + 1 
s2_data = sorted(s2_data) 
 
# calculate enrichments 
master_list = [] 
lib_size = Parameters.size 
for n in range(0,lib_size): 
    seq_record = [] 
    lib_record = lib_data[n] 
    for m in lib_record: 
        seq_record.append(m) 
    s1_record = s1_data[n] 
    for m in s1_record[1:]: 
        seq_record.append(m) 
    s2_record = s2_data[n] 
    for m in s2_record[1:]: 
        seq_record.append(m) 
    enrich_s1 = s1_data[n][2] / lib_data[n][2] 
    seq_record.append(enrich_s1) 
    enrich_s2 = s2_data[n][2] / lib_data[n][2] 
    seq_record.append(enrich_s2)     
    enrich_avg = (enrich_s1 + enrich_s2) / 2 
    seq_record.append(enrich_avg) 
    master_list.append(seq_record) 
print (len(master_list)) 
 
# sort and rank 
master_list = sorted(master_list, key = lambda x: x[-3], reverse = True) 
rank = 1 
for s in master_list: 
    s.append(rank) 
    rank = rank + 1 
master_list = sorted(master_list, key = lambda x: x[-3], reverse = True) 
rank = 1 
for s in master_list: 
    s.append(rank) 
    rank = rank + 1 
master_list = sorted(master_list, key = lambda x: x[-3], reverse = True) 
rank = 1 
for s in master_list: 
    s.append(rank) 
    rank = rank + 1 
 
# separate individual letters and do pairing analysis 
pair_coordinates = Parameters.pairs 
for seq in master_list: 
 276 
    for l in seq[0]: 
        seq.append(l) 
    paired_count = 0 
    for coordinates in pair_coordinates: 
        a = coordinates[0] 
        b = coordinates[1] 
        c = seq[0][a] 
        d = seq[0][b] 
        pair = c + d 
        seq.append(pair) 
        if d in Parameters.valid_pairs[c]: 
            paired_count = paired_count + 1 
    seq.append(paired_count) 
 
# write output 
with open(Parameters.path + '\\' + Parameters.results_file + '.csv', 'w', newline = '') as csvfile: 
    results_writer = csv.writer(csvfile) 
    for seq in master_list: 
        results_writer.writerow(seq) 
         
# analyze data 
with open(Parameters.path + '\\' + Parameters.analysis_file + '.csv', 'w', newline = '') as csvfile: 
    analysis_writer = csv.writer(csvfile) 
 
# Analysis - enrichment of paired sequences 
    if Parameters.lib == 'T2': 
        analysis_writer.writerow(['Paired base distributions']) 
        lib_list = [0, 0, 0] #0, 1, 2, 3 
        s1_list = [0, 0, 0] 
        s2_list = [0, 0, 0] 
        avg_list = [0, 0, 0] 
        for seq in master_list: 
            num_pairs = seq[-1] 
            lib_list[num_pairs] = lib_list[num_pairs] + seq[2] 
            s1_list[num_pairs] = s1_list[num_pairs] + seq[5] 
            s2_list[num_pairs] = s2_list[num_pairs] + seq[8] 
            avg_list[num_pairs] = avg_list[num_pairs] + mean([seq[5],seq[8]]) 
             
        analysis_writer.writerow(['','0','1','2']) 
        analysis_writer.writerow(['Theoretical',(10/16)**2,2*((10/16)*(6/16)),(6/16)**2]) 
        p = lib_list 
        analysis_writer.writerow(['Library',p[0],p[1],p[2]]) 
        p = s1_list 
        analysis_writer.writerow(['S1',p[0],p[1],p[2]]) 
        p = s2_list 
        analysis_writer.writerow(['S2',p[0],p[1],p[2]]) 
        p = avg_list 
        analysis_writer.writerow(['Average S1+S2',p[0],p[1],p[2]]) 
        analysis_writer.writerow(['Fold enrichment',p[0]/lib_list[0],p[1]/lib_list[1],p[2]/lib_list[2]]) 
    else: 
        analysis_writer.writerow(['Paired base distributions']) 
        lib_list = [0, 0, 0, 0] #0, 1, 2, 3 
        s1_list = [0, 0, 0, 0] 
        s2_list = [0, 0, 0, 0] 
        avg_list = [0, 0, 0, 0] 
        for seq in master_list: 
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            num_pairs = seq[-1] 
            lib_list[num_pairs] = lib_list[num_pairs] + seq[2] 
            s1_list[num_pairs] = s1_list[num_pairs] + seq[5] 
            s2_list[num_pairs] = s2_list[num_pairs] + seq[8] 
            avg_list[num_pairs] = avg_list[num_pairs] + mean([seq[5],seq[8]]) 
             
        analysis_writer.writerow(['','0','1','2','3']) 
        
analysis_writer.writerow(['Theoretical',(10/16)**3,3*((10/16)**2*(6/16)),3*((10/16)*(6/16)**2),(6/16)
**3]) 
        p = lib_list 
        analysis_writer.writerow(['Library',p[0],p[1],p[2],p[3]]) 
        p = s1_list 
        analysis_writer.writerow(['S1',p[0],p[1],p[2],p[3]]) 
        p = s2_list 
        analysis_writer.writerow(['S2',p[0],p[1],p[2],p[3]]) 
        p = avg_list 
        analysis_writer.writerow(['Average S1+S2',p[0],p[1],p[2],p[3]]) 
        analysis_writer.writerow(['Fold 
enrichment',p[0]/lib_list[0],p[1]/lib_list[1],p[2]/lib_list[2],p[3]/lib_list[3]]) 
 
    # Analysis - library 
    analysis_writer.writerow(['Library before selection']) 
    base_list = ['A','C','G','U'] 
    lib_count_list = [[0, 0, 0, 0], 
                  [0, 0, 0, 0], 
                  [0, 0, 0, 0], 
                  [0, 0, 0, 0], 
                  [0, 0, 0, 0], 
                  [0, 0, 0, 0]] 
    for seq in master_list: 
        for a in range(0,6): 
            b = seq[0][a] 
            for i in range(0,4): 
                if b == base_list[i]: 
                    current_count = lib_count_list[a][i] + seq[2] 
                    lib_count_list[a][i] = current_count 
    analysis_writer.writerow(['','A','C','G','U']) 
    for p in lib_count_list: 
        analysis_writer.writerow([lib_count_list.index(p) + 1,p[0],p[1],p[2],p[3]]) 
     
    # Analysis - all sequences after selection 
    analysis_writer.writerow(['Library after selection']) 
    count_list = [[0, 0, 0, 0], 
                  [0, 0, 0, 0], 
                  [0, 0, 0, 0], 
                  [0, 0, 0, 0], 
                  [0, 0, 0, 0], 
                  [0, 0, 0, 0]] 
    for seq in master_list: 
        for a in range(0,6): 
            b = seq[0][a] 
            for i in range(0,4): 
                if b == base_list[i]: 
                    current_count = count_list[a][i] + (seq[5]+seq[8]/2) 
                    count_list[a][i] = current_count 
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    for a in range(0,len(count_list)): 
        for b in range (0,len(count_list[a])): 
            count_list[a][b] = count_list[a][b] / lib_count_list[a][b] 
    for a in range(0,len(count_list)): 
        total = 0 
        for b in range (0,len(count_list[a])): 
            total = total + count_list[a][b] 
        for b in range (0,len(count_list[a])): 
            if total > 0: 
                count_list[a][b] = count_list[a][b] / total 
    analysis_writer.writerow(['','A','C','G','U']) 
    for p in count_list: 
        analysis_writer.writerow([count_list.index(p) + 1,p[0],p[1],p[2],p[3]]) 
         
    # Analysis - sequences enriched more than 4 fold 
    analysis_writer.writerow(['Sequences enriched more than 4-fold']) 
    enriched_list = [] 
    for seq in master_list: 
        if seq[12] > 4: 
            enriched_list.append(seq) 
    enriched_count = len(enriched_list) 
    count_list = [[0, 0, 0, 0], 
                  [0, 0, 0, 0], 
                  [0, 0, 0, 0], 
                  [0, 0, 0, 0], 
                  [0, 0, 0, 0], 
                  [0, 0, 0, 0]] 
    for seq in enriched_list: 
        for a in range(0,6): 
            b = seq[0][a] 
            for i in range(0,4): 
                if b == base_list[i]: 
                    current_count = count_list[a][i] + (1/enriched_count) 
                    count_list[a][i] = current_count 
    for a in range(0,len(count_list)): 
        for b in range (0,len(count_list[a])): 
            count_list[a][b] = count_list[a][b] / lib_count_list[a][b] 
    for a in range(0,len(count_list)): 
        total = 0 
        for b in range (0,len(count_list[a])): 
            total = total + count_list[a][b] 
        for b in range (0,len(count_list[a])): 
            if total > 0: 
                count_list[a][b] = count_list[a][b] / total 
    analysis_writer.writerow(['','A','C','G','U']) 
    for p in count_list: 
        analysis_writer.writerow([count_list.index(p) + 1,p[0],p[1],p[2],p[3]]) 
         
    # Analysis - sequences enriched less than 0.25 fold 
    analysis_writer.writerow(['Sequences lost more than 4-fold']) 
    lost_list = [] 
    for seq in master_list: 
        if seq[12] < 0.25: 
            lost_list.append(seq) 
    lost_count = len(lost_list) 
    count_list = [[0, 0, 0, 0], 
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                  [0, 0, 0, 0], 
                  [0, 0, 0, 0], 
                  [0, 0, 0, 0], 
                  [0, 0, 0, 0], 
                  [0, 0, 0, 0]] 
    for seq in lost_list: 
        for a in range(0,6): 
            b = seq[0][a] 
            for i in range(0,4): 
                if b == base_list[i]: 
                    current_count = count_list[a][i] + (1/lost_count) 
                    count_list[a][i] = current_count 
    for a in range(0,len(count_list)): 
        for b in range (0,len(count_list[a])): 
            count_list[a][b] = count_list[a][b] / lib_count_list[a][b] 
    for a in range(0,len(count_list)): 
        total = 0 
        for b in range (0,len(count_list[a])): 
            total = total + count_list[a][b] 
        for b in range (0,len(count_list[a])): 
            if total > 0: 
                count_list[a][b] = count_list[a][b] / total 
    analysis_writer.writerow(['','A','C','G','U']) 
    for p in count_list: 
        analysis_writer.writerow([count_list.index(p) + 1,p[0],p[1],p[2],p[3]]) 
         
    # Analysis - separate by fold enrichment 
    analysis_writer.writerow(['Separate by fold enrichment']) 
    max_enrich = master_list[0][12] 
    min_enrich = master_list[-1][12] 
    q = 1 
    range_list = [1] 
    while q <= (max_enrich): 
        q = q*2 
        range_list.append(q) 
    q = 1 
    while q >= (min_enrich): 
        q = q/2 
        range_list.append(q) 
    range_list = sorted(range_list, reverse = True) 
     
    analysis_writer.writerow(['Max','Min','Count','3 pairs','2 pairs','1 pair','0 pairs'])     
     
    for q in range_list[0:-1]: 
        in_range_list = [] 
        a = q 
        b = q/2 
        for seq in master_list: 
            if seq[12] >= b: 
                if seq[12] < a: 
                    in_range_list.append(seq) 
        count_0 = 0 
        count_1 = 0 
        count_2 = 0 
        count_3 = 0 
        for seq in in_range_list: 
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            p = seq[-1] 
            if p == 0: 
                count_0 = count_0 + 1 
            if p == 1: 
                count_1 = count_1 + 1 
            if p == 2: 
                count_2 = count_2 + 1 
            if p == 3: 
                count_3 = count_3 + 1 
        seqs_in_range = len(in_range_list) 
        fraction_0 = count_0 / seqs_in_range 
        fraction_1 = count_1 / seqs_in_range 
        fraction_2 = count_2 / seqs_in_range 
        fraction_3 = count_3 / seqs_in_range 
        analysis_writer.writerow([q,q/2,seqs_in_range,fraction_3,fraction_2,fraction_1,fraction_0]) 
        
Parameters.py 
from datetime import date 
import os 
 
# Set the directory to your Illumina sequencing folder 
directory = r'C:\Users\Rachel Kelemen\Google Drive\Chatterjee lab\AAV\Illumina' 
# Make a folder for this sequencing run (e.g. 2018_11_12_Test) 
# Make a sub-folder to contain your input files: 
sequencing_run = '2018_11_12_Test' 
input_folder_name = 'Input CSV Files' 
output_folder_name = 'Results Files' 
 
# Tell me about your libraries.  
libraries = ['A1', 
             'A2'] 
# What data sets per library? 
# The first of these should always be 'Library' because it will be the reference for calculating 
enrichment. 
data_types = ['Library', 
             '1xTAG-1', 
             '1xTAG-2'] 
# IMPORTANT! Input files should be named 'library-data_type' e.g. 'A3-library' or 'A3-1xTAG-1' 
# This seems to match how Jon names things 
 
# Which bases are supposed to be paired? 
# Python counts starting at 0 !!!! 
# This assumes that all libraries have the same type of pairs.  
pairs = [[0,5], 
         [1,4], 
         [2,3]] 
# What combinations count as pairs? 
valid_pairs = {'A':['U'], 
               'C':['G'], 
               'G':['C','U'], 
               'U':['A','G']} 
 
# Click the play icon to display the parameters you've set.  
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print (str(date.today()) + ' Parameters:') 
 
print ('\nInput files should be in this folder:') 
input_folder = directory +'\\'+ sequencing_run +'\\'+ input_folder_name 
print (input_folder) 
 
data_sets = [] 
for library in libraries: 
    for data_type in data_types: 
        data_sets.append(library + '-' + data_type) 
                 
print ('\nExpecting input files called:') 
for data_set in data_sets: 
    print (data_set) 
 
print ('\nThese bases are paired:') 
for pair in pairs: 
    print (str(pair[0])+'-'+str(pair[1])) 
 
print ('\nThese count as pairs:') 
for base_1 in valid_pairs: 
    for base_2 in valid_pairs[base_1]: 
        print (base_1 + '-' + base_2) 
 
print ('\nOutput files will be in this folder:') 
output_folder = directory +'\\'+ sequencing_run +'\\'+ output_folder_name 
print (output_folder) 
          
Chapter 5.2 code: Full Illumina data processing pipeline 
Main.py 
""" 
@author: Rachel Kelemen 
@deputy_wizard: Joshua Brown 
Finalized April 2019 
 
Main code to process .fastq files from Illumina sequencing of libraries and selections, 
filter by quality, and generate a .csv output file containing counts, enrichments, 




1. Read in parameter file 
2. Identify the .fastq files for each biosample 
3. Characterize run quality 
4. Quality filter 
5. Mismatch filter 
6. Generate a list of all possible randomized sequence variants 
7. Count sequences 
8. Calculate enrichments 







import datetime as dt 
from read_parameters import read_parameter_file 
from identify_files import find_fastq_files, find_text_files 
from characterize_run_quality import characterize_quality 
from Q_score_filter import Q_score_filter 
from mismatch_filter import mismatch_filter 
from generate_possible_sequence_dict import generate_randomized_sequence_dict, \ 
generate_twist_sequence_dict 
from count_randomized_sequences import count_randomized_sequences, counts_from_csv 
from calculate_enrichments import calculate_enrichments 
from plot_results import plot_results 
 
# Setup 
# Copy the parameter file name and enter it here as a raw string (r'string') 
parameter_file_name = r'C:\Users\Rachel Kelemen\Google Drive\Chatterjee lab\Code\Test data 
Ac1 CSV\2019_04_15 Illumina processing parameters Ac1.csv' 
 
# Which parts of the program do you want to run? 
run_find_fastq_files = False 
run_characterize_quality, limit = False, 10000 
run_Q_score_filter = False 
run_mismatch_filter = False 
run_count_sequences, from_csv = True, True 
run_calculate_enrichments = True 
run_plot_results = True 
 
 
# Track start time 
start_time = time.time() 
 
 
# 1. Read in parameter file 
# read_parameter_file returns p : {'parameter_name': parameter_value} 
print('\n---\nReading parameters\n---') 
p = read_parameter_file(parameter_file_name) 
 
# Make sure all required folders exist 
# These will be used by subsequent functions 
required_folders = ['Plots', 'Results'] 
for folder in required_folders: 
    full_path = p['working_folder_name'] + '\\' + folder 
    if os.path.exists(full_path) == False: 
        os.makedirs(full_path) 
 
# Generate a list of biosamples, based on the runs listed in the parameter file 
print('\n---\nIdentifying biosamples\n---') 
biosamples = [p['lib_run']] 
for run in p['sel_1_runs']: 
    biosamples.append(run) 
if p['sel_2_runs']: 
    for run in p['sel_2_runs']: 
        biosamples.append(run) 
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print('> ' + biosamples[0] + ' (library reference sample)') 
for biosample in biosamples[1:]: 
    print('> ' + biosample) 
 
 
# 2. Identify the .fastq files for each biosample 
# Returns fastq_files: [[biosample_1_file_1, biosample_1_file_2...], 
# [biosample_2_file_1, biosample_2_file_2...]...] 
# This accomodates cases where one biosample is associated with multiple .fastq files. 
if run_find_fastq_files: 
    print('\n---\nLooking for .fastq files in:\n' + p['working_folder_name']) 
    fastq_files = find_fastq_files(p['working_folder_name'], biosamples) 
 
 
# 3. Characterize run quality 
# Generates plots in the folder Plots \ Characterize quality plots 
# Defaults to a limit of 10,000 sequences to consider 
if run_characterize_quality: 
    for fastq_file_list in fastq_files: 
        for fastq_file in fastq_file_list: 
            characterize_quality(fastq_file, p['working_folder_name'], limit, 
                                 p['expected_sequence'], p['exclude_at_start'], 
                                 p['exclude_at_end'], 
                                 randomized_bases=p['randomized_bases']) 
 
 
# 4. Quality filter 
if run_Q_score_filter: 
    print('\n---\nQuality filtering\n---') 
    print('\nQ score filtering parameters for the entire sequence') 
    print('\nNo more than {} bases below Q{}'.format(p['QF'], p['Q1'])) 
    print('and no bases below Q{}'.format(p['Q0'])) 
 
    if p['randomized_bases']: 
        print('Q score filtering parameters for randomized bases') 
        print('No randomized bases below Q{}'.format(p['Q2'])) 
 
    # Set up a list of quality-filtered files 
    Q_score_filtered_files = [] 
 
    # Set up a .csv file to hold the Q score filtering stats 
    stats_file_name = str(dt.date.today()) + ' Q score filtering stats.csv' 
    stats_file_address = p['working_folder_name'] + '\\Results\\' + stats_file_name 
    with open(stats_file_address, 'w', newline='') as stats_file: 
        # Clear the whole file 
        stats_file.truncate(0) 
        header_writer = csv.writer(stats_file) 
        headers = ['Biosample', 'Pct pass', 'Total reads', 'Passing reads', 
                   'Short sequences', 'Q0 fail', 'Q1 fail', 'Q2 fail'] 
        header_writer.writerow(headers) 
 
    # Call Q_score_filter for each biosample and its associated .fastq file(s) 
    # Returns the name of the Q score filtered file and writes stats to the .csv file 
    for biosample, to_filter in zip(biosamples, fastq_files): 
        print('\nQ score filtering:\n' + biosample) 
        filtered_file_name = Q_score_filter(p['working_folder_name'], to_filter, biosample, 
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                                            p['Q1'], p['QF'], p['Q0'], p['Q2'], 
                                            p['expected_sequence'], p['randomized_bases'], 
                                            p['exclude_at_start'], p['exclude_at_end'], 
                                            stats_file_address) 
        Q_score_filtered_files.append(filtered_file_name) 
 
else: 
    # If you're not running this part of the program, presumably you've already generated 
    # filtered files and want to use those. 
    # This calls find_text_files, which returns files from your working folder which end 
    # with Q score filtered.txt 
    if run_mismatch_filter: 
        print('\n---\nUsing previously Q score filtered files') 
        Q_score_filtered_files = find_text_files(p['working_folder_name'], biosamples, 
                                                 'Q score filtered.txt') 
 
 
# 6. Mismatch filter 
if run_mismatch_filter: 
    print('\n---\nMismatch filtering\n---') 
    print('Filters set to:') 
    for m in range(len(p['allowed_mismatch_counts'])): 
        print('> Constant region {}: allow {} mismatches'.format( 
                m+1, p['allowed_mismatch_counts'][m])) 
 
    # Set up a list of mismatch-filtered files 
    mismatch_filtered_files = [] 
 
    # Set up a .csv file to hold the Q score filtering stats 
    stats_file_name = str(dt.date.today()) + ' mismatch filtering stats.csv' 
    stats_file_address = p['working_folder_name'] + '\\Results\\' + stats_file_name 
    with open(stats_file_address, 'w', newline='') as stats_file: 
        # Clear the whole file 
        stats_file.truncate(0) 
        # Write the headers 
        header_writer = csv.writer(stats_file) 
        headers = ['Biosample', 'Pct pass', 'Total reads', 'Passing reads'] 
        for constant_region_coords in p['constant_region_coords']: 
            headers.append(str(constant_region_coords) + ' failed') 
        header_writer.writerow(headers) 
 
    # Call mismatch_filter for each biosample and its associated .fastq file(s) 
    # Returns the name of the mismatch filtered file and stats describing how many 
    # sequences passed. 
    # mismatch_filter also automatically generates plots showing base and mismatch 
    # frequency at each position and writes the same data to .csv files. 
    for biosample, to_filter in zip(biosamples, Q_score_filtered_files): 
        print('\nMismatch filtering:\n'+to_filter) 
        filtered_file_name = mismatch_filter(p['working_folder_name'], to_filter, 
                                             biosample, p['constant_region_coords'], 
                                             p['allowed_mismatch_counts'], 
                                             p['expected_sequence'], stats_file_address, 
                                             tRNA_coords=p['tRNA_coords'], 
                                             randomized_bases=p['randomized_bases']) 




    # If you're not running this part of the program, presumably you've already generated 
    # filtered files and want to use those. 
    # This calls find_text_files, which returns files from your working folder which end 
    # with mismatch_filtered.txt 
    print('\n---\nUsing previously filtered files\n---') 
    mismatch_filtered_files = find_text_files(p['working_folder_name'], biosamples, 
                                             'mismatch filtered.txt') 
 
 
# 7. Count how many times each randomized sequence variant appears in the filtered data 
if run_count_sequences: 
    # Generate a list of all of the sequences we expect in the library 
    print('\n---\nGenerating a list of processed sequences\n---') 
    if p['twist_sequence_file']: 
        # Read the 'names' of sequences from the Twist sequence CSV file 
        # These are the lists of randomized bases 
        print('Twist library') 
        possible_sequence_dict = generate_twist_sequence_dict(biosamples, 
                                                            p['twist_sequence_file']) 
    else: 
        # Generate a list of all possible sequences given the number of randomized bases 
        print('Site saturation library') 
        possible_sequence_dict = generate_randomized_sequence_dict(p['randomized_bases'], 
                                                                   biosamples) 
 
    # count_randomized_sequences updates updates possible_sequence dict with counts and 
    # returns it as sequence_count_dict {Sequence_1:[count_lib, count_sel_1...]...} 
    # Also returns read_counts [total_lib_reads, total_sel_1_reads...] 
    if from_csv: 
        # Identify the .csv files based on biosample names 
        csv_file_list = find_text_files(p['working_folder_name'], biosamples, '.csv') 
 
        # Extract counts from csv files 
        print('\n---\nReading randomized sequence counts from csv\n---') 
        sequence_count_dict, read_counts = \ 
        counts_from_csv(biosamples, csv_file_list, p['working_folder_name'], 
                        possible_sequence_dict) 
 
    else: 
        # Count in each mismatch-filtered sequence file 
        print('\n---\nCounting randomized sequences\n---') 
        sequence_count_dict, read_counts = \ 
        count_randomized_sequences(biosamples, mismatch_filtered_files, 
                                   p['working_folder_name'], possible_sequence_dict, 
                                   p['randomized_bases']) 
 
 
# 8. Calculate enrichments 
# Create sequence_table containing the following information for all sequences: 
# COLUMN   HEADER                     CONTENTS 
# 0        Randomized sequence        [formatted randomized sequence] 
# 1        Full stem sequence         [formatted full stem sequence] 
# 2        Paired bases               [number of paired bases] 
# 3        Raw counts                 [lib_count, sel_1_count, sel_2_count...] 
# 4        Fraction of total          [lib_fraction, sel_1_fraction, sel_2_fraction...] 
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# 5        Fold enrichment            [sel_1_fold_enrichment, sel_2_fold_enrichment...] 
# 6        Enrichment factors         [sel_1_enrichment_factor, sel_2_enrichment_factor...] 
# 7        Enrichment ranks           [sel_1_rank, sel_2_rank...] 
# 8        Average enrichment factor  [average enrichment factor] 
# 9        StDev                      [enrichment factor standard deviation] 
# 10       Rank                       [rank based on average enrichment factor] 
 
if run_calculate_enrichments: 
    # calculate_enrichments writes sequence_table to a csv file 
    # working_folder\Results\lib_name Results.csv 
    # Sequences whose counts in the library run were too low to be identified are written 
    # to a separate file working_folder\Results\lib_name Low Abundance Sequences.csv 
    print('\n---\nCalculating enrichments\n---') 
    sequence_table, low_abundance_table = calculate_enrichments(sequence_count_dict, 
        read_counts, biosamples, p['sel_1_name'], p['sel_2_name'], p['sel_2_runs'], 
        p['output_format'], p['full_seq_format'], p['rand_expected_pairs'], 
        p['working_folder_name'], p['lib_name'], p['min_lib_count']) 
 
 
# 10. Generate plots 
if run_plot_results: 
    print('\n---\nPlotting results') 
    plot_results(p['working_folder_name'], sequence_table, low_abundance_table, biosamples, 
                 p['randomized_bases'], p['sel_1_name'], p['sel_2_name'], p['sel_2_runs'], 
                 p['expected_pairs']) 
 
 
# How long did the run take? 
end_time = time.time() 
print ('\n---\nTotal run time: {:.0f} seconds ({:.2f} minutes)\n---'.format( 




@author: Rachel Kelemen 
Finalized: April 2019 
 
This module contains a function to read a .csv file specifying the parameters for 
Illumina data processing and returns a dictionary of parameters. 
 




import datetime as dt 
 
def read_parameter_file(parameter_file_name): 
    """Read in data processing parameters from a .csv file and output to dictionary 
 
    Parameters 
    --- 
    parameter_file_name : str 
        full path and file name of parameters.csv 
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    Returns 
    --- 
    p : dict 
        {parameter_name: parameter_value} 
 
    Notes 
    --- 
    Converts base index values from SeqBuilder-type counting, which starts at 1, 
    to Python-type counting, which starts at 0. 
 
    The input parameters.csv file is expected to have the following format 
    parameter_name, description, value1, value2... 
 
    The parameters used will be written to output .csv files as well for record-keeping. 
 
    Blank lines are okay, but any line with an entry in the parameter_name (first) 
    column is assumed to contain a parameter to be read. 
    """ 
 
    print('Reading parameters from') 
    print(parameter_file_name) 
 
    # Set up an empty dictionary to hold lines read from the .csv file 
    # After reading the parameter file p0 will look like 
    # {parameter_name: [value1, value2...]} 
    p0 = {} 
 
    # Read parameter file 
    # Track all of the rows - this will be used to write the parameter file used 
    # to another .csv file for record-keeping purposes. 
    rows = [] 
    with open(parameter_file_name, 'r') as parameter_file: 
        parameter_file_reader = csv.reader(parameter_file) 
        for row in parameter_file_reader: 
            rows.append(row) 
            # Only read rows with a value in the parameter_name column 
            if row[0] != '': 
                values = [] 
                for value in row[2:]: 
                    if value != '': 
                        values.append(value) 
                if len(values) == 0: 
                    # Because optional parameters can be left blank 
                    p0[row[0]] = None 
                else: 
                    p0[row[0]] = values 
 
    # Extract and adjust parameters from p0 
    # Set up a final parameter dictionary p 
    p = {} 
 
    # All dictionary values are currently in the form [value1...] 
 
    # Simple parameters 
    # Blank values default to None 
    for sp in ['lib_name', 'lib_run', 'sel_1_name', 'sel_2_name', 
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               'working_folder_name', 'expected_sequence', 
               'twist_sequence_file', 'output_format', 'full_seq_format']: 
        if (sp in p0.keys() and p0[sp]): 
            p[sp] = p0[sp][0] 
        else: 
            p[sp] = None 
 
    # Simple numerical parameters (integers) 
    # Blank values default to 0 
    for np in ['Q0', 'Q1', 'Q2', 'QF', 'exclude_at_start', 'exclude_at_end', 'min_lib_count']: 
        if (np in p0.keys() and p0[np]): 
            p[np] = int(p0[np][0]) 
        else: 
            p[np] = 0 
    # Correct Q2 to default to Q1 so failed bases are not allowed in randomized regions 
    if p['Q2'] == 0: 
        p['Q2'] == p['Q1'] 
    # Correct min_lib_count to 1 to avoid divide by zero errors later 
    if p['min_lib_count'] == 0: 
        p['min_lib_count'] == 0 
 
    # Simple lists 
    for sl in ['sel_1_runs', 'sel_2_runs']: 
        p[sl] = p0[sl] 
 
    # Numerical lists 
    p['allowed_mismatch_counts'] = [] 
    for m in p0['allowed_mismatch_counts']: 
        p['allowed_mismatch_counts'].append(int(m)) 
 
    # Coordinate lists which need integer extraction and counting adjustment 
    # tRNA and constant region coordinates (tRNA coords are optional) 
    if 'tRNA_coords' in p0: 
        p['tRNA_coords'] = [int(p0['tRNA_start'][0])-1, int(p0['tRNA_end'][0])] 
    else: 
        p['tRNA_coords'] = None 
    p['constant_region_coords'] = [] 
    for i, j in zip(p0['constant_region_starts'], p0['constant_region_ends']): 
        p['constant_region_coords'].append([int(i)-1, int(j)]) 
    # List of all randomized bases 
    p['randomized_bases'] = [] 
    for b in p0['randomized_bases']: 
        p['randomized_bases'].append(int(b)-1) 
    # Expected pairs in terms of sequence coordinates 
    if (p0['pairs_5prime'] and p0['pairs_3prime']): 
        p['expected_pairs'] = [] 
        for a, b in zip(p0['pairs_5prime'], p0['pairs_3prime']): 
            p['expected_pairs'].append([int(a)-1,int(b)-1]) 
    else: 
        p['expected_pairs'] = None 
    # Expected pairs in terms of randomized base coordinates 
    p['rand_expected_pairs'] = [] 
    if p['expected_pairs']: 
        for c in p['expected_pairs']: 
            p['rand_expected_pairs'].append([p['randomized_bases'].index(c[0]), 
                                            p['randomized_bases'].index(c[1])]) 
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    # Print output 
    print('\nParameters set to:') 
    for parameter in p: 
        print('> {} : {}'.format(parameter, p[parameter])) 
 
    # Write the initial and adjusted parameters used to .csv files in the working folder 
    # for record-keeping purposes 
    # date lib_name parameters as entered.csv will be an exact copy of the input file 
    as_entered_file_name = str(dt.date.today()) + ' ' + p['lib_name'] + ' parameters as entered.csv' 
    as_entered_file_address = p['working_folder_name'] + '\\' + as_entered_file_name 
    with open(as_entered_file_address, 'w', newline='') as output_file: 
        parameter_writer = csv.writer(output_file) 
        for row in rows: 
            parameter_writer.writerow(row) 
 
    # date lib_name parameters adjusted.csv will be the parameters after adjstment 
    adjusted_file_name = str(dt.date.today()) + ' ' + p['lib_name'] + ' parameters adjusted.csv' 
    adjusted_file_address = p['working_folder_name'] + '\\' + adjusted_file_name 
    with open(adjusted_file_address, 'w', newline='') as output_file: 
        parameter_writer = csv.writer(output_file) 
        for parameter_name in p: 
            parameter_writer.writerow([parameter_name, p[parameter_name]]) 
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This module contains a function to characterize the quality of a run based on the 






import datetime as dt 
import numpy as np 
import matplotlib.pyplot as plt 
from Bio import SeqIO 
from statistics import mean 
 
def characterize_quality(fastq_file_name, working_folder_name, limit, expected_sequence, 
                         exclude_at_start, exclude_at_end, randomized_bases): 
    """Characterize the quality of a Fastq data set based on Phred quality scores 
 
    Parameters 
    --- 
    fastq_file_name : str 
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        File to be characterized 
    working_folder_name : str 
        Folder containing .fastq files 
    limit : int 
        How many sequences to characterize 
    expected_sequence : str 
        The full expected sequences, including excluded positions 
    exclude_at_start : int 
        Number of bases to exclude from analysis at the beginning of the sequence, 
        typically the diversity sequence 
    exclude_at_end : int 
        Number of bases to exclude from analysis at the end of the sequence, often 
        due to decreased quality scores 
    randomized_bases : list 
        List of randomized base coordinates 
 
    Notes 
    --- 
    Output plots are placed working_folder_name\Plots\Run Quality 
 
    The number of sequences to be characterized is limited because reading the whole 
    file is very slow. 
    """ 
 
    # Setup 
    # Number of sequences read - doesn't include short sequences 
    read_count = 0 
    # Number of sequences which are shorter than expected 
    short_Q_scores = 0 
 
    # Possible Q scores 
    Q_score_list = np.arange(41) #Illumina records scores 0 through 41 
 
    # Lists of Q score frequencies [Q0_count, Q1_count...] 
    # Lowest scores for each sequence 
    min_Q_score_counts = list(np.zeros(len(Q_score_list),dtype=int)) 
    # Second lowest scores for each sequence 
    min_Q_score_counts_2 = list(np.zeros(len(Q_score_list),dtype=int)) 
    # Average score for each sequence 
    avg_Q_score_counts = list(np.zeros(len(Q_score_list),dtype=int)) 
    # Total occurrences of each Q score 
    all_Q_score_counts = list(np.zeros(len(Q_score_list),dtype=int)) 
 
    # Average Q score at each position (this includes excluded bases) 
    per_base_avg_scores = list(np.zeros(len(expected_sequence))) 
 
    # Lists of Q score frequencies for randomized bases in each sequence 
    if randomized_bases: 
        # Lowest scores among randomized bases 
        min_rand_Q_score_counts = list(np.zeros(len(Q_score_list),dtype=int)) 
        # Average scores among randomzied bases 
        avg_rand_Q_score_counts = list(np.zeros(len(Q_score_list),dtype=int)) 
        # Total occurrences of each Q score among randomized bases 
        rand_Q_score_counts = list(np.zeros(len(Q_score_list),dtype=int)) 
 




#   Iterate over .fastq file using SeqIO.parse() 
    print('\n---\n'+fastq_file_name) 
    print('Read up to {} sequences'.format(limit)) 
    print ('Started at',dt.datetime.now().strftime('%I:%M:%S')) 
    fastq_file_address = working_folder_name + '\\' + fastq_file_name 
    for seq_record in SeqIO.parse(fastq_file_address,'fastq'): 
        if read_count >= limit: 
            break  # exit the loop if the limit has been reached 
 
        # Extract Q scores from the seq_record 
        full_Q_scores = seq_record.letter_annotations['phred_quality'] 
        # Omit excluded bases from the beginning and end of the sequence 
        Q_scores = full_Q_scores[exclude_at_start:len(expected_sequence)-exclude_at_end+1] 
 
        # Reject any truncated reads and keep a count of how many were rejected 
        if len(full_Q_scores) < len(expected_sequence) - exclude_at_end: 
            short_Q_scores += 1 
 
        # Characterize quality for full-length sequences 
        else: 
            # Average Q scores per base across the whole sequence 
            for i in range(len(full_Q_scores)): 
                per_base_avg_scores[i] += full_Q_scores[i]/limit 
 
            # Randomized base quality 
            if randomized_bases: 
                # Extract randomized base Q scores 
                randomized_base_Q_scores = [] 
                for coord in randomized_bases: 
                    randomized_base_Q_scores.append(full_Q_scores[coord]) 
                # Minimum scores 
                min_rand_Q_score = min(randomized_base_Q_scores) 
                if min_rand_Q_score > 40:  # just in case Q scores > 40 are returned 
                    min_rand_Q_score = 40 
                min_rand_Q_score_counts[min_rand_Q_score] += 1 
                # Average scores 
                avg_rand_Q_score = int(mean(randomized_base_Q_scores)) 
                if avg_rand_Q_score > 40: #just in case Q scores > 40 are returned 
                    avg_rand_Q_score = 40 
                avg_rand_Q_score_counts[avg_rand_Q_score] += 1 
                # Total Q score frequency 
                for Q_score in randomized_base_Q_scores: 
                    rand_Q_score_counts[Q_score] += 1 
 
            # Sort the Q scores in ascending order 
            sorted_Q_scores = sorted(Q_scores) 
            # Minimum scores 
            min_Q_score = sorted_Q_scores[0] 
            if min_Q_score > 40: 
                min_Q_score = 40 
            min_Q_score_counts[min_Q_score] += 1 
            # Second lowest scores 
            min_Q_score_2 = sorted_Q_scores[1] 
            if min_Q_score_2 > 40: 
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                min_Q_score_2 = 40 
            min_Q_score_counts_2[min_Q_score_2] += 1 
            # Average scores 
            avg_Q_score = int(mean(Q_scores)) 
            if avg_Q_score > 40: 
                avg_Q_score = 40 
            avg_Q_score_counts[avg_Q_score] += 1 
            # frequency of each Q score over all positions 
            for Q_score in Q_scores: 
                all_Q_score_counts[Q_score] += 1 
 
            # Increment read count 
            read_count += 1 
 
    # Plot results 
    # Make plotting results folder 
    plot_folder = working_folder_name + '\\Plots\\Run Quality ' + str(limit) 
    if os.path.exists(plot_folder) == False: 
        os.makedirs(plot_folder) 
 
    # Plots where x axis is Q scores and y axis is frequency 
    # Minimum Q scores, 2nd lowest Q scores, Average Q scores, Q score frequencies, 
    # Randomized base minimum Q scores, Randomzied base average Q scores, 
    # Randomized base Q score frequencies 
    plot_by_Q_scores = [min_Q_score_counts, min_Q_score_counts_2, avg_Q_score_counts, 
all_Q_score_counts] 
    if randomized_bases: 
        for a in [min_rand_Q_score_counts, avg_rand_Q_score_counts, rand_Q_score_counts]: 
            plot_by_Q_scores.append(a) 
    stat_names = ['Lowest Q scores per sequence', '2nd lowest Q scores per sequence', 
                  'Average Q scores per sequence', 'Q score frequencies'] 
    if randomized_bases: 
        for a in ['Minimum randomized base Q scores', 'Average randomized base Q scores', 
                  'Q score frequences for randomized bases']: 
            stat_names.append(a) 
    # Plot colors: red for minimum scores, yellow for 2nd lowest, green for average, 
    # blue for total frequencies 
    colors = ['r', 'y', 'g', 'b', 'r', 'g', 'b'] 
 
    # Make plots 
    for stat, stat_name, Color in zip(plot_by_Q_scores, stat_names, colors): 
        fig, ax = plt.subplots(figsize=(4,3)) 
        ax.bar(Q_score_list, stat, edgecolor='black', color=Color) 
        ax.set_title(fastq_file_name + '\n' + stat_name) 
        ax.set_ylabel('Count') 
        ax.set_xlabel('Q score') 
        ax.minorticks_on() 
        plt.tight_layout() 
        # Save figures 
        plot_file_name = plot_folder + '\\' + fastq_file_name[:-6] + ' ' + stat_name + '.png' 
        plt.savefig(plot_file_name, dpi=300) 
        plt.close() 
 
    # Plot average Q score by position 
    # X axis is sequence coordinate and y axis is average Q score 
    fig, ax = plt.subplots(figsize=(12, 3)) 
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    ax.bar(np.arange(1, len(expected_sequence)+1), per_base_avg_scores, color='g', 
edgecolor='w') 
    ax.set_title(fastq_file_name + '\n' + 'Average Q scores by position') 
    ax.set_ylabel('Q score') 
    ax.set_xlabel('Position') 
    ax.axvline(exclude_at_start+0.5, color='black', linestyle='--') 
    ax.axvline(len(expected_sequence)-exclude_at_end+0.5, color='black', linestyle='--') 
    ax.minorticks_on() 
    plt.tight_layout() 
    # Save figure 
    plot_file_name = plot_folder + '\\' + fastq_file_name[:-6] + ' Average Q scores by position.png' 
    plt.savefig(plot_file_name, dpi=300) 
    plt.close() 
 
 
    end_time=time.time() 
 
 
    print ('\n{:,} total reads processed in {:.0f} seconds'.format( 
            short_Q_scores + read_count, end_time-start_time)) 
    print('\nResults:\n{:,} sequences had short Q score lists and were rejected'.format( 
            short_Q_scores)) 
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This module contains a function to read FASTQ files, filter reads using their Phred 





import datetime as dt 
from Bio import SeqIO 
 
def Q_score_filter(working_folder_name, to_filter, biosample, Q1, QF, Q0, Q2, 
                   expected_sequence, randomized_bases, exclude_at_start, exclude_at_end, 
                   stats_file_address): 
    """Read FASTQ files, filter reads by quality scores, and write passing sequences 
    to a text file. 
 
    Parameters 
    --- 
    working_folder_name : str 
        Folder in which FASTQ files can be found 
    to_filter : list 
        List of FASTQ files for the given biosample 
    biosample : string 
        Biosample name 
    Q1 : int 
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        Minimum allowed score for the full sequence 
    QF : int 
        Number of bases below Q1 allowed per sequence 
    Q0 : int 
        Absolute minimum allowed score for bases allowed by QF 
    Q2 : int 
        Minimum allowed score for randomized bases 
    expected_sequence : str 
        Expected sequence for the full read 
    randomized_bases : list 
        Coordinates of each randomized base 
    exclude_at_start : int 
        Number of bases to exclude from analysis at the beginning of the sequence, 
        typically the diversity sequence 
    exclude_at_end : int 
        Number of bases to exclude from analysis at the end of the sequence, often 
        due to decreased quality scores 
    stats_file_address : str 
        File address to which filtering stats should be written 
 
    Returns 
    --- 
    output_file_name : str 
        File to which passing sequences have been written 
    stats : list 
        Statistics describing number of sequences passing or failing on each parameter 
 
    Notes 
    --- 
    Passing sequences are written to working_folder_name\Biosample_Q_score_filtered.txt 
 
    For each parameter, failing sequences are written to working_folder_name\ 
    Biosample_parameter_failed.txt 
    """ 
 
    # Setup 
 
    # Count sequences which fall into each category 
    short_seqs = 0 
    Q0_fail_count = 0 
    Q1_fail_count = 0 
    Q2_fail_count = 0 
    pass_count = 0 
    read_count = 0 
 
    # Holders for sequences to be written to .txt files 
    passed_sequence_holder = [] 
    failed_sequence_holder = [] 
 
    start_time = time.time() 
 
 
    # File names and addresses 
    output_file_name = str(dt.date.today()) + ' ' + biosample + ' Q score filtered.txt' 
    output_file_address = working_folder_name + '\\' + output_file_name 
    failed_output_file_name = str(dt.date.today()) + ' ' + biosample + ' Q score failed.txt' 
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    failed_output_file_address = working_folder_name + '\\' + failed_output_file_name 
 
    # Open input and output files 
    with open(output_file_address, 'a', newline='\n') as output_file,\ 
    open(failed_output_file_address, 'a', newline='\n') as failed_output_file: 
 
        # Clear output files from any previous runs 
        output_file.truncate(0) 
        failed_output_file.truncate(0) 
 
        # Iterate over fastq files using Bio.SeqIO.parse() 
        for input_file_name in to_filter: 
            input_file = working_folder_name + '\\' + input_file_name 
            print ('\nProcessing file:\n' + input_file_name) 
            print ('Started filtering reads at',dt.datetime.now().strftime('%I:%M:%S')) 
            for seq_record in SeqIO.parse(input_file,'fastq'): 
                # Track how many sequences records have been read 
                read_count += 1 
 
                # Start out by assuming the sequence passes filters 
                Q_pass = True 
 
                # Extract the numeric list of Q scores 
                Q_scores = seq_record.letter_annotations['phred_quality'] 
 
                # Reject any truncated sequences and add them to a holder to be written 
                # to a text file 
                if len(Q_scores) < len(expected_sequence)-exclude_at_end or\ 
                len(seq_record.seq) < len(expected_sequence)-exclude_at_end: 
                    Q_pass = False 
                    short_seqs += 1 
                    failed_sequence_holder.append(str(seq_record.seq)+'\n') 
 
                # Filter based on overall sequence quality 
                # No more than QF bases below Q1 
                # No bases below Q0 
                if Q_pass: 
                    base_fail_Q1_count = 0 
                    for Q in Q_scores[exclude_at_start:len(expected_sequence)-exclude_at_end]: 
                        if Q < Q0: 
                            Q_pass = False 
                            Q0_fail_count += 1 
                            failed_sequence_holder.append(str(seq_record.seq)+'\n') 
                            break 
                        if Q < Q1: 
                            base_fail_Q1_count += 1 
                            if base_fail_Q1_count > QF: 
                                Q_pass = False 
                                Q1_fail_count += 1 
                                failed_sequence_holder.append(str(seq_record.seq)+'\n') 
                                break 
 
                # Filter based on randomized sequence quality 
                # No randomized bases below Q2 
                if (Q_pass): 
                    for rb in randomized_bases: 
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                        if Q_scores[rb] < Q2: 
                            Q_pass = False 
                            Q2_fail_count += 1 
                            failed_sequence_holder.append(str(seq_record.seq)+'\n') 
                            break 
 
                # Write passing sequences to holder 
                if Q_pass: 
                    passed_sequence_holder.append(str(seq_record.seq)+'\n') 
                    pass_count += 1 
 
                # Whenever any holder is full, write the sequences in the holder to the 
                # appropriate file and clear the holder. 
                # This is done to avoid generating enormous lists which exceed the 
                # computer's available memory. 
                holder_length = 100000 
 
                if len(passed_sequence_holder) >= holder_length: 
                    for seq in passed_sequence_holder: 
                        output_file.write(seq) 
                    passed_sequence_holder.clear() 
                    print('{:,} sequences passed, {:,} failed'.format(pass_count, 
                          read_count-pass_count)) 
 
                elif len(failed_sequence_holder) >= holder_length: 
                    for seq in failed_sequence_holder: 
                        failed_output_file.write(seq) 




            # At the end of the loop, write the sequences in each holder to the 
            # appropriate file 
            for seq in passed_sequence_holder: 
                output_file.write(seq) 
            passed_sequence_holder.clear() 
            print('{:,} sequences passed, {:,} failed'.format(pass_count, 
                  read_count-pass_count)) 
 
            for seq in failed_sequence_holder: 
                failed_output_file.write(seq) 
            failed_sequence_holder.clear() 
 
    end_time = time.time() 
 
    print ('\nQ score filtering results for ' + biosample) 
    print ('{:,} reads processed'.format(read_count)) 
    print('{:,} sequences had short Q_score lists ({:.2%})'.format(short_seqs, 
          short_seqs/read_count)) 
    print('{:,} sequences failed Q0 = {} ({:.2%})'.format(Q0_fail_count, Q0, 
          Q0_fail_count/read_count)) 
    print('{:,} sequences failed Q1 = {} ({:.2%})'.format(Q1_fail_count, Q1, 
          Q1_fail_count/read_count)) 
    print('{:,} sequences failed Q2 = {} ({:.2%})'.format(Q2_fail_count, Q2, 
          Q2_fail_count/read_count)) 
    print('{:,} sequences passed ({:.2%})'.format(pass_count, pass_count/read_count)) 
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    print('\nFiltered sequences written to:\n' + output_file_name) 
    print('\nTotal run time = {:.0f} seconds ({:.1f} minutes)'.format(end_time-start_time, 
          (end_time-start_time)/60)) 
 
 
    # Write the results to a .csv file 
    # Opening the file in 'a' (append) mode means that lines are added to the end of the 
    # existing file. 
 
    # The structure of this file (set up in Main) is: 
    # ['Biosample', 'Pct pass', 'Total reads', 'Passing reads', 
    # 'Short sequences', 'Q0 fail', 'Q1 fail', 'Q2 fail'] 
 
    # Compile filtering statistics into stats 
    stats = [biosample, (pass_count/read_count), read_count, pass_count, short_seqs, 
             Q0_fail_count, Q1_fail_count, Q2_fail_count] 
    with open(stats_file_address, 'a', newline='') as stats_file: 
        stats_writer = csv.writer(stats_file) 
        stats_writer.writerow(stats) 
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This module contains a function which accomplishes two things: 
1. Filters reads based on agreement with the expected constant regions of the sequence 
2. Plots the frequency of each base at every position in the sequence, as well as the 






import datetime as dt 
import numpy as np 
import matplotlib.pyplot as plt 
from matplotlib.ticker import FuncFormatter 
 
def mismatch_filter(working_folder_name, to_filter, biosample, constant_region_coords, 
                    allowed_mismatch_counts, expected_sequence, stats_file_address, 
                    tRNA_coords = None, randomized_bases = None): 
    """Filters reads based on agreement with expected constant regions and plots base 
    frequency at each position 
 
    Parameters 
    --- 
    working_folder_name : str 
        Working folder 
    to_filter : str 
        Filename to filter e.g. biosample_Q_score_filtered.txt 
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    biosample : str 
        Biosample name 
    constant_region_coords : list 
        List of onstant region start and end coordinates e.g. [[0, 15], [20, 30]...] 
    allowed_mismatch_counts : list 
        Maximum allowed mismatches for each constant region e.g. [2, 5...] 
    expected_sequence : str 
        Full expected sequence, including excluded and randomized regions 
 
    Optional parameters 
    --- 
    tRNA_coords : list 
        First and last bases of the tRNA e.g. [10, 28] 
    randomized_bases : list 
        List of randomized positions e.g. [15, 17...] 
 
    Returns 
    --- 
    output_file_name : str 
        File to which passing sequences have been written 
    stats : list 
        Statistics describing number of sequences passing or failing on each constant region 
 
    Notes 
    --- 
    Passing sequences are written to working_folder_name\Biosample_mismatch_filtered.txt 
 
    For each constant region, failing sequences are written to working_folder_name\ 
    Biosample_constant_region_coords_failed.txt 
 
    Plots are saved to working_folder_name\Plots\Mismatch filter plots 
    """ 
 
    # Setup 
    # Constant region numbers 
    constant_region_numbers = list(np.arange(len(allowed_mismatch_counts), dtype=int)) 
    # Partial expected sequences 
    partial_expected_sequences = [] 
    for i in constant_region_numbers: 




    # Count sequences 
    read_count = 0 
    pass_count = 0 
    mismatch_fail_counts = list(np.zeros(len(allowed_mismatch_counts), dtype=int)) 
 
    # Holders for sequences to be written to txt files 
    passed_sequence_holder = [] 
    failed_sequence_holder = [] 
 
    # Input file 
    input_file_address = working_folder_name + '\\' + to_filter 
 
    # Output file names 
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    output_file_name = str(dt.date.today()) + ' ' + biosample + ' mismatch filtered.txt' 
    output_file_address = working_folder_name + '\\' + output_file_name 
    failed_output_file_name = str(dt.date.today()) + ' ' + biosample + ' mismatch failed.txt' 
    failed_output_file_address = working_folder_name + '\\' + failed_output_file_name 
 
    # Plotting lists 
    base_indices = {'A':0, 'C':1, 'G':2, 'T':3, 'N':4} 
    # Base counts - will be converted to fractions later 
    # [[1A, 2A, 3A...], [1C, 2C, 3C...], [1G, 2G, 3G], [1T, 2T, 3T]] 
    base_count_list = [] 
    for base in ['A', 'C', 'G', 'T', 'N']: 
        base_count_list.append(list(np.zeros(len(expected_sequence), dtype=int))) 
 
    # Mismatch counts - will also be converted to fractions later 
    mismatch_count_list = list(np.zeros(len(expected_sequence), dtype=int)) 
 
 
    print('Started at', dt.datetime.now().strftime('%I:%M:%S')) 
    start_time = time.time() 
 
 
    # Open input and output files 
    with open(input_file_address, 'r', newline='\n') as input_file, \ 
    open(output_file_address, 'a', newline='\n') as output_file, \ 
    open(failed_output_file_address, 'a', newline='\n') as failed_output_file: 
 
        # Clear output files from any previous runs 
        output_file.truncate(0) 
        failed_output_file.truncate(0) 
 
        # Read each line in input file 
        for current_sequence in input_file: 
            read_count += 1 
            mismatch_pass = True 
 
            # Filter 
            # Iterate through constant regions 
            for coords, max_mismatches, partial_expected_sequence, i in zip( 
                    constant_region_coords, allowed_mismatch_counts, 
                    partial_expected_sequences, constant_region_numbers): 
                mismatches = 0 
                # Try a string comparison first = this is true only if the two sequences 
                # are completely identical. 
                if current_sequence[coords[0]:coords[1]] != partial_expected_sequence: 
                    # If the strings are not completely identical, compare each base 
                    # individually. 
                    for c, e in zip(current_sequence[coords[0]:coords[1]], 
                                    partial_expected_sequence): 
                        if c != e: 
                            mismatches += 1 
                            if mismatches > max_mismatches: 
                                mismatch_pass = False 
                                mismatch_fail_counts[i] += 1 
                                failed_sequence_holder.append(current_sequence) 
                                # Stop testing individual positions 
                                break 
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                # If failed, break filtering loop instead of iterating through the 
                # remaining regions 
                if mismatch_pass == False: 
                    break 
 
            # If sequence passed on all regions, add to holder and extract plotting information 
            # It's more efficient to do the filtering and plotting at the same time 
            if mismatch_pass: 
                pass_count += 1 
                # Add to holder 
                passed_sequence_holder.append(current_sequence) 
                # Update base counts and mismatch lists 
                # Convert bases to list indices 
                for i in range(len(expected_sequence)): 
                    # Base counts 
                    base_index = base_indices[current_sequence[i]] 
                    base_count_list[base_index][i] += 1 
                    # Mismatch counts 
                    if current_sequence[i] != expected_sequence[i]: 
                        mismatch_count_list[i] += 1 
 
            # Whenever any holder is full, write the sequences in the holder to the 
            # appropriate file and clear the holder. 
            # This is done to avoid generating enormous lists which exceed the 
            # computer's available memory. 
            holder_length = 100000 
 
            if len(passed_sequence_holder) >= holder_length: 
                for seq in passed_sequence_holder: 
                    output_file.write(seq) 
                passed_sequence_holder.clear() 
                print('{:,} sequences passed, {:,} failed'.format(pass_count, 
                      read_count-pass_count)) 
 
            elif len(failed_sequence_holder) >= holder_length: 
                for seq in failed_sequence_holder: 
                    failed_output_file.write(seq) 
                failed_sequence_holder.clear() 
 
 
        # Write all sequences left in holders at the end of the loop 
        # Passing sequence holder 
        for seq in passed_sequence_holder: 
            output_file.write(seq) 
        passed_sequence_holder.clear() 
        print('{:,} sequences passed, {:,} failed'.format(pass_count, 
              read_count-pass_count)) 
 
        for seq in failed_sequence_holder: 
            failed_output_file.write(seq) 
        failed_sequence_holder.clear() 
 
 
    end_time = time.time() 
    print('\n{:,} reads processed in {:.0f} seconds'.format(read_count, end_time-start_time)) 
    print('{:,} sequences passed ({:.2%})'.format(pass_count, pass_count/read_count)) 
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    print('Written to ', output_file_name) 
 
 
    # Write the results to a .csv file 
    # Opening the file in 'a' (append) mode means that lines are added to the end of the 
    # existing file. 
 
    # The structure of this file (set up in Main) is: 
    # ['Biosample', 'Pct pass', 'Total reads', 'Passing reads', 'Region 1 failed'...] 
 
    # Compile filtering statistics into stats 
    stats = [biosample, (pass_count/read_count), read_count, pass_count] 
    for fail_count in mismatch_fail_counts: 
        stats.append(fail_count) 
    # Write to file as a new line 
    with open(stats_file_address, 'a', newline='') as stats_file: 
        stats_writer = csv.writer(stats_file) 
        stats_writer.writerow(stats) 
 
 
    # Plotting 
 
    # Make plotting results folder 
    plot_folder = working_folder_name + '\\Plots\\Mismatch filtering' 
    if os.path.exists(plot_folder) == False: 
        os.makedirs(plot_folder) 
 
    # Base fractions 
    # [[1A, 2A, 3A...], [1C, 2C, 3C...], [1G, 2G, 3G], [1T, 2T, 3T]] 
    base_fraction_list = [] 
    for base in ['A', 'C', 'G', 'T']: 
        base_fraction_list.append([]) 
    # Mismatch fractions 
    mismatch_fraction_list = [] 
 
    # Convert all count lists to fraction lists 
    for N_count_list, i in zip(base_count_list, [0, 1, 2, 3]): 
        for count in N_count_list: 
            base_fraction_list[i].append(count/pass_count) 
    # Mismatch fractions 
    for count in mismatch_count_list: 
        mismatch_fraction_list.append(count/pass_count) 
 
    # All plots will have tick labels of the format 'Base', or 'coordinate\nBase' every 5. 
    x_labels = [] 
    x_label_colors = [] 
    base_colors = {'A':'g', 'C':'b', 'G':'0', 'T':'r'} 
    for base, index in zip(expected_sequence, np.arange(1, len(expected_sequence)+1)): 
        x_label_colors.append(base_colors[base]) 
        if (index%5 == 0): 
            x_labels.append('{}\n{}'.format(base, index)) 
        else: 
            x_labels.append(base) 
 
    # Make mismatch plot 
    fig, ax = plt.subplots(figsize=(20, 4)) 
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    ax.set_title(biosample) 
    ax.set_ylabel('Mismatch frequency') 
    # Shading should be done before plotting the series because otherwise data points 
    # within the shaded boxes will also be shaded. 
    # Shade tRNA and randomized sequences 
    if tRNA_coords: 
        # Shade the promoter region green 
        ax.axvspan(-0.5, tRNA_coords[0]-0.5, facecolor='xkcd:aqua', alpha=0.15) 
        # Shade the tRNA yellow 
        ax.axvspan(tRNA_coords[0]-0.5, tRNA_coords[1]+0.5, facecolor='xkcd:yellow', 
                   alpha=0.3) 
        # Shade the terminator TTTTTT red 
        ax.axvspan(tRNA_coords[1]+0.5, tRNA_coords[1]+6.5, facecolor='r', alpha=0.15) 
    # Shade randomized bases dull red 
    if randomized_bases: 
        for coord in randomized_bases: 
            ax.axvspan(coord-0.5, coord+0.5, facecolor='xkcd:orange', alpha=0.5) 
    # Plot the series 
    ax.plot(np.arange(len(mismatch_fraction_list)), mismatch_fraction_list, marker='o', 
            markerfacecolor='r', linestyle='', markeredgewidth=0) 
    ax.yaxis.set_major_formatter(FuncFormatter('{0:.0%}'.format)) 
    # Make horizontal gridlines 
    plt.grid(axis='y', color='0.5') 
    ax.set_xticks(np.arange(1, len(expected_sequence)+1)) 
    ax.set_xticklabels(x_labels) 
    for xtick, color in zip(ax.get_xticklabels(), x_label_colors): 
        xtick.set_color(color) 
    plt.tight_layout() 
    # Save figure 
    plot_folder = working_folder_name + '\\Plots\\Mismatch filtering' 
    plot_file_name = plot_folder + '\\' + biosample + ' mismatch frequencies.png' 
    plt.savefig(plot_file_name, dpi=300) 
    plt.close() 
 
    # Make base frequency plot 
    fig, ax = plt.subplots(figsize=(20, 4)) 
    # Plot A, C, G, T 
    ax.yaxis.set_major_formatter(FuncFormatter('{0:.0%}'.format)) 
    ax.set_title(biosample) 
    ax.set_ylabel('Base frequency') 
    # Shade tRNA and randomized sequences 
    if tRNA_coords: 
        # Shade the promoter region green 
        ax.axvspan(-0.5, tRNA_coords[0]-0.5, facecolor='xkcd:aqua', alpha=0.15) 
        # Shade the tRNA yellow 
        ax.axvspan(tRNA_coords[0]-0.5, tRNA_coords[1]+0.5, facecolor='xkcd:yellow', 
                   alpha=0.3) 
        # Shade the terminator TTTTTT red 
        ax.axvspan(tRNA_coords[1]+0.5, tRNA_coords[1]+6.5, facecolor='r', alpha=0.15) 
    # Shade randomized bases dull red 
    if randomized_bases: 
        for coord in randomized_bases: 
            ax.axvspan(coord-0.5, coord+0.5, facecolor='xkcd:orange', alpha=0.5) 
    # Plot series 
    for i, color in zip([0, 1, 2, 3], ['g', 'b', '0', 'r']): 
        ax.plot(np.arange(len(base_fraction_list[i])), base_fraction_list[i], marker='o', 
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            markerfacecolor=color, linestyle='', markeredgewidth=0) 
    # Make horizontal gridlines 
    plt.grid(axis='y', color='0.5') 
    ax.set_xticks(np.arange(1, len(expected_sequence)+1)) 
    ax.set_xticklabels(x_labels) 
    for xtick, color in zip(ax.get_xticklabels(), x_label_colors): 
        xtick.set_color(color) 
    plt.tight_layout() 
    # Save figure 
    plot_folder = working_folder_name + '\\Plots\\Mismatch filtering' 
    plot_file_name = plot_folder + '\\' + biosample + ' base frequencies.png' 
    plt.savefig(plot_file_name, dpi=300) 
    plt.close() 
 
 
    # Write base counts to a csv file 
    # [['Original base', 'A', 'C', 'A'...], ['A', 0.1, 0.2, 0.95...]] 
    csv_file_name = biosample + ' base counts.csv' 
    csv_file_address = working_folder_name + '\\Results\\' + csv_file_name 
 
    with open(csv_file_address, 'w', newline='') as output_file: 
        output_writer = csv.writer(output_file) 
        row_headers = ['A', 'C', 'G', 'T', 'N'] 
        # Write the indices and original sequence to the top rows 
        row = ['Position'] 
        for i in np.arange(1, len(expected_sequence)+1): 
            row.append(i) 
        output_writer.writerow(row) 
        row = ['Original base'] 
        for base in expected_sequence: 
            row.append(base) 
        output_writer.writerow(row) 
        # Write base frequencies 
        for header, base_fractions in zip(row_headers, base_fraction_list): 
            row = [header] 
            for b in base_fractions: 
                row.append(b) 
            output_writer.writerow(row) 
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This module contains two functions which generate dictionaries where each possible 
sequence for a given library is a key. 
 
generate_randomized_sequence_dict is for site-saturation libraries. It generates all 
possible sequences, assuming N at all randomized positions. 
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generate_twist_sequence_dict is for oligo pool libraries. It reads the randomized base 
sequences from the sequence names in the Twist oligo pool .csv file. 
 
Both functions return a dictionary of sequences and counts: 
{sequence: [0, 0, 0...]} 
""" 
 
import numpy as np 
import csv 
 
def generate_randomized_sequence_dict(randomized_bases, biosamples): 
    """Generate all possible sequences for site-saturation libraries with N at all 
    positions. 
 
    Parameters 
    --- 
    randomized_bases : list 
        Randomized positions, used here to indicate how many positions are randomized. 
    biosamples : list 
        List of biosamples, used here to indicate how many placeholder zeros need to be 
        placed in the count list. 
 
    Returns 
    --- 
    possible_sequence_dict : dict 
        Randomized base sequence: count list {sequence: [0, 0, 0...]} 
    """ 
 
    # Setup 
    bases = ['A', 'C', 'G', 'T'] 
 
    # Generate a list of possible sequences. 
    # We start with a list of sequences of length 1. 
    # Each round, we generate new sequences which are one base longer, with each possible 
    # base at the new position. 
    # These go in holder_2 
    # At the end of each round we: 
    #   clear holder_1, 
    #   write the sequences in holder_2 to holder_1 
    #   and then clear holder_2 
    holder_1 = [] 
    holder_2 = [] 
 
    # Start with single-base sequences 
    for base in bases: 
        holder_1.append(base) 
 
    # Loop through and add the next bases one at a time 
    for l in range(1,len(randomized_bases)): 
        for seq in holder_1: 
            for base in bases: 
                holder_2.append(seq + base) 
        holder_1.clear() 
        holder_1 = holder_2.copy() 
        holder_2.clear() 
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    # Sort alphabetically 
    holder_1 = sorted(holder_1) 
 
    # Add complete sequences to possible_sequence_dict as keys 
    # The values are a list of zeroes, one for each biosample. These will be updated 
    # during count_randomized_sequences. 
    possible_sequence_dict = {} 
    for sequence in holder_1: 
        possible_sequence_dict[sequence] = list(np.zeros(len(biosamples),dtype=int)) 
 
    print('\nGenerated {:,} possible sequences:'.format(len(holder_1))) 
    print('[{}...{}]'.format(holder_1[0], holder_1[-1])) 
    return possible_sequence_dict 
 
def generate_twist_sequence_dict(biosamples, twist_sequence_file_address): 
    """Generate all possible sequences for Twist libraries, based on the file used to 
    create the oligo pool. 
 
    Parameters 
    --- 
    twist_sequence_file_address : str 
        File used to generate the oligo pool. The sequence names are the randomized 
        base sequences. 
    biosamples : list 
        List of biosamples, used here to indicate how many placeholder zeros need to be 
        placed in the count list. 
 
    Returns 
    --- 
    possible_sequence_dict : dict 
        Randomized base sequence: count list {sequence: [0, 0, 0...]} 
    """ 
 
    # Read sequence names from the Twist oligo pool .csv file 
    # The sequence names are a list of the randomzied bases for each sequence. 
    possible_sequence_dict = {} 
    with open (twist_sequence_file_address, 'r', newline='') as sequence_file: 
        sequence_file_reader = csv.reader(sequence_file) 
        for line in sequence_file_reader: 
            possible_sequence_dict[line[0]] = list(np.zeros(len(biosamples), dtype=int)) 
 
    print('\nGenerated {:,} possible sequences'.format(len(possible_sequence_dict))) 
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This module contains functions which counts the frequency of each randomized sequence in 
the filtered data for each biosample. 
count_randomized_sequences is for quality and mismatch filtered text files. 
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counts_from_csv is for csv files of sequences and counts from Jon. 
 
Returns a dictionary of sequences and counts: 
{sequence: [lib_count, sel_1_count, sel_2_count...]} 
""" 
 
import numpy as np 
import csv 
 
def count_randomized_sequences(biosamples, filtered_file_list, working_folder_name, 
                               possible_sequence_dict, randomized_bases): 
    """Count the frequency of each randomized sequence in the filtered data for each 
    biosample. 
 
    Parameters 
    --- 
    biosamples : list 
        Biosample names 
    filtered_file_list : list 
        Filtered files to read 
    working_folder_name : str 
        Working folder 
    possible_sequence_dict : dict 
        Dictionary of the form ['Randomized sequence': [0, 0...]] 
    randomized_bases : list 
        Randomized base coordinates 
 
    Returns 
    --- 
    possible_sequence_dict : dict 
        Dictionary of the form ['Randomized sequence': [Lib_count, sel_1_count...]] 
    read_count : list 
        List of the total identified reads for each biosample. 
    stats : list 
        Stats summarizing the filtering results 
        [[Biosample, processed_count, found, not_found]...] 
 
    Notes 
    --- 
    Reads filtered files and updates possible_sequence_dict with counts 
 
    Using randomized sequences as dictionary keys is much faster than using a list 
    because dictionary keys are hashed, making searching much more efficient. 
    """ 
 
    # Setup 
    # stats holds statistics describing how many read matched expected library sequences 
    # for each biosample. [[biosample, processed_count, found, not_found]...] 
    stats = [] 
    # read_counts holds the number of identified reads which matched expected library 
    # sequences for each biosample. This will be used later to calculate enrichment 
    # factors. 
    read_counts = [] 
 
    # Iterate through biosamples 
    for i in list(np.arange(len(biosamples))): 
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        # Track how many sequences were found in the expected library sequences 
        processed_count = 0 
        found = 0 
        not_found = 0 
 
        print('\nProcessing', biosamples[i]) 
 
        # Open the filtered sequence file and read each sequence. 
        filtered_file_address = working_folder_name + '\\' + filtered_file_list[i] 
        with open(filtered_file_address) as filtered_file: 
            for sequence in filtered_file: 
                processed_count += 1 
                # Extract randomized bases 
                extract_random = '' 
                for b in randomized_bases: 
                    extract_random += sequence[b] 
                # Exclude sequences which are not in the expected sequence list from analysis 
                if extract_random in possible_sequence_dict: 
                    possible_sequence_dict[extract_random][i] += 1 
                    found += 1 
 
                else: 
                    not_found += 1 
 
        # Counting statistics 
        stats.append([biosamples[i], processed_count, found, not_found]) 
        read_counts.append(found) 
 
        print('{:,} sequences processed'.format(processed_count)) 
        print('{:,} sequences ({:.2%}) matched possible sequences'.format(found, 
              found/processed_count)) 
        print('{:,} sequences ({:.2%}) did not match possible sequences'.format(not_found, 
              not_found/processed_count)) 
 
 
    # Write counting statistics to a .csv file 
    headers = ['Biosample', 'Reads processed', 'Matched possible sequences', 'No match'] 
    stats_file_name = 'Count possible sequence stats.csv' 
    stats_file_address = working_folder_name + '\\Results\\' + stats_file_name 
    with open(stats_file_address, 'w', newline='') as stats_file: 
        stats_writer = csv.writer(stats_file) 
        stats_writer.writerow(headers) 
        for biosample_stats in stats: 
            stats_writer.writerow(biosample_stats) 
 
 




def counts_from_csv(biosamples, csv_file_list, working_folder_name, 
                        possible_sequence_dict): 
    """Count the frequency of each randomized sequence in the filtered data for each 
    biosample. 
 
    Parameters 
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    --- 
    biosamples : list 
        Biosample names 
    csv_file_list : list 
        CSV files to read 
    working_folder_name : str 
        Working folder 
    possible_sequence_dict : dict 
        Dictionary of the form ['Randomized sequence': [0, 0...]] 
 
    Returns 
    --- 
    possible_sequence_dict : dict 
        Dictionary of the form ['Randomized sequence': [Lib_count, sel_1_count...]] 
    read_count : list 
        List of the total identified reads for each biosample. 
    stats : list 
        Stats summarizing the filtering results 
        [[Biosample, processed_count, found, not_found]...] 
    """ 
 
    # Setup 
    # stats holds statistics describing how many read matched expected library sequences 
    # for each biosample. [[biosample, processed_count, found, not_found]...] 
    stats = [] 
    # read_counts holds the number of identified reads which matched expected library 
    # sequences for each biosample. This will be used later to calculate enrichment 
    # factors. 
    read_counts = [] 
 
    # Iterate through biosamples: 
    # Iterate through biosamples 
    for i in list(np.arange(len(biosamples))): 
        # Track how many sequences were found in the expected library sequences 
        line_count = 0 
        processed_count = 0 
        found = 0 
        not_found = 0 
 
        print('\nProcessing', biosamples[i]) 
 
        # Open the csv file and read each sequence. 
        csv_file_address = working_folder_name + '\\' + csv_file_list[i] 
        with open(csv_file_address, 'r', newline='') as csv_file: 
            count_reader = csv.reader(csv_file) 
            for line in count_reader: 
                line_count += 1 
                extract_random, count = line[0], int(line[1]) 
                processed_count += count 
                if extract_random in possible_sequence_dict: 
                    found += count 
                    possible_sequence_dict[extract_random][i] += count 
                else: 




        # Counting statistics 
        stats.append([biosamples[i], processed_count, found, not_found]) 
        read_counts.append(found) 
 
        print('{:,} total reads'.format(processed_count)) 
        print('{:,} reads ({:.2%}) matched possible sequences'.format(found, 
              found/processed_count)) 
        print('{:,} reads ({:.2%}) did not match possible sequences'.format(not_found, 
              not_found/processed_count)) 
 
 
    # Write counting statistics to a .csv file 
    headers = ['Biosample', 'Reads processed', 'Matched possible sequences', 'No match'] 
    stats_file_name = 'Count possible sequence stats.csv' 
    stats_file_address = working_folder_name + '\\Results\\' + stats_file_name 
    with open(stats_file_address, 'w', newline='') as stats_file: 
        stats_writer = csv.writer(stats_file) 
        stats_writer.writerow(headers) 
        for biosample_stats in stats: 
            stats_writer.writerow(biosample_stats) 
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This module contains a function which calculates the enrichment of each sequence in each 




import numpy as np 
from statistics import mean, stdev 
 
def calculate_enrichments(sequence_count_dict, read_counts, biosamples, sel_1_name, 
                          sel_2_name, sel_2_runs, output_format, full_sequence_format, 
                          rand_expected_pairs, working_folder_name, lib_name, min_lib_count): 
    """Calculates the enrichment of each sequence in eaach selection relative to the 
    library and writes the results to results.csv. 
 
    Parameters 
    --- 
    sequence_count_dict : dict 
    biosample : list 
    sel_1_name : str 
    sel_2_name : str 
    sel_2_runs : list 
    output_format : str 
    full_sequence_format : str 
    rand_expected_pairs : list 
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    working_folder_name : str 
    lib_name : str 
 
    Returns 
    --- 
    results_table : list 
        For each sequence the entry looks like 
        [[randomized_sequence], [full_stem_sequence], []] 
 
    Notes 
    --- 
    results_table structure 
    COLUMN   HEADER                     CONTENTS 
    0        Randomized sequence        [formatted randomized sequence] 
    1        Full stem sequence         [formatted full stem sequence] 
    2        Paired bases               [number of paired bases] 
    3        Raw counts                 [lib_count, sel_1_count, sel_2_count...] 
    4        Fraction of total          [lib_fraction, sel_1_fraction, sel_2_fraction...] 
    5        Fold enrichment            [sel_1_fold_enrichment, sel_2_fold_enrichment...] 
    6        Enrichment factors         [sel_1_enrichment_factor, sel_2_enrichment_factor...] 
    7        Enrichment ranks           [sel_1_rank, sel_2_rank...] 
    8        Average enrichment factor  [average enrichment factor] 
    9        StDev                      [enrichment factor standard deviation] 
    10       Rank                       [rank based on average enrichment factor] 
 
    Results table is written to working_folder\results\lib_name results.csv 
    """ 
 
    # Setup 
    # Set up column indices by name because it's clearer than referring to them by number. 
    (Randomized_sequence, Full_stem_sequence, Paired_bases, 
    Raw_counts, Fraction_of_total, 
    Fold_enrichment, Enrichment_factor, Enrichment_rank, 
    Avg_enrichment_factor, Stdev, Avg_rank) = (0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) 
 
    # Column headers 
    header_list = ['Randomized sequence', 'Full stem sequence', 'Paired bases', 
                   'Raw counts','Fraction of total', 
                   'Fold enrichment', 'Enrichment factors', 'Enrichment ranks', 
                   'Average enrichment factor', 'StDev', 'Average rank'] 
 
    # For pairing analysis, which pairs are considered valid? 
    # Typically GU pairs are "valid" for tRNAs 
    # A future goal is to come up with some metric for pairing strength 
    # Pi stacking between adjacent bases? 
    valid_pairs = {'A':['U'], 
                   'C':['G'], 
                   'G':['C','U'], 
                   'U':['A','G']} 
 
    # Sequences will be added to one of two tables, sequence_table or 
    # low_abundance_table. 
 
    # If there are any sequences which are present in selection runs but not present in 
    # the library, this will cause divide by 0 errors later in the analysis. 
    # Therefore, only certain parts of the analysis - calculating paired bases and % of 
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    # total reads - can be performed for these sequences. 
 
    # Additionally, sequences which are only observed a very small number of times in the 
    # library could lead to inaccurate enrichment factors - if a sequence was seen twice 
    # instead of once in the library, for instance, the enrichment factor would be off 
    # by a factor of two. 
 
    # sequence_table holds sequences which were found >= min_lib_count times in the 
    # library biosample. 
    sequence_table = [] 
    # Enrichment factors will be calculated for these sequences. 
 
    # low_abundance_table holds sequences which were identified < min_lib_count times 
    # in the library biosample. 
    low_abundance_table = [] 
    # Enrichment factors will still be calculated for sequences which were identified 
    # > 0 times in the library biosample, but these values should be used cautiously. 
    # Track how many sequences were not observed at all 
    not_observed = 0 
 
    # Lastly, we'll need to find the highest fold enrichment value for each selection 
    # before we can calculate the enrichment factors. 
    max_fold_enrichments = np.zeros(len(biosamples)) 
 
 
    # Read sequence counts from sequence_count_dict. 
    for sequence in sequence_count_dict: 
        # Set up table row sequence_data 
        sequence_data = [] 
        for header in header_list: 
            sequence_data.append([]) 
 
        # 0. Randomized sequence 
        # Format sequences for output 
        # Replace T's with U's, but keep the original as key_sequence for sequence_count_dict 
        key_sequence = sequence 
        sequence = sequence.replace('T', 'U') 
        if output_format: 
            # output_format is represented as 'NNN/NNN' where each N is to be replaced 
            # with a base from sequence and all other characters are preserved. 
            # Iterate through characters in output_format to generate formatted_sequence. 
            formatted_sequence = '' 
            # i represents the current position in sequence, starting at the beginning. 
            i = 0 
            for c in output_format: 
                if c == 'N': 
                    formatted_sequence += sequence[i] 
                    i += 1 
                else: 
                    formatted_sequence += c 
        else: 
            formatted_sequence = sequence 
        sequence_data[Randomized_sequence].append(formatted_sequence) 
 
        # 1. Full stem sequence 
        # Allows visualization of an entire stem, even if only part of the stem was 
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        # randomized in the lirbary, and facilitates comparison between libraries in the 
        # same region. 
        # Similar to how formatted_sequence is generated 
        if full_sequence_format: 
            full_sequence = '' 
            # i represents the current position in sequence, starting at the beginning. 
            i = 0 
            for c in full_sequence_format: 
                if c == 'N': 
                    full_sequence += sequence[i] 
                    i += 1 
                else: 
                    full_sequence += c 
        else: 
            full_sequence = formatted_sequence 
        sequence_data[Full_stem_sequence].append(full_sequence) 
 
        # 2. Paired bases 
        # Count how many bases in the sequence are paired, based on valid_pairs 
        # This uses sequence, not formatted_sequence 
        # Start with 0 pairs 
        paired = 0 
        # Iterate through expected pairs using rand_expected_pairs coordinates, which only 
        # include the randomized bases (unlike expected_pairs which provides pair 
        # coordinates for the full sequence). 
        for pair in rand_expected_pairs: 
            # Extract coordinates and check for pairs 
            a, b = pair[0], pair[1] 
            if sequence[a] in valid_pairs[sequence[b]]: 
                paired += 1 
        sequence_data[Paired_bases].append(paired) 
 
        # 3. Raw counts and 
        # 4. Fraction of total 
        for raw_count, total in zip(sequence_count_dict[key_sequence], read_counts): 
            sequence_data[Raw_counts].append(raw_count) 
            sequence_data[Fraction_of_total].append(raw_count/total) 
 
        # Sequences found in library biosample 
        # Calculate the change in abundance before and after each selection, 
        # relative to the library. 
        if sequence_data[Raw_counts][0] > 0: 
            # 6. Fold enrichments 
            library_abundance = sequence_data[Fraction_of_total][0] 
            for selection_abundance, i in zip(sequence_data[Fraction_of_total], 
                                              np.arange(len(max_fold_enrichments), dtype=int)): 
                fold_enrichment = selection_abundance / library_abundance 
                sequence_data[Fold_enrichment].append(fold_enrichment) 
                # Update max_fold_enrichments unless the value comes from a low abundance 
                # sequence. 
                if sequence_data[Raw_counts][0] >= min_lib_count: 
                    if fold_enrichment > max_fold_enrichments[i]: 
                        max_fold_enrichments[i] = fold_enrichment 
 
            if sequence_data[Raw_counts][0] >= min_lib_count: 
                sequence_table.append(sequence_data) 
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            else: 
                low_abundance_table.append(sequence_data) 
                not_observed += 1 
 
        # Sequences not found in library biosample 
        # Enrichment cannot be calculated because the library abundance is 0. 
        # Calculate the value if the library count was 1 
        else: 
            # What would library_abundance be if the library count was 1? 
            library_abundance = 1 / read_counts[0] 
            for selection_abundance, i in zip(sequence_data[Fraction_of_total], 
                                              np.arange(len(max_fold_enrichments))): 
                fold_enrichment = selection_abundance / library_abundance 
                sequence_data[Fold_enrichment].append(fold_enrichment) 
                # Do not update fold enrichments. 
            low_abundance_table.append(sequence_data) 
 
 
    # 6. Enrichment factors, 
    # 8. Average enrichment factors, and 
    # 9. StDev 
    # Once finished iterating through all sequences and adding to tables, use 
    # max_fold_enrichments to determine enrichment factor for each sequence 
    # enrichment_factor = fold_enrichment / max_fold_enrichment 
    for table in [sequence_table, low_abundance_table]: 
        for sequence_data in table: 
            for fold_enrichment, max_fold_enrichment in zip(sequence_data[Fold_enrichment], 
                                                            max_fold_enrichments): 
                enrichment_factor = fold_enrichment / max_fold_enrichment 
                sequence_data[Enrichment_factor].append(enrichment_factor) 
            # Calculate average enrichments 
            # If there are distinctly identified sel_1 and sel_2 runs (e.g. 1x vs 2x TAG) 
            # Calculate three means and stdevs: [sel_1_mean, sel_2_mean, all_sels_mean] 
            if sel_2_runs: 
                sel_1_enrichment_factors = sequence_data[Enrichment_factor][1:-len(sel_2_runs)] 
                sel_2_enrichment_factors = sequence_data[Enrichment_factor][-len(sel_2_runs):] 
                sequence_data[Avg_enrichment_factor].append(mean(sel_1_enrichment_factors)) 
                sequence_data[Avg_enrichment_factor].append(mean(sel_2_enrichment_factors)) 
                if len(sel_1_enrichment_factors) > 1: 
                    sequence_data[Stdev].append(stdev(sel_1_enrichment_factors)) 
                else: 
                    sequence_data[Stdev].append(0) 
                if len(sel_2_enrichment_factors) > 1: 
                    sequence_data[Stdev].append(stdev(sel_2_enrichment_factors)) 
                else: 
                    sequence_data[Stdev].append(0) 
            # Calculate the mean enrichment factor and stdev for all selections. 
            all_enrichment_factors = sequence_data[Enrichment_factor][1:] 
            sequence_data[Avg_enrichment_factor].append(mean(all_enrichment_factors)) 
            if len(all_enrichment_factors) > 1: 
                sequence_data[Stdev].append(stdev(all_enrichment_factors)) 
            else: 
                sequence_data[Stdev].append(0) 
 
    # 7. Rank by enrichment factors and 
    # 9. Rank by average enrichment factor(s) 
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    for table in [sequence_table, low_abundance_table]: 
        # Individual selection enrichment factors 
        for i in np.arange(len(biosamples)): 
            # Sort sequence_table by enrichment factor i, largest values first 
            table = sorted(table, key = lambda x: x[Enrichment_factor][i], 
                                    reverse=True) 
            # Add rank+1 to sequence_table (add 1 to start at 1 not 0) 
            for rank in range(len(table)): 
                table[rank][Enrichment_rank].append(rank+1) 
        # Average enrichment factor(s) 
        # How many enrichment factors to expect? 
        if sel_2_runs: 
            n = 3 
        else: 
            n = 1 
        for i in np.arange(n): 
            # Sort sequence_table by enrichment factor i, largest values first 
            table = sorted(table, key = lambda x: x[Avg_enrichment_factor][i], 
                                    reverse=True) 
            # Add rank+1 to sequence_table (add 1 to start at 1 not 0) 
            for rank in range(len(table)): 
                table[rank][Avg_rank].append(rank+1) 
 
    # Sort tables by average enrichment factor outside of the above loop 
    sequence_table = sorted(sequence_table, key = lambda x: x[Avg_enrichment_factor][-1], 
                            reverse=True) 
    low_abundance_table = sorted(low_abundance_table, key = lambda x: 
x[Avg_enrichment_factor][-1], 
                                 reverse=True) 
 
    # Print results 
    print('\nStats for the library run:') 
    print('Of {:,} sequences, {:,} were observed >= {} times'.format( 
            len(sequence_count_dict), len(sequence_table), min_lib_count)) 
    print('{:,} sequences were observed < {} times, with {} not observed'.format( 
            len(low_abundance_table), min_lib_count, not_observed)) 
 
    print('\nMost enriched sequence: ', sequence_table[0][Randomized_sequence]) 
    print('Least enriched sequence: ', sequence_table[-1][Randomized_sequence]) 
 
    print('\nData for the top sequence:') 
    for header, value in zip(header_list, sequence_table[0]): 
        print(header, value) 
 
 
    # Write the results to csv files. 
    # Tables are already sorted by average enrichment factor. 
    # Table structure reminder: 
    ''' 
    COLUMN   HEADER                     CONTENTS 
    0        Randomized sequence        [formatted randomized sequence] 
    1        Full stem sequence         [formatted full stem sequence] 
    2        Paired bases               [number of paired bases] 
    3        Raw counts                 [lib_count, sel_1_count, sel_2_count...] 
    4        Fraction of total          [lib_fraction, sel_1_fraction, sel_2_fraction...] 
    5        Fold enrichment            [sel_1_fold_enrichment, sel_2_fold_enrichment...] 
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    6        Enrichment factors         [sel_1_enrichment_factor, sel_2_enrichment_factor...] 
    7        Enrichment ranks           [sel_1_rank, sel_2_rank...] 
    8        Average enrichment factor  [average enrichment factor] 
    9        StDev                      [enrichment factor standard deviation] 
    10       Rank                       [rank based on average enrichment factor] 
    ''' 
 
    for table, file_name_end in zip([sequence_table, low_abundance_table], [' Results.csv', 
                               ' Low abundance sequences.csv']): 
        output_file_address = working_folder_name + '\\Results\\' + lib_name + file_name_end 
        with open(output_file_address, 'w', newline='') as output_file: 
            # Clear any previous data 
            output_file.truncate(0) 
 
            # Write 
            output_writer = csv.writer(output_file) 
            # Write headers and subheaders 
            header_row = [] 
            subheader_row = [] 
            # Randomized sequence, Full stem sequence, and Paired bases each only 
            # contain 1 value. 
            for header in header_list[Randomized_sequence:Raw_counts]: 
                header_row.append(header) 
                subheader_row.append('') 
            # Raw counts, Fraction of total, Fold enrichment, Enrichment factors, and 
            # Enrichment ranks have one value for each biosample. 
            for header in header_list[Raw_counts:Avg_enrichment_factor]: 
                header_row.append(header) 
                for l in range(len(biosamples)-1): 
                    header_row.append('') 
                for biosample in biosamples: 
                    subheader_row.append(biosample) 
            # Average enrichment factor and Rank 3 values if there are distinct sel_1 and 
            # sel_2 conditions, [Sel_1, Sel_2, and All selections]. 
            if sel_2_runs: 
                for header in header_list[Avg_enrichment_factor:]: 
                    header_row.append(header) 
                    header_row.append('') 
                    header_row.append('') 
                for selection_name in [sel_1_name, sel_2_name, 'All selections']: 
                    subheader_row.append(selection_name) 
            # Otherwise there is just one value for all selections. 
            else: 
                for header in header_list[Avg_enrichment_factor:]: 
                    header_row.append(header) 
                    subheader_row.append('All selections') 
            output_writer.writerow(header_row) 
            output_writer.writerow(subheader_row) 
 
            # Write data 
            for sequence_data in table: 
                data_row = [] 
                for column in sequence_data: 
                    for value in column: 
                        data_row.append(value) 
                output_writer.writerow(data_row) 
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        print('\nData written to') 
        print(output_file_address) 
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This module contains a function which plots the results of a sequencing run in various 




import matplotlib.pyplot as plt 
import numpy as np 
from Bio import motifs 
from Bio.Seq import Seq 
from Bio.Alphabet import IUPAC 
 
def weblogo(fig_file_address, sequence_holder): 
    """A utility function to make weblogos using the Bio.motifs module 
 
    Parameters 
    --- 
    fig_file_address : str 
        Address where the resulting figure should be stored 
    sequence_holder : list 
        A list of biopython sequence objects 
 
    Notes 
    --- 
    Saves a weblogo at the given file address using my defaut settings for visualizing 
    short RNA sequences. 
    """ 
 
    # Make sure sequence_holder contains at least one sequence 
    if len(sequence_holder) > 0: 
        # Make a biopython Motif object from the sequences in sequence_holder 
        m = motifs.create(sequence_holder) 
        # Make a weblogo by probability (aka fraction of each base) 
        m.weblogo(fig_file_address, unit_name='probability', show_fineprint=False, 
                  show_xaxis=False, scale_width=False, stack_width='large', 
                  color_scheme='color_custom', symbols0='A', color0='green', 
                  symbols1='C', color1='blue', symbols2='G', color2='black', 
                  symbols3='U', color3='red',) 
    else: 




def plot_results(working_folder_name, sequence_table, low_abundance_table, biosamples, 
                 randomized_bases, sel_1_name, sel_2_name, sel_2_runs, expected_pairs): 
    """A function which plots the results of a selection. 
 
    Parameters 
    --- 
    working_folder_name : str 
        Working folder 
    sequence_table : list 
        A table containing the results of count_randomized_sequences and 
        calculate_enrichments 
    low_abundance_table : list 
        A table containing the low abundance sequences from count_randomized_sequences and 
        calculate_enrichments 
    biosamples : list 
        List of biosamples 
    randomized_bases : list 
        Randomized base coordinates - used to determine how many there are 
    sel_1_name : str 
        Selection condition 1 
    sel_2_name : str 
        Selection condition 2 
    expected_pairs : list 
        Randomized base pairs rand_expected_pairs 
 
    Notes 
    --- 
    All series of binned plots also include the full pool for comparison. 
 
    Plots generated 
    --- 
    Describing initial library characteristics 
        Plot : library abundance VS library rank 
        Weblogo : 1 % most abundant sequences 
        Weblogo : 1 % least abundant sequences including not observed 
        Weblogo : All low abundance sequences 
 
    Describing enrichment (ignores low abundance sequences) 
        Weblogos : Bin % most enriched 
        Weblogos : Bin % least enriched 
        Weblogos : Each 10% of the library 
        Plots : enrichment factor VS enrichment rank (each individual and average value, 
                incorporate individual values onto standard plot with low alpha) 
    Repeat all of these for fully base paired sequences 
 
    Describing base pairing 
        Stacked bar : Fraction of sequences with N pairs, by bin 
        Bars : Histogram of frequency of each pair type by sequence, by bin 
        Repeat this for fully base paired sequences 
        Plots : enrichment factor VS enrichment rank (average value, low alpha on 
                separate plots by number of pairs) 
 
    Comparing different selection runs 
        Plots : enrichment factor 1 VS enrichment factor 2 for each pairwise selection combo 
        Plot : average sel 1 enrichment factor VS average sel 2 enrichment factor 
    """ 
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    # Setup 
    # Set up column indices from calculate_enrichments. 
    # Some might get flagged that they're assigned but unused - that's fine. 
    (Randomized_sequence, Full_stem_sequence, Paired_bases, 
    Raw_counts, Fraction_of_total, 
    Fold_enrichment, Enrichment_factor, Enrichment_rank, 
    Avg_enrichment_factor, Stdev, Avg_rank) = (0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) 
 
    # Make the plot folders 
    plot_folder = working_folder_name + '\\Plots\\Results' 
    sub_folders = ['\\Library distribution', '\\Enrichment', '\\Base pairing', 
                   '\\Compare selections', '\\Fully paired sequences\\Enrichment', 
                   '\\Fully paired sequences\\Base pairing'] 
    for sub_folder in sub_folders: 
        if os.path.exists(plot_folder + sub_folder) == False: 
            os.makedirs(plot_folder + sub_folder) 
 
    # Plotting requires several different sequence lists 
    # lib_sorted_sequence_table : contains all sequences, high and low abundance, 
    #                             sorted by library abundance 
    # sorted_sequence_table : contains abundant sequences, sorted by average enrichment 
    # paired_sequence_table : contains fully base paired sequences, sorted by average 
    #                         enrichment 
    print('> Generating sorted tables for plotting') 
    # lib_sorted_sequence_table 
    # lib_size is generated from this table 
    lib_sorted_sequence_table = sorted(sequence_table, key = lambda x: x[Fraction_of_total][0], 
                                       reverse=True) 
    lib_sorted_low_abundance_table = sorted(low_abundance_table, key =lambda x: 
x[Fraction_of_total][0], 
                                            reverse=True) 
    for sequence_data in lib_sorted_low_abundance_table: 
        lib_sorted_sequence_table.append(sequence_data) 
    lib_size = len(lib_sorted_sequence_table) 
    # sorted_sequence_table 
    sorted_sequence_table = sorted(sequence_table, key = lambda x: x[Avg_enrichment_factor][-
1], 
                                       reverse=True) 
    # paired_sequence_table 
    paired_sequence_table = [] 
    for sequence_data in sorted_sequence_table: 
        if sequence_data[Paired_bases][0] == len(expected_pairs): 
            paired_sequence_table.append(sequence_data) 
    paired_size = len(paired_sequence_table) 
 
    print('> Plotting library distribution') 
    # Plots describing initial library characteristics 
    # library count VS library rank and 
    # library abundance VS library rank 
    # y values 
    lib_counts = [] 
    lib_abundances = [] 
    for sequence_data in lib_sorted_sequence_table: 
        lib_counts.append(sequence_data[Raw_counts][0]) 
        lib_abundances.append(sequence_data[Fraction_of_total][0]) 
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    # x values 
    lib_ranks = np.arange(len(lib_abundances)) 
    # Make plots 
    for y_data, y_label in zip([lib_counts, lib_abundances], ['Count', 'Abundance']): 
        fig, ax = plt.subplots(figsize=(6,4)) 
        ax.plot(lib_ranks, y_data, marker='o', linestyle='', markeredgewidth=0) 
        ax.grid(axis='y', color='0.5') 
        ax.set_xlabel('Rank') 
        ax.set_ylabel(y_label) 
        ax.set_title('Library distribution') 
        plt.tight_layout 
        # Save 
        fig_file_name = '\\Library distribution ' + y_label + '.png' 
        fig_file_address = plot_folder + '\\Library distribution' + fig_file_name 
        plt.savefig(fig_file_address, dpi=300) 
        # Log version 
        ax.set_yscale('log') 
        plt.tight_layout 
        fig_file_name = '\\Library distribution ' + y_label + ' log.png' 
        fig_file_address = plot_folder + '\\Library distribution' + fig_file_name 
        plt.savefig(fig_file_address, dpi=300) 
        plt.close() 
 
    print('> Generating weblogos by library abundance') 
    # Weblogos for most and least abundant sequences 
    # All sequences and fully base paired sequences 
    # A weblogo for the full library, for comparison 
    sequence_holder = [] 
    for sequence_data in lib_sorted_sequence_table: 
        # Extract randomized sequence and remove /s 
        sequence = sequence_data[Randomized_sequence][0].replace('/','') 
        # Convert to a Biopython Seq object and add to sequence_holder 
        sequence_holder.append(Seq(sequence, IUPAC.unambiguous_rna)) 
        # Make weblogo 
    fig_file_name = '\\Library all sequences.png' 
    fig_file_address = plot_folder + '\\Library distribution' + fig_file_name 
    weblogo(fig_file_address, sequence_holder) 
 
    # Top and bottom 0.1% and 1% 
    bins = [0.01] 
    for b in bins: 
        # Number of sequences in the bin 
        c = int(b*lib_size) 
        most_abundant = lib_sorted_sequence_table[:c] 
        least_abundant = lib_sorted_sequence_table[-c:] 
        for binned, title in zip([most_abundant, least_abundant], ['Top', 'Bottom']): 
            sequence_holder = [] 
            for sequence_data in binned: 
                sequence = sequence_data[Randomized_sequence][0].replace('/','') 
                sequence_holder.append(Seq(sequence, IUPAC.unambiguous_rna)) 
            # Make weblogo 
            fig_file_name = '\\Library ' + title + ' {} sequences.png'.format(c) 
            fig_file_address = plot_folder + '\\Library distribution' + fig_file_name 
            weblogo(fig_file_address, sequence_holder) 
 
    # Low abundance or not observed 
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    not_observed_holder = [] 
    low_abundance_holder = [] 
    for sequence_data in lib_sorted_low_abundance_table: 
        # Check if low abundance or not observed 
        if sequence_data[Raw_counts][0] == 0: 
            sequence = sequence_data[Randomized_sequence][0].replace('/','') 
            not_observed_holder.append(Seq(sequence, IUPAC.unambiguous_rna)) 
        else: 
            sequence = sequence_data[Randomized_sequence][0].replace('/','') 
            low_abundance_holder.append(Seq(sequence, IUPAC.unambiguous_rna)) 
    # Not observed weblogo 
    if len(not_observed_holder) > 0: 
        fig_file_name = '\\Not observed {}.png'.format(len(not_observed_holder)) 
        fig_file_address = plot_folder + '\\Library distribution' + fig_file_name 
        weblogo(fig_file_address, not_observed_holder) 
    # Low abundance weblogo 
    if len(not_observed_holder) > 0: 
        fig_file_name = '\\Low abundance {}.png'.format(len(low_abundance_holder)) 
        fig_file_address = plot_folder + '\\Library distribution' + fig_file_name 
        weblogo(fig_file_address, low_abundance_holder) 
 
 
    print('> Generating weblogos by enrichment') 
    # Weblogos by enrichment 
    # Bin from 0.01% to 10% 
    bins = [0.0001, 0.0003, 0.001, 0.003, 0.01, 0.03, 0.1] 
    for table, folder, size in zip([sorted_sequence_table, paired_sequence_table], 
                                   [plot_folder + '\\Enrichment', 
                                    plot_folder + '\\Fully paired sequences\\Enrichment'], 
                                    [lib_size, paired_size]): 
        for b in bins: 
            # Calculate bin size based on whole library, even though some sequences were 
            # low abundance. 
            c = int(b * size) 
            # Only plot if there's more than one sequence in the bin 
            if c > 4: 
                most_abundant = table[:c] 
                least_abundant = table[-c:] 
                for binned, title in zip([most_abundant, least_abundant], ['Top', 'Bottom']): 
                    sequence_holder = [] 
                    for sequence_data in binned: 
                        sequence = sequence_data[Randomized_sequence][0].replace('/','') 
                        sequence_holder.append(Seq(sequence, IUPAC.unambiguous_rna)) 
                    # Make weblogo 
                    fig_file_name = '\\' + title + ' {:.2f}pct n{} sequences.png'.format(b*100, c) 
                    fig_file_address = folder + '\\' + fig_file_name 
                    weblogo(fig_file_address, sequence_holder) 
 
        # By 10% blocks 
        b = 0.1 
        # Block size - round up 
        c = int(b*len(table)) + 1 
        # Loop through blocks 
        lower_limit = 0 
        while lower_limit < len(table): 
            upper_limit = lower_limit + c 
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            if upper_limit > len(table): 
                upper_limit = len(table) 
            for sequence_data in table[lower_limit:upper_limit]: 
                sequence = sequence_data[Randomized_sequence][0].replace('/','') 
                sequence_holder.append(Seq(sequence, IUPAC.unambiguous_rna)) 
            # Make weblogo 
            fig_file_name = '\\ 10pct block {} to {}.png'.format(lower_limit, upper_limit) 
            fig_file_address = folder + '\\' + fig_file_name 
            weblogo(fig_file_address, sequence_holder) 
            # Clear and go to the next block 
            sequence_holder.clear() 
            lower_limit += c 
 
    print('> Plotting enrichment versus rank') 
    # Plot enrichment factor versus enrichment rank for all selections and averages. 
    # Individual selections 
    for i in np.arange(1, len(biosamples)): 
        enrichment_factors = [] 
        ranks = [] 
        for sequence_data in sorted_sequence_table: 
            enrichment_factors.append(sequence_data[Enrichment_factor][i]) 
            ranks.append(sequence_data[Enrichment_rank][i]) 
        # make plot 
        fig, ax = plt.subplots(figsize=(6,4)) 
        ax.plot(ranks, enrichment_factors, marker='o', linestyle='', markeredgewidth=0) 
        ax.grid(axis='y', color='0.5') 
        ax.set_xlabel('Rank') 
        ax.set_ylabel('Enrichment factor') 
        ax.set_title(biosamples[i]) 
        plt.tight_layout 
        # Save 
        fig_file_name = '\\Enrichment factor vs rank ' + biosamples[i] + '.png' 
        fig_file_address = plot_folder + '\\Enrichment' + fig_file_name 
        plt.savefig(fig_file_address, dpi=300) 
        plt.close() 
 
    # Averages 
    # If two types of selections 
    if sel_2_runs: 
        for i, name in zip([0, 1, 2], [sel_1_name, sel_2_name, 'All selections']): 
            enrichment_factors = [] 
            ranks = [] 
            for sequence_data in sorted_sequence_table: 
                enrichment_factors.append(sequence_data[Avg_enrichment_factor][i]) 
                ranks.append(sequence_data[Avg_rank][i]) 
            # make plot 
            fig, ax = plt.subplots(figsize=(6,4)) 
            ax.plot(ranks, enrichment_factors, marker='o', linestyle='', markeredgewidth=0) 
            ax.grid(axis='y', color='0.5') 
            ax.set_xlabel('Rank') 
            ax.set_ylabel('Average enrichment factor') 
            ax.set_title(name) 
            plt.tight_layout 
            # Save 
            fig_file_name = '\\Average enrichment factor vs rank ' + name + '.png' 
            fig_file_address = plot_folder + '\\Enrichment' + fig_file_name 
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            plt.savefig(fig_file_address, dpi=300) 
            plt.close() 
    else: 
        enrichment_factors = [] 
        ranks = [] 
        for sequence_data in sorted_sequence_table: 
            enrichment_factors.append(sequence_data[Avg_enrichment_factor][0]) 
            ranks.append(sequence_data[Avg_rank][0]) 
        # make plot 
        fig, ax = plt.subplots(figsize=(6,4)) 
        ax.plot(ranks, enrichment_factors, marker='o', linestyle='', markeredgewidth=0) 
        ax.grid(axis='y', color='0.5') 
        ax.set_xlabel('Rank') 
        ax.set_ylabel('Average enrichment factor') 
        ax.set_title('All selections') 
        plt.tight_layout 
        # Save 
        fig_file_name = '\\Average enrichment factor vs rank .png' 
        fig_file_address = plot_folder + '\\Enrichment' + fig_file_name 
        plt.savefig(fig_file_address, dpi=300) 
        plt.close() 
 
 
    # Describe base pairing 
    print('> Plotting base pairing by enrichment') 
    # Stacked bar graph of pairing by bin 
    # Set up colors based on number of expected pairs 
    max_pair_count = len(expected_pairs) 
    # custom colors for plots 
    rainbow = ['1', 'xkcd:red','xkcd:orange','xkcd:yellow', 
              'xkcd:green','xkcd:blue','xkcd:purple', '0'] 
    colors = rainbow[:max_pair_count+1] #because can have 0 pairs, need max + 1 colors 
 
    # Bin from 0.01% to 10% 
    possible_bins = [0.0001, 0.0003, 0.001, 0.003, 0.01, 0.03, 0.1, 1] 
    # We are only interested in bins which would contain more than one sequence. 
    bin_sizes = [] 
    category_labels = [] 
    for b in possible_bins: 
        # Calculate bin size based on whole library, even though some sequences were 
        # low abundance. 
        c = int(b * size) 
        # Only plot if there's more than one sequence in the bin 
        if c > 4: 
            bin_sizes.append(c) 
            category_labels.append('Top {:.2%}\n(n = {:,})'.format(b, c)) 
    # Set up an array of counts of the structure [[0_pair_counts], [1_pair_counts]...] 
    # where each sub-list is [bin_1_count, bin_2_count...] 
    # Data can be accessed as paired_count_table[pair count][bin number] 
    paired_count_table = [] 
    for p in range(len(expected_pairs) + 1): # because with 3 possible pairs we need [0, 1, 2, 3] 
        paired_count_table.append(list(np.zeros(len(bin_sizes)))) 
    # Fill in the array 
    for c, i in zip(bin_sizes, np.arange(len(bin_sizes))): 
        for sequence_data in sequence_table[:c]: 
            paired_count = sequence_data[Paired_bases][0] 
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            paired_count_table[paired_count][i] += (1/c) 
    print(paired_count_table) 
    # Stacked bar charts require using a parameter bottoms which describes where the 
    # bottom of each bar falls for each series. 
    x_pos = np.arange(len(bin_sizes)) 
    bottoms = list(np.zeros(len(bin_sizes))) 
    # Make the stacked bar chart 
    fig, ax = plt.subplots() 
    for series, Color in zip(paired_count_table, colors): 
        print('series', series) 
        print('bottoms', bottoms) 
        ax.bar(x_pos, series, color=Color, edgecolor='0', bottom=bottoms) 
        for d in range(len(series)): 
            bottoms[d] += series[d] 
    ax.set_title('Base pairing by enrichment') 
    ax.set_ylabel('Fraction of total sequences') 
    ax.set_xticks(x_pos) 
    ax.set_xticklabels(category_labels) 
    plt.tight_layout 
    # Save 
    fig_file_name = '\\Base pairing by enrichment - most enriched.png' 
    fig_file_address = plot_folder + '\\Base pairing' + fig_file_name 
    plt.savefig(fig_file_address, dpi=300) 
    plt.close() 
 
    # By 10% blocks 
    category_labels = ['1', '2', '3', '4', '5', '6', '7', '8', '9', '10'] 
    # Set up an array of counts of the structure [[0_pair_counts], [1_pair_counts]...] 
    # where each sub-list is [bin_1_count, bin_2_count...] 
    # Data can be accessed as paired_count_table[pair count][bin number] 
    paired_count_table = [] 
    for p in range(len(expected_pairs) + 1): # because with 3 possible pairs we need [0, 1, 2, 3] 
        paired_count_table.append(list(np.zeros(len(category_labels)))) 
 
    # Fill in the array 
    b = 0.1 
    # Block size - round up 
    c = int(b*len(sequence_table)) + 1 
    # Loop through blocks 
    lower_limit = 0 
    i = 0 
    while (lower_limit < len(sequence_table) and i < 10): 
        upper_limit = lower_limit + c 
        if upper_limit > len(sequence_table): 
            upper_limit = len(sequence_table) 
        for sequence_data in sequence_table[lower_limit:upper_limit]: 
            paired_count = sequence_data[Paired_bases][0] 
            paired_count_table[paired_count][i] += 1 
        i += 1 
    # Stacked bar charts require using a parameter bottoms which describes where the 
    # bottom of each bar falls for each series. 
    x_pos = np.arange(len(category_labels)) 
    bottoms = list(np.zeros(len(category_labels))) 
    # Make the stacked bar chart 
    fig, ax = plt.subplots(figsize=(7,5)) 
    for series, Color in zip(paired_count_table, colors): 
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        plt.bar(x_pos, series, color=Color, edgecolor='0', bottom=bottoms) 
        for d in range(len(series)): 
            bottoms[d] += series[d] 
    ax.set_title('Base pairing by enrichment') 
    ax.set_ylabel('Fraction of total sequences') 
    ax.set_xlabel('Bin') 
    ax.set_xticks(x_pos) 
    ax.set_xticklabels(category_labels) 
    plt.tight_layout 
    # Save 
    fig_file_name = '\\Base pairing by enrichment - 10 pcts.png' 
    fig_file_address = plot_folder + '\\Base pairing' + fig_file_name 
    plt.savefig(fig_file_address, dpi=300) 
    plt.close() 
 
 
    # Compare different selection runs 
    print('> Plotting selection comparisons') 
    # Pairwise compare all selections, sel_a_enrichment_factors vs sel_b_enrichment_factors 
    for i in range(1, len(biosamples)-1): 
        for j in range(i, len(biosamples)): 
            sel_a_data = [] 
            sel_b_data = [] 
            for sequence_data in sorted_sequence_table: 
                sel_a_data.append(sequence_data[Enrichment_factor][i]) 
                sel_b_data.append(sequence_data[Enrichment_factor][j]) 
            # make plot 
            fig, ax = plt.subplots(figsize=(5,5)) 
            ax.plot(sel_a_data, sel_b_data, marker='o', linestyle='', markeredgewidth=0) 
            ax.grid(axis='y', color='0.5') 
            ax.set_xlabel(biosamples[i]) 
            ax.set_ylabel(biosamples[j]) 
            ax.set_title('Enrichment factors') 
            plt.tight_layout 
            # Save 
            fig_file_name = '\\' + biosamples[i] + ' vs ' + biosamples[j] + '.png' 
            fig_file_address = plot_folder + '\\Compare selections' + fig_file_name 
            plt.savefig(fig_file_address, dpi=300) 
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This stand-alone script allows easy comparison of selection results from an Illumina 
sequencing run ("current run") to a previous sequencing run or to a list of previously 




Enter run names, file names, and folder address below. 
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You can compare a current run to multiple past data files. 
Plots and csv files will be written to the working folder. 
 
Input csv files should have the following structure: 




import matplotlib.pyplot as plt 
 
# Enter names and sequences 
working_folder_name = r'C:\Users\Rachel Kelemen\Google Drive\Chatterjee lab\Code\Compare 
Ac1 NGS and Results' 
current_data_name = 'Fastq' 
current_data_file_name = 'Ac1 Results from Fastq for comparison.csv' 
past_data_names = ['CSV'] 
past_data_file_names = ['Ac1 Results from CSV for comparison.csv'] 
 
 
def compare(working_folder_name, current_data_name, current_data_file_name, 
                     past_data_name, past_data_file_name): 
    """ 
    Compares Illumina results from a selection to a previous sequencing run or a list of 
    previously tested hits and activities. 
 
    Parameters 
    --- 
    working_folder_name : str 
        Working folder full address 
    current_data_name : str 
        Name of the current data set as you want it to appear on plots and output files 
    current_data_file_name : str 
        csv file containing the current run results 
    past_data_name : str 
        Name of the past data set as you want it to appear (e.g. Ac2 sequencing or Tested Activity) 
    past_data_file_name : str 
        csv file containing the past run results 
 
    Returns 
    --- 
    None 
 
    Notes 
    --- 
    Plots and results csv files are saved to the working folder. 
    """ 
 
    # Read in current run results, and output to dictionary current_run 
    # Numbers will be read in as strings and must be converted to floats 
    # Using dictionaries instead of lists because searching for matches later will be 
    # much more efficient. 
    current_data_file_address = working_folder_name + '\\' + current_data_file_name 
    current_data = {} 
    total_current = 0 
    # This will have the form {'sequence': [enrichment_factor, stdev]} 
    with open(current_data_file_address) as current_data_file: 
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        current_reader = csv.reader(current_data_file) 
        for row in range(0,1): # skip the header row 
            next(current_reader) 
        for row in current_reader: 
            # Column 0 : sequence 
            # Column 1 : average enrichment factor 
            # Column 2 : standard deviation 
            current_data[row[0]] = [float(row[1]), float(row[2])] 
            total_current += 1 
    print('{:,} sequences read from current data set {}'.format(total_current, 
          current_data_name)) 
 
    # Do the same for past run 
    past_data_file_address = working_folder_name + '\\' + past_data_file_name 
    past_data = {} 
    total_past = 0 
    with open(past_data_file_address) as past_data_file: 
        past_reader = csv.reader(past_data_file) 
        for row in range(0,1): # skip the header row 
            next(past_reader) 
        for row in past_reader: 
            past_data[row[0]] = [float(row[1]), float(row[2])] 
            total_past += 1 
    print('{:,} sequences read from past data set {}'.format(total_past, past_data_name)) 
 
    # Compare runs 
    common_sequences = {} 
    # This will have the format {'sequence': 
    # [current_enrichment_factor, current_stdev, past_enrichment_factor, past_stdev]} 
    # Track how many of the sequences in the current run also occur in the past run 
    match_previous = 0 
    not_match_previous = 0 
    for sequence in current_data: 
        if sequence in past_data: 
            match_previous += 1 
            current_enrichment_factor = current_data[sequence][0] 
            current_stdev = current_data[sequence][1] 
            past_enrichment_factor = past_data[sequence][0] 
            past_stdev = past_data[sequence][1] 
            common_sequences[sequence] = [current_enrichment_factor, current_stdev, 
                            past_enrichment_factor, past_stdev] 
        else: 
            not_match_previous += 1 
    print('{:,} sequences in the current data set matched the past data set ({:.1%})'.format( 
            match_previous, match_previous/total_current)) 
 
    # Write results to csv file 
    results_file_name = 'Compare ' + current_data_name + ' vs ' + past_data_name + '.csv' 
    results_file_address = working_folder_name + '\\' + results_file_name 
    with open(results_file_address, 'w', newline='') as results_file: 
        results_writer = csv.writer(results_file) 
        # Write headers 
        results_writer.writerow(['Sequence', current_data_name, '', past_data_name]) 
        # Write subheaders 
        results_writer.writerow(['', 'Average', 'Stdev', 'Avg', 'Stdev']) 
        for sequence in common_sequences: 
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            row = [sequence] 
            for value in common_sequences[sequence]: 
                row.append(value) 
            results_writer.writerow(row) 
 
    # Make x and y data lists for plotting 
    x_data = [] # Current data 
    y_data = [] # Past data 
    for sequence in common_sequences: 
        x_data.append(common_sequences[sequence][0]) 
        y_data.append(common_sequences[sequence][2]) 
 
    # Plot results 
    # Ideally make elipses with error bars as dimensions? 
    # For now scatter plot is way simpler. 
    fig, ax = plt.subplots(figsize = (5,5)) 
    ax.scatter(x_data, y_data, c='black', alpha=1) 
    ax.set_xlabel(current_data_name) 
    ax.set_ylabel(past_data_name) 
    plt.tight_layout() 
    # Save figure 
    plot_file_name = 'Compare ' + current_data_name + ' vs ' + past_data_name + '.png' 
    plot_file_address = working_folder_name + '\\' + plot_file_name 
    plt.savefig(plot_file_address, dpi=300) 
    plt.close() 
 
for past_data_name, past_data_file_name in zip(past_data_names, past_data_file_names): 
    compare(working_folder_name, current_data_name, current_data_file_name, 
                     past_data_name, past_data_file_name) 
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Intended to be run as a standalone script. 
 




Set the output file address below. 
 
The input sequence should have randomized bases represented as P for paired bases and N 
for unapired bases. 
Specify which bases are paired in paired_bases, and which types of pairs are allowed at 




# Import required modules. 
import csv # module for handling csv files 
import numpy as np # useful for making numbered lists and arrays 
import time # to check how long things take 
 
# Record the start time to track how long the script takes. 
start = time.time() 
 
# Enter your specifics below 
 
# Enter the address of the file where you want to generate the sequences. 
output_file = r'C:\Users\Rachel Kelemen\Google Drive\Chatterjee lab\AAV\Ac5 Twist results\Oligo 
pool generation\Ac5 sequences.csv' 
 
# Enter the full 120-base randomized sequence. 
# Use P to represent a paired randomized base and N to represent an unpaired randomized 
base. 





# Set up a list of indices (from 0...) for the above list 
indices = np.arange(len(oligo_sequence)) 
 
# Enter the coordinates of randomized bases, and define pairs, below. 
# IMPORTANT!!! Python starts counting from 0 NOT 1! 
 
# Different types of pairs to allow 
pair_type_1 = [['A','T'], 
               ['G','C'], 
               ['G','T']] 
pair_type_2 = [['A','T'], 
               ['C','G'], 
               ['G','C'], 
               ['G','T'], 
               ['T','A'], 
               ['T','G']] 
pair_type_3 = [['C','G'], 
               ['G','C'], 
               ['G','T']] 
 
# Paired base indices 
# Enter as index_5':[index_3', pair_type] 
paired_bases = {23:[88, pair_type_1], 
                24:[87, pair_type_2], 
                25:[86, pair_type_2], 
                26:[85, pair_type_2], 
                27:[84, pair_type_2], 
                28:[83, pair_type_3]} 
# Curly bases mean this is a data structure called a dictionary. 
# The 5' coordinate is the "key" for each entry. 
 
# indiviudal bases 
# enter as base:[possible letter strings] 
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individual_bases = {} 
 
# generate a list of all randomized base indices 
# this will be used later to assign sequence names 
randomized_bases = [] 
for r in paired_bases: 
    randomized_bases.append(r) 
    randomized_bases.append(paired_bases[r][0]) 
for r in individual_bases: 
    randomized_bases.append(r) 
randomized_bases.sort() # sort in order. 
 
 
# Generate a list of possible sequences. 
# We start with a single sequence containing 'n' and 'p' in place of randomized bases. 
# Each round, we generate new sequences with each possible base combination, one position 
# or pair at a time. 
# These go in holder_2 
# At the end of each round we: 
#   clear holder_1, 
#   write the sequences in holder_2 to holder_1 
#   and then clear holder_2 
 
holder_1 = [oligo_sequence] # when we start, there's only one sequence in holder_1 
holder_2 = [] # starts empty 
 
name_holder_1 = [] 
name_holder_2 = [] 
 
for base, index in zip(oligo_sequence, indices): # zip iterates through multiple lists 
    # Unpaired randomized bases 
    if base == 'N': 
        if index in individual_bases: # make sure it's actually a key in the dictionary 
            print('Randomized individual base:', index) 
            possible_bases = individual_bases[index] 
 
            for existing_sequence in holder_1: 
                # Generate new sequences with all possible variants at position N 
                for possible_base in possible_bases: 
                    new_sequence = existing_sequence[:index] + possible_base + \ 
                    existing_sequence[index+1:] 
                    # Add each new sequence to holder_2 
                    holder_2.append(new_sequence) 
 
            # Empty holder_1 so it is ready to recieve data from holder_2 
            holder_1.clear() 
            for sequence in holder_2: 
                holder_1.append(sequence) 
            # clear holder_2 so it can be reused 
            holder_2.clear() 
 
            print('Total sequences: {:,}'.format(len(holder_1))) 
 
    # Randomized paired bases 
    elif base == 'P': 
        if index in paired_bases: 
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            index_5 = index 
            index_3 = paired_bases[index][0] 
            print('Randomized paired bases:', index_5, index_3) 
 
            # Pairing information 
            pair_type = paired_bases[index][1] 
 
            for existing_sequence in holder_1: 
                for pair in pair_type: 
                    # pair[0] is the 5' base and pair[1] is the 3' base 
                    new_sequence = existing_sequence[:index_5] + pair[0] + \ 
                    existing_sequence[index_5+1:index_3] + pair[1] + \ 
                    existing_sequence[index_3+1:] 
                    holder_2.append(new_sequence) 
 
            holder_1.clear() 
            for sequence in holder_2: 
                holder_1.append(sequence) 
            holder_2.clear() 
 
            print('Total sequences: {:,}'.format(len(holder_1))) 
 
# Generate a list of sequence names by extracting the randomized base sequence from each 
# sequence in holder_1 
sequence_names = [] 
for sequence in holder_1: 
    name = '' 
    for r in randomized_bases: 
        name += sequence[r] 
    sequence_names.append(name) 
 
 
# track how long this took 
# should be very short 
total_time = time.time() - start 
 
# if a string contains {}, the {} contains the formatting information and the .format() 
# statement contains the values. 
# {:,} formats outputs as 1,000,000  {:.2f} formats output as 2.00 
print('\nComplete in {:.2f} seconds. \n{:,} sequences generated.'.format(total_time, 
      len(holder_1))) 
print('\nSample of generated sequences:') 
print(sequence_names[0] + ': ' + holder_1[0]) # first sequence 
print(sequence_names[-1] + ': ' + holder_1[-1]) # last sequence 
 
 
'''Write your results to a .csv file''' 
# Open files as "with open" so that they will be automatically closed when the loop is done 
with open(output_file, 'w', newline = '') as csvfile: 
    seq_writer = csv.writer(csvfile) # this is a "writer" object 
    for sequence, name in zip(holder_1, sequence_names): 
        row = [name, sequence] # a line in the csv file 
        seq_writer.writerow(row) # write the line 
 
print ('\nSequences written to:\n',output_file) 
 
